Document:

EX-10.2

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Exhibit 10.2 

Execution Version 

SECOND AMENDED AND RESTATED GAS GATHERING AGREEMENT 

by and between 
 HESS
TRADING CORPORATION, 
 as Shipper 

and 
 HESS NORTH DAKOTA
PIPELINES LLC, 
 as Gatherer 

  

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 ARTICLE 1 DEFINITIONS; RULES OF CONSTRUCTION
	  	 	1	 
		
	 Section 1.1    Definitions
	  	 	1	 
	 Section 1.2    References and Rules of Construction
	  	 	2	 
		
	 ARTICLE 2 GATHERING SYSTEM; TERM
	  	 	2	 
		
	 Section 2.1    Gathering System
	  	 	2	 
	 Section 2.2    Term
	  	 	2	 
		
	 ARTICLE 3 SYSTEM SERVICES
	  	 	3	 
		
	 Section 3.1    System Services
	  	 	3	 
	 Section 3.2    Services Standard
	  	 	4	 
	 Section 3.3    Drip Liquids
	  	 	4	 
	 Section 3.4    Exchange of Information
	  	 	4	 
	 Section 3.5    Reports
	  	 	4	 
		
	 ARTICLE 4 DEDICATION OF PRODUCTION
	  	 	5	 
		
	 Section 4.1    Dedication
	  	 	5	 
	 Section 4.2    Conflicting Dedications
	  	 	6	 
	 Section 4.3    Shipper’s Reservations
	  	 	6	 
	 Section 4.4    Releases from Dedication
	  	 	7	 
		
	 ARTICLE 5 DEVELOPMENT PLAN; GATHERING SYSTEM PLAN; GATHERING SYSTEM EXPANSION AND CONNECTION
OF WELLS
	  	 	8	 
		
	 Section 5.1    Development Plans
	  	 	8	 
	 Section 5.2    Gathering System Plans
	  	 	10	 
	 Section 5.3    Agreement on Proposed Development Plan and Gathering
System Plan; Meetings; Amendments to Currently Agreed Development Plan and Gathering System Plan
	  	 	13	 
	 Section 5.4    Expansion of Gathering System; Committed Build-Outs; and
System Acquisitions
	  	 	15	 
		
	 ARTICLE 6 MINIMUM VOLUME COMMITMENT; SHORTFALL CREDITS
	  	 	16	 
		
	 Section 6.1    MVC
	  	 	16	 
	 Section 6.2    MVC Shortfall Credits
	  	 	17	 

  
 i 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 ARTICLE 7 FEES; CHARGES; DEDUCTIONS
	  	 	18	 
		
	 Section 7.1    Fees
	  	 	18	 
	 Section 7.2    Charges
	  	 	23	 
	 Section 7.3    Flaring
	  	 	23	 
	 Section 7.4    Gathering System L&U
	  	 	23	 
	 Section 7.5    Gathering System Fuel
	  	 	23	 
	 Section 7.6    Drip Liquids
	  	 	24	 
		
	 ARTICLE 8 TENDER, NOMINATION AND GATHERING OF PRODUCTION
	  	 	24	 
		
	 Section 8.1    Priority of Service
	  	 	24	 
	 Section 8.2    Governmental Action
	  	 	24	 
	 Section 8.3    Tender of Dedicated Production; Additional Gas and Shipper
Injected Liquids
	  	 	25	 
	 Section 8.4    Nominations, Scheduling and Curtailment
	  	 	25	 
	 Section 8.5    Suspension/Shutdown of Service
	  	 	25	 
	 Section 8.6    Gas Marketing and Transportation
	  	 	26	 
	 Section 8.7    Downstream Delivery Points
	  	 	27	 
		
	 ARTICLE 9 QUALITY AND PRESSURE SPECIFICATIONS
	  	 	27	 
		
	 Section 9.1    Quality Specifications
	  	 	27	 
	 Section 9.2    Pressure
	  	 	28	 
		
	 ARTICLE 10 TERMINATION
	  	 	28	 
		
	 Section 10.1    Termination
	  	 	28	 
	 Section 10.2    Effect of Termination or Expiration of the Term
	  	 	30	 
	 Section 10.3    Damages for Early Termination
	  	 	30	 
		
	 ARTICLE 11 TITLE AND CUSTODY
	  	 	30	 
		
	 Section 11.1    Title
	  	 	30	 
	 Section 11.2    Custody
	  	 	31	 

  
 ii 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 ARTICLE 12 BILLING AND PAYMENT
	  	 	31	 
		
	 Section 12.1    Invoices
	  	 	31	 
	 Section 12.2    Payments
	  	 	31	 
	 Section 12.3    Audit
	  	 	32	 
		
	 ARTICLE 13 REMEDIES
	  	 	32	 
		
	 Section 13.1    Suspension of Performance; Release from
Dedication
	  	 	32	 
	 Section 13.2    No Election
	  	 	33	 
		
	 ARTICLE 14 FORCE MAJEURE
	  	 	33	 
		
	 Section 14.1    Events of Force Majeure
	  	 	33	 
	 Section 14.2    Actions
	  	 	34	 
	 Section 14.3    Strikes, Etc
	  	 	34	 
		
	 ARTICLE 15 REPRESENTATIONS AND COVENANTS
	  	 	34	 
		
	 Section 15.1    Party Representations
	  	 	34	 
	 Section 15.2    Joint Representations
	  	 	35	 
	 Section 15.3    Applicable Laws
	  	 	35	 
	 Section 15.4    Government Authority Modification
	  	 	35	 
	 Section 15.5    Taxes
	  	 	36	 
	 Section 15.6    Exclusive Producer Purchase Right
	  	 	36	 
		
	 ARTICLE 16 INDEMNIFICATION AND INSURANCE
	  	 	36	 
		
	 Section 16.1    Custody and Control Indemnity
	  	 	36	 
	 Section 16.2    Shipper Indemnification
	  	 	36	 
	 Section 16.3    Gatherer Indemnification
	  	 	37	 
	 Section 16.4    Actual Direct Damages
	  	 	37	 
	 Section 16.5    Penalties
	  	 	38	 
	 Section 16.6    Insurance
	  	 	38	 
		
	 ARTICLE 17 ASSIGNMENT
	  	 	38	 
		
	 Section 17.1    Assignment of Rights and Obligations under this
Agreement
	  	 	38	 
	 Section 17.2    Pre-Approved
Assignment
	  	 	39	 

  
 iii 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 ARTICLE 18 SHIPPER GUARANTEE; ADEQUATE ASSURANCES
	  	 	39	 
		
	 Section 18.1      Shipper Guarantee
	  	 	39	 
	 Section 18.2      Adequate Assurances
	  	 	39	 
		
	 ARTICLE 19 MISCELLANEOUS
	  	 	40	 
		
	 Section 19.1      Relationship of the Parties
	  	 	40	 
	 Section 19.2      Notices; Voice Recording
	  	 	40	 
	 Section 19.3      Expenses
	  	 	40	 
	 Section 19.4      Waivers; Rights Cumulative
	  	 	40	 
	 Section 19.5      Confidentiality
	  	 	41	 
	 Section 19.6      Entire Agreement; Conflicts
	  	 	41	 
	 Section 19.7      Amendment
	  	 	42	 
	 Section 19.8      Governing Law; Disputes
	  	 	42	 
	 Section 19.9      Parties in Interest
	  	 	42	 
	 Section 19.10    Preparation of Agreement
	  	 	42	 
	 Section 19.11    Severability
	  	 	42	 
	 Section 19.12    Operating Terms
	  	 	42	 
	 Section 19.13    Counterparts
	  	 	43	 

  
 iv 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 APPENDICES AND EXHIBITS 

 

			
	APPENDIX I	  	OPERATING TERMS AND CONDITIONS
	APPENDIX II	  	DEFINITIONS
		
	EXHIBIT A-1	  	GOLIATH SUBSYSTEM
	EXHIBIT A-2	  	HAWKEYE SUBSYSTEM
	EXHIBIT A-3	  	RED SKY SUBSYSTEM
	EXHIBIT A-4	  	LIQUIDS LINES
	EXHIBIT B-1	  	DEDICATED AREA
	EXHIBIT B-2	  	DEDICATED THIRD PARTY CONTRACTS
	EXHIBIT C	  	CONFLICTING DEDICATIONS
	EXHIBIT D	  	CURRENT DEVELOPMENT PLAN
	EXHIBIT E	  	CURRENT GATHERING SYSTEM PLAN
	EXHIBIT F	  	CURRENT MINIMUM VOLUME COMMITMENTS
	EXHIBIT G-1	  	CURRENT FEES
	EXHIBIT G-2	  	TARIFF FEE RECALCULATION MODEL
	EXHIBIT G-3	  	SECONDARY TERM FEES
	EXHIBIT H	  	RECEIPT POINTS
	EXHIBIT I	  	DELIVERY POINTS
	EXHIBIT J	  	INSURANCE
	EXHIBIT K	  	NOTICE INFORMATION

  
 v 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 SECOND AMENDED AND RESTATED GAS GATHERING AGREEMENT 

THIS SECOND AMENDED AND RESTATED GAS GATHERING AGREEMENT (as the same may be amended from time to time in accordance herewith, this
“Agreement”) is made effective for all purposes (except as expressly set forth herein) as of January 1, 2014 at 12:01 a.m. CCT (the “Effective Time”), by and between Hess Trading Corporation, a
Delaware corporation (“Shipper”), and Hess North Dakota Pipelines LLC, a Delaware limited liability company (“Gatherer”). Shipper and Gatherer are sometimes together referred to in this Agreement as
the “Parties” and individually as a “Party”. 
 RECITALS 

WHEREAS, Shipper and Gatherer entered into that certain Amended and Restated Gas Gathering Agreement, dated as of the Effective Time (such
agreement, as the same has been amended, modified or supplemented as of the date hereof, the “A&R Agreement”). 

WHEREAS, Gatherer owns, operates and maintains the Gathering System (as defined herein), which allows Gatherer to gather Gas (as defined
herein) and Injected Liquids (as defined herein) from various receipt point(s) and to redeliver Gas, Injected Liquids and Drip Liquids (as defined herein) to various delivery point(s). 

WHEREAS, Shipper owns or Controls (as defined herein), and has the right to Tender (as defined herein), certain Gas (such Gas,
“Shipper Gas”) and certain Injected Liquids (such Injected Liquids, “Shipper Injected Liquids”) into the Gathering System, and Gatherer desires to provide the System Services (as defined herein) for
the Shipper Gas and Shipper Injected Liquids, on the terms and subject to the conditions in this Agreement. 
 WHEREAS, the Parties desire
to amend and restate the A&R Agreement to modify certain terms and conditions set forth therein. 
 AGREEMENTS 

NOW, THEREFORE, in consideration of the mutual agreements, covenants, and conditions in this Agreement contained, Gatherer and Shipper hereby
agree to amend and restate the A&R Agreement in its entirety as follows: 
 ARTICLE 1 

DEFINITIONS; RULES OF CONSTRUCTION 

Section 1.1 Definitions. As used in this Agreement, capitalized words and terms shall have the meaning ascribed to such terms in
Appendix II attached hereto. 

  
 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 1.2 References and Rules of Construction. All references in this
Agreement to Exhibits, Appendices, Articles, Sections, subsections and other subdivisions refer to the corresponding Exhibits, Appendices, Articles, Sections, subsections and other subdivisions of or to this Agreement unless expressly provided
otherwise. Titles appearing at the beginning of any Articles, Sections, subsections and other subdivisions of this Agreement are for convenience only, do not constitute any part of this Agreement, and shall be disregarded in construing the language
hereof. The words “this Agreement”, “herein”, “hereby”, “hereunder” and “hereof”, and words of similar import, refer to this Agreement as a whole and not to any particular Article, Section,
subsection or other subdivision unless expressly so limited. The word “including” (in its various forms) means “including without limitation”. All references to “$” or “dollars” shall be deemed references to
“United States dollars”. Each accounting term not defined herein will have the meaning given to it under generally accepted accounting principles. Pronouns in masculine, feminine or neuter genders shall be construed to state and include
any other gender, and words, terms and titles (including terms defined herein) in the singular form shall be construed to include the plural and vice versa, unless the context otherwise requires. References to any Law means such Law as it may be
amended from time to time. 
 ARTICLE 2 

GATHERING SYSTEM; TERM 

Section 2.1 Gathering System. The “Gathering System” means all of the Subsystems, collectively (including,
for the avoidance of doubt, any Subsystem Extensions with respect thereto). As of the execution of this Agreement, there are three existing Subsystems: (a) the “Goliath Subsystem”, which is the Gas gathering system owned by
Gatherer and more particularly described on Exhibit A-1; (b) the “Hawkeye Subsystem”, which is the Gas gathering system owned by Gatherer and more particularly
described on Exhibit A-2; and (c) the “Red Sky Subsystem”, which is the Gas gathering system owned by Gatherer and more particularly described on Exhibit A-3, in each case, as such Subsystems may be modified and/or extended from time to time, including pursuant to a Subsystem Extension. As of the execution of this Agreement, each Subsystem contains certain
“Liquids Lines” that are existing Injected Liquids and Drip Liquids transportation lines owned by Gatherer and more particularly described on Exhibit A-4, in
each case, as such Liquids Lines may be modified and/or extended from time to time, including pursuant to a Subsystem Extension for the relevant Subsystem to which such Liquids Lines are connected. 

Section 2.2 Term. Subject to earlier termination pursuant to Section 10.1 (a) this Agreement shall
commence at the Effective Time and shall remain in effect until (i) with respect to the System Services to be provided on the Goliath Subsystem, the 15th anniversary of the Effective
Time, and (ii) with respect to the System Services to be provided on each of the Hawkeye Subsystem and the Red Sky Subsystem, the 10th anniversary of the Effective Time (each of the
foregoing initial terms, the “Initial Term” with respect to the applicable Subsystem), (b) Gatherer shall have the option, exercisable by the delivery of written Notice to Shipper on or before the date that is three Years
prior to the expiration of each applicable Initial Term, to renew 

  
 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
this Agreement with respect to the System Services to be provided on the applicable Subsystem for (i) in the case of the System Services to be provided on the Goliath Subsystem, one
additional five Year period, and (ii) in the case of the System Services to be provided on each of the Hawkeye Subsystem and the Red Sky Subsystem, one additional ten Year period (each of the foregoing subsequent terms, the
“Secondary Term” with respect to the applicable Subsystem), and (c) thereafter, this Agreement shall automatically renew with respect to the System Services to be provided on the applicable Subsystem for successive
Yearly periods unless terminated by either Party through the delivery of written Notice to the other Party on or before the date that is 180 Days prior to the end of the applicable Secondary Term or the then-current applicable Yearly term, as
applicable (with respect to any Subsystem individually, its Initial Term, its Secondary Term and any subsequent Yearly renewal periods in respect of such Subsystem, collectively, the “Term”). Should Gatherer elect to renew
this Agreement for the Secondary Term in respect of any Subsystem pursuant to this Section 2.2, then, upon the beginning of the applicable Secondary Term (and thereafter during the Term of this Agreement as it pertains to
the System Services to be provided on such Subsystem), the provisions of Section 7.1(i) and Exhibit G-3 shall be applicable with respect to the System Services to be provided
on the applicable Subsystem hereunder. For the avoidance of doubt, during the Initial Term with respect to any Subsystem, the provisions of Section 7.1(i) and Exhibit G-3 shall
not be applicable hereunder with respect to the System Services to be provided on such Subsystem. 
 ARTICLE 3 

SYSTEM SERVICES 

Section 3.1 System Services. Subject to the provisions of this Agreement and rights of all applicable Governmental Authorities,
during the Term applicable to each Subsystem, Gatherer shall provide, or cause to be provided, the following services with respect to Shipper Gas and Shipper Injected Liquids on such Subsystem, in each case, in accordance with the terms and
conditions of this Agreement (collectively, whether in relation to a single Subsystem or the Gathering System as a whole, the “System Services”): 

(a) “Gathering Services”, which means: (i) the receipt of Shipper Gas Tendered by or on behalf of Shipper at the
Receipt Points (other than the Injection Points); (ii) the gathering of such Shipper Gas; (iii) the receipt of Shipper Injected Liquids Tendered by or on behalf of Shipper at the Injection Points; (iv) the redelivery of Gas and,
subject to Section 3.3, Drip Liquids at the relevant Delivery Points (as nominated by Shipper) for Shipper’s account, with an equivalent Thermal Content to such Shipper Gas, less System Fuel and Losses allocated to
Shipper in accordance with this Agreement; (v) the redelivery of Injected Liquids at the relevant Delivery Points (as nominated by Shipper) for Shipper’s account, with an equivalent Thermal Content to such Shipper Injected Liquids, less
System Fuel and Losses allocated to Shipper in accordance with this Agreement; and (vi) the metering of such Shipper Gas and Shipper Injected Liquids at the Receipt Points (including the Injection Points, as applicable) and Delivery Points;

 (b) “Compression Services”, which means the combined dehydrating and compressing, to applicable tariff
requirements, of Shipper Gas on the Gathering System; and 

  
 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (c) those other services to be performed by Gatherer in respect of Shipper Gas and Shipper
Injected Liquids as set forth in this Agreement.  
 Section 3.2 Services Standard. Gatherer agrees to own,
operate, and maintain, at its sole cost, risk and expense, the Gathering System and the other facilities, in each case, necessary to provide the System Services contemplated in this Agreement in accordance with the then-current Development Plan and
Gathering System Plan and in a good and workmanlike manner in accordance with standards customary in the industry in the geographic area where the Gathering System is located. 

Section 3.3 Drip Liquids. The Parties acknowledge and agree that Drip Liquids may result from the normal operation of the
Gathering System and the provision of the System Services to Shipper Gas hereunder. Such Drip Liquids shall be collected by Gatherer at various collection points, including drip pots, dew-pointing locations,
compressor inlet receivers, and pigging collection points, located on each Subsystem (each, a “Drip Point”). 
 (a)
To the extent that any Drip Liquids allocated to Shipper in accordance with this Agreement and collected at a Drip Point are able to be re-delivered by Gatherer via the Liquids Lines from such Drip Point to
the applicable Delivery Point nominated by Shipper, such Drip Liquids shall be so re-delivered by Gatherer. 

(b) Notwithstanding the foregoing, to the extent that any Drip Liquids allocated to Shipper in accordance with this Agreement and collected at
a Drip Point are not able to be re-delivered by Gatherer via the Liquids Lines to the applicable Delivery Point nominated by Shipper, then (i) Gatherer shall have no further obligation to gather or
transport such Drip Liquids, (ii) regardless of the Delivery Point nominated by Shipper with respect to such Drip Liquids, the applicable Drip Point shall be deemed to be the Delivery Point with respect to such Drip Liquids, and
(iii) Shipper shall have the obligation to provide the means to transport such Drip Liquids away from such Drip Points promptly upon such Drip Liquids being collected at such Drip Points. 

Section 3.4 Exchange of Information. Each Party agrees to use its reasonable efforts to provide, on a timely basis, such
information to the other Party as may be reasonably needed by such other Party to perform its obligations hereunder (including, in the case of Gatherer, to provide the System Services hereunder). 

Section 3.5 Reports. Gatherer shall file all necessary reports and/or notices required by applicable Laws with respect to the
performance by Gatherer of the System Services pursuant to this Agreement. 

  
 4 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 ARTICLE 4 

DEDICATION OF PRODUCTION 

Section 4.1 Dedication. 

(a) Subject to the provisions of Section 4.1 through Section 4.4 and Article 17,
Shipper exclusively dedicates and commits to deliver to Gatherer under this Agreement all: 
 (i) Shipper Gas formerly owned
or Controlled by Producer and produced from those oil and gas properties located in the area described on Exhibit B-1 (such area, as the same may be modified from time to time by the Parties hereunder,
the “Dedicated Area”) that are operated by Producer or that are not operated by Producer, but from which Producer has elected to take its applicable production in-kind (such Gas,
“Dedicated Producer Gas”); and 
 (ii) Effective as of January 1, 2019, Shipper Gas that Shipper
owns or Controls through one of the Third Party Contracts described on Exhibit B-2 attached hereto (such Third Party Contracts, the “Dedicated Third Party Contracts”). Shipper
shall have the right from time to time during the Term applicable to each Subsystem to add additional Third Party Contracts as Dedicated Third Party Contracts under this Agreement by delivery of Notice to Gatherer pursuant to
Section 19.2 indicating Shipper’s intent to add a Third Party Contract to Exhibit B-2 as a Dedicated Third Party Contract. Pending any formal amendment of Exhibit
B-2 to update the list of Dedicated Third Party Contracts contained thereon, the Parties acknowledge and agree that Shipper’s delivery of Notice to Gatherer pursuant to this
Section 4.1(a)(ii) and Section 19.2 indicating Shipper’s intent to dedicate a Third Party Contract under this Agreement as a “Dedicated Third Party Contract” shall be sufficient to
classify (A) such Third Party Contract as a “Dedicated Third Party Contract” for all purposes hereunder until Exhibit B-2 is formally amended to include the same, and
(B) all volumes owned or Controlled by Shipper pursuant to such Third Party Contract and delivered to Gatherer hereunder (to the extent such volumes were delivered from and after the last update of Exhibit
B-2 and prior to the delivery of such written notice or after the delivery of such notice) as “Third Party Volumes” for all purposes hereunder. 

provided, however, that notwithstanding anything herein to the contrary, with respect to all periods prior to January 1, 2019, the definition of
“Dedicated Contract” contained in the A&R Agreement and the provisions of the A&R Agreement pertaining to “Dedicated Contracts” shall, in each case, remain applicable hereunder with respect to the System Services provided
during such period, and all volumes of Shipper Gas that Shipper owned or Controlled pursuant to any “Dedicated Contract” shall explicitly constitute “Tariff Volumes” hereunder with respect to such period. 

(b) All Dedicated Producer Gas and all Shipper Gas subject to a Dedicated Third Party Contract that (i) is not described in
Section 4.1(c)(i), (ii) is not subject to a Conflicting Dedication, (iii) has not been reserved and utilized by Shipper pursuant to Section 4.3, and (iv) has not been released (either
temporarily or permanently) from dedication pursuant to Section 4.4, is referred to collectively hereunder as “Dedicated Production”. 

  
 5 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (c) Notwithstanding the foregoing: 

(i) any Dedicated Producer Gas (A) that is produced from a well that was drilled and completed, and is operated, in each
case, by a Non-Party that is not an Affiliate of Shipper, and (B) that such Non-Party operator (and not Shipper or any of Shipper’s Affiliates) markets under
applicable contractual arrangements with respect to such well and such Shipper Gas, shall not be considered “Dedicated Production” hereunder; and 

(ii) no Dedicated Third Party Contract may be amended, modified or otherwise supplemented by Shipper such that the volume of
Dedicated Production resulting therefrom would be reduced without the prior written consent of Gatherer, such consent not to be unreasonably withheld; provided, however, that such restrictions shall not apply to (A) any termination or
expiration of any such Dedicated Third Party Contract pursuant to its terms, or (B) the removal of any individual Well from the coverage of any such Dedicated Third Party Contract that, on average, produces less than 100 Mcf of Gas a Month.

 Section 4.2 Conflicting Dedications. Notwithstanding anything in this Agreement to the contrary, Shipper shall have the right
to comply with each gathering agreement or any commitment or arrangement (including any volume commitment) that would require any Shipper Gas to be gathered on any gathering system or similar system other than the Gathering System (each, a
“Conflicting Dedication”) that (a) is in effect as of January 1, 2018 and is described in Exhibit C, or (b) is applicable and in effect as of the date that Shipper acquires Control of
any Gas produced from lands covered by the Dedicated Area that was not under the Control of Shipper as of January 1, 2018. Notwithstanding the foregoing, Shipper shall only have the right to comply with the applicable Conflicting Dedication up
to and until the first Day of the Month following the termination of such Conflicting Dedication (without giving effect to any right of Shipper to renew or extend the term of such Conflicting Dedication). For the avoidance of doubt, any Shipper Gas
that, but for a Conflicting Dedication, would be considered “Dedicated Production” hereunder, shall, automatically upon the termination of the applicable Conflicting Dedication, be considered “Dedicated Production” hereunder. As
of January 1, 2018, Shipper represents that, except as set forth in Exhibit C, the Dedicated Production is not subject to any Conflicting Dedication.  

Section 4.3 Shipper’s Reservations. Shipper reserves the following rights respecting Dedicated Producer Gas and
all Shipper Gas subject to a Dedicated Third Party Contract for itself: (a) to deliver or furnish to the applicable lessors and holders of other burdens on production such Shipper Gas as is required to satisfy the terms of the applicable oil
and gas leases or other applicable instruments; and (b) the sole and exclusive right to process or arrange for the processing (including for purposes of liquids extraction) of such Shipper Gas. 

  
 6 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 4.4 Releases from Dedication. 

(a) If Gatherer has failed to complete the facilities necessary to connect a Planned Receipt Point to the Gathering System within: 

(i) 90 Days of the applicable Target Completion Date contained in the then-currently agreed Gathering System Plan, then, upon
written Notice from Shipper to Gatherer, Shipper shall be entitled to: 
 (A) in the case of any such written Notice
delivered during the Initial Term applicable to the relevant Subsystem: (1) request a temporary Recalculation Election pursuant to Section 7.1(e)(y), in which case (x) the Dedicated Production Estimate that is
applicable to such Planned Receipt Point will be deemed deleted from the Dedicated Production Estimate contained in the then-currently agreed Development Plan, (y) the Committed Build-Out at issue (and
all Committed Build-Out Costs related thereto) will be deleted from the then-currently agreed Gathering System Plan, and (z) the Fees resulting from such Recalculation Election will be utilized, subject
to the last sentence of this Section 4.4(a)(i)(A), for the remainder of the then-current Year, and (2) a temporary reduction in the then-applicable MVC to reflect the deletion of the applicable portion of the Dedicated
Production Estimate, which reduction in MVC will remain in effect, subject to the last sentence of this Section 4.4(a)(i)(A), for the remainder of the then-current Year. Any such temporary Recalculation Election and
reduction in MVC shall, in each case, be terminated, and the Fees and MVC shall each revert back to their respective levels prior to such election, upon the completion of the connection of the Planned Receipt Point to the applicable Subsystem; or

 (B) in the case of any such written Notice delivered from and after the beginning of the Secondary Term applicable to the
relevant Subsystem: receive a temporary (1) release from the dedication hereunder of the Dedicated Production Estimate that is applicable to such Planned Receipt Point, and (2) reduction in the then-applicable MVC to reflect the temporary
release of the applicable portion of the Dedicated Production Estimate, which temporary release and reduction in MVC will remain in effect, in each case, until the earlier of (x) the end of then-current Year, or (y) the completion of the
connection of the applicable Planned Receipt Point to the applicable Subsystem; or 
 (ii) 180 Days of the applicable Target
Completion Date contained in the then-currently agreed Gathering System Plan, then, upon written Notice from Shipper to Gatherer, the volumes of Dedicated Production applicable to such Planned Receipt Point shall be permanently released from the
dedication under this Agreement and Shipper may deliver and commit such Shipper Gas that was formerly Dedicated Production to such other gatherer or gatherers as it shall determine in its sole discretion. 

(b) Certain Dedicated Production may also be temporarily released from dedication under this Agreement in the event of: 

(i) the Parties agreeing (whether pursuant to Section 5.3(e) or otherwise) upon the Target Completion
Date for a Planned Receipt Point that is greater than three Months following the date on which Shipper requested that such Planned Receipt Point be operational in its applicable proposed Updated Development Plan delivered pursuant to
Section 5.1(a), as more particularly provided in Section 5.3(f)(i); 

  
 7 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (ii) any curtailment or interruption of the System Services to be provided to
Shipper as set forth in Section 8.5(d) or in Section 1.5 of the Operating Terms; 

(iii) a material breach of this Agreement by Gatherer as provided in Section 13.1(b); or 

(iv) an order of a Governmental Authority that causes the curtailment of System Services to Shipper as provided in
Section 8.2. 
 (c) Certain Dedicated Production may also be permanently released from dedication under this
Agreement as expressly provided in Section 5.3(f)(ii). 
 ARTICLE 5 

DEVELOPMENT PLAN; GATHERING SYSTEM PLAN; GATHERING SYSTEM 

EXPANSION AND CONNECTION OF WELLS 

Section 5.1 Development Plans. Shipper has provided Gatherer with a report attached hereto as Exhibit D (the
“Current Development Plan”) describing in detail, as of January 1, 2018, the planned development, drilling, and production activities to take place with respect to Dedicated Production for the
applicable Development Period. The information contained in the Current Development Plan is broken out on a Subsystem-by-Subsystem basis and, with respect to the first
three Years covered by the Current Development Plan, on a Quarter-by-Quarter basis, and, with respect to the remaining Years covered by the Current Development Plan,
also on a Year-by-Year basis. The Current Development Plan attached hereto has been approved by the Parties. 

(a) From time to time during each Year of the Term applicable to each Subsystem, the Parties shall meet to discuss the planned development,
drilling, and production activities that Shipper expects to take place with respect to Dedicated Production for the then-applicable Development Period. Shipper and Gatherer shall each make their respective representatives available to participate in
such meetings and discussions. No later than August 1 of each such Year, Shipper shall provide (or cause to be provided) to Gatherer a proposed update of the then-currently agreed Development Plan, prepared on the same basis as the Current
Development Plan (other than, for the avoidance of doubt, with regard to those matters that are only applicable in respect of Year 2019 and thereafter hereunder, which matters shall be included in the applicable Updated Development Plan even though
they were not addressed in the Current Development Plan) and describing in detail the planned development, drilling, and production activities to take place with respect to Dedicated Production for the then-applicable Development Period (any such
update, an “Updated Development Plan” and, together with the Current Development Plan, each, a “Development Plan”). Notwithstanding anything herein to the contrary, in no event shall Gatherer be
required to agree to any Updated Development Plan and corresponding updated Gathering System Plan that contains a Committed Build-Out that (i) has a corresponding Target Completion Date that occurs after
the end of the Initial Term applicable to the Subsystem to which such Committed Build-Out relates, and (ii) Gatherer, in its sole discretion, does not wish to approve. 

  
 8 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (b) Each proposed Development Plan in respect of Year 2019 and thereafter shall include
information as to the following, in each case, broken out on a Subsystem-by-Subsystem basis and, with respect to the first three Years covered by such Development Plan,
on a Quarter-by-Quarter basis, and, with respect to the remaining Years covered by such Development Plan, also on a Year-by-Year basis: 
 (i) all Wells that, as of the date such Development Plan was
delivered, are currently in existence and (A) the production therefrom is being delivered into the Gathering System, or (B) are awaiting connection to the Gathering System; 

(ii) the Wells that are expected to be drilled during the time period covered by such Development Plan (each such Well
reflected in such Development Plan, a “Planned Well”), and the estimated timing of the drilling of such Planned Wells; 

(iii) forward-looking production estimates for the applicable time period covered by such Development Plan for all Shipper Gas
(broken out between Tariff Volumes and Third Party Volumes) (A) that Shipper reasonably and in good faith believes will become owned or Controlled by Shipper during the time period covered by such Development Plan, and/or (B) that will be
produced from (I) in the aggregate, all Wells then-existing and (II) in the aggregate, any Planned Wells included in such Development Plan. The collective estimates described in subsections (A) and (B) above, with respect to a
particular Quarter, an entire Year, and the applicable Development Period, in the aggregate, are referred to herein as the “Dedicated Production Estimates”. The Dedicated Production Estimates comprised of (A) Tariff
Volumes are referred to herein as “Tariff Volume Estimates”, and (B) Third Party Volumes are referred to herein as “Third Party Volume Estimates”; 

(iv) forward-looking estimates for the applicable time period covered by such Development Plan of the aggregate volumes of
those Shipper Injected Liquids (broken out between Tariff Volumes and Third Party Volumes) that Shipper intends to Tender to the Injection Points hereunder to receive the System Services. The collective estimates described above, with respect to a
particular Quarter, an entire Year, and the applicable Development Period, in the aggregate, are referred to herein as the “System Liquids Estimates” and, together with the Dedicated Production Estimates, as the
“System Production Estimates”; 
 (v) (A) each new receipt point (including the location thereof)
proposed by Shipper with respect to the System Production Estimate reflected in such Development Plan (each such receipt point, including those located at the site of a Planned Well, a “Planned Receipt Point”), (B) each
Receipt Point at which Shipper expects to Tender Shipper Gas and/or Shipper Injected Liquids reflected in such Development Plan into the Gathering System, and (C) the estimated portion of the System Production Estimate contained in such
Development Plan that Shipper expects to Tender at each such Receipt Point and Planned Receipt Point; 

  
 9 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (vi) the earliest date on which each Planned Well included in the Development
Plan is estimated to be completed and producing, which date shall not be earlier than three Months after the January 1st that is immediately subsequent to the date that the Development Plan that
initially reflected such Planned Well was delivered to Gatherer hereunder; 
 (vii) the anticipated characteristics of the
production from the Wells and Planned Wells reflected in such Development Plan (including liquids content and gas and liquids composition) and the projected production volumes and production pressures applicable thereto; provided that Shipper may
utilize the existing and historical production information from similarly situated Wells; 
 (viii) (A) each new delivery
point (including the location thereof) proposed by Shipper with respect to the System Production Estimate reflected in such Development Plan (each such delivery point, a “Planned Delivery Point”), (B) each Delivery Point at
which Shipper expects Shipper Gas reflected in such Development Plan to be redelivered to Shipper, (C) each Delivery Point at which Shipper expects any Drip Liquids allocated to Shipper in accordance with this Agreement and/or Shipper Injected
Liquids to be redelivered to Shipper, and (D) the estimated portion of the System Production Estimate contained in such Development Plan that Shipper expects to be redelivered to Shipper at each such Delivery Point and Planned Delivery Point;

 (ix) any (A) proposed revision to the then-existing Dedicated Area, (B) proposed revision to any then-existing
Dedicated Third Party Contract, and/or (C) any new contract that Shipper elects to add as a Dedicated Third Party Contract; and 

(x) other information reasonably requested by Gatherer that is relevant to the design, construction, and operation of the
Gathering System, including (A) any Subsystem Extension proposed by Shipper, (B) the relevant Receipt Point, Planned Receipt Point, Delivery Point and Planned Delivery Point facilities applicable to such Development Plan, and (C) any
treating, processing, or liquids handling facilities proposed by Shipper that may be required for any Shipper Gas and/or Shipper Injected Liquids to meet applicable Downstream Facility specifications at the Delivery Points. 

Section 5.2 Gathering System Plans. Gatherer has provided Shipper with a report attached hereto as Exhibit E (the
“Current Gathering System Plan”) describing and/or depicting, as of January 1, 2018, the modifications, extensions, enhancements, major maintenance and/or other actions necessary in order for the
Gathering System to be able to provide System Services to Shipper in accordance with the Current Development Plan. The Current Gathering System Plan attached hereto has been approved by the Parties. 

  
 10 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (a) From time to time during each Year of the Term applicable to each Subsystem, the Parties
shall meet to discuss any modifications, extensions, enhancements, major maintenance and/or other actions necessary in order for the Gathering System to be able to provide System Services to Shipper to meet the planned development, drilling, and
production activities that Shipper expects to take place with respect to Dedicated Production for the then-applicable Development Period. Following the receipt of a proposed Updated Development Plan from Shipper, Gatherer shall (i) first
develop and provide to Shipper a high-level summary and estimate of any proposed update to the Current Gathering System Plan or the then-currently agreed Gathering System Plan, as applicable, and (ii) subsequently (and as soon as reasonably
practicable) following the delivery of such summary, develop and provide to Shipper a fully detailed version of such proposed update to the Current Gathering System Plan or the then-currently agreed Gathering System Plan, as applicable, describing
and/or depicting the modifications, extensions, enhancements, major maintenance and/or other actions necessary in order for the Gathering System to be able to provide System Services to Shipper in accordance with the proposed Updated Development
Plan (each such detailed plan, as the then-currently agreed plan may be updated or amended from time to time, a “Gathering System Plan”). 

(b) Each proposed Gathering System Plan in respect of Year 2019 and thereafter shall include information as to the following: 

(i) each Subsystem then-existing and operational (including any Liquids Lines associated therewith); 

(ii) all Receipt Points, Planned Receipt Points, Delivery Points and Planned Delivery Points served or to be served by each
such Subsystem, including the contractual operating pressures and maximum operating pressures thereof; 
 (iii) estimates of
all modifications, enhancements and/or extensions to any Subsystem that (A) would be owned and operated by Gatherer and its Affiliates and (B) would need to be developed, constructed and/or placed into service hereunder to provide the
System Services pursuant to the terms hereof (each, a “Subsystem Extension”), in each case, that are necessary in order for Gatherer to provide the System Services to Shipper Gas and Shipper Injected Liquids as set forth in
the applicable Development Plan (the “Committed Build-Outs”); 
 (iv) estimates of any acquisition by
Gatherer or its Affiliates of any Subsystem Extensions that would be necessary in order for Gatherer to provide the System Services as set forth in the applicable Development Plan (each, a “System Acquisition”); 

(v) the estimated schedule for completing the acquisition and/or construction and placement into service of the planned
Committed Build-Outs and System Acquisitions (such estimate, with respect to each such activity, the “Target Completion Date”); and 

  
 11 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (vi) the estimated (A) Third Party Gathering Fees for such Year,
(B) Combined Gathering Fees for such Year, and (C) changes to the Fees that would result if a Party made a Recalculation Election as a result of such updated Gathering System Plan and applicable Development Plan. 

(c) Simultaneously with the delivery of any proposed Gathering System Plan, Gatherer shall also prepare and deliver to Shipper a report
containing, in respect of Year 2019 and thereafter, the following budget and schedule of information with respect to the applicable proposed Gathering System Plan (each, a “System Budget”): 

(i) the estimated budgeted amounts (other than Maintenance Capital Expenditures and operating expenses) for the construction
and installation of the planned Committed Build-Outs contained in the applicable Gathering System Plan (such amounts, collectively, “Committed Build-Out Costs” and each such estimate, a
“Committed Build-Out Estimate”); 
 (ii) the agreed portion
of estimated budgeted amounts and values (other than Maintenance Capital Expenditures and operating expenses), whether in the form of cash or non-cash consideration, for the acquisition by Gatherer and its
Affiliates of any System Acquisitions contained in the applicable Gathering System Plan (such amounts, to the extent borne by Gatherer and its Affiliates and necessary in order for Gatherer to provide the System Services contemplated by the
applicable Development Plan and Gathering System Plan, collectively, “System Acquisition Costs” and each such estimate, a “System Acquisition Costs Estimate”); 

(iii) the estimated budgeted amounts for all Maintenance Capital Expenditures that Gatherer believes will be necessary to
provide the System Services as contemplated by the applicable Development Plan and Gathering System Plan, including with respect to all Committed Build-Outs included therein (each such estimate, a “Maintenance Capital
Estimate”); 
 (iv) the estimated budgeted amounts for all operating expenses that Gatherer believes will be
necessary to provide the System Services as contemplated by the applicable Development Plan and Gathering System Plan, including with respect to all Committed Build-Outs and System Acquisitions included therein (each such estimate, an
“Operating Expense Estimate”); and 
 (v) an estimated schedule of all maintenance that Gatherer
deems necessary or advisable to perform on the Gathering System in the next Year in order to provide the System Services set forth in the applicable Development Plan and Gathering System Plan, including with respect to all Committed Build-Outs and
System Acquisitions included therein. 

  
 12 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Notwithstanding anything herein to the contrary, Gatherer shall be entitled to update any System Budget (and
any or all of its constituent subparts) following the agreement of the Parties on any proposed Updated Development Plan and its corresponding proposed Gathering System Plan pursuant to Section 5.3(a). 

Section 5.3 Agreement on Proposed Development Plan and Gathering System Plan; Meetings; Amendments to Currently Agreed Development Plan
and Gathering System Plan. 
 (a) The Parties shall use their good faith efforts to agree upon a proposed Updated Development Plan and
corresponding proposed Gathering System Plan on or before December 31st of the Year in which such Updated Development Plan was first delivered to Gatherer. Any failure to agree upon a proposed
Updated Development Plan and its corresponding proposed Gathering System Plan by such date shall mean the then-currently agreed Development Plan and Gathering System Plan shall remain in force until such time as they are replaced by a mutually
agreed Updated Development Plan and updated Gathering System Plan, respectively. 
 (b) Shipper shall make representatives of Shipper
available to discuss the proposed Updated Development Plan from time to time with Gatherer and its representatives at Gatherer’s request. Gatherer shall make representatives of Gatherer available to discuss the proposed Gathering System Plan
from time to time with Shipper and its representatives at Shipper’s request. 
 (c) The Parties and their respective representatives
shall meet not less frequently than quarterly during the Term applicable to each Subsystem. At all such meetings, the Parties shall exchange updated information about the plans for the development and expansion of the properties producing the
then-existing System Production Estimate, including amendments to the then-currently agreed Development Plan, and the Gathering System, including amendments to the then-currently agreed Gathering System Plan and then-current System Budget, and shall
have the opportunity to discuss and provide comments on the other Party’s plans. 
 (d) Shipper may deliver to Gatherer, from time to
time, a proposed amendment to the then-currently agreed Development Plan. Following delivery of such proposed amendment, the Parties shall meet to discuss the adoption of any amendments proposed by Shipper and use their respective good faith efforts
to reach agreement on any such proposed amendment and any necessary corresponding amendments to the then-currently agreed Gathering System Plan. Upon the agreement of the Parties upon any such amendment to the then-currently agreed Development Plan
(and any necessary corresponding amendments to the then-currently agreed Gathering System Plan), Gatherer shall be entitled to update the applicable System Budget to reflect such agreed-upon amendments. 

(e) Should the Parties be unable to reach agreement on (x) any proposed Updated Development Plan or corresponding updated Gathering
System Plan pursuant to Section 5.3(a), (y) any proposed amendment to the then-currently agreed Development Plan and/or any necessary corresponding amendments to the then-currently agreed Gathering System Plan pursuant to
Section 5.3(d), or (z) the decision to install any additional facilities as contemplated pursuant to 

  
 13 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
Section 1.1(b) of the Operating Terms (and/or any amendments to the then-current Gathering System Plan that would be needed to incorporate the installation of such
additional facilities), then either Party may elect, by delivering written Notice to the other Party (each, an “Executive Election”) to invoke the following provisions with respect to such disputed amendments or facilities,
as applicable: 
 (i) any Executive Election delivered hereunder shall include (A) the (1) proposed Updated
Development Plan and/or proposed corresponding updated Gathering System Plan that such electing Party proposes be adopted, (2) amendment to the then-currently agreed Development Plan and/or Gathering System Plan that such electing Party
proposes be adopted, or (3) additional facilities contemplated pursuant to Section 1.1(b) of the Operating Terms that such electing Party proposes be installed (and/or any amendments to the then-current Gathering
System Plan that would be needed to incorporate the installation of such additional facilities), as applicable, and (B) the name and title of (1) the executive who (x) has the authority to settle such dispute, (y) is at a Vice
President or higher level of management and (z) is at a higher level of management than the Persons with direct responsibility for administration of this Agreement or the amendments in dispute (any such Person, an “Executive
Representative”) of such electing Party who will represent such electing Party in resolving such dispute and (2) any other Person who will accompany such Executive Representative; 

(ii) within 15 Days after a Party’s receipt of the applicable Executive Election, the receiving Party shall submit to the
electing Party a written response to such Executive Election that includes (A) the (1) proposed Updated Development Plan and/or proposed corresponding updated Gathering System Plan that such electing Party proposes be adopted,
(2) amendment to the then-currently agreed Development Plan and/or Gathering System Plan that such responding Party proposes be adopted, or (3) additional facilities contemplated pursuant to Section 1.1(b) of the
Operating Terms that such electing Party proposes be installed (and/or any amendments to the then-current Gathering System Plan that would be needed to incorporate the installation of such additional facilities), as applicable, and (B) the name
and title of (1) the Executive Representative of such responding Party who will represent such responding Party in resolving such dispute and (2) any other Person who will accompany such Executive Representative; 

(iii) the Parties shall then attempt in good faith to resolve the applicable dispute by negotiations between their respective
Executive Representatives; and 
 (iv) such Executive Representatives of the Parties shall meet at least weekly (or as more
often as they reasonably deem necessary), at a mutually acceptable time and place, until the applicable dispute has been resolved. 
 Notwithstanding
anything in this Agreement to the contrary, in no event shall Gatherer be required to agree to any Updated Development Plan and corresponding updated Gathering System Plan that contains a Committed Build-Out
that (x) has a corresponding Target Completion Date that occurs after the end of the Initial Term applicable to the Subsystem to which such Committed Build-Out relates, and (y) Gatherer, in its sole
discretion, does not wish to approve, whether pursuant to an Executive Election and the related provisions of this Section 5.3(e) or otherwise. 

  
 14 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (f) In the event that any agreed-upon (whether pursuant to
Section 5.3(e) or otherwise) Updated Development Plan and corresponding updated Gathering System Plan either (x) contain a Committed Build-Out with respect to a Planned Receipt
Point, but the Target Completion Date with respect thereto is more than three Months following the date on which Shipper requested that such Planned Receipt Point be operational in its proposed Updated Development Plan delivered pursuant to
Section 5.1(a), or (y) do not contain a Committed Build-Out with respect to a Planned Receipt Point that was included by Shipper in its proposed Updated Development Plan
delivered pursuant to Section 5.1(a), then: 
 (i) in the circumstances described above in
Section 5.3(f)(x), Shipper shall be entitled to a temporary release from dedication hereunder of the Dedicated Production that would utilize such Planned Receipt Point, with such temporary release (A) being effective
as of the date that Shipper requested such Planned Receipt Point to be operational in its proposed Updated Development Plan delivered pursuant to Section 5.1(a), and (B) ending on the latter of (1) the Target
Completion Date of the applicable Committed Build-Out as contained in such agreed-upon Updated Development Plan and corresponding updated Gathering System Plan, and (2) the date such Committed Build-Out is actually completed and placed into service; or 
 (ii) in the circumstances
described above in Section 5.3(f)(y), if the date on which Shipper requested that such Planned Receipt Point be operational in its proposed Updated Development Plan delivered pursuant to
Section 5.1(a) falls in the Initial Term applicable to the Subsystem to which such Planned Receipt Point relates, then Shipper shall be entitled to a permanent release from dedication hereunder of the Dedicated Production
that would utilize such Planned Receipt Point, with such permanent release being effective as of the date during the Initial Term applicable to such Subsystem that Shipper requested such Planned Receipt Point be operational in its proposed Updated
Development Plan delivered pursuant to Section 5.1(a). 
 Section 5.4 Expansion of
Gathering System; Committed Build-Outs; and System Acquisitions.
 (a) Gatherer shall, at its sole cost and expense, acquire,
design, construct and operate all Committed Build-Outs and System Acquisitions contained in the then-currently agreed Gathering System Plan for the purpose of providing System Services in accordance with this Agreement. 

  
 15 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (b) Gatherer is responsible, at its sole cost, for the acquisition and maintenance of rights
of way, surface use and/or surface access agreements necessary to construct, own and operate the Gathering System and provide the System Services hereunder (including any Committed Build-Outs and System Acquisitions); provided, however, that in the
event (i) any right of way, surface use and/or surface access agreement necessary to construct, own or operate any Committed Build-Out or System Acquisition cannot be obtained by Gatherer on terms and
conditions reasonably acceptable to Gatherer, and (ii) Shipper cannot facilitate Gatherer’s receipt of any such necessary right of way, surface use and/or surface access agreement on terms and conditions reasonably acceptable to Gatherer,
then Gatherer shall not be obligated to complete such Committed Build-Out or System Acquisition. Gatherer agrees to provide Shipper with quarterly updates as to the progress of any then-approved Committed
Build-Outs and System Acquisitions. Additionally, should Gatherer reasonably believe that any Committed Build-Out or System Acquisition will not be completed and placed
in-service by the applicable Target Completion Date reflected in the applicable Gathering System Plan, Gatherer shall send written Notice to Shipper of such delay promptly upon Gatherer’s determination
that such delay will be reasonably likely to occur. 
 (c) The Parties agree to work together in good faith to obtain the necessary permits
and authorizations from the appropriate Governmental Authorities and the necessary consents, rights of way and other authorizations from other Persons necessary to acquire, construct, own and operate each Committed
Build-Out and System Acquisition as expeditiously as reasonably practicable. The Parties further agree to cooperate with each other and to communicate regularly regarding their efforts to obtain such permits,
authorizations, consents and rights of way. 
 (d) Upon the completion of any Committed Build-Out or
System Acquisition constituting (or that include) a Planned Receipt Point or a Planned Delivery Point, the Parties shall update Exhibit H or Exhibit I, as applicable, to include such new Receipt Point or Delivery Point. 

ARTICLE 6 
 MINIMUM
VOLUME COMMITMENT; SHORTFALL CREDITS 
 Section 6.1 MVC. For each Quarter during the Term applicable to each Subsystem,
Shipper shall be obligated to Tender for delivery into each Subsystem a minimum volume of Shipper Gas (each such minimum amount with respect to each Subsystem, a “Minimum Volume Commitment” or “MVC”).
The MVCs for each Subsystem for the Quarters occurring in Year 2018 are set forth on Exhibit F attached hereto. 
 (a) Beginning in
Year 2019, the MVC with respect to each Subsystem for any Quarter occurring in the then-subsequent three Year period shall be equal to 80% of the sum of the (i) applicable Tariff Volume Estimate for such Subsystem and Quarter contained in the
then-currently agreed Development Plan, and (ii) the applicable Third Party Volume Estimate for such Subsystem and Quarter contained in the then-currently agreed Development Plan. 

(b) Notwithstanding the foregoing and regardless of the Tariff Volume Estimates and the Third Party Volume Estimates with respect to any such
Subsystem and Quarter included in any Updated Development Plan thereafter, the MVC for such Quarter and Subsystem contained in any prior Development Plan shall not be reduced by such Updated Development Plan (but the applicable MVC volumes may be
increased). 

  
 16 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (c) Should any Dedicated Production be released (either permanently or temporarily) from the
dedication contained in this Agreement pursuant to Section 4.4, the then-applicable MVC shall be proportionately reduced by the portion of the then-current Tariff Volume Estimate and/or Third Party Volume Estimate (as
applicable) so released. Should any such temporary release from dedication expire, then, upon such expiration, the then-applicable MVC shall be proportionately increased by the portion of the applicable Dedicated Production Estimate that is no
longer released from dedication hereunder. 
 (d) Notwithstanding anything herein to the contrary, with respect to all periods prior to
January 1, 2017, the definition of “MVC” contained in the Original Agreement and the MVC mechanisms contained in Section 6.1 of the Original Agreement shall, in each case, remain applicable hereunder. 

(e) Notwithstanding anything herein to the contrary, with respect to all periods after January 1, 2017 and prior to January 1, 2019,
the definition of “MVC” and the MVC mechanisms contained in Section 6.1 of the A&R Agreement shall, in each case, remain applicable hereunder. 

Section 6.2 MVC Shortfall Credits. If Shipper pays any Shortfall Fee with respect to any Quarter in the Secondary Term applicable
to the Subsystem to which such Shortfall Fee relates or thereafter, then, subject to the other provisions of this Section 6.2, for a period of four full Quarters from the end of the Quarter in which such Shortfall Fee was
accrued, Shipper shall be entitled to a credit with respect to the Combined Gathering Fees payable by Shipper during any such Quarter in connection with volumes of Shipper Gas Tendered by Shipper or for Shipper’s account into the Receipt Points
attributable to the applicable Subsystem for which such Shortfall Fee was incurred during any such Quarter, but only to the extent such volumes are in excess of the aggregate Dedicated Production Estimate for such Subsystem and such Quarter (each
such volume credit, stated in Mcfs, a “MVC Shortfall Credit”). 
 (a) During any subsequent Quarter in which an
earned MVC Shortfall Credit may be utilized by Shipper, Shipper may only utilize such MVC Shortfall Credit for volumes of Shipper Gas delivered into the applicable Subsystem in excess of the aggregate Dedicated Production Estimate for such Subsystem
and such Quarter as contained in the then-currently agreed Development Plan. 
 (b) The use of a MVC Shortfall Credit shall result in
Shipper not being obligated to pay any Combined Gathering Fee attributable to volumes of Shipper Gas, stated in Mcfs, delivered into the Receipt Points applicable to such Subsystem, but only up to the amount of such MVC Shortfall Credit and only
with respect to volumes of Shipper Gas in excess of the aggregate Dedicated Production Estimate for such Subsystem and such Quarter as contained in the then-currently agreed Development Plan. 

(c) Each MVC Shortfall Credit shall expire at the end of the fourth full Quarter following the date on which the applicable Shortfall Fee was
accrued. 

  
 17 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (d) Gatherer shall be responsible for keeping records and balances of any applicable MVC
Shortfall Credits that have been earned by Shipper and providing such balances to Shipper upon Shipper’s request. 
 (e) The Parties
agree that, as of December 31, 2016, there were no outstanding “MVC Shortfall Credits” (as such term is defined in the Original Agreement), and any such amounts that (i) had accrued on or prior to December 31, 2016 pursuant
to the Original Agreement, but (ii) were not utilized by Shipper hereunder with respect to Shipper Gas Tendered to the Gathering System prior to December 31, 2016, shall be of no further force and effect and shall not be given any
application hereunder. Notwithstanding anything herein to the contrary but subject to the first sentence of this Section 6.2(e), with respect to all periods prior to January 1, 2017, the definition of “MVC
Shortfall Credits” contained in the Original Agreement and the MVC Shortfall Credit mechanisms contained in Section 6.2 and elsewhere of the Original Agreement shall, in each case, remain applicable hereunder. 

ARTICLE 7 
 FEES;
CHARGES; DEDUCTIONS 
 Section 7.1 Fees. The Fees to be paid by Shipper to Gatherer for the performance of the System
Services are set forth in this Section 7.1. 
 (a) Subject to the provisions of
Section 6.2 (but only with respect to periods prior to January 1, 2017 and only with respect to the Secondary Term applicable to each Subsystem thereafter), each Month, beginning in Year 2019, Shipper shall pay to
Gatherer the following fees in accordance with the terms of this Agreement for the Gathering Services provided by Gatherer with respect to Shipper Gas and Shipper Injected Liquids received by Gatherer from Shipper or for Shipper’s account
during such Month: 
 (i) with respect to Shipper Gas and Shipper Injected Liquids received into a Receipt Point (including
an Injection Point, in the case of Shipper Injected Liquids) on the Goliath Subsystem: (A) the aggregate volume of Shipper Gas and Shipper Injected Liquids received by Gatherer from Shipper or for Shipper’s account at the applicable
Receipt Points during such Month, stated in Mcfs or MCFE, as applicable, multiplied by (B) the Combined Goliath Gathering Fee; 

(ii) with respect to Shipper Gas and Shipper Injected Liquids received into a Receipt Point (including an Injection Point, in
the case of Shipper Injected Liquids) on the Hawkeye Subsystem: (A) the aggregate volume of Shipper Gas and Shipper Injected Liquids received by Gatherer from Shipper or for Shipper’s account at the applicable Receipt Points during such
Month, stated in Mcfs or MCFE, as applicable, multiplied by (B) the Combined Hawkeye Gathering Fee; and 

  
 18 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (iii) with respect to Shipper Gas and Shipper Injected Liquids received into
a Receipt Point (including an Injection Point, in the case of Shipper Injected Liquids) on the Red Sky Subsystem: (A) the aggregate volume of Shipper Gas and Shipper Injected Liquids received by Gatherer from Shipper or for Shipper’s
account at the applicable Receipt Points during such Month, stated in Mcfs or MCFE, as applicable, multiplied by (B) the Combined Red Sky Gathering Fee. 

For the avoidance of doubt and notwithstanding anything in the foregoing to the contrary, in no event shall any MCFE of Shipper Injected Liquids be charged a
Gathering Fee if (x) such volume of Shipper Injected Liquids was redelivered to Shipper by Gatherer at a Drip Point as Drip Liquids (as the applicable Delivery Point for such Drip Liquids) pursuant to Section 3.3 and
(y) such Drip Liquids are later Tendered by Shipper or for Shipper’s account for reinjection into the Gathering System at an Injection Point. 

(b) Each Month, beginning in Year 2019, Shipper shall pay to Gatherer the following fees in accordance with the terms of this Agreement for
the Compression Services provided by Gatherer solely with respect to Shipper Gas which constitutes Tariff Volumes received by Gatherer from Shipper or for Shipper’s account during such Month: 

(i) with respect to Shipper Gas utilizing Compression Services on the Goliath Subsystem: (A) the aggregate volume of
Shipper Gas utilizing Compression Services on the Goliath Subsystem during such Month, stated in Mcfs, multiplied by (B) the Goliath Compression Fee; 

(ii) with respect to Shipper Gas utilizing Compression Services on the Hawkeye Subsystem: (A) the aggregate volume of
Shipper Gas utilizing Compression Services on the Hawkeye Subsystem during such Month, stated in Mcfs, multiplied by (B) the Hawkeye Compression Fee; and 

(iii) with respect to Shipper Gas utilizing Compression Services on the Red Sky Subsystem: (A) the aggregate volume of
Shipper Gas utilizing Compression Services on the Red Sky Subsystem during such Month, stated in Mcfs, multiplied by (B) the Red Sky Compression Fee. 

For the avoidance of doubt, in no event shall any Mcf of Shipper Gas be charged more than one Compression Fee for the utilization by such Mcf of Gas of the
Compression Services. 
 (c) For any Quarter, beginning in Year 2019, should Shipper fail to Tender an aggregate volume of Shipper Gas to
Gatherer at the Receipt Points for any Subsystem equal to the Goliath MVC, the Hawkeye MVC or the Red Sky MVC, as applicable, for such Quarter, then Shipper shall pay to Gatherer the following fees in accordance with the terms of this Agreement as a
result of such shortfall (such fee, a “Shortfall Fee”): (i) (A) the then-applicable MVC for such Subsystem, minus (B) the aggregate volumes, stated in Mcfs, of Shipper Gas actually delivered into such
Subsystem at the applicable Receipt Points by Shipper or for Shipper’s account during such Quarter, minus (C) the aggregate volumes, stated in Mcfs, of Dedicated Production Tendered for delivery by Shipper or on Shipper’s
account into such Subsystem at the applicable Receipt 

  
 19 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
Points during such Quarter but not received into the Gathering System by Gatherer due to reasons of Force Majeure or curtailment, minus (D) the aggregate volumes, stated in Mcfs, of
Dedicated Producer Gas not Tendered for delivery by Shipper or on Shipper’s account into such Subsystem at the applicable Receipt Points during such Quarter due to reasons of a Force Majeure event affecting Shipper that Gatherer has accepted as
a Force Majeure event hereunder, multiplied by (ii) (A) the Combined Gathering Fee applicable to such Subsystem, plus (B) the Compression Fee applicable to such Subsystem. 

(d) Beginning in Year 2019, if the aggregate Tariff Volume Estimate with respect to any Subsystem contained in any Updated Development Plan is
at least 15% greater than the aggregate Tariff Volume Estimate contained in the most recent, previously agreed-upon Development Plan, then Gatherer shall have the right, at its sole discretion, to elect to permanently increase the Return on Capital
by two percent (2%) for each 15% increase represented by such aggregate increased Tariff Volume Estimate. Such right must be exercised by Gatherer prior to the start of the Year to which such Updated Development Plan that triggered the provisions of
this Section 7.1(d) first applies, and absent such exercise by Gatherer such right to increase the Return on Capital shall be deemed waived by Gatherer. 

(e) (x) at any time on or prior to January 15th of each Year, either Party may make an
election to have the then-currently agreed Fees recalculated with respect to such Year (a “Recalculation Election”); provided, that, prior to the date such Recalculation Election is made, the Parties shall have agreed upon an
Updated Development Plan for such Year or the Parties shall have been unable to agree upon an Updated Development Plan for such Year, and (y) Shipper shall have the right, in accordance with Section 4.4(a)(i), to make
a temporary Recalculation Election with respect to the remainder of the current Year. Upon a Recalculation Election being made pursuant to this Section 7.1(e), the Fees will be recalculated based upon such then-currently
agreed Development Plan. Any such recalculation shall be based on the model attached hereto as Exhibit G-2, which takes into account: 

(i) (A) the aggregate Tariff Volumes contained in a Dedicated Production Estimate that have actually been delivered by Shipper
into the Receipt Points, in each case, prior to such Year during the Term applicable to the relevant Subsystem, and (B) with respect to Recalculation Elections related to the Fees for Year 2019 and thereafter, the aggregate Third Party Volumes
contained in a Third Party Volume Estimate that have actually been delivered by Shipper into the Receipt Points, in each case, prior to such Year during the Term applicable to the relevant Subsystem; provided, however, that such Tariff Volumes and
Third Party Volumes, in the aggregate, shall not, for purposes of the recalculation (1) exceed the applicable Dedicated Production Estimates for such Years as contained in the applicable Development Plans or (2) be deemed to be lower than
the applicable MVC for such Years as contained in the applicable Development Plans; 
 (ii) any Committed Build-Out Costs actually incurred by Gatherer prior to such Year during the Term applicable to the relevant Subsystem, regardless whether or not such amounts are less than, equal to or greater than the applicable
Committed Build-Out Estimates for such Years; 

  
 20 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (iii) the Committed Build-Out
Estimates contained in the then-current System Budget for the current and future Years; 
 (iv) the Maintenance Capital
Estimates (A) for the previous Years of the Term applicable to the relevant Subsystem as contained in the System Budgets applicable to such Years, and (B) contained in the then-current System Budget for the current and future Years; 

(v) the Operating Expense Estimates (A) for the previous Years of the Term applicable to the relevant Subsystem as
contained in the System Budgets applicable to such Years, and (B) contained in the then-current System Budget for the current and future Years; 

(vi) the Historical Capital Expenditures; 

(vii) the System Production Estimates; 

(viii) the then-current Return on Capital; 

(ix) subject to the terms of Exhibit G-2, all (or, as applicable, only the
applicable portion thereof that is necessary in order for Gatherer to provide the System Services contemplated by the applicable Development Plan and System Plan, as such portion is agreed by Gatherer and Shipper at the time of the applicable System
Acquisition) System Acquisition Costs actually incurred by Gatherer or its Affiliates prior to such Year during the Term applicable to the relevant Subsystem, regardless whether or not such amounts are less than, equal to or greater than the
applicable System Acquisition Costs Estimates for such Years; 
 (x) subject to the terms of Exhibit G-2, all (or, as applicable, only the applicable portion thereof that is necessary in order for Gatherer to provide the System Services contemplated by the applicable Development Plan and System Plan, as such
portion is agreed by Gatherer and Shipper at the time of the applicable System Acquisition) System Acquisition Costs Estimates contained in the then-current System Budget for the current and future Years; and 

(xi) the percentage change, from the preceding Year, in the Consumer Price Index as published by the Department of Labor, in
the subsection titled “Consumer Price Index for All Urban Consumers” (such index, the “CPI”). For purposes of any Recalculation Election and notwithstanding anything in the foregoing to the contrary, (A) no
increase or decrease to any Fee resulting solely from a CPI adjustment shall exceed 3.0% for any given Year, and (B) no Fee shall ever be decreased as a result of any applicable CPI percentage change below the original amount of such Fee as set
forth in Exhibit G-1 to the Original Agreement for Year 2014. 

  
 21 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (f) Except as set forth in Section 4.4(a)(i), any Fees recalculated
under Section 7.1(e) shall apply as of January 1st of the Year to which the relevant Updated Development Plan leading to such Recalculation Election first applies, and
shall remain in effect for the remainder of the Term applicable to the relevant Subsystem until such Fees may subsequently be re-calculated pursuant to Section 7.1(e). 

(g) For the avoidance of doubt, the Parties acknowledge that there is no separate Fee chargeable by Gatherer hereunder for System Services
with respect to Drip Liquids (including any Drip Liquids that are subsequently reinjected into the Gathering System by Shipper as Shipper Injected Liquids) and that the Fees chargeable by Gatherer hereunder for Gas are sufficient to compensate
Gatherer for System Services with respect to any Drip Liquids allocated to Shipper in accordance with this Agreement. 
 (h) Following any
(i) Recalculation Election made pursuant to Section 7.1(e), (ii) determination of any Fee pursuant to Section 7.1(i) (once such Section of this Agreement becomes applicable hereunder), or
(iii) other agreement by the Parties upon any changes to any Fee hereunder, whether such changes are agreed pursuant to an agreed Updated Development Plan and related updated Gathering System Plan or otherwise, in each case, the Parties shall
update Exhibit G-1 to reflect such updated Fee amount(s). 
 (i) Notwithstanding anything in
this Agreement to the contrary, effective as of the first Year of the Secondary Term applicable to each Subsystem: 
 (i)
each of the Tariff Gathering Fee and Compression Fee applicable to such Subsystem hereunder shall be recalculated for each Year, effective as of January 1 of each Year, in accordance with the provisions of Exhibit G-3 attached hereto; and 
 (ii) the provisions of
Section 5.2(b)(v), Section 7.1(d), Section 7.1(e) and Section 7.1(f) shall no longer be applicable to the System Services to be provided on such
Subsystem hereunder and, to the extent and only to the extent as it applies to such Subsystem, such Sections shall be disregarded for all purposes of this Agreement. 

(j) Notwithstanding anything herein to the contrary, with respect to all periods prior to January 1, 2017, the definition of
“Fee” and its constituent sub-definitions contained in the Original Agreement and the Fee mechanisms set forth in Section 7.1(a) through 7.1(i) of the Original Agreement shall, in each case,
remain applicable hereunder with respect to the System Services provided prior to January 1, 2017. 
 (k) Notwithstanding anything
herein to the contrary, with respect to all periods after January 1, 2017 and prior to January 1, 2019, the definition of “Fee” and its constituent sub-definitions contained in the A&R
Agreement and the Fee mechanisms set forth in Section 7.1(a) through 7.1(i) of the A&R Agreement shall, in each case, remain applicable hereunder with respect to the System Services provided during such period. 

  
 22 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 7.2 Charges. Each Month, Shipper shall pay to Gatherer an amount equal to
Shipper’s allocated portion of the actual costs incurred by Gatherer for electricity required for the ownership, maintenance and operation of each Subsystem, such allocation to be based upon the aggregate volumes of (a) Shipper Gas and
Shipper Injected Liquids Tendered by Shipper at the applicable Receipt Points and received by Gatherer into such Subsystem during such Month, and (b) Non-Party Gas and
Non-Party Injected Liquids other than Shipper Gas and Shipper Injected Liquids tendered by a Non-Party at the applicable Receipt Points and received by Gatherer into
such Subsystem during such Month; provided, that costs for electricity required for compression will be allocated proportionately among only that Shipper Gas and Non-Party Gas that requires the use of such
compression (such amount as allocated to Shipper for a Month, the “Charges”). 
 Section 7.3 Flaring. In
the event that (a) any volume of Shipper Gas is flared after being delivered into the Gathering System, and (b) (i) such flaring was caused by the Operational Failure of the Gathering System or by the gross negligence or willful misconduct
of Gatherer, then Shipper shall (A) nevertheless be entitled to count such flared volumes of Shipper Gas as having been Tendered to the Gathering System for purposes of meeting any applicable MVC, and (B) shall not be required to pay any
applicable Fees with respect to such flared volumes of Shipper Gas, such volumes of Gas for which Shipper is not obligated to pay Fees to be reflected in the applicable Invoice for such Month, or (ii) such flaring was caused by any other
reason, then Shipper shall not be entitled to any credit or other reduction in Fees as a result of such flaring. Notwithstanding the above, the Parties shall use their commercially reasonable efforts to minimize overall flaring on the Gathering
System. 
 Section 7.4 Gathering System L&U. Shipper acknowledges that certain volumetric losses of Shipper Gas and Shipper
Injected Liquids will occur even if the System Services are conducted in accordance with the provisions of Section 3.2, and such losses attributable to Gathering System L&U shall be shared and allocated among all
shippers on each Subsystem in the proportion that each such shipper Tenders Gas and Injected Liquids to the applicable Receipt Points on such Subsystem. Shipper’s allocated share of the Gathering System L&U for each Subsystem shall be based
on actual losses attributable to Gathering System L&U on such Subsystem and shall not be subject to any minimum or maximum limits. 

Section 7.5 Gathering System Fuel. Reductions in volumes of Shipper Gas due to the usage of Shipper Gas as measured Gathering
System Fuel shall be shared and allocated among all shippers on each Subsystem in the proportion that each such shipper Tenders Gas to the applicable Receipt Points on such Subsystem. Shipper’s allocated share of the Gathering System Fuel for
each Subsystem shall be based on actual usage of Gathering System Fuel on such Subsystem and shall not be subject to any minimum or maximum limits. For the avoidance of doubt, no residue gas utilized as fuel for the operation of the Gathering System
shall be allocated to shippers on the Gathering System (including Shipper) and no shipper’s Gas volumes on the Gathering System (including Shipper’s) shall be reduced as a result of utilizing any such residue gas as fuel for the operation
of the Gathering System. 

  
 23 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 7.6 Drip Liquids. All Drip Liquids recovered at the Drip Points by
Gatherer through the operation of the Gathering System and allocated to Shipper in accordance with this Agreement shall be the property of Shipper, and Gatherer shall have no claim of ownership with respect thereto. 

ARTICLE 8 
 TENDER,
NOMINATION AND GATHERING OF PRODUCTION 
 Section 8.1 Priority of Service. 

(a) All Dedicated Production Tendered to the Receipt Points shall, up to an aggregate volume of **% of the then-current total capacity of each
Subsystem, be entitled to Anchor Shipper Firm Service. 
 (b) All Additional Gas shall, only to the extent such volumes of Additional Gas
(together with all quantities of Dedicated Production Tendered to the applicable Subsystem) are both (i) needed by Shipper to fulfill the then-applicable MVC for such Subsystem, and (ii) less than or equal to **% of the then-current total
capacity of such Subsystem, be entitled to Anchor Shipper Firm Service. 
 (c) All Additional Gas and Shipper Injected Liquids shall, to the
extent such volumes of Additional Gas and Shipper Injected Liquids (together with all other quantities of Shipper Gas and Shipper Injected Liquids Tendered to the applicable Subsystem, including any Dedicated Production) are in excess of the
then-applicable MVC for such Subsystem, but less than or equal to **% of the then-current total capacity of such Subsystem, be entitled to Firm Service. 

(d) All Additional Gas and Shipper Injected Liquids not described in subsections (b) through (c) above shall only be entitled to
Interruptible Service. 
 Section 8.2 Governmental Action. In the event any Governmental Authority issues an order requiring
Gatherer to allocate capacity on the Gathering System to another shipper, Gatherer shall do so by (a) first, reducing Gas and/or Injected Liquids, as applicable, entitled to Interruptible Service, (b) second, reducing Gas
and/or Injected Liquids, as applicable, entitled to Firm Service, and shall only curtail receipts of Gas and/or Injected Liquids, as applicable, entitled to Firm Service (which curtailment shall be done in accordance with
Section 8.5) to the extent necessary to allocate such capacity as required by the Governmental Authority to such other shipper, after complete curtailment of Interruptible Service, and (c) third, reducing Gas
entitled to Anchor Shipper Firm Service, and shall only curtail receipts of Gas entitled to Anchor Shipper Firm Service (which curtailment shall be done in accordance with Section 8.5) to the extent necessary to allocate
such capacity as required by the Governmental Authority to such other shipper, after complete curtailment of Interruptible Service and Firm Service. In such event 

  
 24 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
Gatherer shall not be in breach or default of its obligations under the Agreement and shall have no liability to Shipper in connection with or resulting from any such curtailment; provided,
however, that Gatherer shall, at Shipper’s request, temporarily release from the dedication under this Agreement all of Shipper’s volumes of Dedicated Production interrupted or curtailed as the result of such allocation, but only for the
duration of such mandated allocation. Notwithstanding the foregoing, should any Governmental Authority issue an order requiring Gatherer to allocate capacity on the Gathering System to a shipper other than Shipper, Gatherer agrees to use its
commercially reasonable efforts to cooperate with, and support, Shipper in such actions that Shipper may in good faith take against such Governmental Authority and/or order; provided, however, that Gatherer shall not be required to cooperate in any
such undertaking that Gatherer, in its good faith opinion, believes would materially and adversely affect Gatherer or the Gathering System. 

Section 8.3 Tender of Dedicated Production; Additional Gas and Shipper Injected Liquids. Subject to Article 14 and
all applicable Laws, each Day during the Term applicable to each Subsystem Shipper shall Tender to the Gathering System at each applicable Receipt Point all of the Dedicated Production available to Shipper at such Receipt Point up to the applicable
capacity of such Receipt Point. Shipper shall have the right to Tender to Gatherer for System Services under this Agreement Additional Gas and Shipper Injected Liquids; provided that, subject to Section 8.1, any such
Additional Gas and Shipper Injected Liquids shall only be entitled to Interruptible Service unless otherwise agreed in writing by the Parties. 

Section 8.4 Nominations, Scheduling and Curtailment. Nominations and scheduling of Gas and Injected Liquids available for,
and interruptions and curtailment of, System Services under this Agreement shall be performed in accordance with the applicable Operating Terms set forth in Appendix I. 

Section 8.5 Suspension/Shutdown of Service. 

(a) During any period when all or any portion of the Gathering System is shut down because of necessary maintenance, repairs or modifications
or Force Majeure or because such shutdown is necessary to avoid injury or harm to persons, property, the environment, or the integrity of the Gathering System, receipts and/or deliveries of Gas (including any Drip Liquids allocated to Shipper in
accordance with this Agreement) and/or Injected Liquids may be curtailed as set forth in Section 1.5 of the Operating Terms. In such cases, Gatherer shall have no liability to Shipper, except to the extent such shut down is
caused by the gross negligence or willful misconduct of Gatherer (and then Gatherer shall have liability only to the extent of such gross negligence or willful misconduct). 

(b) Gatherer shall have the right to curtail or interrupt receipts and deliveries of Gas (including any Drip Liquids allocated to any shipper
in accordance with this Agreement) and/or Injected Liquids for brief periods to perform necessary maintenance of and repairs or modifications to (including modifications required to perform its obligations under this Agreement) the Gathering System;
provided, however, that Gatherer shall use its commercially reasonable efforts 

  
 25 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
to (i) coordinate its maintenance, repair, and modification operations on the Gathering System with the operations of Shipper and (ii) schedule maintenance, repair, and modification
operations on the Gathering System so as to avoid or minimize, to the greatest extent possible, service curtailments or interruptions on the Gathering System. Gatherer shall provide Shipper with (A) 30 Days prior Notice of any upcoming normal and
routine maintenance, repair, and modification projects that Gatherer has planned that would result in a curtailment or interruption of Shipper’s deliveries of Gas (including any Drip Liquids allocated to Shipper in accordance with this
Agreement) and/or Injected Liquids on the Gathering System and the estimated time period for such curtailment or interruption, whether or not such maintenance, repair or modifications activities are contained in the then-current System Budget, and
(B) Notice of any amendment, modification or other change to the schedule of maintenance, repair or modifications activities contained in the then-current System Budget. 

(c) It is specifically understood by Shipper that operations and activities on facilities upstream or downstream of the Gathering System
beyond Gatherer’s control may impact operations on the Gathering System, and the Parties agree that Gatherer shall have no liability therefor unless any such impact was caused by the gross negligence or willful misconduct of Gatherer (and then
Gatherer shall have liability only to the extent of such gross negligence or willful misconduct). Shipper is required to obtain, maintain or otherwise secure capacity on or into the Downstream Facilities applicable to each Delivery Point that is
sufficient to accommodate the volumes of Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids, as applicable, that were nominated by Shipper to such Delivery Points. Notwithstanding
the provisions of Section 8.6, should Shipper fail to arrange such adequate downstream transportation, Gatherer may (i) cease receipts of Shipper Gas and/or Shipper Injected Liquids at the Receipt Points, or
(ii) may continue receipts of Shipper Gas and/or Shipper Injected Liquids at the Receipt Points and then deliver and sell any such Shipper Gas (including any Drip Liquids allocated to such Shipper Gas in accordance with this Agreement) and/or
Shipper Injected Liquids to any purchaser at its sole discretion, accounting to Shipper for the net value received from the sale of such Gas (after costs of transportation, taxes, and other costs of marketing). 

(d) If at any time Gatherer interrupts or curtails receipts and deliveries of Gas and/or Injected Liquids pursuant to this
Section 8.5 (other than Section 8.5(c)) for a period of 30 consecutive Days, then, at Shipper’s written request, the affected volumes of Dedicated Production shall be temporarily released from
dedication to this Agreement for a period commencing as of the date of such request and ending as of the next first Day of a Month following the expiration date of Shipper’s mitigating commercial arrangement for such Dedicated Production;
provided that, in any event, such period shall end no more than 180 Days following Shipper’s receipt of Notice from Gatherer that such receipts and deliveries are no longer interrupted or curtailed. 

Section 8.6 Gas Marketing and Transportation. As between the Parties, Shipper shall be solely responsible for, and shall make all
necessary arrangements at and downstream of the Delivery Points for, receipt, further transportation, processing, and marketing of Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and Shipper Injected
Liquids. 

  
 26 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 8.7 Downstream Delivery Points. Gatherer shall use its commercially
reasonable efforts to maintain, and shall act as a reasonable and prudent operator in maintaining, all interconnect and operating agreements with Non-Parties reasonably necessary to facilitate the re-delivery of Shipper Gas and Shipper Injected Liquids to Shipper at the Delivery Points. 
 ARTICLE 9

 QUALITY AND PRESSURE SPECIFICATIONS 

Section 9.1 Quality Specifications. Each (x) Mcf of Gas delivered at the Receipt Points by Shipper to Gatherer shall meet the
quality specifications set forth in Section 1.1(a)(i) of the Operating Terms (as revised in accordance with Section 1.1(b) of the Operating Terms), and (y) each MCFE of Injected Liquids
delivered at the Injection Points by Shipper to Gatherer shall meet the quality specifications set forth in Section 1.1(a)(ii) of the Operating Terms (as revised in accordance with Section 1.1(b)
of the Operating Terms). Additionally, all Gas and Injected Liquids delivered at the Receipt Points by Shipper on any Day shall, collectively, meet the quality specifications set forth in Section 1.1(a)(iii) of the
Operating Terms (as revised in accordance with Section 1.1(b) of the Operating Terms). 
 (a) Provided that the
Shipper Gas and Shipper Injected Liquids delivered to the Receipt Points comply with each applicable quality specification set forth in Section 1.1 of the Operating Terms, all Gas (including any Drip Liquids allocated to
Shipper in accordance with this Agreement) and Injected Liquids that are redelivered at the Delivery Points by Gatherer to Shipper shall meet the quality specifications of the applicable Downstream Facilities at the relevant Delivery Points;
provided, however, that in the event any such quality specifications of the applicable Downstream Facilities change from and after the date of this Agreement, Gatherer’s obligations under this Section 9.1(a) shall be
subject to the provisions of Section 1.1(b) of the Operating Terms. 
 (b) The Parties recognize and agree that
all Shipper Gas and Shipper Injected Liquids gathered by Gatherer through the Gathering System may be commingled with other Gas and/or Injected Liquids volumes received and, subject to Gatherer’s obligation to redeliver to Shipper at the
Delivery Points Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids, as applicable, that satisfies the applicable quality specifications of the Delivery Points, (i) such Gas (including
any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids shall be subject to such changes in quality, composition and other characteristics as may result from such commingling, and (ii) Gatherer shall
have no other obligation to Shipper associated with changes in quality of Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) or Injected Liquids as the result of such commingling. 

  
 27 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 9.2 Pressure. Shipper shall Tender or cause to be Tendered Shipper Gas
and/or Shipper Injected Liquids, as applicable, to each applicable Receipt Point at sufficient pressure to enter the Gathering System against its contractual operating pressure, but not in excess of the maximum operating pressure for such Receipt
Point. Gatherer shall redeliver Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Shipper Injected Liquids at each applicable Delivery Point at pressures not in excess of the maximum operating
pressure for such Delivery Point. 
 (a) Shipper shall have the means to ensure that Shipper Gas and Shipper Injected Liquids are prevented
from entering the Gathering System at pressures in excess of the applicable maximum operating pressure, and Gatherer shall have the obligation and right to restrict the flow of Gas and Injected Liquids into the Gathering System to protect the
Gathering System from over pressuring. 
 (b) Gatherer’s obligation to redeliver Gas (including any Drip Liquids allocated to Shipper
in accordance with this Agreement) and/or Injected Liquids, as applicable, to a given Delivery Point shall, subject to Gatherer’s compliance with Section 8.7, be subject to the operational limitations of the Downstream
Facility receiving such Gas (or Drip Liquids) or Injected Liquids, including the Downstream Facility’s capacity, measurement capability, operating pressures and any operational balancing agreements as may be applicable. 

ARTICLE 10 
 TERMINATION

 Section 10.1 Termination. 

(a) This Agreement may be terminated in its entirety as follows: 

(i) by Gatherer upon written Notice to Shipper, if Shipper fails to pay pursuant to Section 12.2 any
Invoice rendered pursuant to Section 12.1 and such failure is not remedied within 30 Days of written Notice of such failure to Shipper by Gatherer; 

(ii) by one Party upon written Notice to the other Party, if such second Party fails to perform or comply with any material
warranty, covenant or obligation contained in this Agreement (other than (A) as provided above in Section 10.1(a)(i), (B) for reasons of Force Majeure in accordance with Article 14, or
(C) with respect to any material warranty, covenant or obligation contained in this Agreement for which this Agreement expressly sets forth a specific remedy or consequence (other than termination) as a result of any breach of, or failure to
comply with, such material warranty, covenant or obligation), and such failure has not been remedied within 60 Days after receipt of written Notice from the non-defaulting Party of such failure; 

  
 28 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (iii) by Gatherer upon written Notice to Shipper, if Shipper or Shipper
Parent (A) makes an assignment or any general arrangement for the benefit of creditors, (B) files a petition or otherwise commences, authorizes, or acquiesces in the commencement of a proceeding or cause under any bankruptcy or similar Law
for the protection of creditors or has such petition filed or proceeding commenced against either of them, or (C) otherwise becomes bankrupt or insolvent (however evidenced); 

(iv) by Gatherer upon written Notice to Shipper pursuant to the provisions of Section 15.4(c); and

 (v) by Gatherer upon written Notice to Shipper pursuant to the provisions of Section 18.2. 

(b) This Agreement may be terminated with respect to any Subsystem if such Subsystem is Uneconomic during any six consecutive Months, by
Gatherer upon written Notice to Shipper delivered within 180 Days following the end of such sixth consecutive Month. 
 (i)
As used herein, “Uneconomic” means that (A) the total direct operating costs and expenses incurred by Gatherer in the operation of such Subsystem (including general and administrative expenses, insurance costs and any
out of pocket repair and/or maintenance costs and expenses) exceeds (B) the total net revenues received by Gatherer for the operation of such Subsystem, all as determined in accordance with United States generally accepted accounting
principles. 
 (ii) Should Gatherer reasonably believe that any Subsystem will be Uneconomic for more than three consecutive
Months, Gatherer shall advise Shipper of such belief and shall provide Shipper with supporting documentation reasonably necessary to confirm such Uneconomic status. 

(iii) Promptly following Gatherer advising Shipper of such potential Uneconomic status, the Parties shall meet to discuss
Gatherer’s belief and related calculations and any measures that may be taken by the Parties to mitigate and/or reverse the Uneconomic status of such Subsystem. 

(iv) Should (A) the Parties fail to reach agreement upon any such appropriate mitigation measures prior to the date upon
which Gatherer would otherwise be entitled to terminate this Agreement pursuant to this Section 10.1(b), (B) the Parties reasonably believe that agreement upon such mitigation measures will nevertheless be possible, and
(C) Shipper makes Gatherer whole during any such Uneconomic periods occurring during such negotiation period such that, due to Shipper’s payment efforts, the operation of such Subsystem is not Uneconomic to Gatherer (whether through
Shipper paying of the operating costs of such Subsystem or otherwise), then for so long as subparts (B) and (C) of this Section 10.1(b)(iv) remain true, Gatherer shall not be entitled to exercise its termination rights
pursuant to this Section 10.1(b). 

  
 29 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (v) Upon the implementation of any such mitigating measures hereunder, should
(A) the Uneconomic condition cease to exist for three consecutive Months, and (B) the reversion of any such mitigating measures not be reasonably likely to cause such Uneconomic condition to return, then any terms of this Agreement
affected by such mitigating measures will revert back to the terms in effect prior to Gatherer’s declaration of Uneconomic status pursuant to this Section 10.1(b). 

Section 10.2 Effect of Termination or Expiration of the Term. 

(a) Upon the end of the Term with respect to any Subsystem (whether pursuant to a termination pursuant to
Section 10.1(a) or otherwise), this Agreement shall forthwith become void as to such Subsystem and the Parties shall have no liability or obligation under this Agreement, except that (i) the termination of this
Agreement (whether with respect to a single Subsystem or the entirety of the Gathering System) shall not relieve any Party from any expense, liability or other obligation or remedy therefor which has accrued or attached prior to the date of such
termination, and (ii) the provisions of Section 16.2 through Section 16.5, and Article 19 (other than Section 19.3), and such portions of Appendix II as
are necessary to give effect to the foregoing, shall, in each case, survive such termination and remain in full force and effect indefinitely with respect to such Subsystem. 

(b) Upon the termination of this Agreement with respect to any Subsystem (whether pursuant to Section 10.1(b) or
otherwise), this Agreement, shall, only with respect to such Subsystem, forthwith become void and the Parties shall have no liability or obligation under this Agreement with respect to such Subsystem, except that (i) the termination of this
Agreement with respect to such Subsystem shall not relieve any Party from any expense, liability or other obligation or remedy therefor which has accrued or attached prior to the date of such termination with respect to such Subsystem, and
(ii) the provisions of Section 16.2 through Section 16.5 shall survive such termination and remain in full force and effect indefinitely with respect to such Subsystem. 

Section 10.3 Damages for Early Termination. If a Party terminates this Agreement pursuant to
Section 10.1(a)(i), Section 10.1(a)(ii), Section 10.1(a)(iii), or Section 10.1(a)(v), then such terminating Party may pursue any and all remedies
at law or in equity for its claims resulting from such termination, subject to Section 16.4. 
 ARTICLE 11

 TITLE AND CUSTODY 

Section 11.1 Title. The act of Tendering Gas and/or Injected Liquids to the Receipt Points by Shipper shall be deemed a warranty
of title to such Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids by Shipper, or a warranty of the right of Shipper to deliver such Gas (including any Drip Liquids allocated to Shipper
in accordance with this Agreement) and/or Injected Liquids for gathering under this Agreement. By Tendering Gas and/or Injected Liquids for delivery into the Gathering System at the Receipt Point(s), Shipper also agrees to indemnify, defend and hold
Gatherer harmless from any and all Losses resulting from any claims by a Non-Party of title or rights to such Gas 

  
 30 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
(including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids, other than any claims arising out of Gatherer’s breach of its warranty made in
the succeeding sentence of this Section 11.1. By receiving Shipper Gas and/or Shipper Injected Liquids at the Receipt Points, Gatherer (a) warrants to Shipper that Gatherer has the right to accept and redeliver such
Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids, less any System Fuel and Losses, free and clear of any title disputes, liens or encumbrances arising by, through or under Gatherer, but
not otherwise, and (b) agrees to indemnify, defend and hold Shipper harmless from any and all Losses resulting from title disputes, liens or encumbrances arising by, through or under Gatherer, but not otherwise. Title to Shipper’s share of
System Fuel and Losses shall be transferred to Gatherer at the Receipt Points. 
 Section 11.2 Custody. From and after the
delivery of Shipper Gas and/or Shipper Injected Liquids to Gatherer at the Receipt Point(s), until Gatherer’s redelivery of such Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids to
or for Shipper’s account at the applicable Delivery Point(s), as between the Parties, Gatherer shall have custody and control of such Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected
Liquids. In all other circumstances, as between the Parties, Shipper shall be deemed to have custody and control of such Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Injected Liquids. 

ARTICLE 12 
 BILLING AND
PAYMENT 
 Section 12.1 Invoices. On or before the 25th Day of
each Month, Gatherer will render to Shipper an invoice, divided out on a Subsystem-by-Subsystem basis (each, an “Invoice”), for all Fees
(including the calculations thereof) owed for System Services provided to Shipper for the preceding Month, all Charges attributable to the preceding Month and any other amounts as may be due under this Agreement for the preceding Month, net of
(a) any deductions to which Shipper is entitled in respect of flaring in accordance with Section 7.3, and (b) any other credits or deductions to which Shipper is entitled hereunder, including any MVC Shortfall
Credit. Each Invoice shall also contain the volumes of all System Fuel and Losses allocated to Shipper with respect to each Subsystem in accordance with this Agreement. Gatherer shall include with each Invoice such information in its possession as
is reasonably sufficient to explain and support both the amounts due and any adjustments to amounts previously invoiced. 

Section 12.2 Payments. Unless otherwise agreed by the Parties, payments of amounts included in any Invoice delivered pursuant to
this Agreement shall be due and payable, in accordance with each Invoice’s instructions, on or before the later of (a) the last Day of each Month and (b) the date that is ten Business Days after Shipper’s receipt of the
applicable Invoice. All payments by Shipper under this Agreement shall be made by electronic funds transfer of immediately available funds to the account designated by Gatherer in the applicable Invoice. Any amounts not paid by the due date will be
deemed delinquent and will accrue interest at the Interest 

  
 31 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
Rate, such interest to be calculated from and including the due date but excluding the date the delinquent amount is paid in full. All Invoices shall be paid in full, but payment of any disputed
amount shall not waive the payor’s right to dispute the Invoice in accordance with this Section 12.2. Shipper may, in good faith (i) dispute the correctness of any Invoice or any adjustment to an Invoice rendered
under this Agreement or (ii) request an adjustment of any Invoice for any arithmetic or computational error, in each case, within 24 Months following the date on which the applicable Invoice (or adjustment thereto) was received by Shipper. Any
dispute of an Invoice by Shipper or Invoice adjustment requested by Shipper shall be made in writing and shall state the basis for such dispute or adjustment. Upon resolution of the dispute, any required payment shall be made within ten Business
Days of such resolution, along with interest accrued at the Interest Rate from and including the due date but excluding the date paid. 

Section 12.3 Audit. Each Party has the right, at its sole expense and during normal working hours, to examine the records of the
other Party to the extent reasonably necessary to verify the accuracy of any statement, charge or computation made pursuant to the provisions of this Agreement. The scope of such examination will be limited to the previous 24 Months calculated
following the end of the Month in which such Notice of audit, statement, charge or computation was presented. No Party shall have the right to conduct more than one audit during any Year. If any such examination reveals any inaccuracy in any
statement or charge, the necessary adjustments in such statement or charge and the payments necessitated thereby shall be made within ten Business Days of resolution of the inaccuracy. This Section 12.3 will survive any
termination of the Agreement for the later of (a) a period of 24 Months from the end of the Month in which the date of such termination occurred and (b) until a dispute initiated within such 24 Month period is finally resolved, in each
case for the purpose of such statement and payment objections. 
 ARTICLE 13 

REMEDIES 

Section 13.1 Suspension of Performance; Release from Dedication. 

(a) If Shipper fails to pay pursuant to Section 12.2 any Invoice rendered pursuant to
Section 12.1 and such failure is not remedied within five Business Days of written Notice of such failure to Shipper by Gatherer, Gatherer shall have the right to suspend performance under this Agreement until such
amount, including interest at the Interest Rate, is paid in full. 
 (b) In the event a Party fails to perform or comply with any material
warranty, covenant or obligation contained in this Agreement (other than as provided in Section 13.1(a)), and such failure has not been remedied within 30 Days after receipt of written Notice from the other Party of such
failure, then the non-defaulting Party shall have the right to suspend its performance under this Agreement. If Shipper elects to suspend performance as the result of Gatherer’s uncured material
default, then the Dedicated Production affected by such default shall be deemed to be temporarily released from the terms of this Agreement during the period of such suspension of performance. 

  
 32 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 13.2 No Election. In the event of a default by a Party under this
Agreement, the other Party shall be entitled in its sole discretion to pursue one or more of the remedies set forth in this Agreement, or such other remedy as may be available to it under this Agreement, at Law or in equity, subject, however, to the
limitations set forth in Article 16. No election of remedies shall be required or implied as the result of a Party’s decision to avail itself of any remedy under this Agreement. 

ARTICLE 14 
 FORCE
MAJEURE 
 Section 14.1 Events of Force Majeure. An event of “Force Majeure” means, an event that
(a) is not within the reasonable control of the Party claiming suspension (the “Claiming Party”), (b) that prevents the Claiming Party’s performance or fulfillment of any obligation of the Claiming Party under this
Agreement (other than the payment of money), and (c) that by the exercise of due diligence the Claiming Party is unable to avoid or overcome in a reasonable manner. An event of Force Majeure includes, but is not restricted to: (i) acts of
God; (ii) wars (declared or undeclared); (iii) insurrections, hostilities, riots, industrial disturbances, blockades or civil disturbances; (iv) epidemics, landslides, lightning, earthquakes, washouts, floods, fires, storms or storm
warnings; (v) acts of a public enemy, acts of terror, or sabotage; (vi) explosions, breakage or accidents to machinery or lines of pipe; (vii) hydrate obstruction or blockages of any kind of lines of pipe; (viii) freezing of
wells or delivery facilities, partial or entire failure of wells, and other events beyond the reasonable control of Shipper that affect the timing of production or production levels; (ix) mining accidents, subsidence, cave-ins and fires; and (x) action or restraint by any Governmental Authority (so long as the Claiming Party has not applied for or assisted in the application for, and has opposed where and to the extent
reasonable, such action or restraint). Notwithstanding anything herein to the contrary, an event of Force Majeure specifically excludes the following occurrences or events: (A) the loss, interruption, or curtailment of interruptible
transportation on any Downstream Facility necessary to take delivery of Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Shipper Injected Liquids at any Delivery Point, unless and only to the
extent the same event also curtails firm transportation at the same Delivery Point; (B) increases or decreases in Shipper Gas and/or Shipper Injected Liquids supply (other than any such increase or decrease caused by the actions described in
subpart (x) above), allocation or reallocation of Shipper Gas and/or Shipper Injected Liquids production by the applicable well operators; (C) loss of markets; (D) loss of supply of equipment or materials; (E) failure of
specific, individual wells or appurtenant facilities in the absence of an event of Force Majeure broadly affecting other wells in the same geographic area; and (F) price changes due to market conditions with respect to the purchase or sale of
Gas and/or Injected Liquids gathered hereunder or the economics associated with the delivery, connection, receipt, gathering, compression, dehydration, treatment, processing or redelivery of such Gas and/or Injected Liquids. 

  
 33 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 14.2 Actions. If either Gatherer or Shipper is rendered unable by an
event of Force Majeure to carry out, in whole or part, its obligations under this Agreement and such Claiming Party gives Notice and reasonably full details of the event to the other Party as soon as practicable after the occurrence of the event,
then, during the pendency of such Force Majeure, but only during that period, the obligations of the Claiming Party shall be canceled or suspended, as applicable, to the extent required; provided, however, that notwithstanding anything in the
foregoing to the contrary, neither Party shall be relieved from any indemnification obligation or any obligation to make any payments hereunder as the result of Force Majeure, regardless which Party is affected. The Claiming Party shall use
commercially reasonable efforts to remedy the Force Majeure condition with all reasonable dispatch, shall give Notice to the other Party of the termination of the Force Majeure, and shall resume performance of any suspended obligation promptly after
termination of such Force Majeure. If the Claiming Party is Shipper and such Force Majeure is an event affecting a Delivery Point (but not all Delivery Points), such commercially reasonable efforts shall require, to the extent of capacity available
to Shipper at the applicable Downstream Facilities, Shipper to nominate Shipper Gas and/or Shipper Injected Liquids for redelivery at those Delivery Points not affected by such Force Majeure. For the avoidance of doubt, if and to the extent Gatherer
is delayed in completing any Committed Build-Outs or System Acquisitions by a Force Majeure event, then the Target Completion Date applicable thereto shall be extended for a period of time equal to that during which such obligations of Gatherer were
delayed by such events. 
 Section 14.3 Strikes, Etc. The settlement of strikes or lockouts shall be entirely within the
discretion of the Claiming Party, and any obligation hereunder to remedy a Force Majeure event shall not require the settlement of strikes or lockouts by acceding to the demands of the opposing Person(s) when such course is inadvisable in the sole
discretion of the Claiming Party. 
 ARTICLE 15 

REPRESENTATIONS AND COVENANTS 

Section 15.1 Party Representations. 

(a) Each Party represents and warrants to the other Party as follows: (i) there are no suits, proceedings, judgments, or orders by or
before any Governmental Authority that materially adversely affect (A) its ability to perform its obligations under this Agreement or (B) the rights of the other Parties hereunder, (ii) it is duly organized, validly existing, and in
good standing under the Laws of the jurisdiction of its formation, and it has the legal right, power and authority and is qualified to conduct its business, and to execute and deliver this Agreement and perform its obligations hereunder,
(iii) the making and performance by it of this Agreement is within its powers, and have been duly authorized by all necessary action on its part, (iv) this Agreement constitutes a legal, valid, and binding act and obligation of it,
enforceable against it in accordance with its terms, subject to bankruptcy, insolvency, reorganization and other Laws affecting creditors’ rights generally, and with regard to equitable remedies, to the discretion of the court before which
proceedings to obtain same may be pending, and (v) there are no bankruptcy, insolvency, reorganization, receivership or other arrangement proceedings pending or being contemplated by it. 

  
 34 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (b) Shipper represents and warrants to Gatherer that, during the Term applicable to each
Subsystem, Shipper has the sole and exclusive right to purchase all Gas owned or Controlled by Producer and produced from those oil and gas properties located in the Dedicated Area that are operated by Producer, or that are not operated by Producer,
but from which Producer has elected to take its applicable production in-kind (such right, collectively, the “Exclusive Producer Purchase Right”). 

Section 15.2 Joint Representations. Shipper and Gatherer jointly acknowledge and agree that (a) the movement of Shipper Gas
(including any Drip Liquids allocated to Shipper in accordance with this Agreement) and Shipper Injected Liquids on the Gathering System under this Agreement constitutes (and is intended to constitute for purposes of all applicable Laws) a movement
of Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) or Shipper Injected Liquids, in each case, that is not subject to the jurisdiction of the Federal Energy Regulatory Commission pursuant to the Natural
Gas Act or Section 311 of the Natural Gas Policy Act, (b) the Fees have been freely negotiated and agreed upon as a result of good faith negotiations and are not discriminatory or preferential, but are just, fair, and reasonable in light
of the Parties’ respective covenants and undertakings herein during the term of this Agreement, and (c) neither Shipper nor Gatherer had an unfair advantage over the other during the negotiation of this Agreement. 

Section 15.3 Applicable Laws. This Agreement is subject to all valid present and future Laws, regulations, rules and orders of
Governmental Authorities now or hereafter having jurisdiction over the Parties, this Agreement, or the System Services performed under this Agreement or the Gathering System and other facilities utilized under this Agreement. 

Section 15.4 Government Authority Modification. It is the intent of the Parties that the rates and terms and conditions
established by any Governmental Authority having jurisdiction shall not alter the rates or terms and conditions set forth in this Agreement. If any Governmental Authority having jurisdiction modifies the rates or terms and conditions set forth in
this Agreement, then (in addition to any other remedy available to the Parties at Law or in equity): 
 (a) the Parties hereby agree to
negotiate in good faith to enter into such amendments to this Agreement and/or a separate arrangement in order to give effect, to the greatest extent possible, to the rates and other terms and conditions set forth in this Agreement; 

(b) the Parties agree to vigorously defend and support in good faith the enforceability of the rates and terms and conditions of this
Agreement; and 
 (c) in the event that the Parties are not successful in accomplishing the objectives set forth in (a) and (b) above
such that, following the failure to accomplish such objectives, Gatherer is not in substantially the same economic position as it was prior to any such regulation, then Gatherer may terminate this Agreement upon the delivery of written Notice of
termination to Shipper. 

  
 35 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 15.5 Taxes. Shipper shall pay or cause to be paid, and agrees to
indemnify and hold harmless Gatherer and its Affiliates from and against the payment of, all excise, gross production, severance, sales, occupation, and all other taxes, charges, or impositions of every kind and character required by statute or by
any Governmental Authority with respect to Shipper Gas, Shipper Injected Liquids and/or the handling thereof prior to receipt thereof by Gatherer at the Receipt Points. Subject to Section 15.4, Gatherer shall pay or cause
to be paid all taxes and assessments, if any, imposed upon Gatherer for the activity of gathering of Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Shipper Injected Liquids after receipt at the
Receipt Points and prior to redelivery thereof by Gatherer at the Delivery Points. Gatherer shall refund to Shipper any tax paid on Shipper’s behalf (a) that is successfully disputed, and (b) for which Gatherer has actually received a
refund. 
 Section 15.6 Exclusive Producer Purchase Right. Shipper covenants and agrees that, during the Term applicable to each
Subsystem, it shall not, without the prior written consent of Gatherer (such consent to be given or withheld in Gatherer’s sole discretion), materially alter, modify or amend the Exclusive Producer Purchase Right, including any contract or
other arrangement forming a part of such right (and shall not commit or agree to do so), in any manner that would adversely affect the volumes of Gas (a) to which Shipper is entitled pursuant to the Exclusive Producer Purchase Right, or
(b) delivered to Gatherer by Shipper hereunder. 
 ARTICLE 16 

INDEMNIFICATION AND INSURANCE 

Section 16.1 Custody and Control Indemnity. EXCEPT FOR LOSSES COVERED BY THE INDEMNITIES IN
SECTION 11.1, THE PARTY HAVING CUSTODY AND CONTROL OF GAS AND/OR INJECTED LIQUIDS, AS APPLICABLE, UNDER THE TERMS OF SECTION 11.2 SHALL BE RESPONSIBLE FOR AND SHALL RELEASE, DEFEND, INDEMNIFY AND
HOLD HARMLESS THE OTHER PARTY AND SUCH OTHER PARTY’S GROUP FROM AND AGAINST EACH OF THE FOLLOWING: (A) ANY LOSSES ASSOCIATED WITH ANY PHYSICAL LOSS OF SUCH GAS AND/OR INJECTED LIQUIDS (OTHER THAN SYSTEM FUEL AND LOSSES), INCLUDING THE
VALUE OF SUCH LOST GAS AND/OR INJECTED LIQUIDS, AND (B) ANY DAMAGES RESULTING FROM THE RELEASE OF ANY SUCH GAS AND/OR INJECTED LIQUIDS; PROVIDED, HOWEVER, THAT NO INDEMNIFIED PERSON OR A MEMBER OF SUCH INDEMNIFIED PERSON’S GROUP SHALL BE
ENTITLED TO INDEMNIFICATION PURSUANT TO THIS Section 16.1 WITH RESPECT TO ITS OWN NEGLIGENCE OR WILLFUL MISCONDUCT. 

Section 16.2 Shipper Indemnification. SUBJECT TO Section 16.1, SHIPPER AGREES TO AND SHALL RELEASE,
DEFEND, INDEMNIFY AND HOLD HARMLESS GATHERER, AND GATHERER’S DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, PARENT, AFFILIATES AND SUBSIDIARIES, (ALL OF THE FOREGOING, THE “Gatherer Group”) FROM AND AGAINST ALL LOSSES WHICH IN
ANY WAY RESULT FROM ANY OF THE FOLLOWING: (A) THE OWNERSHIP, DESIGN, CONSTRUCTION, MAINTENANCE OR OPERATION OF SHIPPER’S FACILITIES; PROVIDED, HOWEVER, 

  
 36 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
THAT NO MEMBER OF THE GATHERER GROUP SHALL BE ENTITLED TO INDEMNIFICATION PURSUANT TO THIS SECTION 16.2 WITH RESPECT TO THE NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY
MEMBER OF THE GATHERER GROUP, (B) ANY SHIPPER GAS AND/OR SHIPPER INJECTED LIQUIDS, AS APPLICABLE, DELIVERED INTO THE GATHERING SYSTEM THAT DO NOT MEET EACH OF THE APPLICABLE QUALITY SPECIFICATIONS SET FORTH IN
SECTION 1.1(A) OF THE OPERATING TERMS (AS REVISED IN ACCORDANCE WITH SECTION 1.1(B) OF THE OPERATING TERMS), AND (C) THE PAYMENT OR CALCULATION OF ANY PROCEEDS, ROYALTIES OR OTHER BURDENS ON PRODUCTION DUE BY
ANY PRODUCER TO APPLICABLE LESSORS, LANDOWNERS, ROYALTY HOLDERS OR OTHER INTEREST HOLDERS (INCLUDING CO-OWNERS OF WORKING INTERESTS), AS APPLICABLE, WITH RESPECT TO ANY GAS AND/OR INJECTED LIQUIDS DELIVERED
INTO THE GATHERING SYSTEM BY OR ON BEHALF OF SHIPPER. 
 Section 16.3 Gatherer Indemnification. SUBJECT TO
Section 16.1 AND Section 16.5, GATHERER AGREES TO AND SHALL RELEASE, DEFEND, INDEMNIFY AND HOLD HARMLESS SHIPPER, AND SHIPPER’S DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, PARENT, AFFILIATES AND
SUBSIDIARIES, (ALL OF THE FOREGOING, THE “Shipper Group”) FROM AND AGAINST ALL LOSSES WHICH IN ANY WAY RESULT FROM THE OWNERSHIP, DESIGN, CONSTRUCTION, MAINTENANCE OR OPERATION OF THE GATHERING SYSTEM; PROVIDED, HOWEVER, THAT
NO MEMBER OF THE SHIPPER GROUP SHALL BE ENTITLED TO INDEMNIFICATION PURSUANT TO THIS SECTION 16.3 WITH RESPECT TO (A) THE NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY MEMBER OF THE SHIPPER GROUP, OR (B) ANY SHIPPER GAS
AND/OR SHIPPER INJECTED LIQUIDS DELIVERED INTO THE GATHERING SYSTEM THAT DO NOT MEET EACH OF THE APPLICABLE QUALITY SPECIFICATIONS SET FORTH IN SECTION 1.1(A) OF THE OPERATING TERMS (AS REVISED IN ACCORDANCE WITH SECTION
1.1(B) OF THE OPERATING TERMS). 
 Section 16.4 Actual Direct Damages. A PARTY’S (OR A MEMBER OF SUCH PARTY’S
GROUP’S) DAMAGES RESULTING FROM A BREACH OR VIOLATION OF ANY REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR CONDITION CONTAINED IN THIS AGREEMENT OR ANY ACT OR OMISSION ARISING FROM OR RELATED TO THIS AGREEMENT SHALL BE LIMITED TO ACTUAL
DIRECT DAMAGES AND SHALL NOT INCLUDE ANY OTHER LOSS OR DAMAGE, INCLUDING INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, PRODUCTION, OR REVENUES, AND EACH PARTY EXPRESSLY RELEASES THE OTHER PARTY
AND THE MEMBERS OF SUCH OTHER PARTY’S GROUP FROM ALL SUCH CLAIMS FOR LOSS OR DAMAGE OTHER THAN ACTUAL DIRECT DAMAGES; PROVIDED, THAT THE LIMITATION TO DIRECT DAMAGES ONLY SHALL NOT APPLY TO ANY DAMAGE, CLAIM OR LOSS ASSERTED BY OR AWARDED TO
THIRD PARTIES AGAINST A PARTY AND FOR WHICH THE OTHER PARTY WOULD OTHERWISE BE RESPONSIBLE UNDER THIS AGREEMENT. 

  
 37 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 16.5 Penalties. EXCEPT FOR INSTANCES OF GROSS NEGLIGENCE OR WILLFUL
MISCONDUCT BY GATHERER, SHIPPER SHALL RELEASE, INDEMNIFY, DEFEND AND HOLD GATHERER AND THE GATHERER GROUP HARMLESS FROM ANY LOSSES, INCLUDING ANY SCHEDULING PENALTIES OR MONTHLY BALANCING PROVISIONS, IMPOSED BY A DOWNSTREAM FACILITY IN ANY
TRANSPORTATION CONTRACTS OR SERVICE AGREEMENTS ASSOCIATED WITH, OR RELATED TO, SHIPPER GAS OR SHIPPER INJECTED LIQUIDS, INCLUDING ANY PENALTIES IMPOSED PURSUANT TO A DOWNSTREAM FACILITY’S TARIFF (IF APPLICABLE), OR WHICH MAY BE CAUSED BY
OFO’S, PDA’S, OTHER PIPELINE ALLOCATION METHODS, UNSCHEDULED PRODUCTION, OR BY UNAUTHORIZED PRODUCTION. 
 Section 16.6
Insurance. The Parties shall carry and maintain no less than the insurance coverage set forth in Exhibit J. 

ARTICLE 17 
 ASSIGNMENT

 Section 17.1 Assignment of Rights and Obligations under this Agreement. 

(a) Shipper shall be entitled to assign its rights and obligations under this Agreement (in whole or in part) to another Person; provided that
(i) such transferee has also been assigned the Exclusive Producer Purchase Right (including any contract or other arrangement forming a part of such right), (ii) the transferee specifically assumes all of Shipper’s rights and
obligations hereunder, and (iii) the transferee has, in Gatherer’s good faith and reasonable judgment, the financial and operational capability to perform and fulfill Shipper’s obligations hereunder. Gatherer shall be entitled to
assign its rights and obligations under this Agreement (in whole or in part) to another Person; provided that (A) such Person has acquired all or a portion of the Gathering System (including any Subsystem thereof) and (B) the portion of
the rights and obligations of Gatherer under this Agreement to be transferred to such Person correspond to the interest in the Gathering System so transferred to such Person. 

(b) This Agreement shall be binding upon and inure to the benefit of the respective permitted successors and assigns of the Parties. Any
attempted assignment made without compliance with the provisions set forth in this Section 17.1 shall be null and void ab initio. 

(c) Any release of any of Dedicated Production from dedication under this Agreement pursuant to Section 4.4 shall
not constitute an assignment or transfer of such Dedicated Production for the purposes of this Article 17. 

  
 38 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 17.2 Pre-Approved Assignment.
Each Party shall have the right, without the prior consent of the other Party, to (a) mortgage, pledge, encumber or otherwise impress a lien or security interest upon its rights and interest in and to this Agreement and (b) make a transfer
pursuant to any security interest arrangement described in (a) above, including any judicial or non-judicial foreclosure and any assignment from the holder of such security interest to another Person.

 ARTICLE 18 
 SHIPPER
GUARANTEE; ADEQUATE ASSURANCES 
 Section 18.1 Shipper Guarantee. Concurrently with the execution of the Original Agreement,
Shipper delivered to Gatherer a guarantee from Hess Corporation, the indirect owner of 100% of the issued and outstanding shares of Shipper (“Shipper Parent”), which guarantee provides a guarantee of all of Shipper’s
obligations under this Agreement. 
 Section 18.2 Adequate Assurances. If (a) Shipper fails to pay any Invoice according to
the provisions hereof and such failure continues for a period of five Business Days after written Notice of such failure is provided to Shipper or (b) Gatherer has reasonable grounds for insecurity regarding the performance by Shipper of any
obligation under this Agreement, then Gatherer, by delivery of written Notice to Shipper, may, singularly or in combination with any other rights it may have, demand Adequate Assurance by Shipper. As used herein, “Adequate
Assurance” means, at the option of Shipper, (i) the advance payment in cash by Shipper to Gatherer for System Services to be provided under this Agreement in the following Month or (ii) delivery to Gatherer by Shipper of an
Adequate Letter of Credit in an amount equal to not less than the aggregate amounts owed from Shipper to Gatherer hereunder for the prior two Month period. If (A) Shipper fails to provide Adequate Assurance to Gatherer within 48 hours of
Gatherer’s request therefor pursuant to this Section 18.2 or (B) Shipper or Shipper Parent suffers any of the actions described in Section 10.1(a)(iii), then, in either case, Gatherer
shall have the right to, at its sole option, terminate this Agreement upon written Notice to Shipper or suspend or reduce all services under this Agreement without prior Notice to Shipper, in each case, without limiting any other rights or remedies
available to Gatherer under this Agreement or otherwise. If Gatherer exercises the right to terminate this Agreement or suspend or reduce any System Services under this Section 18.2, then Shipper shall not be entitled to
take, or cause to be taken, any action hereunder or otherwise against Gatherer for such termination, suspension or reduction. Failure of Gatherer to exercise its right to terminate this Agreement or suspend or reduce any System Service as provided
in this Section 18.2 shall not constitute a waiver by Gatherer of any rights or remedies Gatherer may have under this Agreement, applicable Law, or otherwise. 

  
 39 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 ARTICLE 19 

MISCELLANEOUS 

Section 19.1 Relationship of the Parties. The rights, duties, obligations and liabilities of the Parties under this Agreement
shall be individual, not joint or collective. It is not the intention of the Parties to create, and this Agreement shall not be deemed or construed to create, a partnership, joint venture or association or a trust. This Agreement shall not be deemed
or construed to authorize any Party to act as an agent, servant or employee for any other Party for any purpose whatsoever except as explicitly set forth in this Agreement. In their relations with each other under this Agreement, the Parties shall
not be considered fiduciaries. 
 Section 19.2 Notices; Voice Recording. All notices and communications required or
permitted to be given under this Agreement shall be considered a “Notice” and be sufficient in all applicable respects if (a) given in writing and delivered personally, (b) sent by bonded overnight courier,
(c) mailed by U.S. Express Mail or by certified or registered United States Mail with all postage fully prepaid, (d) transmitted by facsimile (provided that any such fax is confirmed by written confirmation), or (e) by electronic mail
with a PDF of the notice or other communication attached (provided that any such electronic mail is confirmed by written confirmation), in each case, addressed to the appropriate Person at the address for such Person shown in Exhibit K. Any
Notice given in accordance herewith shall be deemed to have been given when (i) delivered to the addressee in person or by courier, (ii) transmitted by electronic communications during normal business hours, or if transmitted after normal
business hours, on the next Business Day (in each case, provided that any such electronic communication is confirmed in writing), or (iii) upon actual receipt by the addressee after such notice has either been delivered to an overnight courier
or deposited in the United States Mail if received during normal business hours, or if not received during normal business hours, then on the next Business Day, as the case may be. Any Person may change their contact information for notice by giving
Notice to the other Parties in the manner provided in this Section 19.2. Either Party may, from time-to-time, agree and request that certain
Notices or statements, such as operational, scheduling, nominations, or Invoices, be sent by alternative means, such as e-mail, facsimile or otherwise. The Parties hereby agree that, to the extent permitted by
Law, each Party may electronically record telephone conversations between the Parties in connection with oral notices, nominations, scheduling, or other operational communications between the Parties for purposes of confirming and documenting such
communications, with or without the use of a prior warning tone or Notice. 
 Section 19.3 Expenses. Except as otherwise
specifically provided, all fees, costs and expenses incurred by the Parties in negotiating this Agreement shall be paid by the Party incurring the same, including legal and accounting fees, costs and expenses. 

Section 19.4 Waivers; Rights Cumulative. Any of the terms, covenants, or conditions hereof may be waived only by a written
instrument executed by or on behalf of the Party waiving compliance. No course of dealing on the part of any Party, or their respective officers, employees, agents, or representatives, and no failure by a Party to exercise any of its rights under
this Agreement, shall, in either case, operate as a waiver thereof or affect in any way the right of such Party at a later time to enforce the performance of such provision. No waiver by any Party of any condition, or any breach of any term or
covenant contained in this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach or a waiver of any other condition or of any breach of any other term or
covenant. The rights of the Parties under this Agreement shall be cumulative, and the exercise or partial exercise of any such right shall not preclude the exercise of any other right. 

  
 40 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 19.5 Confidentiality. For the Term of this Agreement and for one year
after the termination of this Agreement, the Parties shall keep confidential the terms of this Agreement, including, but not limited to, the Fees, the volumes delivered (and redelivered) hereunder, all other material terms of this Agreement and any non-public information and materials delivered pursuant to this Agreement (collectively, “Confidential Information”), except as follows: 

(a) to the extent disclosures of Confidential Information may be reasonably required to effectuate the performance of this Agreement by either
Party or the construction, operation or maintenance of the Gathering System; 
 (b) to meet the requirements of any applicable Law or of a
Governmental Authority with jurisdiction over the matter for which information is sought, and in that event, the disclosing Party shall provide prompt written Notice to the other Party, if legally permitted to do so, of the requirement to disclose
the Confidential Information and shall take or assist the other Party in taking all reasonable legal steps available to suppress the disclosure or extent of disclosure of the information; 

(c) in a sales process involving all or a portion of the Gathering System; provided that the Parties take all reasonable steps to ensure that
the confidentiality of Confidential Information is maintained as a result of such sales process; and 
 (d) to those employees, consultants,
agents, advisors and equity holders of each Party who need to know such Confidential Information for purposes of, or in connection with, the performance of such Party’s obligations under this Agreement; provided that the Party disclosing the
Confidential Information to those Persons shall be liable to the other Party for any damages suffered due to a failure by any of such Persons to maintain the confidentiality of the Confidential Information on the basis set forth in this Agreement.

 Section 19.6 Entire Agreement; Conflicts. THIS AGREEMENT CONSTITUTES THE ENTIRE AGREEMENT OF THE PARTIES PERTAINING TO THE
SUBJECT MATTER HEREOF AND SUPERSEDES ALL PRIOR AGREEMENTS, UNDERSTANDINGS, NEGOTIATIONS, AND DISCUSSIONS, WHETHER ORAL OR WRITTEN, OF THE PARTIES OR THEIR PREDECESSORS PERTAINING TO THE SUBJECT MATTER HEREOF OR THE GATHERING SYSTEM. THERE ARE NO
WARRANTIES, REPRESENTATIONS, OR OTHER AGREEMENTS AMONG THE PARTIES RELATING TO THE SUBJECT MATTER HEREOF EXCEPT AS SPECIFICALLY SET FORTH IN THIS AGREEMENT, INCLUDING THE EXHIBITS AND APPENDICES HERETO, AND NO PARTY SHALL BE BOUND BY OR LIABLE FOR
ANY ALLEGED REPRESENTATION, PROMISE, INDUCEMENT OR STATEMENT OF INTENTION NOT SO SET FORTH. 

  
 41 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 19.7 Amendment. This Agreement may be amended only by an instrument in
writing executed by the Parties and expressly identified as an amendment or modification. 
 Section 19.8 Governing Law;
Disputes. THIS AGREEMENT AND THE LEGAL RELATIONS AMONG THE PARTIES SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS, EXCLUDING ANY CONFLICTS OF LAW RULE OR PRINCIPLE THAT MIGHT REFER CONSTRUCTION OF SUCH
PROVISIONS TO THE LAWS OF ANOTHER JURISDICTION. ALL OF THE PARTIES CONSENT TO THE EXERCISE OF JURISDICTION IN PERSONAM BY THE UNITED STATES FEDERAL DISTRICT COURTS LOCATED IN HARRIS COUNTY, TEXAS FOR ANY ACTION ARISING OUT OF THIS AGREEMENT OR ANY
TRANSACTION CONTEMPLATED HEREBY. ALL ACTIONS OR PROCEEDINGS WITH RESPECT TO, ARISING DIRECTLY OR INDIRECTLY IN CONNECTION WITH, OUT OF, RELATED TO, OR FROM THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY SHALL BE EXCLUSIVELY LITIGATED IN THE
UNITED STATES FEDERAL DISTRICT COURTS HAVING SITES IN HARRIS COUNTY, TEXAS (AND ALL APPELLATE COURTS HAVING JURISDICTION THEREOVER). EACH PARTY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

Section 19.9 Parties in Interest. Nothing in this Agreement shall entitle any Non-Party to
any claim, cause of action, remedy or right of any kind. 
 Section 19.10 Preparation of Agreement. Both Parties and their
respective counsel participated in the preparation of this Agreement. In the event of any ambiguity in this Agreement, no presumption shall arise based on the identity of the draftsman of this Agreement. 

Section 19.11 Severability. If any term or other provision of this Agreement is invalid, illegal, or incapable of being enforced
by any rule of Law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
adverse manner to any Party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
Parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. 

Section 19.12 Operating Terms. The Operating Terms are incorporated into this Agreement for all purposes. 

  
 42 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Section 19.13 Counterparts. This Agreement may be executed in any number of
counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all of such counterparts shall constitute for all purposes one agreement. Any signature hereto delivered by a Party by electronic mail shall be deemed
an original signature hereto. 
 [signature page follows] 

  
 43 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 IN WITNESS WHEREOF, the Parties have executed this Agreement, in each case, to be effective
as of the Effective Time. 
  

									
	SHIPPER:	 		 	GATHERER:
			
	HESS TRADING CORPORATION	 		 	HESS NORTH DAKOTA PIPELINES LLC
					
	By:	 	 /s/ Steven A. Villas
	 		 	By:	 	 /s/ John A. Gatling

	Name:	 	Steven A. Villas	 		 	Name:	 	John A. Gatling
	Title:	 	President	 		 	Title:	 	Vice President, Bakken Midstream

  
 Signature Page to 

Amended and Restated Gas Gathering Agreement 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 APPENDIX I 

OPERATING TERMS AND CONDITIONS 

1.1 Quality Specifications. 

(a) Quality Specifications. All Shipper Gas and Shipper Injected Liquids Tendered at the Receipt Points shall conform to the following
specifications, as applicable: 
 (i) Shipper Gas. All Shipper Gas Tendered at any Receipt Point shall conform to the following
specifications: 
 (A) Hydrogen Sulfide: 

(1) The Gas delivered hereunder into any Receipt Point upstream of the Ross, Myrtle, Sorkness, and Wheelock compressor stations shall not
contain more than a total of ** parts per million (** ppm) by volume of hydrogen sulfide.  
 (2) Notwithstanding the foregoing and
for the avoidance of doubt, Gas containing hydrogen sulfide shall only be accepted if the applicable Downstream Facility is commercially capable of treating for such contaminant. 

(B) Carbon Dioxide: The Gas delivered hereunder shall not contain more than ** percent (**%) by volume of carbon dioxide. 

(C) Nitrogen: The Gas delivered hereunder shall not contain more than four percent (4.0%) by volume of nitrogen. 

(D) Oxygen: The Gas delivered hereunder shall not contain any oxygen. 

(E) Other Constituents: The Gas delivered hereunder shall be commercially free from well treating chemicals, liquid water, dirt, dust,
crude oil, gums, iron particles, arsenic, mercury, selenium, radon, antimony and other impurities or noncombustible gases, in each case, which, individually or in the aggregate, would adversely affect the utilization or processing of such Gas. 

(F) Hydrocarbon Dew Point: The Gas delivered hereunder to the high pressure side of the Compression Services shall have a hydrocarbon
dew point temperature equal to or less than thirty degrees (30°) Fahrenheit at the then-current operating pressure at the applicable Receipt Point. 

(ii) Shipper Injected Liquids. All Shipper Injected Liquids Tendered at any Injection Point shall conform to the following
specifications: 

  
 Appendix I - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (A) Oxygen: The Injected Liquids delivered hereunder shall not contain any oxygen.

 (B) Other Constituents: The Injected Liquids delivered hereunder shall be commercially free from well treating chemicals, liquid
water, dirt, dust, crude oil, gums, iron particles, arsenic, mercury, selenium, radon, antimony and other impurities, in each case, which, individually or in the aggregate, would adversely affect the utilization of such Injected Liquids, or any
residue gas produced therefrom, at any applicable Downstream Facility. 
 (iii) Shipper Gas and Shipper Injected Liquids.
Notwithstanding anything in the foregoing to the contrary, the aggregate volumes of Shipper Gas and Shipper Injected Liquids Tendered at the Receipt Points on each Day during the Term applicable to each Subsystem shall, when aggregated together and
determined on an average basis for each such Day, conform to the following specifications: 
 (A) Carbon Dioxide: The aggregate
volumes of Shipper Gas and Shipper Injected Liquids delivered hereunder in any Day shall not contain more than ** percent (**%) by volume of carbon dioxide. 

(B) Hydrogen Sulfide: 

(1) The aggregate volumes of Shipper Gas and Shipper Injected Liquids delivered hereunder in any Day shall not contain more than a total of **
percent (**%) by volume of hydrogen sulfide and not less than a total of ** percent (**%) by volume of hydrogen sulfide; provided, however, that Shipper shall also be entitled to deliver Shipper Gas and Shipper Injected Liquids hereunder that do
not, in the aggregate for all volumes of such Shipper Gas and Shipper Injected Liquids delivered hereunder in any Day, contain more than a total of ** parts per million (** ppm) by volume of hydrogen sulfide. 

(2) Notwithstanding the foregoing and for the avoidance of doubt, Shipper Gas and Shipper Injected Liquids containing hydrogen sulfide shall
only be accepted if the applicable Downstream Facility is commercially capable of treating for such contaminant. 
 (C) Sum of Hydrogen
Sulfide plus Carbon Dioxide: The sum of (a) the hydrogen sulfide content, plus (b) the carbon dioxide content, in each case, of the aggregate volumes of Shipper Gas and Shipper Injected Liquids delivered hereunder in any Day
shall not exceed ** percent (**%) by volume. 
 (D) Nitrogen: The aggregate volumes of Shipper Gas and Shipper Injected Liquids
delivered hereunder in any Day shall not contain more than three and one-tenth of one percent (3.1%) by volume of nitrogen. 

(E) Oxygen: The aggregate volumes of Shipper Gas and Shipper Injected Liquids delivered hereunder in any Day shall not contain any
oxygen. 

  
 Appendix I - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (F) Gross Heating Value after processing: The residue gas that would be produced from
the aggregate volume of Shipper Gas and Shipper Injected Liquids delivered hereunder in any Day shall have a calculated Gross Heating Value of not less than 967 Btus per cubic foot at Standard Base Conditions. 

(b) Downstream Facilities. Notwithstanding the quality specifications above, if a Downstream Facility notifies either Party of
different or additional quality specifications required at any Delivery Point that are more stringent than the specifications shown above, such Party will promptly notify the other Party of any such different or additional specifications as soon as
practicable after being notified of such specifications. 
 (i) Following the Parties’ receipt of a notice from a Downstream Facility
as described in Section 1.1(b) of the Operating Terms above, the Parties shall promptly meet to discuss such different or additional quality specifications and agree upon the Parties’ collective response to such
Downstream Facility. Each Party agrees to use its commercially reasonable efforts to meet and agree upon such response within any applicable time limitation imposed by such Downstream Facility, any binding contractual commitment of either Party, or
any Governmental Authority (including any applicable Law), as applicable. 
 (ii) In the event that Gatherer would be required to install
any processing or treatment facilities in order to meet any such different or additional Downstream Facility quality specifications, the Parties shall meet to determine (A) what additional facilities would be needed, (B) whether or not the
Parties agree that such additional facilities should be installed, and (C) what amendments to the then-current Gathering System Plan and System Budget would be needed to incorporate the installation of such additional facilities. 

(iii) In the event that the Parties do not mutually agree (A) that such additional facilities should either be installed or not
installed, or (B) on the amendments to the then-current Gathering System Plan that would be needed to incorporate the installation of such additional facilities, then, in each case, the provisions of Section 5.3(e)
shall be applied by the Parties with respect to such dispute. 
 (iv) In the event that the Parties mutually agree (or it is determined
pursuant to Section 5.3(e)) (A) that such additional facilities should be installed, and (B) upon the amendments to the then-current Gathering System Plan that would be needed to incorporate the installation of such
additional facilities, then Gatherer shall be provided such period of time as would be reasonably needed to install and place into service such additional facilities. 

(v) Following the date upon which any such additional facilities are installed and placed into service, such different or additional
Downstream Facility quality specifications will be considered as the quality specifications with respect to the applicable Delivery Points under this Agreement for as long as required by such Downstream Facility. 

  
 Appendix I - Page 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (c) Nonconforming Gas or Injected Liquids. Should, at any time during the Term
applicable to the relevant Subsystem, either Party become aware that (i) any Mcf of Gas Tendered by Shipper into the Gathering System does not meet any of the quality specifications in Section 1.1(a)(i) of the
Operating Terms (as revised in accordance with Section 1.1(b) of the Operating Terms), (ii) any MCFE of Injected Liquids Tendered by Shipper into the Gathering System does not meet any of the quality specifications in
Section 1.1(a)(ii) of the Operating Terms (as revised in accordance with Section 1.1(b) of the Operating Terms), or (iii) the aggregate volumes of Gas and Injected Liquids Tendered by Shipper
into the Gathering System on any Day does not meet the quality specifications in Section 1.1(a)(iii) of the Operating Terms (as revised in accordance with Section 1.1(b) of the Operating Terms),
then, in any such case, such Party shall immediately notify the other Party of such failure and nonconforming Shipper Gas and/or Shipper Injected Liquids and, if known, the extent of the deviation from such specifications. Upon any such
notification, Shipper shall determine the expected duration of such failure and notify Gatherer of the efforts Shipper is undertaking to remedy such deficiency. 

(d) Failure to Meet Specifications. If any Shipper Gas and/or Shipper Injected Liquids delivered into the Gathering System fail to meet
each of the applicable quality specifications in Section 1.1(a) of the Operating Terms (as revised in accordance with Section 1.1(b) of the Operating Terms) when Tendered at the Receipt Points,
Gatherer shall have the right to cease accepting such Gas and/or Injected Liquids into the Gathering System or reject such Gas and/or Injected Liquids from entering the Gathering System, as applicable. 

(e) Acceptance of Nonconforming Gas or Injected Liquids. Without limiting the rights and obligations of Gatherer pursuant to
clause (d) immediately above, Gatherer may elect to accept receipt at any Receipt Point of Shipper Gas and/or Shipper Injected Liquids that fails to meet any of the quality specifications stated above. Such acceptance by Gatherer shall not be
deemed a waiver of Gatherer’s right to refuse to accept non-specification Shipper Gas and/or Shipper Injected Liquids at a subsequent time. 

(f) Liability for Nonconforming Gas or Injected Liquids. With respect to any Shipper Gas (including any Drip Liquids allocated to
Shipper in accordance with this Agreement) and/or Shipper Injected Liquids that fail to meet each of the applicable quality specifications under Section 1.1(a) of the Operating Terms (as revised in accordance with
Section 1.1(b) of the Operating Terms) when Tendered at the Receipt Points, Shipper shall be responsible for (i) any fees charged by any Downstream Facility; (ii) any costs incurred by Gatherer and agreed to by
Shipper in order to avoid such fees for such Gas and/or Injected Liquids; and (iii) any costs, expenses or damages incurred by Gatherer (including with respect to any damages incurred to the Gathering System). Additionally, Shipper shall always
be responsible for fees charged by a Downstream Facility due to non-specification Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or non-specification Shipper Injected Liquids and will indemnify the Gatherer Group from claims by a Downstream Facility arising from non-specification Shipper Gas (including any
Drip Liquids allocated to Shipper in accordance with this Agreement) and/or non-specification Shipper Injected Liquids. 

  
 Appendix I - Page 4 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (g) Liability for Nonconforming Commingled Gas or Injected Liquids. With respect to
any Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and/or Shipper Injected Liquids that (i) fail to meet the quality specifications of any Downstream Facility under
Section 1.1(b) of the Operating Terms, but (ii) meet each of the applicable quality specifications set forth in this Section 1.1(a) of the Operating Terms (as revised in accordance with
Section 1.1(b) of the Operating Terms) when Tendered at the applicable Receipt Point, Shipper shall not be responsible for (A) any fees charged by any Downstream Facility as a result thereof; or (B) any other
costs, expenses or damages incurred by Gatherer (including with respect to any damages incurred to the Gathering System) with respect to such commingled Gas and/or Injected Liquids. 

1.2 Nomination Procedures; Coordination; Compliance. 

(a) Nominations. The Parties shall, as soon as reasonably practicable following the date hereof, use their commercially reasonable
efforts to agree upon a nomination procedure with respect to receipts and deliveries of Shipper Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and Shipper Injected Liquids at the Receipt Points and Delivery
Points. As a general rule, Shipper shall use its commercially reasonable efforts to make, and Gatherer shall use commercially reasonable efforts to comply with, nominations made or requested under this Agreement in a manner that is reasonably likely
to (i) maximize volumetric throughput in the Gathering System (whether relating to Shipper Gas, Shipper Injected Liquids or other volumes in the Gathering System), (ii) utilize any excess capacity available at any Receipt Points and Delivery
Points on the Gathering System, and (iii) maximize the volumetric deliveries to those Delivery Points connected to Downstream Facilities governed by the GPA (whether relating to Shipper Gas, Shipper Injected Liquids or other volumes in the
Gathering System). Notwithstanding anything in the foregoing to the contrary, provided, however, that Shipper shall not make or request any nominations that would reasonably be expected to result in a violation of, or the practical
impossibility of compliance with, performance of any contractual commitments of Gatherer Group with respect to any processing facility or other Downstream Facility which is not wholly owned by Gatherer or the Gatherer Group of which Shipper has been
made aware to the extent relating to Downstream Facilities that are not wholly-owned by the Gatherer Group. 
 (b) Coordination with
Receiving Transporters. The Parties recognize that Gatherer must coordinate its actions with those of the Downstream Facilities. Accordingly, upon 30 Days written Notice to Shipper, Gatherer may modify provisions of this Agreement to implement
standards promulgated by NAESB and adopted by any Downstream Facility as it relates to the Gathering System or to otherwise coordinate the provisions of this Agreement with the operating conditions, rules, or tariffs of the Downstream Facilities,
and Shipper agrees to execute such amendment(s) to this Agreement proposed by Gatherer in good faith that reflect such modifications. 
 (c)
Shipper Compliance. Shipper covenants and agrees that it shall, in relation to each requested receipt or delivery of Shipper Gas and/or Shipper Injected Liquids (i) act in accordance and in a manner consistent with the applicable
nomination, and (ii) observe and comply with (A) the terms and conditions of this Agreement, including these Operating Terms, (B) Applicable Requirements, and (C) the Gathering System Rules. 

  
 Appendix I - Page 5 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 1.3 Measurement Devices. 

(a) All Gas and Injected Liquids Tendered hereunder at a Receipt Points shall be measured, prior to delivery into the Gathering System, by a
suitable measurement device to be furnished and installed (or caused to be furnished and installed) by Gatherer, and subsequently kept in repair (or caused to be kept in repair) by Gatherer, and located at or near such Receipt Point. Such Gas
measurement devices shall be installed, and the meter run fabricated and installed, in accordance with the American Petroleum Institute Manual of Petroleum Measurement Standards (the “MPMS”) Chapter 14.3, Part 2 April
2000, Reaffirmed May 2011, utilizing EGM (electronic gas measurement) installed pursuant to MPMS Chapter 21.1, August 1993, Reaffirmed August 2011. Such Injected Liquids Turbine or Coriolis measurement devices shall be installed in accordance with
the MPMS Chapter 5.3, November 2011, Measurement of Liquid Hydrocarbons by Turbine Meter, or MPMS Chapter 5.6 October 202, Reaffirmed March 2008, Measurement of Liquid Hydrocarbons by Coriolis Meters. 

(b) Gas metered hereunder shall be computed in units of Mcf and Injected Liquids metered hereunder shall be computed in units of MCFE. Such
Gas shall be measured in accordance with the MPMS Chapter 14.3, Part 3 August 1992, Reaffirmed February 2009, and such Injected Liquids shall be measured in accordance with the MPMS, Chapter 5.3 November 2011, Measurement of Liquid Hydrocarbons
by Turbine Meter or MPMS Chapter 5.6 October 202, Reaffirmed March 2008, Measurement of Liquid Hydrocarbons by Coriolis Meters, in each case, as the same may be amended from time to time, in a manner generally accepted by the gas producing industry,
with the following exception: the atmospheric pressure used by Gatherer where Gas and Injected Liquids are measured shall be as set prescribed by the Standard Base Conditions. 

(c) Gatherer shall inspect (or cause to be inspected) said measurement devices semi-annually, and adjust and repair (or caused to be adjusted
and repaired) the same as necessary. Gatherer shall notify Shipper in writing prior to such measurement device calibrations in order that Shipper may have a representative present to witness same, and the measurement device(s) shall be open to
inspection at all times by Shipper in the presence of Gatherer. In case any question arises as to the accuracy of the measurement, said measurement devices shall be tested upon the demand of either Party. The expense of such tests shall be borne by
the Party demanding same if the measurement device is found to be correct, and by Gatherer if found incorrect. A registration within one percent (1.0%) of correct shall be considered correct, but the measurement device shall be adjusted to zero
error. Settlement for any period of inoperable or inaccurate measurement shall be in accordance with the average readings taken during the last preceding ten Days when the measurement device was registering accurately and the first ten Days after
the measurement device was restored to accuracy. If Gatherer and Seller are unable to agree as to the time period during which the measurement device was inoperative or inaccurate it is agreed that volume adjustments shall be limited to no more than
one-half of the operational Days from the date of the last calibration to the date of the correct calibration. 

  
 Appendix I - Page 6 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (d) If the measurement equipment is found to be measuring inaccurately and the amount of Gas
delivered cannot be ascertained or computed from the reading, then the Gas and Injected Liquids delivered will be estimated and agreed upon by the Parties based on the best data available, using the first available of the following: 

(i) The registration of any check meter or meters if installed and accurately registering; 

(ii) The correction of the errors, if the percentage of error is ascertainable by meter calibration, test, or mathematical calculation; 

(iii) The estimation based on comparison of the quantity of deliveries with deliveries during preceding periods under similar conditions when
the meter was registering accurately. 
 (e) If requested, Gatherer shall send the charts or electronic data, as available to Gatherer, to
Shipper for checking, after which they are to be returned to Gatherer within 90 Days. 
 1.4 Gas Quality Determination. 

(a) All Gas and Injected Liquids tests conducted pursuant to this Agreement, whether by Gatherer or Shipper (or their respective
representatives, shall be based on the applicable standards and specifications published in the American Gas Association (“AGA”) Committee Reports, the AGA Gas Measurement Manual, the MPMS, the Gas Processors Association
(“GSPA”) Technical Standards, the GSPA Plant Operations Test Manual, and the American Society for Testing Materials Standards – Section 5, in each case, as amended from time to time. Specifically, as related to
(i) Gas sampling techniques, the Parties (or their respective representatives) shall utilize GSPA Standard 2166-86, and (ii) Injected Liquids sampling techniques, the Parties (or their respective
representatives) shall utilize GSPA Standard 2174-93, in each case, as amended from time to time, for obtaining Receipt Point Gas and Injected Liquids samples hereunder. 

(b) Semi-annually, or as often as Gatherer deems advisable, Gatherer shall obtain a representative sample of Shipper Gas and Shipper Injected
Liquids at each Receipt Point and, by a chromatographic gas analysis, determine the test content and Gross Heating Value of such Shipper Gas and Shipper Injected Liquids. The first such determination shall be made within a reasonable time after
delivery of Gas and Injected Liquids into the Gathering System begins hereunder, with such time not to exceed 30 Days, and shall apply until the first Day of the Month following the next determination. The period for determination shall be selected
by Gatherer. Gatherer shall notify Shipper in writing of the date of taking the test. Shipper may witness the tests or make joint tests with its own appliances at Shipper’s sole cost. The Gas and Injected

  
 Appendix I - Page 7 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
Liquids used in the content tests shall be measured in Standard Cubic Feet. The specific gravity of the Gas and Injected Liquids tested shall be determined by any method adopted as standard by
the GSPA. The percentage of hydrogen sulfide in the Gas and Injected Liquids shall be determined by the GSPA Length of Stain Tube Method, or any other generally accepted industry method should the Length of Stain Tube Method be changed. Use of a
chromatographic gas analysis will provide the composition of the remaining components in the Gas and Injected Liquids stream. For all Gas and Injected Liquids analyses contemplated hereunder, Gatherer shall have the right, but not the obligation, to
change methods to meet recent industry standards; provided that such methods are deemed to be cost effective as determined by Gatherer in its sole business judgment. 

1.5 Curtailment of Gas and Injected Liquids. If capacity on the Gathering System, or any Subsystem thereof, is interrupted, curtailed
or reduced, or capacity is insufficient for the needs of all shippers desiring to use such capacity, the holders of Interruptible Service will be curtailed first, the holders of Firm Service shall be curtailed second, and the holders of Anchor
Shipper Firm Service shall be curtailed last. As among the holders of each of Firm Service and Anchor Shipper Firm Service, the capacity available on each Subsystem to each such class of service under the preceding sentence shall be allocated among
the holders of the applicable class of service on a pro rata basis, based on the percentage derived by dividing the Daily average volume of Gas and Injected Liquids actually Tendered by each holder of the applicable class of service to Receipt
Points on such Subsystem during the prior 90 Day period by the total volume of such Gas and Injected Liquids actually Tendered by all holders of the applicable class of service during such period to Receipt Points on such Subsystem. As among holders
of Interruptible Service, the capacity available to such service, if any, shall be allocated pro rata among the holders of such service based on the percentage derived by dividing the Daily average volume of Gas and Injected Liquids actually
Tendered by each holder of Interruptible Service to Receipt Points on such Subsystem during the prior 60 Day period by the total volume of such Gas and Injected Liquids actually Tendered by all holders of Interruptible Service to Receipt Points on
such Subsystem during such period. During periods of curtailment on the Gathering System, the Parties shall meet to review alternative options for Shipper to optimize its overall volume throughput and related revenues in light of the specific
constraints causing such curtailment on the Gathering System. 
 1.6 Allocations. Allocations required for determining payments or
Fees due under this Agreement shall be made by Gatherer. This Section 1.6 of the Operating Terms shall be based upon the measurements taken and quantities determined for the applicable Month. 

(a) The following definitions shall be applicable: “Fuel Point” means a point on the Gathering System where Gathering
System Fuel is measured, sampled, calculated or consumed. 

  
 Appendix I - Page 8 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 (b) Gathering System Fuel shall be allocated to each Receipt Point upstream of the applicable
Fuel Point by multiplying (i) the Gathering System Fuel, stated in Mcfs, measured at the applicable Fuel Point during the applicable Month by (ii) a fraction, (A) the numerator of which is the volume of Gas, stated in Mcfs,
received into the Gathering System at such Receipt Point during such Month, and (B) the denominator of which is the aggregate volume of Gas, stated in Mcfs, received into the Gathering System at all Receipt Points upstream of the applicable
Fuel Point during such Month. 
 (c) The Gathering System L&U in any Month shall be determined by subtracting (i) the sum of
(A) the Thermal Content of all volumes of Gas (including any Drip Liquids allocated to Shipper in accordance with this Agreement) and Injected Liquids actually delivered to the Delivery Points on the Gathering System during such Month, and
(B) the Thermal Content of all volumes of Gas consumed as Gathering System Fuel measured at all Fuel Points on the Gathering System during such Month, from (ii) the Thermal Content of all volumes of all Gas and Injected Liquids received
into the Gathering System at all Receipt Points. 
 (d) Drip Liquids recovered at the Drip Points by Gatherer shall be allocated to Shipper
as follows, in each case, on a Subsystem-by-Subsystem basis: Shipper shall be allocated that portion of the Drip Liquids recovered at the Drip Points on a Subsystem
equal to the proportion that (i) the Thermal Content of the aggregate volumes of Shipper Gas Tendered by Shipper at the Receipt Points on such Subsystem and received by Gatherer into the Gathering System during such Month, bears to
(ii) the Thermal Content of the aggregate volumes of all Gas (including Non-Party Gas and Shipper Gas) tendered by a shipper (whether Shipper or a Non-Party) at the
Receipt Points on such Subsystem and received by Gatherer into the Gathering System during such Month. 
 1.7 Mcf Equivalents. For
purposes of this Agreement, an Injected Liquid “Mcf Equivalent” or “MCFE” will be calculated as follows: 

** 
 For purposes of the formula included above, the following
abbreviations have the meanings set forth below. 
  

	 	(a)	 “A” = MCFE of Injected Liquids. 

 

	 	(b)	 “Q” = Barrels of Injected Liquids. 

 

	 	(c)	 “i” = Components of Injected Liquids (including
C1, C2, C3, C4, C5+, H2S, CO2, N2). 

  

	 	(d)	 “yi” = Volume percentage of Injected Liquid
component “i”, divided by 100. 

  

	 	(e)	 “vi” = Volume factor of Injected Liquid
component “i” (as taken from Table A below), measured in gallon/ft3. 

  
 Appendix I - Page 9 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

							
	 Table A1

	 Injected Liquids Components
	 	 	  	 Volume Factor

	 	 	 	  	(ft3 ideal gas/gal liquid)
	 Methane
	  	C1	 		  	59.138
	 Ethane
	  	C2	 		  	37.488
	 Propane
	  	C3,	 		  	36.391
	 i-butane
	  	iC4,	 		  	30.637
	 n-butane
	  	nC4,	 		  	31.801
	 i-pentane
	  	iC5	 		  	27.414
	 n-pentane
	  	nC5	 		  	27.658
	 Pentanes-plus
	  	C5+,	 		  	22.947(*)
	 hydrogen sulfide
	  	H2S	 		  	74.16
	 carbon dioxide
	  	CO2	 		  	58.746
	 nitrogen
	  	N2	 		  	91.128
	 (*) estimated as (iC5 + nC5)/2 x 1/1.2

  

	1 	 Table A information taken from Gas Processors Association Publication Standard
2145-09, “Table of Physical Constants for Hydrocarbons and Other Compounds of Interest to the Natural Gas Industry”, 2009. The Parties agree that Table A shall be updated from time to time as
necessary to reflect the latest edition of Gas Processors Association Publication Standard 2145. 

  
 Appendix I - Page 10 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 APPENDIX II 

DEFINITIONS 
 As used in
this Agreement, capitalized words and terms shall have the meaning ascribed to such terms as set forth below. 
 “A&R
Agreement” has the meaning given to such term in the recitals to this Agreement. 
 “Additional Gas”
means any Shipper Gas that is not Dedicated Production. 
 “Adequate Assurance” has the meaning given such term in
Section 18.2. 
 “Adequate Letter of Credit” means one or more direct-pay, irrevocable, standby letters of credit from a major U.S. commercial bank or a foreign bank with a U.S. branch office in either case having a credit rating of at least
“A-” (or its equivalent successor rating) from Standard & Poor’s Corporation or “A3” (or its equivalent successor rating) from Moody’s Investor Services, Inc. 

“Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more
intermediaries, Controls, or is Controlled by, or is under common Control with, such Person. 
 “AGA” has the
meaning given such term in Section 1.4(a) of the Operating Terms. 
 “Agreement” has the
meaning given such term in the preamble to this Agreement. 
 “Anchor Shipper Firm Service” means that type of
System Service that (a) has the highest priority call on capacity of all of the Gathering System, or any Subsystem thereof, (b) shall only be subject to interruption or curtailment by reason of an event of Force Majeure, necessary
Gathering System maintenance, or as otherwise expressly set forth in this Agreement, and (c) in any event, has a higher priority than Interruptible Service, Firm Service and any other permissible level of service established by Gatherer with
respect to the Gathering System. 
 “Applicable Requirements” means (a) any applicable pipeline’s
operating and engineering standards, (b) any and all applicable local state and federal Laws, and (c) any applicable operating regulations or directions of any Governmental Authority. 

“Bakken Area” means, collectively, the following Counties located in North Dakota: Adams, Billings, Bottineau, Bowman,
Burke, Burleigh, Divide, Dunn, Golden Valley, Hettinger, McHenry, McIntosh, McKenzie, McLean, Mercer, Morton, Mountrail, Renville, Slope, Stark, Walsh, Ward and Williams. 

“Btu”, “Gross Heating Value”, and “Thermal Content” means the amount
of heat required to raise the temperature of one avoirdupois pound of pure water from fifty-eight and one-half degrees Fahrenheit (58.5° F) to fifty-nine and
one-half degrees Fahrenheit (59.5° F) at a constant pressure of fourteen and seventy-three hundredths (14.73) pounds per square inch absolute. 

  
 Appendix II - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Business Day” means a Day (other than a Saturday or Sunday) on which
commercial banks in New York, New York are generally open for business. 
 “CCT” means the time in the Central Time
Zone, whether actual or programmed as Central Standard Time or Daylight Savings Time, or such other time as the Parties may agree upon. 

“Charges” has the meaning given such term in Section 7.2. 

“Claiming Party” has the meaning given such term in Section 14.1. 

“Combined Gathering Fee” means the Combined Goliath Gathering Fee, the Combined Hawkeye Gathering Fee and/or the
Combined Red Sky Gathering Fee, as the context requires. 
 “Combined Goliath Gathering Fee” has the meaning set
forth in Exhibit G-2. 
 “Combined Hawkeye Gathering Fee” has the
meaning set forth in Exhibit G-2. 
 “Combined Red Sky Gathering Fee”
has the meaning set forth in Exhibit G-2. 
 “Committed Build-Out Costs” has the meaning given such term in Section 5.2(c)(i). 

“Committed Build-Out Estimate” has the meaning given such term in
Section 5.2(c)(i). 
 “Committed Build-Outs” has the meaning given such term in
Section 5.2(b)(iii). 
 “Compression Services” has the meaning given such term in
Section 3.1(b). 
 “Compression Fees” means the Goliath Compression Fee, the Hawkeye
Compression Fee and/or the Red Sky Compression Fee, as the context requires. 
 “Confidential Information” has the
meaning given such term in Section 19.5. 
 “Conflicting Dedication” has the meaning given
such term in Section 4.2. 
 “Control” and its derivatives (a) with respect to any
Person, mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting shares, by contract, or otherwise, and (b) with respect to
any Gas (including any Drip Liquids allocable thereto) and/or Injected Liquids, means the right or obligation (pursuant to a marketing, agency, operating, unit or similar agreement or otherwise) of a Person to market such Gas and/or Injected
Liquids, as applicable; provided that such Person has elected or is obligated to market such Gas and/or Injected Liquids on behalf of a Non-Party. 

  
 Appendix II - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “CPI” has the meaning given such term in
Section 7.1(e)(xi). 
 “Current Development Plan” has the meaning given such term in
Section 5.1. 
 “Current Gathering System Plan” has the meaning given such term in
Section 5.2. 
 “Day” means a period of time beginning at 9:00 a.m. CCT on a calendar day
and ending at 9:00 a.m. CCT on the succeeding calendar day. The term “Daily” shall have the correlative meaning. 

“Dedicated Area” has the meaning given such term in Section 4.1(a)(i). 

“Dedicated Producer Gas” has the meaning given such term in Section 4.1(a)(i). 

“Dedicated Production” has the meaning given such term in Section 4.1(b). 

“Dedicated Production Estimates” has the meaning given such term in Section 5.1(b)(iii).

 “Dedicated Third Party Contracts” has the meaning given such term in
Section 4.1(a)(ii). 
 “Delivery Point” means the points of interconnection of the
Gathering System described on Exhibit I, which Exhibit may be updated from time to time by the Parties pursuant to this Agreement, including pursuant to the agreement on an Updated Development Plan and related updated Gathering System Plan
pursuant to Article 5. 
 “Development Period” means, as of any date of determination, the greater of
(a) the then-remaining Term of this Agreement (such remaining Term to be calculated using the assumptions that (i) Gatherer has elected to renew this Agreement for the Secondary Term applicable to each Subsystem and (ii) no Party has
elected to terminate the Agreement pursuant to Section 2.2(c)) and (b) thirteen (13) years. 

“Development Plan” has the meaning given such term in Section 5.1(a). 

“Downstream Facility” means (a) any pipeline downstream of any Delivery Point on the Gathering System, or
(b) a processing facility downstream of any Delivery Point (i) to which Shipper has dedicated, or in the future elects to dedicate, any Shipper Gas and/or Shipper Injected Liquids for processing, or (ii) at which Shipper has arranged
for Shipper Gas and/or Shipper Injected Liquids to be processed prior to delivery to a pipeline described in part (a) above. 

“Drip Liquids” means that portion of the Shipper Gas that is received into the Gathering System (without manual
separation or injection) and that condenses in, and is recovered from, the Gathering System as a liquid. 
 “Drip
Point” has the meaning given such term in Section 3.3. 

  
 Appendix II - Page 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Effective Time” has the meaning given such term in the preamble to
this Agreement. 
 “Exclusive Producer Purchase Right” has the meaning given such term in
Section 15.1(b). 
 “Executive Election” has the meaning given such term in
Section 5.3(e). 
 “Executive Representative” has the meaning given such term in
Section 5.3(e)(i). 
 “Fees” mean, collectively, (a) the Combined Gathering Fees,
Tariff Gathering Fees and/or Third Party Gathering Fees (as the context requires), (b) the Compression Fees and (c) the Shortfall Fees. 

“Firm Service” means that type of System Service that (a) other than Anchor Shipper Firm Service, has the highest
priority call on capacity of all of the Gathering System, or any Subsystem thereof, (b) shall only be subject to interruption or curtailment by reason of an event of Force Majeure, necessary Gathering System maintenance, or as otherwise
expressly set forth in this Agreement, and (c) in any event, has a higher priority than Interruptible Service. 
 “Force
Majeure” has the meaning given such term in Section 14.1. 
 “Fuel Point” has
the meaning given such term in Section 1.6(a) of the Operating Terms. 
 “Gas” means any
mixture of gaseous hydrocarbons, consisting essentially of methane and heavier hydrocarbons, including (unless otherwise expressly provided herein) liquefiable hydrocarbons and Drip Liquids, and including inert and noncombustible gases, in each
case, produced from beneath the surface of the earth. 
 “Gatherer” has the meaning given to it in the preamble of
this Agreement. 
 “Gatherer Group” has the meaning given such term in Section 16.2. 

“Gathering Services” has the meaning given such term in Section 3.1(a). 

“Gathering System” has the meaning given such term in Section 2.1. 

“Gathering System Fuel” means all Gas and electric power measured and utilized as fuel for the Gathering
System, including Gas and electric power utilized as fuel for compressor stations, stated in Mcfs or kilowatt hours, as applicable; provided, however, that “Gathering System Fuel” shall not include any (a) Gas or
electric power used as a result of Gatherer’s gross negligence or willful misconduct or (b) any residue gas utilized as fuel for the Gathering System. 

“Gathering System L&U” means any Gas and/or Injected Liquids received into the Gathering System that is lost or
otherwise not accounted for incident to, or occasioned by, the gathering, treating, compressing, stabilization, and redelivery, as applicable, of Gas (and any Drip Liquids allocable thereto) and/or Injected Liquids, including Gas (and any Drip
Liquids allocable 

  
 Appendix II - Page 4 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
thereto) and/or Injected Liquids released through leaks, instrumentation, relief valves, flares, and blow downs of pipelines, vessels, and equipment; provided, however, that “Gathering
System L&U” shall not include any Gas (or any Drip Liquids allocable thereto) and/or Injected Liquids that are lost as a result of Gatherer’s gross negligence or willful misconduct.  

“Gathering System Plan” has the meaning given such term in Section 5.2(a). 

“Gathering System Rules” means the rules communicated to Shipper by Gatherer, in each case, pertaining to access,
safety, conduct and use of the Gathering System. 
 “Goliath Compression Fee” has the meaning given such term in
Exhibit G-1. 
 “Goliath MVC” means the MVC
applicable to the Goliath Subsystem. 
 “Goliath Subsystem” has the meaning given such term in
Section 2.1. 
 “Governmental Authority” means any federal, state, local, municipal,
tribal or other government; any governmental, regulatory or administrative agency, commission, body or other authority exercising or entitled to exercise any administrative, executive, judicial, legislative, regulatory or taxing authority or power;
and any court or governmental tribunal, including any tribal authority having or asserting jurisdiction. 
 “GPA”
means that certain Second Amended and Restated Gas Processing and Fractionation Agreement, dated effective as of the Effective Time, by and between Shipper and Hess Bakken Processing LLC, as the same may be amended, amended and restated, modified or
supplemented from time to time. 
 “Group” means (a) with respect to Shipper, the Shipper Group, and
(b) with respect to Gatherer, the Gatherer Group. 
 “GSPA” has the meaning given such term in
Section 1.4(a) of the Operating Terms. 
 “Hawkeye Compression Fee” has the meaning given
such term in Exhibit G-1. 
 “Hawkeye MVC” means
the MVC applicable to the Hawkeye Subsystem. 
 “Hawkeye Subsystem” has the meaning given such term in
Section 2.1. 
 “Historical Capital Expenditures” means $**. 

“Initial Term” has the meaning given such term in Section 2.2. 

“Injected Liquids” means ethane, propane, methane, normal butane, isobutane, and C5+, and mixtures thereof that are in
a liquid state as Tendered into the Gathering System at the Injection Points for the System Services. 

  
 Appendix II - Page 5 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Injection Point” means a Receipt Point that is marked
“NGL” on the “Gas/NGL” column of Exhibit H. 
 “Interest Rate” means, on the applicable
date of determination (a) the prime rate (as published in the “Money Rates” table of The Wall Street Journal, eastern edition, or if such rate is no longer published in such publication or such publication ceases to be
published, then as published in a similar national business publication as mutually agreed by the Parties), plus (b) an additional two percentage points (or, if such rate is contrary to any applicable Law, the maximum rate permitted by
such applicable Law). 
 “Interruptible Service” means all obligations of Gatherer to provide System Services with
respect to Gas (and any Drip Liquids allocable to such Gas) and/or Injected Liquids, which obligations are designated as interruptible and as to which obligations Gatherer may interrupt its performance thereof for any or no reason. 

“Invoice” has the meaning given such term in Section 12.1. 

“Laws” means any applicable statute, law, rule, regulation, ordinance, order, code, ruling, writ, injunction, decree
or other official act of or by any Governmental Authority. 
 “Liquids Lines” has the meaning given such term in
Section 2.1. 
 “Loss” or “Losses” means any actions, claims,
settlements, judgments, demands, liens, losses, damages, fines, penalties, interest, costs, expenses (including expenses attributable to the defense of any actions or claims), attorneys’ fees and liabilities, including Losses for bodily injury,
death, or property damage. 
 “Maintenance Capital Estimate” has the meaning given such term in
Section 5.2(c)(iii). 
 “Maintenance Capital Expenditures” means cash expenditures
(including expenditures for the construction of new capital assets or the replacement, improvement or expansion of existing capital assets) by Gatherer that are made to maintain, over the long term, the operating capacity of the Gathering System.
For purposes of this definition, “long term” generally refers to a period of not less than 12 Months. 
 “Material
Dedicated Third Party Contract” means those Dedicated Third Party Contracts that (a) collectively account for Third Party Volumes comprising at least **% of the Third Party Volume Estimate, or (b) individually account for
Third Party Volumes expected to be greater than ** Mcf per Day, to the extent that such Dedicated Third Party Contract is not covered by subpart (a) of this definition.” 

“Mcf” means 1,000 Standard Cubic Feet. 

“MCFE” or “Mcf Equivalent” has the meaning given such term in
Section 1.7 of the Operating Terms. 

  
 Appendix II - Page 6 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Minimum Volume Commitment” or “MVC” has the
meaning given such term in Section 6.1. 
 “Month” means a period of time beginning at
9:00 a.m. CCT on the first Day of a calendar month and ending at 9:00 a.m. CCT on the first Day of the next succeeding calendar month. The term “Monthly” shall have the correlative meaning. 

“MPMS” has the meaning given such term in Section 1.3(a) of the Operating Terms. 

“MVC Shortfall Credits” has the meaning given such term in Section 6.2. 

“NAESB” means North American Energy Standards Board, or its successors. 

“Non-Party” means any Person other than a Party to this Agreement. 

“Non-Party Gas” means Gas owned by a
Non-Party. 
 “Non-Party Injected
Liquids” means Injected Liquids owned by a Non-Party. 

“Notice” has the meaning given such term in Section 19.2. 

“OFO” means an operational flow order or similar order respecting operating conditions issued by a Downstream
Facility. 
 “Operating Expense Estimate” has the meaning given such term in
Section 5.2(c)(iv). 
 “Operating Terms” means those additional terms and conditions
applicable to the System Services provided under this Agreement, as set forth in Appendix I. 
 “Operational
Failure” means any explosions, breakage or accidents to machinery or lines of pipe that are not caused by the gross negligence or willful misconduct of Shipper. 

“Original Agreement” means that certain Gas Gathering Agreement, dated effective as of the Effective Time, by and
between Shipper and Gatherer, as amended by (a) that certain First Amendment to Gas Gathering Agreement, entered into on April 2, 2015 and dated effective as of the Effective Time, (b) that certain Second Amendment to Gas Gathering
Agreement, entered into on July 1, 2015 and dated effective as of the Effective Time, and (c) that certain Third Amendment to Gas Gathering Agreement, entered into on December 2, 2016 and dated effective as of the Effective Time. 

“Party” or “Parties” has the meaning given such term in the preamble to this Agreement. 

“PDA” means, with respect to a Receipt Point or Delivery Point, a predetermined allocation directive from, or
agreement with, Shipper. 

  
 Appendix II - Page 7 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Person” means any individual, corporation, company, partnership,
limited partnership, limited liability company, trust, estate, Governmental Authority or any other entity. 
 “Planned Delivery
Point” has the meaning given such term in Section 5.1(b)(viii). 
 “Planned Receipt
Point” has the meaning given such term in Section 5.1(b)(v). 
 “Planned
Well” has the meaning given such term in Section 5.1(b)(ii). 
 “Producer”
means Hess Bakken Investments II, LLC, a Delaware limited liability company, and any of such Person’s successors and assigns. 

“Psia” means pounds per square inch absolute. 

“Quarter” means a period of three consecutive Months, commencing on the first day of January, the first day of April,
the first day of July and the first day of October in any Year. 
 “Recalculation Election” has the meaning given
such term in Section 7.1(e). 
 “Receipt Point” means the connecting flanges on the
Gathering System that are described on Exhibit H, which Exhibit may be updated from time to time by the Parties pursuant to this Agreement, including pursuant to the agreement on an Updated Development Plan and related updated Gathering
System Plan pursuant to Article 5. 
 “Red Sky Compression Fee” has the meaning given such term in
Exhibit G-1. 
 “Red Sky MVC” means the MVC
applicable to the Red Sky Subsystem. 
 “Red Sky Subsystem” has the meaning given such term in
Section 2.1. 
 “Residual Value” has the meaning given such term in Exhibit G-2. 
 “Return on Capital” means ** percent (**%), as such return level may
be modified by Gatherer pursuant to the provisions of Section 7.1(d). 
 “Secondary Term”
has the meaning given such term in Section 2.2. 
 “Shipper” has the meaning given such
term in the preamble of this Agreement. 
 “Shipper Gas” has the meaning given such term in the recitals to this
Agreement. 
 “Shipper Group” has the meaning given such term in Section 16.3. 

“Shipper Injected Liquids” has the meaning given such term in the recitals to this Agreement. 

  
 Appendix II - Page 8 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Shipper Parent” has the meaning given such term in
Section 18.1. 
 “Shortfall Fee” has the meaning given such term in
Section 7.1(c). 
 “Standard Base Conditions” means a pressure of fourteen and seventy
three hundredths (14.73) Psia at a temperature of sixty degrees Fahrenheit (60°F). The atmospheric pressure used by Gatherer where Gas is measured shall be assumed to be thirteen and five tenths (13.5) Psia, irrespective of the actual elevation
of the measurement station(s) above sea level or variations in atmospheric pressure that may occur from time to time. 

“Standard Cubic Foot” means the volume of Gas contained in one cubic foot of space at Standard Base Conditions. 

“Subsystem” means any of the Goliath Subsystem, Hawkeye Subsystem or Red Sky Subsystem, as the same may be amended or
modified by a Subsystem Extension. 
 “Subsystem Extension” has the meaning given such term in
Section 5.2(b)(iii). 
 “System Acquisition Costs” has the meaning given such term in
Section 5.2(c)(ii). 
 “System Acquisition Costs Estimate” has the meaning given such term
in Section 5.2(c)(iv). 
 “System Acquisitions” has the meaning given such term in
Section 5.2(b)(iii). 
 “System Budget” has the meaning given such term in
Section 5.2(c). 
 “System Fuel and Losses” means, with respect to each Subsystem, the sum
of: (a) all Gathering System Fuel; (b) all Gathering System L&U; and (c) any volume of Shipper Gas that is flared after being delivered into such Subsystem in each case, whether estimated or measured. 

“System Liquids Estimates” has the meaning given such term in Section 5.1(b)(iv). 

“System Production Estimates” has the meaning given such term in Section 5.1(b)(iv). 

“System Services” has the meaning given such term in Section 3.1. 

“Target Completion Date” has the meaning given such term in Section 5.2(b)(v). 

“Tariff Gathering Fee” means the Tariff Goliath Gathering Fee, the Tariff Hawkeye Gathering Fee and/or the Tariff Red
Sky Gathering Fee, as the context requires. 
 “Tariff Goliath Gathering Fee” has the meaning set forth in
Exhibit G-2. 
 “Tariff Hawkeye Gathering Fee” has the meaning set
forth in Exhibit G-2. 

  
 Appendix II - Page 9 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 “Tariff Red Sky Gathering Fee” has the meaning set forth in
Exhibit G-2. 
 “Tariff Volume Estimates” has the meaning given such
term in Section 5.1(b)(iii). 
 “Tariff Volumes” means Shipper Injected Liquids and
Shipper Gas that are not Third Party Volumes, and specifically includes all Dedicated Producer Gas and all Additional Gas. 

“Tender” and its derivatives mean, with respect to Gas or Injected Liquids, the act of Shipper’s making Shipper
Gas and/or Shipper Injected Liquids available or causing Shipper Gas and/or Shipper Injected Liquids to be made available to the Gathering System at a Receipt Point. 

“Term” has the meaning given such term in Section 2.2. 

“Third Party Contract” means any contract that is entered into from time to time between Shipper, on the one hand, and
a Non-Party, on the other hand, (a) pursuant to which Shipper obtains ownership or Control of Shipper Gas or Shipper Injected Liquids at or upstream of a Receipt Point, and (b) with respect to which
Shipper requests that System Services be provided hereunder for such Shipper Gas or Shipper Injected Liquids from the applicable Receipt Point. 

“Third Party Contract Fee” means, with respect to each Mcf (or MCFE, as applicable) of Third Party Volume, the amount
that Shipper is entitled to receive from its counterparty pursuant to the terms of the applicable Dedicated Third Party Contract governing such Third Party Volumes, whether in the form of (a) cash payments, (b) the right to receive a
percentage of proceeds from the sale of such counterparty’s Third Party Volumes, (c) deducts from, or credits to, amounts owed by Shipper to such counterparty (whether under such Third Party Contract or otherwise), or (d) otherwise,
in each case, as consideration for the System Services to be provided to such Mcf (or MCFE, as applicable) of Third Party Volume under the terms of such Third Party Contract. For the purposes of calculating each Third Party Contract Fee, no amounts
comprising any Third Party Contract Fee hereunder may be included in the calculation of the applicable “Third Party Contract Fee” (as defined in the GPA) relating to the same Third Party Contract under the GPA (and vice versa). In order to
effect the division of any such consideration received by Shipper under such Third Party Contract between the Third Party Contract Fee hereunder and the applicable “Third Party Contract Fee” (as defined in the GPA) under the GPA in respect
of the same Third Party Contract, the Parties acknowledge and agree that all consideration under such Third Party Contract to which Shipper is entitled shall (i) first, be converted to an expected fee per Mcf or MCFE, as applicable, to be
realized by Shipper based on the forecasted market prices contained in the then-current Development Plan for the periods covered by such Third Party Contract, (ii) second, to the extent the consideration in such Third Party Contract is
specifically allocated to either the System Services under this Agreement or the “System Services” (as defined in the GPA) under the GPA, allocated to either this Agreement or the GPA, as applicable, and (iii) third, to the extent the
consideration in such Third Party Contract is not specifically allocated to either the System Services under this Agreement or the “System Services” (as defined in the GPA) under the GPA, such consideration shall be allocated between this
Agreement and the GPA by Gatherer in a good faith manner that reasonably represents the allocation of costs and services 

  
 Appendix II - Page 10

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 
between this Agreement and the GPA, which allocation the Parties agree shall initially be **% of such consideration to this Agreement and **% of such consideration to the GPA. Any portion of such
consideration allocated to this Agreement under either subpart (ii) or subpart (iii), as applicable, (A) shall be applied first to Fees owed by Shipper other than Third Party Gathering Fees, and (B) any remainder of such consideration
shall be applied to Third Party Gathering Fees owed by Shipper. 
 “Third Party Gathering Fee” means the Third Party
Goliath Gathering Fee, the Third Party Hawkeye Gathering Fee and/or the Third Party Red Sky Gathering Fee, as the context requires. 

“Third Party Goliath Gathering Fee” has the meaning set forth in Exhibit
G-2. 
 “Third Party Hawkeye Gathering Fee” has the meaning set forth in
Exhibit G-2. 
 “Third Party Red Sky Gathering Fee” has the meaning
set forth in Exhibit G-2. 
 “Third Party Volume Estimates” has the
meaning given such term in Section 5.1(b)(iii). 
 “Third Party Volumes” means Shipper
Injected Liquids and Shipper Gas owned or Controlled by Shipper pursuant to the terms of the Dedicated Third Party Contracts, with such volumes being determined by the amount of all Third Party Volumes Tendered by Shipper pursuant to this Agreement
during the applicable Year (in each case, stated in Mcfs or MCFEs, as applicable) as measured at the applicable Receipt Points. Any volume of Shipper Gas that (a) is delivered by or on behalf of Shipper hereunder, (b) constitutes Dedicated
Producer Gas, and (c) that is delivered at a meter controlled by a Person other than a Party or its Affiliates shall not, for the avoidance of doubt, be characterized hereunder as a Third Party Volume. 

“Uneconomic” has the meaning given such term in Section 10.1(b)(i). 

“Updated Development Plan” has the meaning given such term in Section 5.1(a). 

“Well” means a well for the production of hydrocarbons that is either producing, or is intended to produce,
Dedicated Production. 
 “Year” means a period of time on and after January 1 of a calendar year through and
including December 31 of the same calendar year; provided that the first Year shall commence on the execution date of the Original Agreement and run through December 31 of that calendar year, and the last Year shall commence on
January 1 of the calendar year and end on the Day on which this Agreement terminates. 

  
 Appendix II - Page 11

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT A-1 

GOLIATH SUBSYSTEM 
 The Goliath Subsystem
consists of existing pipelines, interconnections, facilities, equipment, appurtenances and surface rights, in each case, located north of the Little Missouri River and in Williams County, North Dakota. 

The Goliath Subsystem (a) commences at the Receipt Points denoted in the “Tariff Field” column of Exhibit H as “GO”, and
(b) terminates at the applicable Delivery Points described in Exhibit I. 
 The Goliath Subsystem includes those Liquids Lines identified on
Exhibit A-4 that are marked “GO” in the Tariff Field column. 

  
 Exhibit A-1 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT A-2 

HAWKEYE SUBSYSTEM 
 The Hawkeye Subsystem
consists of existing pipelines, interconnections, facilities, equipment, appurtenances and surface rights, in each case, located in McKenzie, Williams and Mountrail Counties, North Dakota. 

The Hawkeye Subsystem (a) commences at the Receipt Points denoted in the “Tariff Field” column of Exhibit H as “HA”, and
(b) terminates at the applicable Delivery Points described in Exhibit I. 
 The Hawkeye Subsystem includes those Liquids Lines identified on
Exhibit A-4 that are marked “HA” in the Tariff Field column. 

  
 Exhibit A-2 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT A-3 

RED SKY SUBSYSTEM 
 The Red Sky Subsystem
consists of existing pipelines, interconnections, facilities, equipment, appurtenances and surface rights, in each case, located north of the Little Missouri River and in Williams, Mountrail, Divide and Burke Counties, North Dakota. 

The Red Sky Subsystem (a) commences at the Receipt Points denoted in the “Tariff Field” column of Exhibit H as “RS”, and
(b) terminates at the applicable Delivery Points described in Exhibit I. 
 The Red Sky Subsystem includes those Liquids Lines identified on
Exhibit A-4 that are marked “RS” in the Tariff Field column. 

  
 Exhibit A-3 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT A-4 

LIQUIDS LINES 
  

													
	 Description
	  	 Size
	  	 Beginning
Location
	  	 Delivery Point
	  	 Source
	  	 Tariff
Field
	  	 Existing /
Future

	 1.  Goliath NGL Line
	  	**	  	Wheelock Compressor Station	  	TGP	  	Liquids from Wheelock	  	GO	  	Existing
							
	 2.  Sorkness NGL Line
	  	**	  	Sorkness Compressor Station	  	Red Sky NGL Line	  	Liquids from Sorkness	  	RS	  	Existing
							
	 3.  Red Sky NGL Line
	  	**	  	Ross Compressor Station	  	Silurian	  	Liquids from Ross, Sorkness, Myrtle	  	RS	  	Existing
							
	 4.  NGL line from Hawkeye to Silurian (Repurposed from HP Wet Gas Line).
	  	**	  	Hawkeye Compressor Station	  	Silurian	  	Liquids from Hawkeye	  	HA	  	Existing

  
 Exhibit A-4 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT B-1 

DEDICATED AREA 
 For
purposes of this Agreement, as of January 1, 2018, the “Dedicated Area” is the entire Bakken Area. 

  
 Exhibit B-1 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT B-2 

DEDICATED THIRD PARTY CONTRACTS 
  

					
	 Counter Party
	  	 Contract#
	  	
Termination2

	 **
	  	15-GPA-0006	  	 **

	 **
	  	G-0282	  	**
	 **
	  	16-GPA-0022	  	 **

	 **
	  	16-GPA-0025	  	 **

	 **
	  	16-GPA-0024	  	 **

	 **
	  	G-0316	  	**
	 **
	  	G-0300	  	**
	 **
	  	G-0411	  	**
	 **
	  	17-GPA-0028	  	 **

	 **
	  	17-GPA-0029	  	 **

	 **
	  	GAS-2003-000033	  	 **

	 **
	  	G-0388	  	**
	 **
	  	G-0385	  	**
	 **
	  	16-GPA-0017	  	 **

	 **
	  	G-0281	  	**
	 **
	  	18-GPA-0030	  	 **

	 **
	  	16-GPA-0016	  	 **

	 **
	  	16-GPA-0021	  	 **

	 **
	  	G-0283	  	**
	 **
	  	16-GPA-0023	  	 **

	 **
	  	G-4141	  	**
	 **
	  	16-GPA-0015	  	 **

	 **
	  	G-0318	  	**
	 **
	  	16-GPA-0020	  	 **

	 **
	  	G-0326	  	**

  

	2 	 See Key on Page 2 of Exhibit B-2 for list of abbreviations

  
 Exhibit B-2 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

					
	 Counter Party
	  	 Contract#
	  	
Termination2

	 **
	  	G-0347	  	**
	 **
	  	G-0354	  	**
	 **
	  	G-0339	  	**
	 **
	  	G-0359	  	**
	 **
	  	G-0358	  	**
	 **
	  	GAS-2005-000034	  	 **

	 **
	  	G-0410	  	**

  

			
	 Abbreviation
	  	Definition
	 LOL
	  	Life of Lease
	 MTM
	  	Month to Month
	 YTY
	  	Year to Year

  
 Exhibit B-2 - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT C 

CONFLICTING DEDICATIONS 
  

							
	 Party
	  	 Agreement
	  	 Effective
	  	Expiration
	 **
	  	**	  	**	  	**
	 **
	  	**	  	**	  	**
	 **
	  	**	  	**	  	**
	 **
	  	**	  	**	  	**
	 **
	  	**	  	**	  	**

 For the avoidance of doubt, no Shipper Gas subject to a Conflicting Dedication is, or shall be, included in any Dedicated
Production Estimates contained in any Development Plan delivered by Shipper hereunder while the applicable Conflicting Dedication is still in effect. 

  
 Exhibit C - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT D 

CURRENT DEVELOPMENT PLAN 
 Notwithstanding
anything in Section 5.1 to the contrary, the Parties acknowledge that (a) the Current Development Plan contained in this Exhibit D does not contain all of the information called for by
Section 5.1 with respect to each Development Plan, as it is recognized that current Shipper reporting, process, and system capabilities limit the Current Development Plan to the detail shown below, and (b) the Current
Development Plan contained in this Exhibit D has been prepared and is presented in accordance with the requirements of Section 5.1 of the A&R Agreement, and (c) in respect of Development Plans prepared for
Year 2019 and thereafter, each such Updated Development Plan shall be prepared in accordance with Section 5.1 of this Agreement. 

SCHEDULE 1 – DEDICATED PRODUCTION ESTIMATES BY RECEIPT POINT (Quarterly) 

 

																																																	
	 MMcfd
	  	1Q18	 	 	2Q18	 	 	3Q18	 	 	4Q18	 	 	1Q19	 	 	2Q19	 	 	3Q19	 	 	4Q19	 	 	1Q20	 	 	2Q20	 	 	3Q20	 	 	4Q20	 
	 Goliath System Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - High Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - Low Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (Does not require compression)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (high pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (low pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye System Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - High Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - Low Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (Does not require compression)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (high pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (low pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Red Sky System Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - High Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - Low Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (Does not require compression)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (high pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (low pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 

  
 Exhibit D - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 SCHEDULE 1 – DEDICATED PRODUCTION ESTIMATES BY RECEIPT POINT (Annual) 

 

																																																					
	 MMcfd
	  	2021	 	 	2022	 	 	2023	 	 	2024	 	 	2025	 	 	2026	 	 	2027	 	 	2028	 	 	2029	 	 	2030	 	 	2031	 	 	2032	 	 	2033	 
	 Goliath System Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - High Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - Low Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (Does not require compression)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (high pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (low pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye System Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - High Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - Low Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (Does not require compression)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (high pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (low pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Red Sky System Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - High Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - Low Pressure
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (Does not require compression)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (high pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Gathering to TGP - 3rd Party (low pressure)
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 

  
 Exhibit D - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 SCHEDULE 2 – DEDICATED PRODUCTION ESTIMATES BY DELIVERY POINT3 
  

																																																									
	 MMcfd
	  	1Q18	 	 	2Q18	 	 	3Q18	 	 	4Q18	 	 	1Q19	 	 	2Q19	 	 	3Q19	 	 	4Q19	 	 	1Q20	 	 	2Q20	 	 	3Q20	 	 	4Q20	 	 	 	 	 	 	 
	 TGP High Pressure Inlet
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 				 			
	 TGP Low Pressure Inlets
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 				 			
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 				 			
	 Total
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 				 			
															
	 	  	 	 	 	2021	 	 	2022	 	 	2023	 	 	2024	 	 	2025	 	 	2026	 	 	2027	 	 	2028	 	 	2029	 	 	2030	 	 	2031	 	 	2032	 	 	2033	 
	 TGP High Pressure Inlet
	  				 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 TGP Low Pressure Inlets
	  				 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
		  				 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total
	  				 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 

  

	3 	 Schedule 2 is broken out by general Delivery Point groups, and not by individual Delivery Points. See lead in
paragraph to this Exhibit D. 

  
 Exhibit D - Page 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT E 

CURRENT GATHERING SYSTEM PLAN 
 The Current
Gathering System Plan includes the information required by Section 5.2(b) of the A&R Agreement. The Parties acknowledge and agree that, in respect of Gathering System Plans prepared for Year 2019 and thereafter, each
such updated Gathering System Plan shall be prepared in accordance with Section 5.2(b) of this Agreement and include the additional information required thererby: 

Section 5.2(b)(i): See Exhibit A-1, Exhibit
A-2, Exhibit A-3, and Exhibit A-4. 

Section 5.2(b)(ii): See Exhibit H and Exhibit I. 

Section 5.2(b)(iii): See Schedule 1 attached below. 

Section 5.2(b)(iv): See Schedule 1 attached below. 

Section 5.2(b)(v): See Schedule 2 attached below. 

SCHEDULE 1: SUBSYSTEM EXTENSIONS AND TARGET COMPLETION DATES 
  

			
	Subsystem Extension	  	 Target

Completion

Date

	Various Red Sky Subsystem Extension Items	  	2030
	Various Hawkeye Subsystem Extension Items	  	2030
	Various Goliath Subsystem Extension Items	  	2030

  
 Exhibit E - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 SCHEDULE 2: CHANGES TO FEES DUE TO A RECALCULATION
ELECTION4 
  

			
	FEE TYPE:	  	FEE AMOUNT:
	Gathering Fees5:	  	
	Goliath Gathering Fee	  	$**/Mcf
	Hawkeye Gathering Fee	  	$**/Mcf
	Red Sky Gathering Fee	  	$**/Mcf
		
	Compression Fees:	  	
	Goliath Compression Fee	  	$**/Mcf
	Hawkeye Compression Fee	  	$**/Mcf
	Red Sky Compression Fee	  	$**/Mcf

  
  

	4 	 The 2018 Fee Calculation Model is based on nine months actuals plus three months forecast for the year 2017.
The last three months of the forecast for 2017 will be updated with 2017 actuals in the 2019 Fee Calculation Model. 

	5 	 The Gathering Fees (as defined in the A&R Agreement) will be applied in Year 2018 on a per Mcf basis (in
the case of Shipper Gas) and a per MCFE basis (in the case of Shipper Injected Liquids), as applicable 

  
 Exhibit E - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Included below is the System Budget that corresponds to the Current Gathering System Plan set forth in this
Exhibit E. The System Budget below includes the information required by Section 5.2(c) of the A&R Agreement. The Parties acknowledge and agree that, in respect of System Budgets prepared for Year 2019 and
thereafter, each such updated System Budget shall be prepared in accordance with Section 5.2(c) of this Agreement and include the additional information required thereby: 

Section 5.2(c)(i): See Schedule A attached below. 

Section 5.2(c)(ii): See Schedule B attached below. 

Section 5.2(c)(iii) & (iv): See Schedule C attached below. 

SCHEDULE A: COMMITTED BUILD-OUT COSTS 

 

																									
	 $(thousands)
	  	2018	 	 	2019	 	 	2020	 	 	2021	 	 	2022	 	 	2023	 
	 Red Sky - Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Red Sky - Gas Compression
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye - Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye - Gas Compression
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Goliath - Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Goliath - Gas Compression
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 

 SCHEDULE B: MAINTENANCE CAPITAL ESTIMATES 
  

																									
	 $(thousands)
	  	2018	 	 	2019	 	 	2020	 	 	2021	 	 	2022	 	 	2023	 
	 Red Sky - Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Red Sky - Gas Compression
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye - Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye - Gas Compression
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Goliath – Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Goliath - Gas Compression
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 

  
 Exhibit E - Page 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 SCHEDULE C: OPERATING EXPENSE ESTIMATES6 AND
ESTIMATED SCHEDULE OF MAINTENANCE 
  

																									
	 $(thousands)
	  	2018	 	 	2019	 	 	2020	 	 	2021	 	 	2022	 	 	2023	 
	 Red Sky Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Hawkeye Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
	 Goliath Gas Gathering
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 Total
	  	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 	 	 	*	* 

  
  

	6 	 The 2018 Fee Calculation Model is based on an estimated operating expense budget and reflected in Schedule C of
this Exhibit E. The Operating Expense Estimate that was approved by the Hess Infrastructure Partners GP LLC Board on December 8, 2016 will be used in the 2019 Fee Calculation Model. 

  
 Exhibit E - Page 4 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT F 

CURRENT MINIMUM VOLUME COMMITMENTS 
  

																																																	
	 	  	Applicable MVC for 2018/2019 - higher of 2017 or 2 018 nomination	 	  	 	 	  	 	 	  	 	 	  	 	 	  	 	 	  	 	 
	 Gas Gathering (MMcf/d)
	  	Q1 2118	 	  	Q2 2018	 	  	Q3 2018	 	  	Q4 2018	 	  	Q1 2019	 	  	Q2 2019	 	  	Q3 2019	 	  	Q4 2019	 	  	Ql 2020	 	  	Q2 2020	 	  	Q3 2020	 	  	Q4 2020	 
	 Goliath
	  	 	12.074	 	  	 	27.955	 	  	 	23.432	 	  	 	23.564	 	  	 	28.468	 	  	 	20.456	 	  	 	14.521	 	  	 	26.893	 	  	 	27.719	 	  	 	25.071	 	  	 	28.743	 	  	 	25.702	 
	 Hawkeye
	  	 	142.911	 	  	 	132.144	 	  	 	137.956	 	  	 	137.954	 	  	 	134.531	 	  	 	129.936	 	  	 	137.670	 	  	 	158.638	 	  	 	172.933	 	  	 	173.975	 	  	 	181.010	 	  	 	177.387	 
	 Red Sky
	  	 	99.893	 	  	 	95.774	 	  	 	94.724	 	  	 	93.023	 	  	 	68.773	 	  	 	60.361	 	  	 	72.960	 	  	 	74,403	 	  	 	71.622	 	  	 	71.670	 	  	 	79.692	 	  	 	81.679	 

  
 Exhibit F - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT G-1 

CURRENT FEES 
  

					
	 FEE TYPE:
	  	FEE AMOUNT7:	 
	 Gathering Fees8:
	  			
	 Goliath Gathering Fee
	  	$	*	*/Mcf 
	 Hawkeye Gathering Fee
	  	$	*	*/Mcf 
	 Red Sky Gathering Fee
	  	$	*	*/Mcf 
		
	 Compression Fees:
	  			
	 Goliath Compression Fee
	  	$	*	*/Mcf 
	 Hawkeye Compression Fee
	  	$	*	*/Mcf 
	 Red Sky Compression Fee
	  	$	*	*/Mcf 

  
  

 

	7 	 The 2018 Fee Calculation Model is based on nine months actuals plus three months forecast for the year 2017.
The last three months of the forecast for 2017 will be updated with 2017 actuals in the 2019 Fee Calculation Model. 

	8 	 The Gathering Fees (as defined in the A&R Agreement) will be applied in Year 2018 on a per Mcf basis (in
the case of Shipper Gas) and a per MCFE basis (in the case of Shipper Injected Liquids), as applicable. For Year 2019 and thereafter, the Combined Gathering Fees, Tariff Gathering Fees and Third Party Gathering Fees will be added in any updates of
this Exhibit G-1 and shall also apply on a per Mcf basis (in the case of Shipper Gas) and a per MCFE basis (in the case of Shipper Injected NGLs), as applicable. 

  
 Exhibit G-1 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT G-2 

TARIFF FEE RECALCULATION MODEL 

Calculation Methodology prior to January 1, 2019 

Notwithstanding anything herein to the contrary, with respect to all periods prior to January 1, 2019, the provisions of Exhibit G-2 set forth in the A&R Agreement shall, in each case, remain applicable hereunder with respect to such period. 

Calculation Methodology as of January 1, 2019 
  

	 	•	 	 The production profile used will be based on the Current Development Plan (or agreed, Updated Development Plan
with respect to Year 2019, as applicable). To the extent appropriate, the production profile is adjusted by an operating factor of **% to reflect realistic operations. Further, the Current Development Plan will be adjusted to reflect major
maintenance and turnarounds. 

  

	 	•	 	 Initial capital (opening balance) is based upon net book value as of December 31, 2013.

  

	 	•	 	 Committed Build-Out Costs, Maintenance Capital Estimates and System
Acquisition Estimates are based on the Current Gathering System Plan (or agreed, updated Gathering System Plan with respect to Year 2019, as applicable). 

  

	 	•	 	 Operating Expense Estimates are derived from the Current Gathering System Plan (or agreed, updated Gathering
System Plan with respect to Year 2019, as applicable). 

  

	 	•	 	 Includes projected public company and executive management costs allocated on a pro rata basis to the assets.

  

	 	•	 	 Includes major maintenance and turnaround expenses 

 

	 	•	 	 “Residual Value” equals the aggregate of the following calculations made with respect to
each Subsystem, (a) the sum of initial capital, Committed Build-Out Costs and System Acquisition Costs over the Initial Term (10 or 15 years depending on the Subsystem), in each case, as such foregoing
terms and concepts are applicable to such Subsystem only, multiplied by (b) (i) one, minus (ii) (A) the ratio of cumulative throughput on such Subsystem from the Current Development Plan (or agreed, Updated Development Plan
with respect to Year 2019, as applicable) in the Initial Term (10 or 15 years depending on the Subsystem) applicable to such Subsystem, divided by (B) the cumulative throughput on such Subsystem from the Current Development Plan (or
agreed, Updated Development Plan with respect to Year 2019, as applicable) over the full plan period (20 years). 

  

	 	•	 	 The Return on Capital (unadjusted), using a mid-year convention, was
utilized. 

  
 Exhibit G-2 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

	 	•	 	 Tariff Gathering Fees are expressed as an escalating $/Mcf or $/MCFE figure required to achieve the Return on
Capital. 

  

	 	•	 	 Tariff Gathering Fees are escalated based on the average annual percentage change in the CPI for the 10 years
prior to each Recalculation Election date and will be expressed on an annual basis in forward years. 

  

	 	•	 	 Market-based Fees not subject to target return calculation but subject to CPI escalation: 

 

	 	•	 	 Compression Fees 

  

	 	•	 	 If applicable, pass-through costs (power and utilities, other) and market-based revenue streams (compression
fees, short-haul/injection fees, other) are set to offset costs to be recovered. 

 Combined Gathering Fees: 

 

	 	•	 	 The “Tariff Goliath Gathering Fee” will be as calculated for each Year beginning with
2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Tariff Hawkeye Gathering Fee” will be as calculated for each Year beginning with
2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Tariff Red Sky Gathering Fee” will be as calculated for each Year beginning with
2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Third Party Goliath Gathering Fee” will be as calculated for each Year beginning
with 2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Third Party Hawkeye Gathering Fee” will be as calculated for each Year beginning
with 2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Third Party Red Sky Gathering Fee” will be as calculated for each Year beginning
with 2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Combined Goliath Gathering Fee” will be as calculated for each Year beginning with
2019 pursuant to this Exhibit G-2. 

  

	 	•	 	 The “Combined Hawkeye Gathering Fee” will be as calculated for each Year beginning with
2019 pursuant to this Exhibit G-2. 

  
 Exhibit G-2 - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

	 	•	 	 The “Combined Red Sky Gathering Fee” will be as calculated for each Year beginning with
2019 pursuant to this Exhibit G-2. 

  
 Exhibit G-2 - Page 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Redetermination Methodology 

Each year, if a Recalculation Election is made pursuant to Section 7.1(e), the Tariff Gathering Fees will be recalculated to reflect:

  

	 	•	 	 The enumerated items in Section 7.1(e)(i) through (xi). 

 

	 	•	 	 Should Gatherer and its Affiliates transfer, sell or otherwise dispose, in whole or in part, of any System
Acquisition, then the System Acquisition Costs and System Acquisition Cost Estimates applicable to such portion of such System Acquisition so disposed shall be deducted from the recalculation model as of the Year of such disposition, regardless if
the cash or non-cash consideration received by Gatherer and its Affiliates in respect of such sale or other disposition is equal to in excess of such System Acquisition Costs and System Acquisition Cost
Estimates applicable to such portion of such System Acquisition so disposed. 

  

	 	•	 	 The present value of prior year(s) revenue and throughput will be subtracted from the “Required Cost
Recovery” and “Escalating Tariff Throughput” (as each such term is used in the following example calculations) calculations so that the new Fees reflect costs to be recovered over the remaining Term applicable to each Subsystem
coupled with expected throughput. 

  

	 	•	 	 Operating Expense Estimates based upon the latest updated Gathering System Plan for the applicable year and
subsequent years. Prior year(s) operating expenses will not be trued-up to actuals. 

  

	 	•	 	 Projected public company and executive management costs allocated on a pro rata basis to the assets.

  

	 	•	 	 Major maintenance and turnaround expenses not otherwise included in the above listed items.

  

	 	•	 	 Any scheduled downtime of the Gathering System. 

 

	 	•	 	 Adjusted Residual Value based on latest Updated Development Plan. 

 

	 	•	 	 All other assumptions will be the same as the Original Methodology set forth above. 

  
 Exhibit G-2 - Page 4 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Each Year beginning in 2019, the Third Party Gathering Fee and Combined Gathering Fee for each Subsystem will
be calculated (or recalculated, as applicable) as follows: 
  

	 	•	 	 The Third Party Gathering Fee for each Subsystem for each Year beginning in 2019 shall be calculated (or
recalculated, as applicable) for such Year (irrespective of whether a Recalculation Election is made) as follows for such Year: (a) an amount equal to the sum of (i) the Third Party Contract Fee for each Material Dedicated Third Party
Contract applicable to such Subsystem for such Year, multiplied by (ii) the Third Party Volume Estimate (only to the extent such estimate relates to the Material Third Party Contracts) associated with such Subsystem for such Year
attributable to such Material Dedicated Third Party Contract; divided by (b) the total Third Party Volume Estimate (only to the extent such estimate relates to the Material Dedicated Third Party Contracts) for such Subsystem and such Year. An
example of such calculation is included below. 

  

	 	•	 	 The Combined Gathering Fee for each Subsystem for each Year beginning in 2019 shall be calculated (or
recalculated, as applicable) for such Year (irrespective of whether a Recalculation Election is made) as follows for such Year: (a) (i) an amount equal to (A) the Third Party Gathering Fee applicable to such Subsystem for such Year,
multiplied by (B) the Third Party Volume Estimate applicable to such Subsystem for such Year; plus (ii) an amount equal to (A) the Tariff Volume Estimate applicable to such Subsystem for such Year, multiplied by
(B) the then-applicable Tariff Gathering Fee applicable to such Subsystem; divided by (b) an amount equal to (i) the Third Party Volume Estimate applicable to such Subsystem for such Year, plus (ii) the Tariff Volume
Estimate applicable to such Subsystem for such Year. An example of such calculation is included below. 

  
 Exhibit G-2 - Page 5 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Examples 

Third Party Gathering Fee Example: An example calculation of the Third Party Gathering Fee for a given Subsystem for Year “X”
is set forth below: 
  

									
	 Third Party Contracts
	  	Third Party Contract Fees
(Estimated)
($/Mcf or MCFE)	 	 	Third Party Volume
Estimates	 
	 Contract “A”:
	  	$	         	** 	 	 	        	** 
	 Contract “B”:
	  	$	     	** 	 	 	        	** 
	 Contract “C”:
	  	$	         	** 	 	 	        	** 
	 Third Party Gathering Fee for Year “X”:
	  
	 	$	*	*/Mcf 

 Combined Gathering Fee Example: An example calculation of the Combined Gathering Fee for the same
Subsystem for Year “X” is set forth below: 
  

									
	 	  	Applicable Fee
(Mcf/d)	 	 	Dedicated Production
Estimates (MMcf/d)	 
	 Third Party Volumes:
	  	$	         	**9 	 	  	         	**10 
	 Tariff Volumes:
	  	$	         	**11 	 	  	         	**12 
	 Combined Gathering Fee for Year “X”:
	  
	 	$	*	*/Mcf 

  
  

	9 	 To be the Third Party Gathering Fee applicable to such Subsystem for Year “X”. 

	10 	 To be the Third Party Volume Estimate applicable to such Subsystem for Year “X”.

	11 	 To be the Tariff Gathering Fee applicable to such Subsystem for Year “X”. 

	12 	 To be the Tariff Volume Estimate applicable to such Subsystem for Year “X”. 

  
 Exhibit G-2 - Page 6 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Example Fee Calculation (Hawkeye and Red Sky) 

 

																													
	Example Fee Calculation - Gas Gathering Combined Fee
															
	 	  	 	 	 Calculations / Notes
	 	2013	 	2014	 	2015	 	2016	 	2017	 	2018	 	2019	 	2020	 	2021	 	2022	 	2023	 	2024
	A	  	Discounting Date	 		 	31-Dec	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun
	B	  	IRR**	 		 		 		 		 		 		 		 		 		 		 		 		 	
	C	  	Tariff Escalation Index **	 	CPI –annual update	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**
		  		 		 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  

	 Cost Estimates
	 		 		 		 		 		 		 		 		 	
	D	  	Initial Capital	 		 	Actual	 		 		 		 		 		 		 		 		 		 		 	
	E	  	System Acquisition Costs	 		 		 		 		 		 		 		 		 		 		 		 		 	
	F	  	Committed Build-Out Costs	 		 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	
	G	  	Maintenance Capital Estimates	 		 		 	SP	 	SP	 	SP	 	SP	 	SP	 	#	 	#	 	#	 	#	 	#	 	
	H	  	Operating Expenses	 		 		 	SP	 	SP	 	SP	 	SP	 	SP	 	#	 	#	 	#	 	#	 	#	 	
	I	  	Total Costs Before Add backs	 	D + E + F + G + H	 	Actual	 	Actual/SP	 	Actual/SP	 	Actual/SP	 	Actual/SP	 	Actual/SP	 	#	 	#	 	#	 	#	 	#	 	
	 Add backs (decreases required cost recovery)
	 		 		 		 		 		 		 		 		 	
	J	  	Power & Utilities Pass-through*	 		 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	
	K	  	Compression Revenues*	 	=$*** C * High Pressure Gas Tariff Vol.	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	
	L	  	Third-Party Contract Revenues	 	= AA	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	
	M	  	Residual Value	 	See description	 		 		 		 		 		 		 		 		 		 		 		 	#
		  		 		 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  

	N	  	Total Add backs	 	= J + K + L + M	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#
	O	  	Net Total Costs	 	= I - N	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#
	P	  	Required Cost Recovery	 	= XNPV (B, A, O) - 
XNPV (2014 - 2018 Actual Revenue)	 	PV @ **%
as of
1/1/14	 		 		 		 		 		 		 		 		 		 		 	
	 Throughput Estimate (Mbbls or MMcf)
	 		 		 		 		 		 		 		 		 	
	Q	  	Tariff Volumes	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	
	R	  	Third Party Volumes	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	
	S	  	Total Throughput Volumes	 	= Q + R	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	
	T	  	Operating Factor	 		 		 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	
	U	  	Net Throughput	 	= S * T	 		 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
	V	  	Escalated Tariff Throughput	 	= Q * T * V	 		 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		  	  
	 	  
	 	  
	 		 		 		 		 		 		 		 		 		 		 	
	W	  	Escalating Tariff Throughput	 	= XNPV (B, A, V) - 
XNPV (2014 - 2018 Actual Throughput)	 	PV @ **%
as of
1/1/14	 		 		 		 		 		 		 		 		 		 		 	
	 Tariff Rate & Tariff Revenue
	 		 		 		 		 		 		 		 		 	
	X	  	2019 Tariff Rate in 2014$	 	= P / W	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	
	Y	  	Tariff Revenue*	 	= XNPV (B, A, Y) - 
XNPV(2014 - ‘18 Actual Revenue) = P	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	X * C *
Q * T	 	X * C *
Q * T	 	X * C *
Q * T	 	X * C *
Q * T	 	X * C *
Q * T	 	
	 Third Party Contract Rate & Third Party Contract
Revenue
	 		 		 		 		 		 		 		 		 	
	 	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  

	Z	  	Third Party Contract Rate	 	See description	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	
	AA	  	Third Party Contract Revenues*	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	
	 Combined Fee & Combined Revenue
	 		 		 		 		 		 		 		 		 	
	AB	  	Combined Revenue	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	
	AC	  	2019 Combined Fee in 2019$	 	= 2019 AB / 2019 V	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	
		 		 		 		 		 		 		 		 		 		 		 		 	

  

	*	 Note: Not applicable to all tarriffs 

  
 Exhibit G-2 - Page 7 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 Example Fee Calculation—Goliath Gas Gathering Combined Fee 

 

																																									
	 	 	 	 	 	 	Calculations / Notes	 	2013	 	2014	 	2015	 	2016	 	2017	 	2018	 	2019	 	2020	 	2021	 	2022	 	2023	 	2024	 	2025	 	2026	 	2027	 	2028	 	2029
		 	 A
	 	Discounting Date	 		 	31-Dec	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun	 	30-Jun
		 	 B
	 	IRR**	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 C
	 	Tariff Escalation Index**	 	CPI–annual update	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**	 	**
		 	 Cost Estimates
	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 D
	 	Initial Capital	 		 	Actual	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 E
	 	System Acquisition Costs	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 F
	 	Committed Build-Out Costs	 		 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 G
	 	Maintenance Capital Estimates	 		 		 	SP	 	SP	 	SP	 	SP	 	SP	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 H
	 	Operating Expenses	 		 		 	SP	 	SP	 	SP	 	SP	 	SP	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 I
	 	Total Costs Before Add backs	 	D + E + F + G + I	 	Actual	 	Actual/SP	 	Actual/SP	 	Actual/SP	 	Actual/SP	 	Actual/SP	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	Add backs (decreases required cost recovery)	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 J
	 	Power & Utilities Pass-through*	 		 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 K
	 	Compression Revenues*	 	=$** * C * High Pressure
Gas Tariff Vol.	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 L
	 	Third-Party Contract Revenues	 	= AA	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 M
	 	Residual Value	 	See description	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	#
		 		 		 		 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  
	 	  

		 	 N
	 	Total Add backs	 	= J + K + L + M	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#
		 	 O
	 	Net Total Costs	 	= I - N	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#
		 	P	 	Required Cost Recovery	 	= XNPV (B, A, O) -
XNPV (2014 - 2018
Actual Revenue)	 	PV @
**%
as of
1/1/14	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	Throughput Estimate (Mbbls or MMcf)	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 Q
	 	Tariff Volumes	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 R
	 	Third Party Volumes	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 S
	 	Total Throughput Volumes	 	= Q + R	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 T
	 	Operating Factor	 		 		 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	%	 	
		 	 U
	 	Net Throughput	 	= S * T	 		 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 V
	 	Escalated Tariff Throughput	 	= Q * T * C	 		 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	W	 	Escalating Tariff Throughput	 	= XNPV (B, A, V) - 
XNPV (2014 - 2018
Actual Throughput)	 	PV @
**%
as of
1/1/14	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	Tariff Rate & Tariff Revenue	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 X
	 	2019 Tariff Rate in 2014$	 	= P / W	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	X * C	 	
		 	 Y
	 	Tariff Revenue*	 	= XNPV (B, A, Y) -
XNPV(2014 - ‘18
Actual Revenue) = P	 		 	Actual	 	Actual	 	Actual	 	Actual	 	Actual	 	X * C *
Q * T	 	X * C *
Q * T	 	X * C
* Q * T	 	X * C
* Q * T	 	X * C
* Q * T	 	X * C
* Q * T	 	X * C
* Q * T	 	X * C
* Q * T	 	X * C
* Q * T	 	X *C
* Q * T	 	
		 	Third Party Contract Rate & Third Party Contract Revenue	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 Z
	 	Third Party Contract Rate	 	See description	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	#	 	
		 	 AA
	 	Third Party Contract Revenues*	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	Z * R * T	 	
		 	Combined Fee & Combined Revenue	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		 	 AB
	 	Combined Revenue	 		 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	= Y + AA	 	
		 	AC	 	2019 Combined Fee in 2019$	 	= 2019 AB / 2019 V	 		 	n/a	 	n/a	 	n/a	 	n/a	 	n/a	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	= AB / U	 	

 * Note: Not applicable to all tarriffs 

  
 Exhibit G-2 - Page 8 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT G-3 

SECONDARY TERM FEE 
 Effective as of the
first Year of the Secondary Term, each Tariff Gathering Fee and Compression Fee hereunder shall be calculated in the following manner: 
 1. For the first
Year of the Secondary Term applicable to any Subsystem, each such Fee shall be an amount equal to the simple average of: (a) an amount equal to (i) the amount of such Fee for the third to last Year of the applicable Initial Term,
increased by (ii) the percentage change in the CPI from the third to last Year of the applicable Initial Term to the first Year of the applicable Secondary Term, (b) an amount equal to (i) the amount of such Fee for the next to
last Year of the applicable Initial Term, increased by (ii) the percentage change in the CPI from the next to last Year of the applicable Initial Term to the first Year of the applicable Secondary Term, and (c) an amount equal to
(i) the amount of such Fee for the last Year of the applicable Initial Term, increased by (ii) the percentage change in the CPI from the last Year of the applicable Initial Term to the first Year of the applicable Secondary Term.

 2. For each Subsystem and each Year during the applicable Term following the first Year of the applicable Secondary Term, each such Fee shall be an
amount equal to: (a) the amount of such Fee for the immediately preceding Year (as calculated pursuant to Section 7.1(i)), increased by (b) the percentage change in the CPI from the then-immediately
preceding Year to such current Year. 
 3. For purposes of determining any such Fee pursuant to this Exhibit
G-3 during the applicable Secondary Term and thereafter (a) no increase to any such Fee resulting from any application of the CPI adjustment described above in subpart (2)(b) shall exceed 3.0% for any
given Year, and (b) no such Fee shall ever be decreased as a result of any application of the CPI adjustment described above in subpart (2)(b) to an amount less than the amount of such Fee as calculated pursuant to
Section 7.1(i) for the prior Year. 
 For the avoidance of doubt, the calculation of any Third Party Gathering Fee and Combined
Gathering Fee for each such Year shall each remain as set forth on Exhibit G-2 (other than the Tariff Gathering Fee applicable to such Subsystem and calculations, which will instead be as determined
pursuant to this Exhibit G-3 instead of Exhibit G-2). 

  
 Exhibit G-3 - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT H 

RECEIPT POINTS 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 3 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 4 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 5 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 6 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 7 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 8 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 9 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 10 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 11 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 12 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 13 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 14 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 15 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 16 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 17 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 18 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 19 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 20 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 21 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 22 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 23 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 24 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 25 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 26 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 27 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 28 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 29 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 30 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 31 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 32 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 33 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 34 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 35 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 36 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 37 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 38 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 39 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 40 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 41 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 42 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 43 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 44 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 45 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 46 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 47 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 48 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	METER_NUMBER	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 49 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 50 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 51 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 52 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 53 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 54 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 55 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 56 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 57 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 58 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 59 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 60 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 61 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 62 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 63 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 64 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 65 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 66 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 67 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 68 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 69 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 70 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 71 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 72 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 73 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 74 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 75 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit H - Page 76 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Meter Name
	  	 Truck/Pipeline
	  	 Gas/NGL
	  	 METER_NUMBER
	  	Tariff
Field	  	Field Name	  	Source
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

 Note: GO=Goliath, RS=Red Sky, HA=Hawkeye 

  
 Exhibit H - Page 77 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT I 

DELIVERY POINTS 
  

													
	 Delivery Point
	  	 Downstream

Facility
	  	 Originating Facility
	  	 Gas /
Liquids
	  	Notes	  	Meter#	  	Existing /
Future
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit I - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

													
	 Delivery Point
	  	 Downstream Facility
	  	 Originating Facility
	  	 Gas /
Liquids
	  	Notes	  	Meter #	  	Existing /
Future
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**
	 **
	  	**	  	**	  	**	  	**	  	**	  	**

  
 Exhibit I - Page 2 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT J 

INSURANCE 
 Each of the
Parties shall maintain or self-insure, and shall require its applicable subcontractors or agents who (a) in the case of Gatherer, are providing any of the System Services hereunder, or (b) in the case of Shipper, are delivering any Gas
and/or Injected Liquids to the Receipt Points and/or receiving any Gas, Injected Liquids and/or Drip Liquids at the Delivery Points hereunder, in each case, to maintain or self-insure, during the Term, the following insurance coverage: 

 

	 	1.	 Workers’ Compensation Insurance, covering obligations under all applicable Laws and employer’s
liability insurance in the amount of $1,000,000 per occurrence. 

  

	 	2.	 General Liability Insurance, including contractual liability, with limits of $1,000,000 combined single
limit per occurrence bodily injury and property damage with a $2,000,000 annual aggregate. 

  

	 	3.	 Automobile Liability Insurance, with limits of $1,000,000 combined single limit per occurrence bodily
injury and property damage. Such automobile insurance will apply to all owned and non-owned vehicles. 

  
 Exhibit J - Page 1 

 TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THE REDACTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH TWO ASTERISKS (**). 
  

 EXHIBIT K 

NOTICE INFORMATION 
 If to
Gatherer: 
 Hess North Dakota Pipelines LLC 
 1501
McKinney Street 
 Houston, Texas 77010 
 Attn:Director,
Commercial—Midstream 
 Fax: (713) 496-8028 

Email: michael.frailey@hess.com 
 with a
copy to: 
 Hess North Dakota Pipelines LLC 
 1501 McKinney
Street 
 Houston, Texas 77010 
 Attn: Operations Director 

Fax: (713) 496-8028 

Email: jtamborski@hess.com 
 If to Shipper:

 Hess Trading Corporation 
 1501 McKinney Street 

Houston, Texas 77010 
 Attn: Senior Manager, Commercial 

Fax: (713) 496-4449 
 Email: jpaganis@hess.com 

with copies to: 
 Hess Trading Corporation 

1501 McKinney Street 
 Houston, Texas 77010 

Attn: HTC Pipeline Scheduler 
 Fax: (866) 581-8748 
 Email: ssalch@hess.com 

  
 Exhibit K - Page 1EX-10.11

 Exhibit 10.11 

Execution Version 

LICENSE AGREEMENT 

between 
 MEDIMMUNE
LIMITED 
 and 

PHASEBIO PHARMACEUTICALS, INC. 

Dated as of November 21, 2017 
  

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1
	 	 DEFINITIONS
	  	 	1	 
			
	 ARTICLE 2
	 	 GRANT OF RIGHTS
	  	 	22	 
			
	 2.1.
	 	 Grants to Licensee
	  	 	22	 
	 2.2.
	 	 Grants to MedImmune
	  	 	23	 
	 2.3.
	 	 Sublicenses
	  	 	23	 
	 2.4.
	 	 Retention of Rights; Limitations Applicable to License Grants
	  	 	26	 
	 2.5.
	 	 Exclusivity
	  	 	28	 
	 2.6.
	 	 Trademark License Agreement
	  	 	29	 
			
	 ARTICLE 3
	 	 MANUFACTURING, DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES
	  	 	30	 
			
	 3.1.
	 	 Technical Services
	  	 	30	 
	 3.2.
	 	 Manufacturing
	  	 	30	 
	 3.3.
	 	 Development
	  	 	32	 
	 3.4.
	 	 Regulatory Activities
	  	 	32	 
	 3.5.
	 	 Commercialization
	  	 	34	 
	 3.6.
	 	 Statements and Compliance with Applicable Law
	  	 	38	 
	 3.7.
	 	 Markings
	  	 	41	 
	 3.8.
	 	 Subcontracting
	  	 	42	 
	 3.9.
	 	 Alliance Managers
	  	 	42	 
	 3.10.
	 	 Product Positioning Principles
	  	 	42	 
			
	 ARTICLE 4
	 	 PAYMENTS AND RECORDS
	  	 	43	 
			
	 4.1.
	 	 Upfront Payment
	  	 	43	 
	 4.2.
	 	 [***] Fee
	  	 	43	 
	 4.3.
	 	 Technical Services Costs
	  	 	43	 
	 4.4.
	 	 Milestones
	  	 	44	 
	 4.5.
	 	 Royalties
	  	 	46	 
	 4.6.
	 	 Royalty Payments and Reports
	  	 	47	 
	 4.7.
	 	 Mode of Payment; Offsets
	  	 	48	 
	 4.8.
	 	 Taxes
	  	 	48	 
	 4.9.
	 	 Interest on Late Payments
	  	 	49	 
	 4.10.
	 	 Financial Records
	  	 	50	 
	 4.11.
	 	 Audit
	  	 	50	 
	 4.12.
	 	 Audit Dispute
	  	 	50	 

  

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

i 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 5
	 	 INTELLECTUAL PROPERTY
	  	 	51	 
			
	 5.1.
	 	 Ownership of Intellectual Property
	  	 	51	 
	 5.2.
	 	 Maintenance and Prosecution of Patents
	  	 	54	 
	 5.3.
	 	 Enforcement of Patents
	  	 	57	 
	 5.4.
	 	 Infringement Claims by Third Parties
	  	 	62	 
	 5.5.
	 	 Invalidity or Unenforceability Defenses or Actions
	  	 	63	 
	 5.6.
	 	 Product Trademarks
	  	 	64	 
	 5.7.
	 	 Corporate Names, Licensed Trademarks and Product Trademarks
	  	 	65	 
			
	 ARTICLE 6
	 	 CONFIDENTIALITY AND NON-DISCLOSURE
	  	 	66	 
			
	 6.1.
	 	 Confidentiality Obligations
	  	 	66	 
	 6.2.
	 	 Permitted Disclosures
	  	 	67	 
	 6.3.
	 	 Use of Name
	  	 	70	 
	 6.4.
	 	 Public Announcements
	  	 	70	 
	 6.5.
	 	 Publications
	  	 	72	 
	 6.6.
	 	 Securities Laws
	  	 	72	 
	 6.7.
	 	 Return of Confidential Information
	  	 	73	 
			
	 ARTICLE 7
	 	 REPRESENTATIONS AND WARRANTIES
	  	 	73	 
			
	 7.1.
	 	 Mutual Representations and Warranties
	  	 	73	 
	 7.2.
	 	 Additional Representations and Warranties of MedImmune
	  	 	74	 
	 7.3.
	 	 DISCLAIMER OF WARRANTIES
	  	 	75	 
	 7.4.
	 	 Anti-Bribery and Anti-Corruption Compliance
	  	 	75	 
			
	 ARTICLE 8
	 	 INDEMNITY
	  	 	75	 
			
	 8.1.
	 	 Indemnification of MedImmune
	  	 	75	 
	 8.2.
	 	 Indemnification of Licensee
	  	 	76	 
	 8.3.
	 	 Indemnification Procedures
	  	 	76	 
	 8.4.
	 	 Special, Indirect and Other Losses
	  	 	78	 
	 8.5.
	 	 Insurance
	  	 	78	 
			
	 ARTICLE 9
	 	 TERM AND TERMINATION
	  	 	78	 
			
	 9.1.
	 	 Term and Expiration
	  	 	78	 
	 9.2.
	 	 Termination
	  	 	79	 
	 9.3.
	 	 Rights in Bankruptcy
	  	 	84	 

  

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

ii 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 9.4.
	 	 Consequences of Termination
	  	 	85	 
	 9.5.
	 	 Remedies
	  	 	97	 
	 9.6.
	 	 Accrued Rights; Surviving Obligations
	  	 	97	 
			
	 ARTICLE 10
	 	 MISCELLANEOUS
	  	 	99	 
			
	 10.1.
	 	 Force Majeure
	  	 	99	 
	 10.2.
	 	 Export Control
	  	 	99	 
	 10.3.
	 	 Assignment
	  	 	99	 
	 10.4.
	 	 Certain Transactions Involving MedImmune and its Affiliates
	  	 	100	 
	 10.5.
	 	 Severability
	  	 	101	 
	 10.6.
	 	 Dispute Resolution
	  	 	102	 
	 10.7.
	 	 Expedited Determination of Royalty Rate
	  	 	103	 
	 10.8.
	 	 Governing Law, Jurisdiction and Service
	  	 	104	 
	 10.9.
	 	 Notices
	  	 	105	 
	 10.10.
	 	 Entire Agreement; Amendments
	  	 	106	 
	 10.11.
	 	 English Language
	  	 	107	 
	 10.12.
	 	 Equitable Relief
	  	 	107	 
	 10.13.
	 	 Waiver and Non-Exclusion of Remedies
	  	 	107	 
	 10.14.
	 	 No Benefit to Third Parties
	  	 	107	 
	 10.15.
	 	 Further Assurance
	  	 	107	 
	 10.16.
	 	 Relationship of the Parties
	  	 	108	 
	 10.17.
	 	 References
	  	 	108	 
	 10.18.
	 	 Construction
	  	 	108	 
	 10.19.
	 	 Counterparts
	  	 	108	 

  

			
	SCHEDULES	  	
		
	Schedule 1.46	  	Emerging Market Countries
	Schedule 1.79	  	Licensed Know-How
	Schedule 1.80	  	Licensed Patents
	Schedule 1.85	  	Licensee Corporate Names
	Schedule 1.96	  	MEDI2452
	Schedule 1.98	  	MedImmune Corporate Names
	Schedule 3.1.1	  	Technical Transfer Documents
	Schedule 3.1.2(a)	  	Transferred Inventory
	Schedule 3.1.2(b)	  	GLP Samples
	Schedule 3.1.4	  	IND Deliverables

  

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

iii 

 TABLE OF CONTENTS 

 

			
	 	  	Page
	Schedule 3.3.1(d)	  	Supply of Ticagrelor Active Metabolite ([***])
	Schedule 3.4.1(b)	  	Existing Regulatory Documentation
	Schedule 3.4.4(e)	  	Serious Adverse Event Reporting Timelines

  

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

iv 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is made and entered into as of November 21, 2017 (the
“Effective Date”) by and between MedImmune Limited, a limited liability company formed under the laws of the United Kingdom having a place of business at Milstein Building, Granta Park, Cambridge CB21 6GH, United Kingdom
(“MedImmune”) and PhaseBio Pharmaceuticals, Inc., a corporation formed under the laws of Delaware having its place of business at 1 Great Valley Parkway, Suite 30, Malvern, Pennsylvania 19355, United States
(“Licensee”). MedImmune and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

Recitals 
 WHEREAS,
MedImmune owns or controls certain intellectual property rights with respect to MEDI2452 (as defined herein) and Licensed Products (as defined herein) in the Territory (as defined herein); and 

WHEREAS, MedImmune wishes to grant to Licensee, and Licensee wishes to take, a license under such intellectual property rights to
develop and commercialize Licensed Products in the Field in the Territory, in each case in accordance with the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1. “AAA” has the meaning set forth in Section 10.6.3. 

1.2. “Acceptance” means, with respect to a Drug Approval Application, that the applicable Regulatory Authority has
accepted such Drug Approval Application for substantive review as evidenced by Licensee’s receipt of notice from such Regulatory Authority of such acceptance or other evidence that such Regulatory Authority has commenced its substantive review
of such Drug Approval Application. 
 1.3. “Additional Compound” means any anti-ticagrelor antibody or antibody
fragment other than MEDI2452: that is either (a) covered or claimed by the Licensed Patents or 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
(b) a Derivative, excluding in each case any Excluded Compound. For clarity, an Additional Compound excludes the Ticagrelor Compound and any AstraZeneca Product. 

1.4. “Affiliate” means, with respect to a Person, any Person that, directly or indirectly, through one (1) or more
intermediaries, controls, is controlled by or is under common control with such first Person at any time for so long as such Person controls, is controlled by or is under common control with such first Person. For purposes of this definition,
“control” and, with correlative meanings, the terms “controlled by” and “under common control with” means: (a) the possession, directly or indirectly, of the power to direct the management or policies of a business
entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise; or (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or
other ownership interests of a business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). 

1.5. “Agreement” has the meaning set forth in the preamble hereto. 

1.6. “Alliance Manager” has the meaning set forth in Section 3.9. 

1.7. “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as
amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

1.8. “Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or
other requirements of the Regulatory Authorities, that may be in effect from time to time, including the FFDCA, the PHSA and the Anti-Corruption Laws. 

1.9. “Approved Product Positioning Principles” has the meaning set forth in Section 3.10. 

1.10. “Arbitration Notice” has the meaning set forth in Section 10.6.2. 

1.11. “Arbitrators” has the meaning set forth in Section 10.6.3. 

1.12. “Assigned Regulatory Documentation” has the meaning set forth in Section 3.4.1(b). 

1.13. “AstraZeneca Product” means any drug product containing the Ticagrelor Compound, including any such products
sold, offered for sale or distributed by MedImmune or any of its Affiliates, licensees or successors-in-interest. 

1.14. “AstraZeneca Product Improvements” means any invention, discovery, development or modification with respect to
the AstraZeneca Product or relating to the Exploitation thereof, whether or not patented or patentable, including any enhancement in the 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 2 

 
efficiency, operation, manufacture, ingredients, preparation, presentation, formulation, means of delivery or dosage of the AstraZeneca Product, any discovery or development of any new or
expanded methods of treatment, use or indications for the AstraZeneca Product or any discovery or development that improves the stability, safety or efficacy of the AstraZeneca Product, in each case that are conceived, discovered, developed or
otherwise made by or on behalf of one or both of the Parties or their Affiliates, or in the case of Licensee or its Affiliates, its or their Sublicensees (including by its or their Third Party contractors) under or in connection with this Agreement
or the conduct of any activities hereunder, including in the case of Licensee or its Affiliates or any of its or their Sublicensees (or its or their Third Party contractors), in connection with any Exploitation of any Licensed Compound or Licensed
Product. 
 1.15. “AstraZeneca Product Know-How” means: (a) to the
extent owned or controlled by MedImmune or any of its Affiliates, Information related to the AstraZeneca Product or AstraZeneca Product Improvements or the Exploitation thereof; and (b) Information related to the AstraZeneca Product or
AstraZeneca Product Improvements or the Exploitation thereof that, in each case, is generated by or on behalf of Licensee or its Affiliates or any of its or their Sublicensees, in connection with any Exploitation of any Licensed Compound or Licensed
Product, other than any such Information that: (i) has been published by MedImmune or any of its Affiliates and is not claimed by a Valid Claim of a Patent owned or controlled by MedImmune or any of its Affiliates; or (ii) has been
published by a Third Party (other than a Sublicensee) that did not receive such Information directly or indirectly from Licensee or any of its Affiliates or Sublicensees and did not generate such Information on behalf of Licensee or any of its
Affiliates or Sublicensees. 
 1.16. “AstraZeneca Product Patents” means any Patent that claims AstraZeneca Product Know-How or otherwise claims any AstraZeneca Product Improvement or the Exploitation thereof. 
 1.17.
“AstraZeneca Product References” means any and all references to, mentions of or claims with respect to the AstraZeneca Product (including any and all references to, mentions of or claims with respect to the Ticagrelor
Compound). 
 1.18. “Auditor” has the meaning set forth in Section 4.11. 

1.19. “Biosimilar Filer” has the meaning set forth in Section 5.3.8. 

1.20. “Biosimilar Product” means, with respect to a particular Licensed Product in a particular country in the
Territory, any pharmaceutical product that (a) is claimed to be interchangeable with such Licensed Product or otherwise references or relies on the prior approval (or the safety or efficacy data submitted in support of the prior approval) of
such Licensed Product to support a Drug Approval Application submitted under Section 351(k) of the PHSA or any corresponding foreign application in the Territory; (b) is approved for sale for at least one indication that is the same as an
indication for which the License Product is approved 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 3 

 
for sale in such country; and (c) is sold in such country by a Third Party that is not a direct or indirect sublicensee of Licensee or its Affiliates. 

1.21. “BLA” means a biologics license application (within the meaning of 21 C.F.R. 601.2) filed with the FDA
seeking Regulatory Approval to market and sell any Licensed Product as a biologic in the United States. 
 1.22. “BPCI
Act” means the Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, title VII, subtitle A, as may be amended from time to time, together with any rules, regulations and
requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 
 1.23.
“Breaching Party” has the meaning set forth in Section 9.2.1(a). 
 1.24. “Brilinta Competing
Product” means any P2Y12 receptor antagonist, other than the AstraZeneca Product or Generic Ticagrelor Product. 
 1.25.
“Business Day” means a day other than a Saturday or Sunday or a day on which banking institutions in New York, New York, United States, London, United Kingdom or Mölndal, Sweden are permitted or required to be closed. 

1.26. “Calendar Quarter” means each successive period of three (3) calendar months commencing on January 1,
April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or
October 1 after the Effective Date and the last Calendar Quarter shall end on the last day of the Term. 
 1.27.
“Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date
and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term. 

1.28. “Combination Product” means a pharmaceutical product that is comprised of or contains a Licensed Compound as an
active ingredient together with one (1) or more other active ingredients and is sold either as a fixed dose/unit or as separate doses/units in a single package. 

1.29. “Commercialization” means, in respect of a Licensed Compound or Licensed Product, any and all activities directed
to the preparation for sale of, offering for sale of or sale of such product, including activities related to marketing, promoting, distributing and importing such product and interacting with Regulatory Authorities regarding any of the foregoing.
When used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization and “Commercialized” has a corresponding meaning. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 4 

 1.30. “Commercialization Dispute” has the meaning set forth in
Section 3.5.7. 
 1.31. “Commercialization Plan” has the meaning set forth in Section 3.5.4. 

1.32. “Commercially Reasonable Efforts” means, with respect to the performance of Development, Manufacturing or
Commercialization activities with respect to a Licensed Compound or a Licensed Product by Licensee, the carrying out of such activities in a sustained and diligent manner and using efforts and resources comparable to the efforts and resources
commonly used by biopharmaceutical companies of a size and with resources or access to resources similar to that of Licensee, for high-priority compounds or products of such companies at a similar stage in development or product life, taking into
account issues of patent coverage, measures of relative safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of such Licensed Product, the regulatory structure involved and other relevant technical,
legal, scientific and medical considerations. With respect to efforts to Commercialize a Licensed Product, “Commercially Reasonable Efforts” shall be determined on a
Market-by-Market basis, without regard to the particular circumstances of Licensee, including any other product opportunities of Licensee and without regard to any
payments owed by Licensee to MedImmune under this Agreement; provided, however, that in determining whether Licensee is using Commercially Reasonable Efforts to Commercialize a Licensed Product in Canada or Mexico, it is appropriate to
consider the effect that the Commercialization of such Licensed Product in Canada or Mexico reasonably could have on the Commercialization of such Licensed Product in the United States (including the establishment of government-approved pricing for
such Licensed Product). 
 1.33. “Commercial Viability Issue” means, with respect to the Licensed Products in each of
the United States, the EU Market and China, the existence of objective circumstances arising after the Effective Date with respect to such Market (other than a Safety/Efficacy Issue), as a result of which a company in the biopharmaceutical industry
would reasonably be expected to elect not to continue to fund or conduct the development or commercialization of the Licensed Products for such Market in light of the overall business case with respect to the Licensed Products in such Market, taking
into account relevant commercial factors, including the additional time and Development costs required to obtain or maintain Regulatory Approval in such Market, the product profile, the competitiveness of the marketplace and the proprietary position
of the Licensed Products and other commercial factors customarily considered in a business case analysis (e.g., forecasted sales volumes, net selling price per unit, cost of goods per unit, commercialization costs and other data indicating
anticipated revenues in such Market or country, as applicable (including, with respect to the EU Market, for each Major European Market)). 

1.34. “Competing Product” means any agent intended to neutralize, abrogate or reverse the antiplatelet activity of the
Ticagrelor Compound. 
 1.35. “Confidential Information” has the meaning set forth in Section 6.1. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 5 

 1.36. “Control” means, with respect to any item of Information,
Regulatory Documentation, material, Patent or other intellectual property right, and subject to Section 10.3, possession by a Person of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by
virtue of any license granted to a Party pursuant to this Agreement), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent
or other intellectual property right as provided for herein without violating the terms of any agreement with any Third Party. 
 1.37.
“Derivative” means, provided that the conditions set forth in Section 2.4.4(a) or Section 2.4.4(b) are and continue to be satisfied, an anti-ticagrelor antibody or antibody fragment that satisfies the following
conditions ((a) and (b)): (a) directly or indirectly, in whole or in part, uses or otherwise relates to, or modifies or is otherwise derived from, (i) MEDI2452, (ii) any anti-ticagrelor antibody or antibody fragment covered or claimed
by the Licensed Patents, or (iii) any Licensed Know-How, and (b) is conceived or discovered by or on behalf of Licensee or any of its Affiliates or Sublicensees in the course or as a result of
activities conducted pursuant to, and in accordance with the terms and conditions of, this Agreement. 
 1.38.
“Development” means, in respect of a Licensed Compound or Licensed Product, all activities related to research, pre-clinical and other non-clinical
testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies,
including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably
useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval for such Licensed Compound or Licensed Product. When used as a verb, “Develop” means
to engage in Development. 
 1.39. “Development Plan” has the meaning set forth in Section 3.3.3. 

1.40. “Dispute” has the meaning set forth in Section 10.6.1. 

1.41. “Dispute Auditor” has the meaning set forth in Section 4.12. 

1.42. “Dollars” or “$” means United States Dollars. 

1.43. “Drug Approval Application” means a BLA or any corresponding foreign application in the Territory, including,
with respect to a country in the European Union, a marketing authorization application filed with the EMA pursuant to the centralized approval procedure or with the applicable Regulatory Authority of a country in the European Union with respect to
the mutual recognition or any other national approval. 
 1.44. “Effective Date” has the meaning set forth in the
preamble hereto. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 6 

 1.45. “EMA” means the European Medicines Agency and any successor
agency thereto. 
 1.46. “Emerging Market Country” means each country set forth on
Schedule 1.46. 
 1.47. “EU Market” means all countries in the European Union taken as a
whole. 
 1.48. “European Union” means the economic, scientific and political organization of European Union member
states as it may be constituted from time to time, specifically including any territory that was a European Union member state as of the Effective Date, whether or not such territory is a participating member as of the applicable time. 

1.49. “Excluded Compound” has the meaning set forth in Section 2.4.4(c). 

1.50. “Excluded Distributor” means a Third Party distributor of Licensed Product appointed or contracted by Licensee or
any of its Affiliates or any of its or their respective Sublicensees in a particular country of the Territory, in circumstances where such Third Party purchases its requirements of Licensed Product from Licensee or its Affiliates or any of its or
their respective Sublicensees, which Third Party distributor either: (a) has no royalty or other payment obligation to Licensee or any of its Affiliates or any of its or their respective Sublicensees that is calculated based on amounts invoiced
or received by or on behalf of such Third Party distributor (or any of its Affiliates) for sales of Licensed Product in such country; or (b) does not take title to Licensed Product, does not invoice Licensed Product sales to Third Party
customers in such country, and is responsible only for inventory management and distribution on behalf of Licensee or any of its Affiliates or any of its or their respective Sublicensees in such country. 

1.51. “Exclusive Period” means, subject to Section 9.4.2(j), Section 9.4.3(j) and Section 10.4.2,
(a) in the case of the conduct of human clinical trials with respect to a Competing Product, the period of five (5) years beginning on the Effective Date, and (b) in the case of the sale or offer for sale of a Competing Product, the
period of seven (7) years beginning on the Effective Date. 
 1.52. “Exploit” means, in respect of a compound or
product, to use, sell, have sold or offer for sale, including to develop (including Develop), make, have made, manufacture (including Manufacture and have Manufactured), commercialize (including Commercialize), register, hold or keep (whether for
disposal or otherwise), have used, import, export, transport, distribute, promote, market or have sold or otherwise dispose of such compound or product. “Exploitation” means the act of Exploiting a compound or product. 

1.53. “FDA” means the United States Food and Drug Administration and any successor agency thereto. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 7 

 1.54. “FFDCA” means the United States Food, Drug, and
Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 

1.55. “Field” means any use or purpose, including the treatment, palliation, diagnosis or prevention of any human
disorder or condition. 
 1.56. “First Commercial Sale” means, with respect to a Licensed Product and a country in
the Territory, the first sale for monetary value for use or consumption by the end user of such Licensed Product in such country after approval of a Drug Approval Application for such Licensed Product has been obtained in such country. 

1.57. “FTE” means the equivalent of the work of one (1) employee full time for one (1) Calendar Year
(consisting of at least a total of eighteen hundred fifty (1850) hours per Calendar Year) of work directly related to the performance of the Technical Services by MedImmune or its Affiliate. 

1.58. “FTE Costs” means, with respect to MedImmune or its Affiliate for any period, the applicable FTE Rate multiplied
by the applicable number of FTEs of MedImmune or such Affiliate performing Technical Services during such period. 
 1.59.
“FTE Rate” means, as of the Effective Date, [***]. 
 1.60. “GAAP” means, with respect to a
Party or its Affiliates or its or their sublicensees, United States generally accepted accounting principles, International Financial Reporting Standards or such other similar national standards as such Party, Affiliates or its or their sublicense
adopts, in each case, consistently applied. 
 1.61. “Generic Competition Threshold” means (a) with respect to
[***], the end of the second (2nd) consecutive Calendar Quarter in which unit sales of Generic Ticagrelor Products in [***] represent [***] percent [***] or more of aggregate unit sales of the AstraZeneca Product and Generic Ticagrelor Products
combined in [***], (b) with respect to [***], the end of the second (2nd) consecutive Calendar Quarter in which unit sales of Generic Ticagrelor Products in [***] represent [***] percent [***] or more of aggregate unit sales of the AstraZeneca
Product and Generic Ticagrelor Products combined in [***], and (c) with respect to [***], the end of the second (2nd) consecutive Calendar Quarter in which unit sales of Generic Ticagrelor Products in [***] represent [***] percent [***] or more
of aggregate unit sales of the AstraZeneca Product and Generic Ticagrelor Products combined in [***]; in each case ((a) through (c)), as determined by taking into consideration applicable and available sales data obtained from a reputable
independent source (e.g., IQVIA) selected by MedImmune and reasonably acceptable to Licensee. For purposes of this definition, references to AstraZeneca Product exclude Generic Ticagrelor Products. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 8 

 1.62. “Generic Ticagrelor Product” means an oral formulation of the
Ticagrelor Compound that is (a) sold, offered for sale or distributed under: (i) in the U.S., an ANDA (as defined in the FFDCA) that refers to the AstraZeneca Product as the reference listed drug, (ii) in the EU, a marketing
authorization for a generic medicinal product granted in accordance with Article 10 of Directive 2001/83/EC or (iii) in any other country or jurisdiction, an equivalent of provisions set forth in clause (i) or clause (ii) and
(b) approved in the applicable country or jurisdiction for at least one of the indications for which the AstraZeneca Product is approved in such country or jurisdiction. For purposes of this definition, references to AstraZeneca Product exclude
Generic Ticagrelor Products. 
 1.63. “Global Commercial Viability Issue” means, with respect to the Licensed
Products, that a Commercial Viability Issue exists in both the United States and the EU Market. 
 1.64. “Global
Safety/Efficacy Issue” has the meaning set forth in Section 1.132. 
 1.65. “GLP Samples” has the
meaning set forth in Section 3.1.2. 
 1.66. “Governmental Authority” means any federal, state, national, state,
provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing
authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 

1.67. “IND” means (a) an investigational new drug application filed with the FDA for authorization to commence
clinical studies and its equivalent in other countries or regulatory jurisdictions and (b) all supplements and amendments that may be filed with respect to the foregoing. 

1.68. “Indemnification Claim Notice” has the meaning set forth in Section 8.3.1. 

1.69. “Indemnified Party” has the meaning set forth in Section 8.3.1. 

1.70. “Independent Expert” has the meaning set forth in Section 9.2.4(c). 

1.71. “Information” means technical or scientific know-how, trade secrets,
methods, processes, formulae, designs, specifications and data, including: biological, chemical, pharmacological, toxicological, pre-clinical, clinical, safety, manufacturing and quality control data and
assays; in each case, whether or not confidential, proprietary, patented or patentable. 
 1.72. “Infringement” has
the meaning set forth in Section 5.3.1. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 9 

 1.73. “Initiation” means, with respect to a Phase II Clinical Trial
or a Pivotal Trial, the dosing of the first patient with a Licensed Product in the specified clinical trial. 
 1.74.
“Invention” means any invention, whether or not patentable, made, conceived, generated or reduced to practice in the course or as a result of the conduct of activities conducted pursuant to this Agreement. 

1.75. “Joint Invention” means any Invention made jointly by, on the one hand, one or more employees, consultants or
contractors of MedImmune or AstraZeneca and, on the other hand, one or more employees, consultants or contractors of Licensee, excluding AstraZeneca Product Improvements. 

1.76. “Joint Patents” means Patents claiming Joint Inventions, excluding AstraZeneca Product Patents. 

1.77. “Knowledge” means, with respect to MedImmune, the actual knowledge, without any duty to conduct any
investigation, with respect to such facts and information of the following: (a) MedImmune’s Patent Attorney who, as of the Effective Date, is engaged in the development program with respect to MEDI2452 and (b) MedImmune’s Vice
President, Global Intellectual Property. 
 1.78. “Licensed Compound” means (a) MEDI2452 and (b) any
Additional Compound, in each case excluding Excluded Compounds. 
 1.79. “Licensed
Know-How” means the Information Controlled by MedImmune and its Affiliates that is set forth on Schedule 1.79, transferred pursuant to
Schedule 3.1.4 or otherwise included in the Technical Transfer Documents, but excluding any AstraZeneca Product Know-How (whether or not included or disclosed in Information set forth
on Schedule 1.79, Schedule 3.1.4 or included in the Technical Transfer Documents). For clarity, Licensed Know-How excludes any research, discovery or
development tools or technology, including Information with respect to any such research, discovery or development tools or technology used by MedImmune in relation to: (a) MEDI2452; or (b) any anti-ticagrelor antibody or antibody fragment
other than MEDI2452 that is covered or claimed by the Licensed Patents. 
 1.80. “Licensed Patents” means
(a) the Patents set forth on Schedule 1.80 and (b) any Patents filed with MedImmune’s consent pursuant to the last two sentences of Section 5.1.2, but, in each case, excluding any AstraZeneca Product
Patents. 
 1.81. “Licensed Product” means any product that is comprised of or contains a Licensed Compound, alone or
in combination with one (1) or more other active ingredients, in any and all forms, presentations, dosages and formulations. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 10 

 1.82. “Licensed Product Agreement” means, with respect to a Licensed
Product, any agreement entered into by and between Licensee or any of its Affiliates or its or their Sublicensees, on the one hand, and one (1) or more Third Parties, on the other hand, relating to the Exploitation of such Licensed Product in
the Field in the Territory, including (a) any agreement pursuant to which Licensee, its Affiliates or its or their Sublicensees receives any license or other rights to Exploit such Licensed Product (including pursuant to Section 4.5.3(c)),
(b) supply agreements pursuant to which Licensee, its Affiliates or its or their Sublicensees obtain or will obtain quantities of such Licensed Product, (c) clinical trial agreements with respect to such Licensed Product, (d) contract
research organization agreements relating to such Licensed Product, and (e) service agreements relating to such Licensed Product. 

1.83. “Licensed Trademarks” means any Trademarks with respect to the AstraZeneca Product designated in the
Trademark License Agreement that are licensed or sublicensed by MedImmune to Licensee pursuant to the Trademark License Agreement. 

1.84. “Licensee” has the meaning set forth in the preamble hereto. 

1.85. “Licensee Corporate Names” means the Trademarks, names and logos of Licensee identified on
Schedule 1.85 and such other Trademarks, names and logos as Licensee may designate in writing from time to time. 

1.86. “Licensee Indemnitees” has the meaning set forth in Section 8.2. 

1.87. “Licensee Regulatory Documentation” means Regulatory Documentation Controlled by Licensee or any of its
Affiliates with respect to a Licensed Compound or a Licensed Product at any time during the Term. 
 1.88. “Licensee
Termination Know-How” means: 
 (a) any Information covered or claimed by the PhaseBio
Selected Patents; and 
 (b) without limitation to clause (a), to the extent Controlled by Licensee or any of its Affiliates or its or their
Sublicensees during the Term, any other Information that (i) was actually used, practiced or incorporated by Licensee or any of its Affiliates or its or their Sublicensees or (ii) both (A) was actually used, practiced or incorporated
by a Third Party contractor on behalf of Licensee or any of its Affiliates or its or their Sublicensees and (B) is Controlled by Licensee or any of its Affiliates or its or their Sublicensees; in each case, in the Development, Manufacture or
Exploitation of any Licensed Compound or Licensed Product prior to termination of this Agreement. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 11 

 1.89. “Licensee Termination Patents” means: 

(a) PhaseBio Selected Patents that are reasonably necessary or useful (or, with respect to patent applications, would be reasonably necessary
or useful if such Patent applications were to issue as patents) for the Exploitation of any Licensed Compound or Licensed Product; and 

(b) without limitation to clause (a), any other PhaseBio Patent that claims any invention or discovery that either: (i) was actually
used, practiced or incorporated by Licensee or any of its Affiliates or its or their Sublicensees in the course or as a result of the Development, Manufacture or Exploitation of any Licensed Compound or Licensed Product prior to termination of this
Agreement; or (ii) both (A) was actually used, practiced or incorporated by a Third Party contractor on behalf of Licensee or any of its Affiliates or its or their Sublicensees in the course or as a result of the Development, Manufacture
or other Exploitation of any Licensed Compound or Licensed Product prior to termination of this Agreement and (B) is Controlled by Licensee or any of its Affiliates or its or their Sublicensees. 

1.90. “Losses” has the meaning set forth in Section 8.1. 

1.91. “Major European Country” means any of France, Germany, Italy, Spain and the United Kingdom. 

1.92. “Manufacture” and “Manufacturing” means, in respect of a Licensed Compound or Licensed Product,
all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of such Licensed Compound or Licensed Product or any intermediate thereof, including process development, process
qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality
assurance and quality control. 
 1.93. “Market” means each Emerging Market Country, the EU Market or any country
that is neither an Emerging Market Country nor a country within the EU Market. 
 1.94. “Market-Specific Safety/Efficacy
Issue” has the meaning set forth in Section 1.132. 
 1.95. “Material Anti-Corruption Law Violation”
means a violation by a Party or its Affiliate of an Anti-Corruption Law relating to the subject matter of this Agreement that would, if it were publicly known, have a material adverse effect on the other Party or its Affiliate because of its
relationship with such Party. 
 1.96. “MEDI2452” means the anti-ticagrelor antibody fragment product known as
MEDI2452, as further defined by the protein sequence set forth in Schedule 1.96. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 12 

 1.97. “MedImmune” has the meaning set forth in the preamble hereto.

 1.98. “MedImmune Corporate Names” means the Trademarks, names and logos of MedImmune identified on
Schedule 1.98 and such other Trademarks, names and logos as MedImmune may designate in writing from time to time. 

1.99. “MedImmune Indemnitees” has the meaning set forth in Section 8.1. 

1.100. “NDA” means a New Drug Application filed with the FDA in conformance with Applicable Law, or the foreign
equivalent of any such application in any other country filed with a Regulatory Authority to obtain marketing approval for a pharmaceutical product. 

1.101. “Net Sales” means, with respect to a Licensed Product for any period, the gross amount invoiced by Licensee, its
Affiliates or its or their Sublicensees (each, a “Selling Party”) to Third Parties (including Excluded Distributors) for the sale of a Licensed Product (“Invoiced Sales”) after deduction for: 

1.101.1. [***]; 

1.101.2. [***];  

1.101.3. [***]; 

1.101.4. [***]; 

1.101.5. [***]; 

1.101.6. [***]; and 

1.101.7. [***]; 
 provided that,
in each case, 1.101.1 through 1.101.7, (a) each such deduction is calculated in a manner consistent with Licensee’s customary practice for pharmaceutical products and consistent with GAAP, (b) each such deduction is directly allocable
or apportioned on a good faith and fair basis to Licensed Products, and (c) no amount is deducted more than once. 
 Any of the
deductions listed above that involves a payment by a Selling Party shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by such Selling Party. For purposes of determining Net Sales, a Licensed Product shall be deemed
to be sold when invoiced. Sale of a Licensed Product by a Selling Party to another Selling Party for resale by such entity to a Third Party (including Excluded Distributors) for use or consumption by the end user shall not be deemed a sale for
purposes of this definition of “Net Sales,” provided that the subsequent resale of such Licensed Product to a Third Party (including Excluded 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 13 

 
Distributors) is included in the computation of Net Sales. In addition, transfers or dispositions of Licensed Products as free promotional samples in commercially reasonable amounts, consistent
with prevailing pharmaceutical industry standards, or in any patient assistance, test marketing program, named-patient program or compassionate use program (so long as such Licensed Products are provided without charge) and Licensed Products donated
to non-profit institutions or government agencies, or used in research, development or regulatory activities, including, without limitation, clinical trials, shall be disregarded in determining Net Sales. 

In the event that a Licensed Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product for
the purpose of determining royalties due hereunder shall be calculated as follows: 
 (a) where both such Licensed Product containing the
applicable Licensed Compound as its sole active pharmaceutical ingredient (“Single-Agent Product”) and product containing only the Other Active(s) in such Combination Product as active pharmaceutical ingredients are sold separately
in such country, with respect to a Calendar Quarter, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such country during such Calendar Quarter calculated pursuant to the foregoing definition of “Net
Sales” by [***]; provided that the invoice price in a country for each Single-Agent Product that contains only the Licensed Compound(s) and each product that contains solely the Other Active(s) included in the Combination Product shall
be for a quantity comparable to that used in such Combination Product and of substantially the same class, purity and potency; 
 (b) if the
Single-Agent Product is sold in such country, but none of the Other Active(s) is sold separately in such country, with respect to a Calendar Quarter, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product in such
country during such Calendar Quarter calculated pursuant to the foregoing definition of “Net Sales” by [***]; 
 (c) if no
Single-Agent Product is sold in such country, but product containing the Other Active(s) in such Combination Product are sold separately in such country, with respect to a Calendar Quarter, Net Sales shall be calculated by multiplying actual Net
Sales of such Combination Product in such country during such Calendar Quarter calculated pursuant to the foregoing definition of “Net Sales” by [***]. 

(d) if neither Single-Agent Product nor product containing the Other Active(s) in such Combination Product as its sole active ingredient(s) is
sold separately in such country, the Parties [***]. 
 In the case of pharmacy incentive programs, hospital performance incentive programs,
chargebacks, disease management programs, similar programs or discounts on portfolio product offerings, all rebates, discounts and other forms of reimbursements [***]; provided that (a) any such allocation to a Licensed Product shall be
done in accordance with Applicable Law, 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 14 

 
including any price reporting laws, rules and regulations and (b) subject to clause (a), all such rebates, discounts and other forms of reimbursements [***]. 

Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies and procedures of Licensee, its Affiliates or its or
their Sublicensees, which must be in accordance with GAAP. 
 1.102. “Non-Breaching
Party” has the meaning set forth in Section 9.2.1(a). 
 1.103. “Notice Period” means the
Section 9.2.1(a) Notice Period or the Section 9.2.1(b) Notice Period, as applicable. 
 1.104. “Other
Active” means any active pharmaceutical ingredient contained in a Combination Product that is not a Licensed Compound. 
 1.105.
“Other Adverse Event” has the meaning set forth in Section 3.4.4(f). 
 1.106. “Out-of-Pocket Expenses” means, with respect to the Technical Services, MedImmune’s or its Affiliate’s actual, documented, out-of-pocket expenses incurred in performing such Technical Services. 
 1.107.
“Party” and “Parties” have the meaning set forth in the preamble hereto. 
 1.108.
“Patents” means: (a) all national, regional and international patents and patent applications, including provisional patent applications; (b) all patent applications filed either from such patents, patent applications
or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals,
converted provisionals and continued examination applications; (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, innovation patents and
design patents and certificates of invention; (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and
extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)); and (e) any similar rights, including so-called pipeline
protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents. 

1.109. “Payment” has the meaning set forth in Section 4.8.1. 

1.110. “Permitted Competing Product” has the meaning set forth in Section 10.4.1. 

1.111. “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 15 

 
joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a
government. 
 1.112. “Pharmacovigilance Agreement” has the meaning set forth in Section 3.4.4(a). 

1.113. “Phase II Clinical Trial” means a human clinical trial that would satisfy the definition of “Phase 2”
set forth in 21 C.F.R. 312.21(b) (as amended or any replacement thereof), regardless of where such trial is conducted. 
 1.114.
“Phase III Clinical Trial” means a human clinical trial that would satisfy the definition of “Phase 3” set forth in 21 C.F.R. 312.21(c) (as amended or any replacement thereof), regardless of where such trial is
conducted. 
 1.115. “PhaseBio Know-How” means: 

(a) all Information that is Controlled by Licensee or any of its Affiliates as of the Effective Date or at any time during the Term and
directed to any Licensed Compound or Licensed Product; and 
 (b) without limitation to clause (a), all Information that (i) is
conceived or developed by Licensee or any of its Affiliates or any of its or their Sublicensees in the course or as a result of Development, Manufacture or other Exploitation of any Licensed Compound or Licensed Product or (ii) both (A) is
conceived or developed by a Third Party contractor on behalf of Licensee or any of its Affiliates or any of its or their Sublicensees in the course or as a result of Development, Manufacture or other Exploitation of any Licensed Compound or Licensed
Product and (B) is Controlled by Licensee or any of its Affiliates or any of its or their Sublicensees; 
 but excluding in each case ((a) and (b))
AstraZeneca Product Know-How, Joint Know-How and any Information to the extent covered or claimed by any Patent described in clause (b) of the definition of
Licensed Patents. 
 1.116. “PhaseBio Patents” means: 

(a) all Patents Controlled by Licensee or any of its Affiliates as of the Effective Date or at any time during the Term that claim any
Licensed Compound or Licensed Product or the Exploitation thereof; and 
 (b) without limitation to clause (a), any Patent that claims
PhaseBio Know-How described in clause (b) of the definition of PhaseBio Know-How; 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 16 

 
but excluding in each case ((a) and (b)) AstraZeneca Product Patents, Joint Patents, and any Patent described in clause (b) of the definition of Licensed Patents. 

1.117. “PhaseBio Selected Patents” means any PhaseBio Patent that claims any invention, discovery, development or
modification with respect to a Licensed Compound or Licensed Product, including any new or expanded method of treatment or use of a Licensed Compound or Licensed Product, or any modification or improvement to the formulation, means of delivery or
dosage or method of Manufacture of a Licensed Compound or Licensed Product, which invention, discovery, development or modification in each case (a) is conceived or developed by Licensee or any of its Affiliates or any of its or their
Sublicensees in the course or as a result of Development, Manufacture or other Exploitation of any Licensed Compound or Licensed Product or (b) both (i) is conceived or developed by a Third Party contractor on behalf of Licensee or any of
its Affiliates or any of its or their Sublicensees in the course or as a result of Development, Manufacture or other Exploitation of any Licensed Compound or Licensed Product and (ii) is Controlled by Licensee or any of its Affiliates or any of
its or their Sublicensees. 
 1.118. “PHSA” means the Public Health Service Act as set forth at 42 U.S.C. Chapter 6A,
as may be amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 

1.119. “Pivotal Trial” means a human clinical trial (whether or not a Phase III Clinical Trial) of a
pharmaceutical product that is prospectively designed to, together with prior data and information concerning such product, (a) establish that such product is safe and effective for its intended use in any indication, and (b) form the
primary basis (alone or with one or more additional Pivotal Trials) of an effectiveness claim in support of an initial Regulatory Approval for such product in the United States for any indication or its foreign counterpart. 

1.120. “Product Labeling” means, with respect to a Licensed Product in a country in the Territory, (a) the
Regulatory Authority-approved full prescribing information for such Licensed Product for such country, including any required patient information and (b) all labels and other written, printed or graphic
matter upon a container, wrapper or any package insert utilized with or for such Licensed Product in such country. 
 1.121.
“Product Trademarks” means the Trademark(s) with respect to any Licensed Product used or to be used by Licensee or its Affiliates or its or their Sublicensees for the Commercialization of Licensed Products in the Territory and
any registrations thereof or any pending applications relating thereto in the Territory, including any unregistered Trademark rights related to the Licensed Products as may exist through use before, on or after the Effective Date (excluding, in any
event, any Licensed Trademarks, MedImmune Corporate Names, Licensee Corporate Names and any Trademarks that consist of or include any corporate name or corporate logo of the Parties or their Affiliates or its or their (sub)licensees (or
Sublicensees)). 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 17 

 1.122. “Promotional Materials” means all written, printed,
electronic or graphic material created, utilized or distributed by Licensee or any of its Affiliates or its or their Sublicensees or Third Party contractors for the promotion, sale or marketing of Licensed Products. 

1.123. “Proposed Product Positioning Principles” has the meaning set forth in Section 3.10. 

1.124. “Redacted Agreement” has the meaning set forth in Section 6.2.7. 

1.125. “Regulatory Approval” means, with respect to a particular Licensed Product and a particular country in the
Territory, any and all approvals (including approvals of Drug Approval Applications), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market such Licensed Product in such
country, including, where applicable, (a) pricing or reimbursement approval in such country, (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or
authorization related thereto), and (c) labeling approval. 
 1.126. “Regulatory Authority” means any applicable
supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of
any Licensed Compound or Licensed Products in the Territory, including the FDA in the United States and the EMA in the European Union. 

1.127. “Regulatory Documentation” means: all (a) applications (including all INDs and Drug Approval Applications),
registrations, licenses, authorizations and approvals (including Regulatory Approvals); (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any
communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files; and (c) clinical and other data contained or relied upon in any of the foregoing; in each
case ((a), (b) and (c)) relating to any Licensed Compound or Licensed Product. 
 1.128. “Regulatory Exclusivity
Period” means, with respect to a Licensed Product in a country in the Territory, any period of exclusivity (other than Patent exclusivity) granted or afforded by Applicable Law or by a Regulatory Authority in such country that confers
exclusive marketing rights with respect to such Licensed Product in such country. 
 1.129. “Representatives” has the
meaning set forth in Section 7.4. 
 1.130. “Responsible Party” has the meaning set forth in Section 5.2.5.

 1.131. “Royalty Term” means, with respect to each Licensed Product and each country in the Territory, the period
beginning on the date of the First Commercial Sale of such 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 18 

 
Licensed Product in such country and ending on the latest to occur of (a) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country, (b) the
expiration of the last-to-expire Licensed Patent covering the manufacture, use or sale of such Licensed Product in such country, and (c) the expiration of
Regulatory Exclusivity Period, if any, for such Licensed Product in such country. 
 1.132. “Safety/Efficacy Issue”
means, with respect to a Licensed Product: (a) a Regulatory Authority or safety data review board for the clinical trials of such Licensed Product has required (i) termination or suspension of all clinical trials of such Licensed Product
in a country due to safety issues or (ii) following approval of a Drug Approval Application for a Licensed Product in a country, a Regulatory Authority withdraws such approval in such country due to safety issues, in each case ((i) and (ii))
for reasons related to a Licensed Compound and not, for example, due to Other Actives contained in such Licensed Product or to Manufacturing-related deficiencies or defects (in either case ((i) or (ii)), a “Market-Specific Safety/Efficacy
Issue” with respect to the applicable country); or (b) it is reasonably determined that (i) the medical risk/benefit of such Licensed Product is so unfavorable that it would be incompatible with the welfare of patients to Develop
or Commercialize (or to continue to Develop or Commercialize) such Licensed Product or (ii) the efficacy of such Licensed Product, as evidenced by the ability of a Licensed Compound to bind to or inactivate antiplatelet efficacy of the
Ticagrelor Compound or its active metabolite, is so minimal that it would not be commercially reasonable to continue to Develop such Licensed Product, in each case ((i) and (ii)) for reasons related to a Licensed Compound and not, for example, due
to Other Actives contained in such Licensed Product or to Manufacturing-related deficiencies or defects (in either case ((i) or (ii)), a “Global Safety/Efficacy Issue”). 

1.133. “Safety Team” has the meaning set forth in Section 3.4.4(a). 

1.134. “Sale Transaction” has the meaning set forth in Section 10.3.1. 

1.135. “Section 9.2.1(a) Notice Period” has the meaning set forth in Section 9.2.1(a). 

1.136. “Section 9.2.1(a) Termination Notice” has the meaning set forth in Section 9.2.1(a).

 1.137. “Section 9.2.1(b) Notice Period” has the meaning set forth in Section 9.2.1(b).

 1.138. “Section 9.2.1(b) Termination Notice” has the meaning set forth in
Section 9.2.1(b). 
 1.139. “Section 9.2.4 Matter” has the meaning set forth in
Section 9.2.4(a). 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 19 

 1.140. “Senior Officer” means, with respect to MedImmune, its senior
representative for the cardiovascular therapy area and with respect to Licensee, its Chief Executive Officer. 
 1.141.
“Serious Adverse Event” has the meaning set forth in Section 3.4.4(e). 
 1.142. “Spontaneous
Adverse Event” has the meaning set forth in Section 3.4.4(c). 
 1.143. “Standby License” has the
meaning set forth in Section 2.3.2. 
 1.144. “Standby License Request” has the meaning set forth in
Section 2.3.2. 
 1.145. “Strategic Transaction” has the meaning set forth in Section 10.4.1. 

1.146. “Sublicense” means a sublicense under the grants in Section 2.1. 

1.147. “Sublicensee” means a Third Party that is granted a Sublicense, but excluding any Excluded Distributor. 

1.148. “Surviving Sublicense” has the meaning set forth in Section 2.3.2. 

1.149. “Surviving Sublicense Requirements” has the meaning set forth in Section 2.3.2. 

1.150. “Technical Services” means the activities performed, and the deliverables provided, by or on behalf of MedImmune
pursuant to Section 3.1.1, Section 3.1.2, Section 3.1.3, Section 3.1.4, Section 3.1.5 and the last sentence of Section 5.2.2. For the avoidance of doubt, the Technical Services specifically exclude
(a) MedImmune’s review of and comment on Development Plans, Commercialization Plans, Promotional Materials, and Licensee’s medical materials, (b) MedImmune’s drafting and negotiation of the Pharmacovigilance Agreement,
(c) MedImmune’s review of and comment on Licensee’s Patent prosecution, maintenance, enforcement and defense activities, (d) MedImmune’s exercise of any other review and comment rights under this Agreement. 

1.151. “Technical Services Costs” means the FTE Costs and Out-of-Pocket Expenses that are incurred by MedImmune or its Affiliate on or after the Effective Date in performing the Technical Services; provided, however, that with respect to the Technical
Services set forth in Section 3.1.1, Technical Services Costs shall not include any FTE Costs with respect to such Technical Services. For the avoidance of doubt, the Technical Services Costs specifically exclude any labor costs, out-of-pocket expenses, or other costs or expenses incurred by MedImmune or its Affiliate in: (a) reviewing and commenting on Development Plans, Commercialization Plans,
Promotional Materials, and Licensee’s medical materials, (b) drafting and negotiating the Pharmacovigilance Agreement, (c) reviewing and commenting 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 20 

 
on Licensee’s Patent prosecution, maintenance, enforcement and defense activities, and (d) exercising any other review and comment rights of MedImmune under this Agreement. 

1.152. “Technical Transfer Documents” has the meaning set forth in Section 3.1.1. 

1.153. “Term” has the meaning set forth in Section 9.1. 

1.154. “Terminated Territory” means each country or Market with respect to which this Agreement is terminated by
MedImmune pursuant to Section 9.2.1(b) or by Licensee pursuant to Section 9.2.4(d)(i), Section 9.2.4(d)(iii) or Section 9.2.5, or if this Agreement is terminated in its entirety, the entire Territory. 

1.155. “Terminated Territory Discussion Period” has the meaning set forth in Section 9.4.3(d)(i). 

1.156. “Termination Discussion Period” has the meaning set forth in Section 9.4.2(d)(i). 

1.157. “Termination Notice” means the Section 9.2.1(a) Termination Notice or the Section 9.2.1(b) Termination
Notice, as applicable. 
 1.158. “Territory” means the entire world, other than the Terminated Territory. 

1.159. “Third Party” means any Person other than MedImmune, Licensee and their respective Affiliates. 

1.160. “Third Party Acquirer” has the meaning set forth in Section 10.3.1. 

1.161. “Third Party Claims” has the meaning set forth in Section 8.1. 

1.162. “Third Party Infringement Claim” has the meaning set forth in Section 5.4. 

1.163. “Third Party Patent Right” has the meaning set forth in Section 4.5.3(c). 

1.164. “Ticagrelor Compound” means 
(1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio) -3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
 
 1.165. “Trademark” means any word, name,
symbol, color, shape, designation or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration rights, program name, delivery
form name, certification mark, collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source, origin or quality, whether or not registered, and all statutory

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 21 

 
and common law rights therein and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing. 

1.166. “Trademark License Agreement” has the meaning set forth in Section 2.6. 

1.167. “Transferred Inventory” has the meaning set forth in Section 3.1.2. 

1.168. “United States” or “U.S.” means the United States of America and its territories and
possessions (including the District of Columbia and Puerto Rico). 
 1.169. “Valid Claim” means (a) a claim of
any issued and unexpired Patent whose validity, enforceability or patentability has not been affected by (i) irretrievable lapse, abandonment, revocation, dedication to the public or disclaimer or (ii) a holding, finding or decision of
invalidity, unenforceability or non-patentability by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, such holding, finding or
decision being final and unappealable or unappealed within the time allowed for appeal, or (b) a claim of a pending Patent application that was filed and is being prosecuted in good faith and has not been intentionally abandoned without the
possibility of reinstatement and that has been pending for less than seven (7) years from the filing date from which such claim takes priority. If a claim of a patent application that ceased to be a Valid Claim under clause (b) of the
preceding sentence because of the passage of time later issues as a part of a patent within clause (a) of the preceding sentence, then it shall again be considered a Valid Claim effective as of the issuance of such patent. 

1.170. “VAT” has the meaning set forth in Section 4.8.3.  

1.171. [***] means [***]. 

1.172. “Withholding Taxes” has the meaning set forth in Section 4.8.1. 

ARTICLE 2 
 GRANT OF
RIGHTS 
 2.1. Grants to Licensee. Subject to Section 2.3 and Section 2.4 and the other terms and conditions of this
Agreement, MedImmune hereby grants to Licensee an exclusive (including with regard to MedImmune and its Affiliates) license, with the right to grant sublicenses in accordance with Section 2.3, under the Licensed
Know-How, Licensed Patents, and MedImmune’s interest in Joint Inventions and Joint Patents, solely to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory and for no
other purpose; provided, however, that the license granted to Licensee in this Section 2.1 shall include each Additional Compound solely to the extent that Licensee complies with Section 2.4.4 with respect to such Additional
Compound and only for as long as such Additional Compound is not an Excluded Compound. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 22 

 2.2. Grants to MedImmune. Licensee hereby grants to MedImmune and its Affiliates:
(a) a worldwide, non-exclusive, royalty-free, irrevocable license and right of reference, with the right to grant sublicenses through multiple tiers of sublicensees and further rights of reference under
Licensee’s interests in the Assigned Regulatory Documentation and the Licensee Regulatory Documentation; and (b) a non-exclusive license, with the right to grant sublicenses through multiple tiers of
sublicensees, to use the Product Trademarks (as such use is approved by Licensee in advance in writing, such approval not to be unreasonably withheld, conditioned or delayed), in each case ((a) and (b)), solely (x) to Exploit the AstraZeneca
Product and any AstraZeneca Product Improvements and (y) to perform or exercise MedImmune’s obligations or rights under this Agreement and for no other purpose. 

2.3. Sublicenses. 

2.3.1. In General. Licensee shall have the right to grant sublicenses (or further rights of reference), through multiple tiers of
sublicensees, under the license and rights of reference granted in Section 2.1, to its Affiliates and Third Parties; provided that any such sublicenses shall be consistent with, and expressly made subject to, the terms and conditions of
this Agreement. Licensee shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement to the same extent as applicable to Licensee hereunder (in each case, regardless of whether a particular term or condition of
this Agreement makes express reference to Sublicensees), including, for clarity, Section 2.5.2, Section 3.5.5, Section 3.5.6, Section 3.5.7, Section 5.1.2, Section 5.1.6, Section 6.4, Section 6.5,
Section 9.4.2 and Section 9.4.3. Licensee hereby (a) guarantees the performance of its Affiliates and Sublicensees and the grant of any such sublicense shall not relieve Licensee of its obligations under this Agreement, except to the
extent they are satisfactorily performed by such Affiliate or Sublicensee and (b) waives any requirement that MedImmune exhaust any right, power or remedy, or proceed against any Affiliate or Sublicensee for any obligation or performance under
this Agreement prior to proceeding directly against Licensee. A copy of any sublicense agreement executed by Licensee pursuant to which Licensee sublicenses any license or rights of reference granted hereunder shall be provided to MedImmune within
[***] after its execution; provided that the terms of any such sublicense agreement to the extent not pertinent to an understanding of a Party’s obligations or benefits under this Agreement may be redacted. 

2.3.2. Selected Sublicense Arrangements. Prior to entering into any sublicense with any Third Party pursuant to Section 2.3.1 with
respect to the U.S., EU Market or China, Licensee shall have the right, at its election, to request that MedImmune consider in good faith agreeing to provide such proposed Sublicensee with certain rights, including, as appropriate, a direct standby
license of applicable intellectual property rights, to enable such proposed Sublicensee to retain its role with respect to the Licensed Products in such Market following termination of this Agreement by MedImmune pursuant to Section 9.2.1 or
Section 9.2.2 in its entirety, or by MedImmune pursuant to Section 9.2.1 with respect to such Market, as applicable (such rights, collectively, a “Standby License”). Licensee may make such request by written notice to
MedImmune, which notice shall identify the proposed Sublicensee 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 23 

 
and the scope of the Sublicense that Licensee proposes to grant to such proposed Sublicensee (a “Standby License Request”). If Licensee delivers a Standby License Request to
MedImmune, the Parties shall promptly engage in good faith discussions with Licensee regarding the terms and conditions pursuant to which MedImmune would consider agreeing to grant such Standby License, which terms and conditions shall at a minimum
include the following ((a) through (f), collectively, the “Surviving Sublicense Requirements”): 
 (a) an agreement by the
proposed Sublicensee that, following such termination of this Agreement, such proposed Sublicensee will perform and continue to perform the relevant activities with respect to the Licensed Product(s) proposed to be sublicensed to it that Licensee
would have been obligated to perform under this Agreement with respect to such Licensed Product(s) under this Agreement in the absence of such termination of this Agreement, in each case in the applicable Market(s) or to the extent otherwise
reasonably necessary to enable Exploitation of the Licensed Product(s) for such Market(s); 
 (b) that MedImmune will not be required to
assume any obligations or liabilities in respect of such Sublicense that are in addition to, or greater in scope than, MedImmune’s obligations or liabilities set forth in this Agreement, unless MedImmune otherwise agrees in writing; 

(c) an express acknowledgment and agreement by such proposed Sublicensee that, following such termination of this Agreement, the obligations
of Licensee under this Agreement and the Pharmacovigilance Agreement (i) to the extent applicable to the rights and licenses granted to such Sublicensee and required by MedImmune pursuant to the Surviving Sublicense will be direct obligations
of such Sublicensee to MedImmune (and that, without limitation to Section 9.6, termination of this Agreement in its entirety or in a Terminated Territory with respect to Licensee will not terminate such obligations with respect to such
Sublicensee), and (ii) MedImmune will have the right to enforce (x) such obligations and (y) any terms of this Agreement which are otherwise applicable to such Sublicensee, in each case ((x) and (y)) directly against such Sublicensee;

 (d) that, effective upon termination of this Agreement by MedImmune pursuant to Section 9.2.1 or Section 9.2.2, (i) any
payment obligations to Licensee arising after such termination under such Sublicense in consideration for such Sublicense will become direct payment obligations of such Sublicensee to MedImmune, directly payable to MedImmune (it being understood,
however, that, except with respect to any payments due as compensation for any performance obligations that MedImmune elects to assume or perform in connection with a Standby License, MedImmune would not be entitled to receive payments due to
Licensee under such sublicense that are for value other than, and not in consideration for, such Sublicense– e.g., payments of Licensee’s fully-burdened cost of performing bona fide research and development activities for or with
such Sublicensee, reimbursements of reasonable and documented external costs incurred by Licensee in performing such activities, and payments for 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 24 

 
equity or debt securities of Licensee or any of its Affiliates), and (ii) MedImmune will have the right to enforce such obligations directly against such Sublicensee; 

(e) that in the event of any subsequent termination of any such Sublicense, MedImmune will automatically receive from such Sublicensee the
full scope of rights provided in Section 9.4.2 or 9.4.3, as applicable, with respect to the applicable Licensed Product(s) in the applicable Market(s) as if such Sublicensee were subject to such terms without qualifying as having a
“Surviving Sublicense” as such term is used in such sections; and 
 (f) that any rights afforded to such Sublicensee under any
Standby License will require that any such Sublicensee remain in compliance with this Agreement and the applicable Sublicense. 
 MedImmune
shall consider any such Standby License Request in good faith and shall provide Licensee with its decision as to whether MedImmune agrees to provide such Standby License within [***] from delivery of the applicable Standby License Request. MedImmune
shall not unreasonably withhold, condition, or delay its agreement with respect to the grant of a Standby License (it being understood, without limitation, that MedImmune may not condition its agreement with respect to such Standby License on the
payment by Licensee, its Affiliate or the applicable Third Party of any additional financial consideration to MedImmune or any of its Affiliates beyond the payments negotiated between Licensee and such Third Party except as compensation for any
additional performance obligations that MedImmune elects to assume or perform); provided, however, that MedImmune shall retain sole discretion to withhold agreement with respect to any other grant of rights in connection therewith or the
assumption of any obligations or liabilities in addition to, or that are greater in scope than, MedImmune’s obligations or liabilities set forth in this Agreement but shall not unreasonably delay its response to any such Standby License
Request. Any Standby License (or other rights) granted by MedImmune to a proposed Sublicensee pursuant to this Section 2.3.2 shall be deemed a “Surviving Sublicense”. In addition, in the event that MedImmune agrees to grant a
Standby License to any Sublicensee with respect to a country other than the U.S., a country in the EU Market or China, then upon entering into such agreement, such agreement shall also be referred to as a Surviving Sublicense for purposes of this
Agreement. 
 2.3.3. Acknowledgments Regarding Sublicensing. 

(a) MedImmune acknowledges that Licensee’s ability to comply with its diligence obligations under Sections 3.3.1 and 3.5.1 with
respect to Licensed Products in the Field in each of the EU Market and China may depend on its ability to grant Sublicenses to Third Parties in such Markets. 

(b) MedImmune further acknowledges that if (i) Licensee delivers a Standby License Request to MedImmune requesting MedImmune’s
agreement to grant a Standby License to a bona fide proposed Sublicensee of Licensed Products in the Field in the EU Market or China that is both willing to agree to terms and conditions of Sublicense that

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 25 

 
would comply with the requirements of Section 2.3.1 and the Surviving Sublicense Requirements, and unwilling to enter into a Sublicense agreement with Licensee for such Market without such
Standby License, and (ii) MedImmune does not agree to grant such Standby License, or does not respond to such Standby License Request, or does not engage in good faith discussions with Licensee regarding such Standby License within [***] of
such Standby License Request, such refusal by MedImmune may impede the Development and Commercialization of Licensed Products in the Field in such Market and have an adverse effect on Licensee’s timelines for such Development and
Commercialization. 
 2.4. Retention of Rights; Limitations Applicable to License Grants. 

2.4.1. Retained Rights of MedImmune. Notwithstanding anything to the contrary in this Agreement and without limitation of any rights
granted or reserved to MedImmune pursuant to any other term or condition of this Agreement, MedImmune hereby expressly retains, on behalf of itself and its Affiliates (and on behalf of its licensors, (sub)licensees and contractors) the non-exclusive right under the Licensed Know-How and Licensed Patents, in each case for MedImmune and its Affiliates (a) to (i) perform MedImmune’s obligations
and to exercise their respective rights under this Agreement, (ii) Exploit the AstraZeneca Product in any field (including the Field) anywhere in the Territory and (iii) subject to Section 2.5.1, Exploit any compound or product other
than any Licensed Compound or Licensed Product and (b) without limitation to clause (a), in the case of Licensed Know-How, subject to Section 2.5.1, to Exploit any compound other than
(x) MEDI2452 or (y) any compound claimed in the Licensed Patents or, in each case ((x) and (y)), any product containing a compound covered by clause (x) or (y). 

2.4.2. No Other Rights Granted by MedImmune. Except as expressly provided herein, MedImmune grants no other right or license, including
any rights or licenses to the Licensed Know-How, the Licensed Patents, the MedImmune Corporate Names, or any other Patent, Trademark or other intellectual property rights not otherwise expressly granted
herein. Without limitation to the foregoing, the Parties agree that the rights and licenses granted to Licensee under this Agreement do not include rights or licenses to develop, manufacture or commercialize, or otherwise Exploit, the Ticagrelor
Compound or any AstraZeneca Product for any purpose. 
 2.4.3. No Other Rights Granted by Licensee. Except as expressly provided
herein, Licensee grants no other right or license, including any rights or licenses to the PhaseBio Know-How, PhaseBio Patents, Licensee Termination Patents, Licensee Termination
Know-How, the Assigned Regulatory Documentation, the Licensee Regulatory Documentation, the Product Trademarks, or any other Patent, Trademark or other intellectual property rights not otherwise expressly
granted herein. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 26 

 2.4.4. Rights with Respect to Additional Compounds. Notwithstanding the
license grants in Section 2.1, Licensee shall have the right and license to Exploit Additional Compounds solely in accordance with this Section 2.4.4. 

(a) In the event that Licensee has continued to satisfy its obligations pursuant to Section 3.3.1 to use Commercially Reasonable Efforts
to Develop MEDI2452, and MEDI2452 is advancing through clinical development, or in the event that a Drug Approval Application for MEDI2452 has received Regulatory Approval in one or more Markets, Licensee may (directly, or indirectly through one or
more Affiliates or Sublicensees), on at least [***] prior written notice to MedImmune at its sole expense, and while continuing to pursue Development, Regulatory Approval and Commercialization of MEDI2452 in accordance with this Agreement, also
Exploit one or more Additional Compounds (and Licensed Products containing any such Additional Compound(s)) under and in accordance with this Agreement; provided that such Exploitation does not adversely affect the clinical development of, or
obtaining or maintaining regulatory approval for, MEDI2452, including the timelines with respect thereto. 
 (b) In the event a
Safety/Efficacy Issue occurs or exists with respect to MEDI2452, then Licensee shall so notify MedImmune and Licensee may, with MedImmune’s prior written consent, not to be unreasonably withheld, conditioned or delayed, at its sole expense,
elect to Exploit one or more Additional Compounds (and Licensed Products containing any such Additional Compound(s)) under and in accordance with this Agreement. 

(c) Without limitation to Section 2.4.4(a) or Section 2.4.4(b) or Licensee’s reporting and other obligations with respect to
Licensed Compounds under Article 3, at least [***] prior to any IND filing by or on behalf of Licensee (or any Affiliate or Sublicensee) with respect to any Additional Compound, Licensee shall (i) identify to MedImmune the protein sequence
of the applicable antibody or antibody fragment and (ii) provide to MedImmune such evidence or other documentation demonstrating that such antibody or antibody fragment satisfies the definition of an Additional Compound. If MedImmune reasonably
determines that such antibody or antibody fragment does not satisfy the definition of an Additional Compound and so notifies Licensee in writing, or if Licensee fails to identify to MedImmune the protein sequence of, or provide to MedImmune the
evidence or other documentation with respect to, such antibody or antibody fragment pursuant to the foregoing sentence, such antibody or antibody fragment shall automatically be deemed to be excluded from the definition of an Additional Compound and
the license grants under Section 2.1 unless MedImmune otherwise expressly agrees pursuant to an amendment to this Agreement entered into pursuant to Section 10.10. Each antibody or antibody fragment that is deemed to be so excluded
pursuant to the foregoing sentence from and after such exclusion shall be an “Excluded Compound”. 
 (d) Without limitation
to Section 2.4.1 or Section 2.4.2 or any other term or condition of this Agreement, Licensee covenants to MedImmune that, subject 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 27 

 
to Section 2.4.4(a) and Section 2.4.4(b), none of Licensee, any of its Affiliates or its or their successors or any Sublicensee, directly or indirectly shall Exploit any Excluded
Compound or any product containing an Excluded Compound. In the event of Licensee’s breach of this Section 2.4.4, without limitation to any claim for damages or other right or remedy of MedImmune hereunder or at law or in equity, Licensee
shall pay to MedImmune, in relation to any such Excluded Compound and any product containing an Excluded Compound or any Exploitation thereof, an amount equal to the milestones and royalties that would have otherwise been payable pursuant to
Article 4 as if such Excluded Compound or product was a Licensed Product hereunder. For clarity, nothing contained herein is intended to imply, and shall not be construed, to grant to Licensee any license rights to Exploit any Excluded Compound
or use any Licensed Compound for any purpose in connection with any product other than a Licensed Product. 
 2.4.5. Licensed Know-How. MedImmune has used good faith efforts to identify and set forth on Schedule 1.79 all of the material Information Controlled by MedImmune and its Affiliates that satisfies all
of clauses (a), (b) and (c) as follows: (a) is in the possession and Control of MedImmune or its Affiliates and can be transferred to Licensee, (b) was generated by MedImmune or any of its Affiliates and was actually used by
MedImmune or any of its Affiliates, in each case in the conduct of MedImmune’s and its Affiliates’ development program for MEDI2452 prior to the Effective Date and (c) is reasonably necessary for the further Development of, or to
obtain or maintain any Patent with respect to, MEDI2452 or any Licensed Product containing MEDI2452 as each exists as of the Effective Date. In the event that, within [***] following the Effective Date, Licensee reasonably determines that MedImmune
omitted any such material Information from Schedule 1.79, Licensee’s sole and exclusive remedy with respect to such omission shall be for MedImmune to transfer to Licensee the applicable Information. Licensee
acknowledges and agrees that (i) neither the Licensed Know-How nor the Technical Transfer Documents are intended to, and shall not be construed to, convey, license or otherwise transfer to Licensee any
rights with respect to Information owned by or in the possession of [***] and the Licensed Know-How excludes any such Information and (ii) the Licensed Know-How
excludes any research, discovery or development tools or technology, including Information with respect to any such research, discovery or development tools or technology used by MedImmune in relation to: (A) MEDI2452 or (B) any
anti-ticagrelor antibody or antibody fragment other than MEDI2452 that is covered or claimed by the Licensed Patents. 
 2.5.
Exclusivity. 
 2.5.1. Exclusivity Commitment of MedImmune. Subject to Section 3.3.1(e) and Sections 10.3 and 10.4,
during the applicable Exclusive Period, MedImmune shall not, and shall cause its Affiliates not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold, any Competing Product.
Notwithstanding the foregoing, (a) nothing herein is intended to prevent, or shall be construed as preventing, MedImmune or its Affiliates from performing its regulatory obligations 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 28 

 
with respect to the AstraZeneca Product and (b) if with respect to any country, (i) in order to obtain or maintain regulatory approval for the AstraZeneca Product in such country a
Regulatory Authority requires that a product that acts as an antidote to, or neutralizes, abrogates or reverses the antiplatelet activity of the Ticagrelor Compound be developed or commercialized in such country, and (ii) MedImmune has provided
Licensee an opportunity for the Parties to discuss in good faith but the Parties have not reached agreement as to whether, and the terms on which, MedImmune would be granted the right to Develop, obtain and maintain Regulatory Approval for and
commercialize a Licensed Product in such country pursuant to Section 3.3.1(e), then MedImmune or its Affiliate shall be permitted to conduct human clinical trials for, and sell, offer for sale and have sold, a Competing Product in such country
unless Licensee can reasonably demonstrate that Licensee (x) is continuing to Develop, and (y) has used and is continuing to use Commercially Reasonable Efforts to Develop, in each case ((x) and (y)) a Licensed Compound and a Licensed
Product for such country, including taking all necessary steps to obtain and maintain Regulatory Approval with respect to such Licensed Product in such country. 

2.5.2. Exclusivity Commitment of Licensee. During the applicable Exclusive Period, Licensee shall not, and shall cause its Affiliates
and Sublicensees not to, either by itself or through a Third Party, conduct human clinical trials of, or sell, offer for sale or have sold: 

(a) any Competing Product (other than a Licensed Compound or Licensed Product) alone or in combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients; 
 (b) any combination (whether fixed
dose or co-packaged) with one (1) or more other active ingredients of Licensed Compound or Licensed Product and a Competing Product; 

(c) any agent that is intended as an antidote to, or is intended to neutralize, abrogate or reverse the antiplatelet activity of, (i) any
Brilinta Competing Product alone or in combination (whether fixed dose or co-packaged) with one (1) or more other active ingredients or (ii) both the Ticagrelor Compound and a Brilinta Competing
Product; 
 (d) without limitation to the foregoing, any agent with dual activity as (i) an antidote to, or for use as an agent to
neutralize, abrogate or reverse the antiplatelet activity of, the Ticagrelor Compound and (ii) an antidote to, or for use as an agent to neutralize, abrogate or reverse the antiplatelet activity of, any Brilinta Competing Product; or 

(e) any Brilinta Competing Product. 

2.6. Trademark License Agreement. No later than the date on which Licensee files the first Drug Approval Application with
respect to any Licensed Product, or such earlier date as the Parties may mutually agree, upon the request of either Party, the Parties shall negotiate in good faith the terms and conditions of a trademark license agreement (the

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 29 

 
“Trademark License Agreement”) pursuant to which MedImmune would grant Licensee a non-exclusive license (or sublicense), with the right to
grant sublicenses as approved by MedImmune in advance in writing (such approval not to be unreasonably withheld, conditioned or delayed), to use the Licensed Trademarks (a) to make additional submissions to Regulatory Authorities with respect
to obtaining and maintaining Regulatory Approval with respect to a Licensed Product, (b) in Promotional Materials that comply with Section 3.5.6, and (c) as may be otherwise approved by MedImmune in advance in writing. In addition to
such other terms and conditions as may be agreed by the Parties, any such Trademark License Agreement shall include (i) a list of the Licensed Trademarks, which may be updated by MedImmune from time to time on written notice to Licensee, and
(ii) the jurisdictions in or for which each such Licensed Trademark may be used. No royalties or other payments in addition to those set forth in Article 4 shall be due by Licensee in respect of any license granted pursuant to the
Trademark License Agreement. 
 ARTICLE 3 

MANUFACTURING, DEVELOPMENT, REGULATORY 

AND COMMERCIALIZATION ACTIVITIES 

3.1. Technical Services. 

3.1.1. Technical Transfer. As promptly as practicable after the Effective Date, but in any event within [***] after the Effective Date,
MedImmune shall transfer, or shall cause to be transferred, to Licensee via the electronic data room established by MedImmune in connection with the negotiation of this Agreement or any other method as mutually agreed between the Parties copies of
the technical documents set forth on Schedule 3.1.1 (the “Technical Transfer Documents”). MedImmune shall ensure that such technical documents in the electronic data room are downloadable and printable and
that downloaded and printed versions of such technical documents do not bear any watermark. For clarity, MedImmune shall have no obligation to perform a Manufacturing technology transfer with respect to any Licensed Compound or Licensed Product;
provided, however, that the transfer pursuant to this Section 3.1.1 includes the identification of, and written documentation with respect to, the assay(s) used for stability testing of MEDI2452, in each case to the extent included in
the Technical Transfer Documents. MedImmune provides no assurances or guarantee that the Technical Transfer Documents alone will, following such transfer, enable Licensee to Manufacture successfully any Licensed Compound or any Licensed Product.

 3.1.2. Transfer of Existing Inventory and GLP Samples. Subject to the terms and conditions of this Agreement, effective as of the
Effective Date, MedImmune shall, or shall cause its applicable Affiliates to convey and assign to Licensee or its designee, and Licensee shall accept from MedImmune or such Affiliates, (a) the inventory of existing MEDI2452 drug substance and
drug product, drug product reference standards, stability study samples and IVSS bag protectant solely with respect to inventory owned by and in the possession of MedImmune (the “Transferred Inventory”), which Transferred Inventory
as of 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 30 

 
the Effective Date is set forth on Schedule 3.1.2(a) and (b) the existing GLP toxicology samples of MEDI2452 (the “GLP Samples”), including those located at
Cryostore, Greenwich London, which GLP Samples existing as of the Effective Date are set forth on Schedule 3.1.2(b). Unless otherwise agreed, MedImmune shall continue to arrange for the storage of the GLP Samples at a Third Party
contractor’s facility for a period of up to [***] following the Effective Date and Licensee shall reimburse MedImmune for any reasonable costs incurred in connection with such storage within [***] after receipt of an invoice therefor. Licensee
acknowledges that neither the Transferred Inventory nor the GLP Samples are intended for commercial sale. Licensee shall use the Transferred Inventory and GLP Samples solely for Development purposes. Licensee shall, pursuant to Section 4.3,
reimburse MedImmune for its Technical Services Costs incurred in connection with such transfer and storage, including the packaging, documentation production, releasing and other Manufacturing activities performed by MedImmune or its Affiliates in
connection with the transfer of the Transferred Inventory and GLP Samples to Licensee. Licensee shall arrange for shipping of the Transferred Inventory and GLP Samples (following any storage period) at Licensee’s cost. Within [***] after the
Effective Date, with respect to the Transferred Inventory, and at such time prior to the first anniversary of the Effective Date as Licensee has made suitable arrangements to receive delivery of the GLP Samples, with respect to the GLP Samples,
MedImmune shall deliver or have delivered the Transferred Inventory or GLP Samples, as applicable to Licensee EXW (as defined in Incoterms 2010) MedImmune’s Third Party vendor’s warehouses set forth on
Schedule 3.1.2(a) or (b), as applicable. Notwithstanding the foregoing or any other term or condition of this Agreement, Licensee acknowledges and agrees that MedImmune shall have no liability to Licensee with respect to,
and shall have no obligation to replace, any Transferred Inventory, GLP Samples or any quantities of active metabolite provided under Section 3.3.1(d) that are lost or destroyed, or spoil or expire, prior to delivery to Licensee. 

3.1.3. [***] Manufacturing. Licensee shall be solely responsible for (a) obtaining from [***] any documentation with
respect to the Manufacturing process utilized by [***] for the supply of Licensed Compounds and Licensed Products (including material batch records, cell bank testing results, and upstream process development reports), and (b) negotiating a
license, supply or other agreement with [***] for continued Development and Manufacturing with respect to Licensed Compounds and Licensed Products. 

3.1.4. IND Deliverables. As promptly as practicable after the Effective Date, but in any event within [***] after the Effective
Date, MedImmune shall deliver to Licensee the deliverables set forth on Schedule 3.1.4 for Licensee’s use in preparing an IND with respect to Licensed Product. Licensee shall, pursuant to Section 4.3, reimburse
MedImmune for its Technical Services Costs incurred after the Effective Date in preparing and delivering such deliverables. 
 3.1.5.
Consultation with MedImmune. Licensee shall have the right for a period of [***] after the Effective Date to request reasonable consultation with relevant employees of MedImmune or its Affiliates with respect to the Licensed Compounds or
Licensed 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 31 

 
Products, which consultation shall be provided at MedImmune’s discretion, not to be unreasonably withheld; provided that such consultation shall not materially disrupt
MedImmune’s business. Licensee shall, pursuant to Section 4.3, reimburse MedImmune for its Technical Services Costs incurred in connection with any such consultation. MedImmune expressly disclaims any representation or warranty with
respect to any consultation or any Information provided in connection therewith by MedImmune or its Affiliates. 
 3.1.6. Limitation of
MedImmune Support and FTEs. Except to the extent specifically included in the Technical Services or expressly set forth in the preceding provisions of this Section 3.1 or the last sentence of Section 5.2.2, MedImmune shall have no
obligation to provide transition or other support with respect to the Technical Transfer Documents, the Licensed Patents, the Licensed Know-How, the Assigned Regulatory Documentation, any Licensed Compound or
Licensed Product or otherwise. Notwithstanding anything to the contrary hereunder, unless otherwise agreed by the Parties in writing, MedImmune shall not be required to perform Technical Services (a) after the Effective Date in excess of [***]
in the aggregate or (b) after [***]the Effective Date, nor shall Licensee be obligated to compensate MedImmune for Technical Services in excess of one (1) FTE in the aggregate. 

3.2. Manufacturing. From and after the Effective Date, subject to MedImmune’s retained rights under Section 2.4.1, as between
the Parties, Licensee shall be solely responsible for all aspects of the Manufacturing of Licensed Compounds and Licensed Products in the Field in the Territory at Licensee’s own cost and expense. For clarity, MedImmune shall not be required to
provide any support with respect to Manufacturing other than those obligations of MedImmune expressly provided in Section 3.1. Licensee shall use Commercially Reasonable Efforts to Manufacture Licensed Compounds and Licensed Products in
sufficient quantities for the conduct of the Development Plans and Commercialization Plans and to otherwise comply with its obligations under this Agreement. 

3.3. Development. 

3.3.1. Diligence. 
 (a)
After the Effective Date, subject to MedImmune’s retained rights under Section 2.4.1 and to Section 3.3.3, and except as set forth in Section 3.3.1(d), as between the Parties, Licensee shall be solely responsible for all aspects
of the Development of Licensed Compounds and Licensed Products in the Field in the Territory at Licensee’s own cost and expense, including (i) obtaining any quantities of the AstraZeneca Product required for Licensee’s Development
activities from commercially available channels; (ii) identifying and engaging a contract research organization or other vendor to perform testing of Licensed Compound drug substance or drug product; and (iii) sourcing an assay reagent for
the performance of stability assays. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 32 

 (b) Licensee shall use Commercially Reasonable Efforts to Develop, and obtain and maintain
Regulatory Approvals for, Licensed Products for use in the Field (x) in the United States, China and the Major European Countries and (y) in other countries throughout the Territory where it is commercially reasonable (consistent with the
definition of Commercially Reasonable Efforts) to do so; provided that, in the case of any other country covered by clause (y), Licensee shall not be required pursuant to this sentence to Develop or obtain Regulatory Approval for a
Licensed Product in such country if the reasonably expected period of exclusivity for such Licensed Product in such country (whether by virtue of an anticipated Valid Claim of a Licensed Patent or the Regulatory Exclusivity Period with respect to
which the Licensed Product is expected to be eligible upon receipt of Regulatory Approval or other available data or similar exclusivity) is less than five (5) years assuming the exercise of Commercially Reasonable Efforts to Develop, and
obtain and maintain Regulatory Approval for, such Licensed Product in such country. For clarity, the Parties acknowledge that Developing, and obtaining and maintaining Regulatory Approvals for, Licensed Products for use in the Field in the United
States and the Major European Countries is a higher timing priority in Licensee’s global development strategy than Developing, and obtaining and maintaining Regulatory Approvals for, Licensed Products for use in the Field in China, and that,
accordingly, the use of Commercially Reasonable Efforts to perform such activities in (i) the U.S. and the Major European Countries, on the one hand, and (ii) China, on the other hand, does not require that such activities in China be
conducted on the same or similar timeline as such activities in the U.S. and the Major European Countries. 
 (c) In the event that Licensee
achieves First Commercial Sale of a Licensed Product in the United States, a Major European Country or China on or before December 31, 2021, Licensee shall so notify MedImmune in writing and provide supporting documentation with respect thereto
and the commencement of the Royalty Term shall be delayed until July 1, 2022. 
 (d) Without limitation to the last sentence of
Section 2.5.1, upon Licensee’s request, MedImmune shall (or shall cause its applicable Affiliates to) use commercially reasonable efforts to supply Licensee or its designee those quantities of existing ticagrelor active metabolite (AR-C124910XX) on the terms and conditions set forth on Schedule 3.3.1(d) for Licensee’s use in analytical assay development with respect to the Licensed Compounds and Licensed
Products. 
 (e) If Licensee elects, including pursuant to the first sentence of Section 3.3.1(b), not to Develop or seek or obtain
Regulatory Approval for a Licensed Product, or to Commercialize a Licensed Product in any country or jurisdiction in the Territory where the AstraZeneca Product is being developed or commercialized by or on behalf of MedImmune or its Affiliates or
its or their (sub)licensees or successors and the applicable Regulatory Authority conditions the marketing or sale of the AstraZeneca Product on the availability of a Licensed Product, Licensee shall promptly notify MedImmune in writing of such
election, and, upon MedImmune’s request, the Parties shall discuss in good faith the terms and 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 33 

 
conditions pursuant to which MedImmune may obtain the right, but not the obligation, to Develop or obtain Regulatory Approval for and Commercialize such Licensed Product in such country or
jurisdiction. 
 3.3.2. Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to,
maintain, in good scientific manner, complete and accurate books and records pertaining to Development of the Licensed Compounds and Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement.
Such books and records shall (a) be appropriate for patent and regulatory purposes, (b) be in compliance with Applicable Law, (c) properly reflect all work done and results achieved in the performance of its Development activities
hereunder, and (d) be retained by Licensee for such period as may be required by Applicable Law. In the event (i) of a dispute with respect to Licensee’s performance of its Development obligations set forth in Section 3.3.1,
(ii) of termination of this Agreement in its entirety or with respect to any Market, or (iii) that access to such books and records is reasonably required by MedImmune or its Affiliates in connection with the exercise of its rights under
Article 5, MedImmune shall have the right, during normal business hours and upon reasonable notice, to inspect and copy any or all such books and records pursuant to this Section 3.3.2; provided that MedImmune shall maintain such
records and information disclosed therein in accordance with Article 6. 
 3.3.3. Development Plans. No later than [***],
Licensee shall provide MedImmune with an initial written development plan for the Licensed Products. In addition, and without limiting Section 3.3.2, prior to Licensee’s receipt of Regulatory Approval in the United States, China and at
least one Major European Country, within [***] following the end of each Calendar Year beginning with Calendar Year 2018, Licensee shall provide MedImmune with Licensee’s then-current written development plan for the Licensed Products,
including a listing of those countries in the Territory with respect to which Licensee is pursuing Development or intends to seek Regulatory Approval (each, a “Development Plan”). MedImmune shall have the right to review and provide
comments to Licensee on each Development Plan within [***] of receipt of such Development Plan, which comments Licensee shall consider in good faith. Without limiting the generality of the foregoing, Licensee promptly shall provide MedImmune with
key Development results from any clinical trial with respect to a Licensed Product, including top-line data from any Pivotal Trial readout, in each case reasonably in advance of any public announcement of such
results. 
 3.4. Regulatory Activities. 

3.4.1. Regulatory Approvals; Assigned Regulatory Documentation. 

(a) Subject to MedImmune’s retained rights under Section 2.4.1, except as otherwise set forth in this Section 3.4, Licensee
shall have the sole right and responsibility, at Licensee’s own cost and expense, to prepare, submit, obtain, and maintain 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 34 

 
Drug Approval Applications (including the setting of the overall regulatory strategy therefor), Regulatory Approvals, and other submissions (including INDs) to Regulatory Authorities, and to
conduct communications with the Regulatory Authorities, for Licensed Products in the Field in the Territory, in its name. The Parties acknowledge that regulatory matters with respect to the Licensed Compounds or Licensed Products will reasonably
require coordination with regulatory matters with respect to the AstraZeneca Product and agree to cooperate in good faith with each other as reasonably necessary for and in relation to each Party to obtain and maintain regulatory approvals
(including Regulatory Approvals) with respect to the product that such Party has the right to commercialize (including Commercialize) under this Agreement (i.e., Licensed Product in the case of Licensee and AstraZeneca Product in the case of
MedImmune). Prior to submitting any written or electronic communication to a Regulatory Authority in a country of the Territory with respect to AstraZeneca Product that would reasonably be expected to require a change to the Regulatory Authority-approved full prescribing information for the AstraZeneca Product for such country, Licensee shall consult with MedImmune in good faith. Licensee shall keep MedImmune reasonably informed of its efforts to
obtain and maintain Regulatory Approval for any Licensed Product in the Territory and developments with respect thereto, including Licensee’s expected timing with respect to submission and receipt of any and all Regulatory Approvals. 

(b) Except to the extent prohibited by Applicable Law, MedImmune hereby assigns to Licensee or its designated Affiliate all Regulatory
Documentation possessed and owned by MedImmune or any of its Affiliates exclusively relating to MEDI2452 (the “Assigned Regulatory Documentation”). MedImmune has used good faith efforts to identify and set forth on
Schedule 3.4.1(b) all such material Regulatory Documentation Controlled by MedImmune or its Affiliates in existence on the Effective Date. Notwithstanding the foregoing, MedImmune shall be permitted to retain copies of the
Assigned Regulatory Documentation for purposes of Exploiting the AstraZeneca Product and otherwise. 
 3.4.2. Regulatory Interactions.
Without limitation to Section 3.3.3 or Section 3.4.1(a), Licensee shall, except to the extent a need for exigent action prevents it from doing so, provide MedImmune with copies of Licensee’s initial Drug Approval Application
relating to each Licensed Compound or Licensed Product to the FDA or EMA, as applicable, and to such other Regulatory Authorities as MedImmune may reasonably request, a reasonable amount of time (but no less than [***]) prior to the anticipated date
for the applicable submission to allow MedImmune to review and comment on such Drug Approval Application, and Licensee shall consider all comments and proposed revisions from MedImmune in good faith in connection with effecting such submission.
Licensee shall consult with MedImmune regarding, and keep MedImmune informed of, the status of the preparation of the dossier rationale and proposed labeling with respect to each Licensed Product. Upon MedImmune’s request, Licensee shall
promptly (and in any event, within [***]) provide to MedImmune access to and copies of any Regulatory Documentation necessary or reasonably useful for MedImmune to Exploit the AstraZeneca Product or update the label with respect thereto. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 35 

 3.4.3. Recalls, Suspensions or Withdrawals. Licensee shall notify MedImmune promptly
(but in no event later than [***] in the case of commercially distributed Licensed Product) following its determination that any event, incident or circumstance has occurred that may result in the need for a recall, market suspension, or market
withdrawal of a Licensed Product in the Field in the Territory and shall include in such notice the reasoning behind such determination and any supporting facts. As between the Parties, Licensee shall have the right to make the final determination
whether to voluntarily implement any such recall, market suspension, or market withdrawal in the Field in the Territory; provided that, to the extent practicable under the circumstances, prior to any implementation of such a recall of a
commercially distributed Licensed Product (including samples), or market suspension or market withdrawal of a Licensed Product, Licensee shall consult with MedImmune and shall consider MedImmune’s comments in good faith. If a recall, market
suspension, or market withdrawal of a Licensed Product in the Field in the Territory is mandated by a Regulatory Authority in the Territory, then, as between the Parties, Licensee shall initiate such a recall, market suspension, or market withdrawal
in compliance with Applicable Law. For all recalls, market suspensions, or market withdrawals undertaken pursuant to this Section 3.4.3, as between the Parties, Licensee shall be solely responsible for the execution thereof. Subject to
Article 8, Licensee shall be responsible for all costs of any such recall, market suspension, or market withdrawal. 
 3.4.4.
Pharmacovigilance. 
 (a) Promptly after the Effective Date, the Parties and their respective Affiliates shall appoint a joint safety
governance team (the “Safety Team”) comprised of an equal number of representatives of each Party to discuss (i) the exchange of safety information with respect to the Licensed Products and AstraZeneca Products and
(ii) the negotiation of a written safety agreement (the “Pharmacovigilance Agreement”), which shall be agreed and executed as promptly as practicable following the Effective Date but in any event no later than [***] after the
Effective Date. The Safety Team shall be advisory only and shall not have any decision-making authority. The Pharmacovigilance Agreement will (A) address the Parties’ responsibilities in the Territory in relation to pharmacovigilance
obligations for the Development and Commercialization of Licensed Compounds and Licensed Products and AstraZeneca Products in the Territory under 21 C.F.R. sections 312.32 or 314.80 or under corresponding Applicable Law outside the United States)
with respect to pre-clinical or clinical laboratory, animal toxicology and pharmacology studies, clinical studies and commercial experiences with a Licensed Product and AstraZeneca Products and
(B) include such specific responsibilities of the Safety Team and such guidelines for the operation of the Safety Team as the Parties may agree. 

(b) Notwithstanding Section 3.4.4(a), Licensee shall establish, hold and maintain a safety database for the Licensed Compounds and
Licensed Products and Licensee shall be solely responsible for complying with its pharmacovigilance responsibilities in the Territory, as applicable. MedImmune and its Affiliates shall have the right, during normal business hours and upon reasonable
notice, to access and copy safety 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 36 

 
reporting information for the Licensed Products in the Territory. To the extent reasonably required by Licensee in relation to the Exploitation of a Licensed Product or obtaining and maintaining
Regulatory Approval for a Licensed Product, MedImmune shall cooperate in good faith to provide Licensee with appropriate access to material safety reporting information for the AstraZeneca Product solely for use in relation to the Exploitation of a
Licensed Product in accordance with the terms of this Agreement. 
 (c) With respect to any AstraZeneca Product, unless otherwise agreed by
the Parties in writing, Licensee shall notify in writing MedImmune or such Affiliate as MedImmune may designate of any adverse events and other safety-relevant information and complaints associated with such AstraZeneca Product in the Territory
(each, a “Spontaneous Adverse Event”) of which Licensee becomes aware, outside the conduct of clinical studies within [***] after Licensee first learns of such Spontaneous Adverse Event. 

(d) Licensee shall notify MedImmune according to the timelines above, regardless of seriousness, causality, and whether or not the AstraZeneca
Product was used in accordance with the authorized Summary of Product Characteristics (SPC) or any other conditions laid down for marketing of the AstraZeneca Product in accordance with applicable legal requirements including: (i) reports of
suspected transmission of an infectious agent for the AstraZeneca Product and (ii) reports of lack of effect, pregnancy, lactation/paternal exposure, medication error, overdose, off-label use, drug
interaction, abuse or misuse of the AstraZeneca Product, falsified/counterfeit product, or occupational exposure with or without an associated adverse event of the AstraZeneca Product. 

(e) Additionally, unless otherwise agreed, Licensee shall notify in writing MedImmune or such Affiliate as MedImmune may designate, of any
serious adverse events and other safety-relevant information and complaints associated with such AstraZeneca Product in the Territory (each, a “Serious Adverse Event”) of which Licensee becomes aware under the conduct of clinical
studies within timelines set forth on Schedule 3.4.4(e), after Licensee first learns of such Serious Adverse Event, as a processed report (e.g., CIOMS or E2B file). 

(f) Licensee shall notify in writing MedImmune of any other safety-relevant information and complaints associated with such AstraZeneca
Product in the Territory that is not a Serious Adverse Event (each, an “Other Adverse Event”) of which Licensee becomes aware in the course of conducting clinical trials promptly after Licensee first learns of such Other Adverse
Event. 
 (g) Licensee shall cooperate with MedImmune to investigate and follow-up on any such
Serious Adverse Events or Other Adverse Events associated with such AstraZeneca Product. For clarity, MedImmune or its Affiliate shall have final decision-making authority as to whether and how to report safety information pertaining to

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 37 

 
any AstraZeneca Product, and Licensee shall have final decision-making authority as to whether and how to report safety information pertaining to any Licensed Product. 

(h) Without limitation to any of the foregoing, Licensee shall ensure that all applicable patient authorizations and consents required under
Applicable Law, including the Health Insurance Portability and Accountability Act of 1996 and the EU Data Protection Directive 95/46/EC, in connection with safety information pertaining to the Licensed Compounds and Licensed Products from any
sources, permit such sharing of safety information with MedImmune or its Affiliate, including patient information required to contact the reporter where the source is outside the conduct of a clinical study. 

3.5. Commercialization. 

3.5.1. Diligence. As between the Parties, Licensee shall, subject to the remainder of this Section 3.5, be solely
responsible for Commercialization of the Licensed Products in the Field throughout the Territory at Licensee’s own cost and expense. Licensee shall use Commercially Reasonable Efforts to Commercialize the Licensed Products in the
Field (x) in the United States, China and the Major European Countries and (y) in each other Market throughout the Territory in which it is commercially reasonable to Commercialize the Licensed Products. For clarity, the Parties
acknowledge that, based on Licensee’s global development strategy (as described in Section 3.3.1(b)), Commercializing Licensed Products in the Field in the United States and the Major European Countries is a higher timing priority in
Licensee’s global development strategy than Commercializing Licensed Products in the Field in China, and that, accordingly, the use of Commercially Reasonable Efforts to perform such activities in (i) the U.S. and the Major European
Countries, on the one hand, and (ii) China, on the other hand, does not require that such activities in China be conducted on the same or similar timeline as such activities in the U.S. and the Major European Countries. 

3.5.2. Booking of Sales; Distribution. Licensee shall invoice and book sales, establish all terms of sale (including pricing and
discounts), and warehouse and distribute the Licensed Products in the Field in the Territory and perform or cause to be performed all related services. Subject to Section 3.4.3, Licensee shall handle all returns, recalls or withdrawals, order
processing, invoicing, collection, distribution, and inventory management with respect to the Licensed Products in the Field in the Territory. 

3.5.3. Commercialization Records. Without limitation of Section 4.10, Licensee shall maintain complete and accurate books and
records pertaining to Commercialization of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement, which shall be in compliance with Applicable Law. Such records shall be retained by Licensee
for such period as may be required by Applicable Law. In the event of a dispute with respect to Licensee’s performance of its Commercialization obligations set forth in Section 3.5.1, MedImmune shall have the right, during normal business
hours and upon reasonable notice, to inspect and copy all such books and records with respect to 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 38 

 
such dispute maintained pursuant to this Section 3.5.3; provided that MedImmune shall maintain such records and information disclosed therein in accordance with Article 6. 

3.5.4. Commercialization Plans. Without limiting Section 3.5.3, commencing at least [***] prior to the anticipated filing of the
first Drug Approval Application for each Licensed Product anywhere in the Territory, within [***] following the end of each Calendar Year, Licensee shall provide MedImmune with Licensee’s then-current written Commercialization Plan for the
Licensed Product(s) (each, a “Commercialization Plan”). MedImmune shall have the right to review and provide comments to Licensee on each Commercialization Plan within [***] of receipt of such Commercialization Plan, which comments
Licensee shall consider in good faith; provided, however, that MedImmune’s right to review and provide comments to Licensee, and Licensee’s obligation to consider such comments, with respect to those portions of any
Commercialization Plan relating to a particular Market shall expire on the later of (a) such time as the Generic Competition Threshold in such Market is first met or exceeded and (b) expiration of the last to expire Valid Claim of the
Patents owned or controlled by MedImmune or its Affiliates that claim the manufacture, use or sale of the AstraZeneca Product in such Market. 

3.5.5. Commercialization Strategy. On a
Market-by-Market basis, until the later of (a) such time as the Generic Competition Threshold in a particular Market is first met or exceeded and
(b) expiration of the last to expire Valid Claim of the Patents owned or controlled by MedImmune or its Affiliates that claim the manufacture, use or sale of the AstraZeneca Product in such Market, Licensee shall use Commercially Reasonable
Efforts to align its Commercialization strategy and Promotional Materials of the Licensed Products in such Market with the positioning, brand equity and overall commercial strategy for the AstraZeneca Product in such Market as may be communicated
from time to time to Licensee by MedImmune or its Affiliate; provided, however, Licensee shall not be obligated to so align its Commercialization strategy and Promotional Materials of the Licensed Products in any manner that, upon the
advice of Licensee’s regulatory advisors or legal counsel, Licensee determines would be inconsistent with Applicable Law in such Market. 

3.5.6. Promotional Materials. Without limiting Section 3.5.5 or any term or condition of the Trademark License Agreement,
MedImmune shall have the right to review and approve any and all Promotional Materials (including any information for use on the Internet), and including any updates or modifications thereto, that contain any AstraZeneca Product References. Licensee
shall provide any Promotional Materials to MedImmune for review (by MedImmune and its Affiliates) at least [***] prior to submission of such Promotional Materials (or such updates or modifications) to a Regulatory Authority or [***] prior to the
printing of such materials for distribution to the public, whichever comes first. MedImmune shall notify Licensee whether MedImmune approves such Promotional Materials within [***] of receipt of such Promotional Materials, such approval not to be
unreasonably withheld or conditioned. In no event shall (a) Licensee seek approval of or include in Promotional Materials any AstraZeneca Product Reference that is not (i) supported by the approved labeling for the AstraZeneca Product or
presents an unbalanced view of the AstraZeneca Product considering the approved labeling for the AstraZeneca Product as a whole or (ii) consistent with the approved labeling for the Licensed Product, and (b) MedImmune have any obligation
to approve any 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 39 

 
AstraZeneca Product References that use any Trademark with respect to the AstraZeneca Product other than a Licensed Trademark. Subject to Section 5.7.2, Licensee’s obligation to provide
MedImmune with its Promotional Materials and any updates and modifications thereto and MedImmune’s or such Affiliate’s right to review and approve such Promotional Materials shall expire with respect to such Promotional Materials on a
global basis at such time as the Generic Competition Threshold is first met or exceeded in all of the United States, the EU Market and China. In the event that Licensee reasonably believes MedImmune has breached its obligation to not unreasonably
withhold or condition an approval with respect to Promotional Materials that include AstraZeneca Product References, such dispute shall be decided in accordance with Section 3.5.7. During the resolution of any such dispute, Licensee and its
Affiliates and its and their Sublicensees and Third Party contractors, as applicable, shall be prohibited from using the portion(s) of the Promotional Materials that are subject to the dispute. In addition to any approved AstraZeneca Product
References with respect to the AstraZeneca Product for which Regulatory Approval is owned by AstraZeneca or any of its Affiliates (or its or their successors), Licensee shall have the right to include in Promotional Materials used in a country
references to any Generic Ticagrelor Product that obtained Regulatory Approval from the applicable Regulatory Authorities in such country, provided that all such references (1) are consistent with the approved labeling for each
applicable product, (2) do not present an unbalanced view of the applicable Generic Ticagrelor Product(s), and (3) are subject to the Promotional Material review and approval process set forth above. In addition, Licensee medical
information and materials prepared by Licensee may include reprints of scientific or medical journal articles or reference publications regarding the AstraZeneca Product that, in each case, follow FDA’s “Good Reprint Practices for the
Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices” guidance. Notwithstanding the foregoing, MedImmune shall have the right
to withdraw its approval with respect to, or require amendment of, any Promotional Materials containing any AstraZeneca Product Reference that, in the reasonable determination of MedImmune, (A) do not comply with Applicable Law or (B) are
not aligned with the then-current positioning, brand equity and overall commercial strategy for the AstraZeneca Product as determined by MedImmune on an annual basis in connection with MedImmune’s or its Affiliates’ annual brand-planning
cycle and communicated by MedImmune to Licensee annually following the conclusion of such planning cycle. In the event MedImmune withdraws or amends its approval with respect to any AstraZeneca Product Reference, Licensee shall, at its own cost and
expense, use reasonable efforts to cease the use of any Promotional Material containing such AstraZeneca Product Reference or adopt the amended AstraZeneca Product Reference, as applicable, (x) within [***] of MedImmune’s notification or
such shorter period required by Applicable Law, in the case of any such withdrawal or amendment pursuant to clause (A) above; or (y) within [***] of MedImmune’s notification, in the case of any such withdrawal or amendment pursuant to
clause (B) above. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 40 

 3.5.7. Commercialization Disputes. If a dispute arises between the Parties in
connection with or relating to any Commercialization activity of Licensee or right of MedImmune under Section 3.5.4, Section 3.5.5 or Section 3.5.6 (a “Commercialization Dispute”), then either Party shall have the
right to refer such Commercialization Dispute to MedImmune’s senior representative for the AstraZeneca Product and Licensee’s Chief Financial Officer or VP of Marketing/Chief Commercial Officer (or their respective designees) for attempted
resolution by good faith negotiations during a period of [***]. Any final decision mutually agreed to by such senior representatives (or such designees) shall be conclusive and binding on the Parties. If such senior representatives (or such
designees) are unable to resolve any such Commercialization Dispute within such [***] period, then either Party shall have the right to refer such Commercialization Dispute to the Senior Officers for attempted resolution by good faith negotiations
during a period of [***]. Any final decision mutually agreed to by the Senior Officers shall be set forth in writing and signed by both Parties, whereupon it will be conclusive and binding on the Parties. In the event that the Senior Officers do not
agree with respect to any Commercialization Dispute, such Commercialization Dispute shall not be subject to dispute resolution as set forth in Section 10.6, unless a Party is in breach or is alleged to be in breach of its obligations under this
Agreement. 
 3.6. Statements and Compliance with Applicable Law. Licensee shall, and shall cause its Affiliates to, comply with all
Applicable Law with respect to the Exploitation of Licensed Products. Licensee shall avoid, and shall cause its Affiliates and its and their Sublicensees to avoid, taking or failing to take any actions that Licensee knows or reasonably should know
would have an adverse effect on the goodwill or reputation of MedImmune or its Affiliate, the AstraZeneca Product, the Licensed Products or any Trademark associated therewith. Without limitation to the foregoing, Licensee shall in all material
respects conform its practices and procedures relating to the Commercialization of the Licensed Products in the Territory and educating the medical community in the Territory with respect to the Licensed Products to any applicable industry
association regulations, policies and guidelines, as the same may be amended from time to time, and Applicable Law. 
 3.7. Markings.
To the extent requested by MedImmune in writing or otherwise required by Applicable Law, the Promotional Materials (including web and social media content), packaging, and Product Labeling for the Licensed Products used by Licensee, its Affiliates
and its and their Sublicensees in connection with the Commercialization of the Licensed Products in the Territory shall contain such MedImmune Corporate Name(s), as designated by MedImmune, in a manner mutually approved by MedImmune and Licensee and
subject to Section 5.7 (such approval not to be unreasonably withheld by Licensee); provided, however, that in no event shall Licensee or any of its Affiliates or Sublicensees be required to give any such MedImmune Corporate Name the
same or greater prominence than any Licensee Corporate Name or Product Trademark on any such Promotional Materials (including web and social media content), packaging, and Product Labeling for the Licensed Products. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 41 

 3.8. Subcontracting. Licensee may subcontract with a Third Party to perform
obligations of Licensee hereunder (including by appointing one or more distributors); provided that (a) no such permitted subcontracting shall relieve Licensee of any obligation hereunder (except to the extent satisfactorily performed by
such subcontractor) or any liability and Licensee shall be and remain fully responsible and liable therefor and (b) the agreement pursuant to which Licensee engages any Third Party subcontractor must, except as otherwise provided in
Section 5.1.6, (i) be consistent in all material respects with the relevant provisions of this Agreement, and (ii) contain terms obligating such subcontractor to comply with the confidentiality, intellectual property and all other
relevant provisions of this Agreement. Licensee shall be responsible for the compliance of each subcontractor with all of the applicable terms and conditions of this Agreement. 

3.9. Alliance Managers. Each Party shall appoint an individual (each, an “Alliance Manager”) who shall oversee contact
between the Parties for all matters and shall have such other responsibilities as the Parties may agree in writing after the Effective Date. A Party may replace the individual serving as its Alliance Manager at any time by notice in writing to the
other Party. The Alliance Managers shall work together to manage and facilitate communication between the Parties under this Agreement, including the resolution (in accordance with the terms of this Agreement) of issues between the Parties that
arise in connection with this Agreement. The Alliance Managers shall not have final decision-making authority with respect to any matter under this Agreement. 

3.10. Product Positioning Principles. Without limitation to the foregoing or any other term or condition of this Agreement, within [***]
after the Effective Date, the Parties shall meet to discuss MedImmune’s or its Affiliates’ positioning of the AstraZeneca Product. Within [***] of such meeting, Licensee shall provide MedImmune with a written proposal detailing the core
principles for the positioning of the Licensed Product, including the target profile for the Licensed Product, proposed label claims (or the actual label claims, if then applicable) for the Licensed Product and the proposed positioning of the
Licensed Product in relation to the AstraZeneca Product, including proposed AstraZeneca Product References for use in such Proposed Product Positioning Principles. Thereafter, on an annual basis, Licensee shall prepare and provide to MedImmune
proposed updates thereto (any proposed product positioning principles or proposed updates thereto, the “Proposed Product Positioning Principles”). Licensee shall align its Proposed Product Positioning Principles with the
positioning, brand equity and overall commercial strategy for the AstraZeneca Product as may be communicated to Licensee by MedImmune on an annual basis in connection with MedImmune’s or its Affiliates’ annual brand-planning cycle. In
addition to any approved AstraZeneca Product References with respect to the AstraZeneca Product for which the Regulatory Approval is owned by AstraZeneca or any of its Affiliates (or its or their successors), Licensee shall have the right to include
in Proposed Product Positioning Principles references to any Generic Ticagrelor Product that obtained Regulatory Approval from the applicable Regulatory Authorities, provided that all such references (1) are consistent with the approved
labeling for each applicable product, and (2) do not present an unbalanced view of the applicable Generic Ticagrelor Product(s). Proposed Product Positioning Principles may take the form of slide decks, talking points or other similar aids for
use in communications of Licensee or any of its Affiliates or its or their Sublicensees with Third Parties relating to the Licensed Product. Proposed 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 42 

 
Product Positioning Principles may utilize in relation to the AstraZeneca Product only Information that is or becomes part of the public domain by public use, public general knowledge or the like
through no breach of this Agreement by Licensee or any of its Affiliates or its or their Sublicensees and shall not utilize Confidential Information of MedImmune or its Affiliates unless MedImmune consents in writing. MedImmune shall have the right
to review and approve Proposed Product Positioning Principles, including any AstraZeneca Product References used in such Proposed Product Positioning Principles. MedImmune shall notify Licensee whether MedImmune approves any Proposed Product
Positioning Principles within [***] of receipt of such Proposed Product Positioning Principles in accordance with the foregoing, such approval not to be unreasonably withheld or conditioned (any such approved product positioning principles or
approved updates thereto, the “Approved Product Positioning Principles”). In no event shall (a) Licensee seek approval of or include in Proposed Product Positioning Principles (or Approved Product Positioning Principles) any
AstraZeneca Product Reference that is not (i) supported by the approved labeling for the AstraZeneca Product or that present an unbalanced view of the AstraZeneca Product considering the approved labeling for the AstraZeneca Product as a whole
or (ii) consistent with the approved labeling for the Licensed Product (if then applicable), and (b) MedImmune have any obligation to approve any AstraZeneca Product References that use any Trademark with respect to the AstraZeneca Product
other than a Licensed Trademark. Subject to Section 5.7.2, Licensee’s obligation to provide MedImmune with its Proposed Product Positioning Principles and any updates and modifications thereto and MedImmune’s or such Affiliate’s
right to review and approve such Proposed Product Positioning Principles shall expire on a global basis at such time as the Generic Competition Threshold is first met or exceeded in all of the United States, the EU Market and China. 

ARTICLE 4 
 PAYMENTS AND
RECORDS 
 4.1. Upfront Payment. In partial consideration of the rights granted by MedImmune to Licensee hereunder, no later than
[***] following the Effective Date, Licensee shall pay MedImmune a nonrefundable and noncreditable upfront amount of One Hundred Thousand Dollars ($100,000). 

4.2. [***] Fee. No later than [***] following MedImmune’s delivery to Licensee of a true and complete copy of any invoice
issued by [***] to MedImmune for the storage fee payable by MedImmune to [***] pursuant to that certain Storage Agreement by and between MedImmune and [***], effective as of January 1, 2017, Licensee shall reimburse MedImmune for such storage
fee. 
 4.3. Technical Services Costs. Within [***] after the end of each Calendar Quarter after the Effective Date, MedImmune
shall invoice Licensee for the Technical Services 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 43 

 
Costs incurred by MedImmune or its Affiliates in connection with the performance of the Technical Services, which invoice shall include reasonable detail regarding the applicable Technical
Services performed and the FTE Costs and the Out-of-Pocket Expenses incurred in performing such Technical Services and shall be accompanied by appropriate documentation
of Out-of-Pocket Expenses, and Licensee shall reimburse MedImmune for such Technical Services Costs within [***] of Licensee’s receipt of such invoice. 

4.4. Milestones. 

4.4.1. Development and Regulatory Milestones. In partial consideration of the rights granted by MedImmune to Licensee hereunder,
Licensee shall pay to MedImmune each of the following one-time, nonrefundable, noncreditable milestone payments within [***] after the first achievement of the corresponding milestone event: 

 

			
	 Development or Regulatory Milestone Event
	  	 Development or Regulatory Milestone Payment

		
	Initiation of first Phase II Clinical Trial of a Licensed Product	  	[***]
		
	Initiation of first Pivotal Trial of a Licensed Product; provided that if a Pivotal Trial is determined to be a Pivotal Trial after Initiation, then this milestone event shall occur on the earlier of the Initiation of the
next Pivotal Trial for such Licensed Product and the filing of a Drug Approval Application for such Licensed Product	  	[***]
		
	Acceptance by FDA, EMA or the applicable Regulatory Authority of a Major European Country or China (whichever occurs first) of the first Drug Approval Application for a Licensed Product	  	[***]
		
	Approval by FDA, EMA or the applicable Regulatory Authority of a Major European Country or China (whichever occurs first) of the first Drug Approval Application for a Licensed Product	  	[***]

 In the event that the first achievement of a milestone event set forth above in this Section 4.4.1 occurs without any
preceding milestone event having been achieved and the corresponding 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 44 

 
milestone payment having been paid, then the milestone payment corresponding to each such skipped milestone event shall become due and payable concurrently with the milestone payment
corresponding to the achieved milestone event. 
 4.4.2. Commercial Milestones. In partial consideration of the rights granted by
MedImmune to Licensee hereunder, within [***] after end of the Calendar Quarter in which each of the Net Sales milestones set forth below in this Section 4.4.2 is first achieved, Licensee shall pay to MedImmune the corresponding one-time, nonrefundable, noncreditable milestone payment set forth below: 
  

			
	 Commercial Milestone Event
	  	 Milestone Payment

		
	Aggregate worldwide Net Sales of all Licensed Products for any and all indications first equal or exceed Five Hundred Million Dollars ($500,000,000)	  	[***]
		
	Aggregate worldwide Net Sales of all Licensed Products for any and all indications first equal or exceed One Billion Dollars ($1,000,000,000)	  	[***]

 For clarity, in the event that, pursuant to Section 3.3.1(c), the Royalty Term does not take effect until June 30,
2022, Net Sales with respect to the period prior to June 30, 2022 shall nevertheless be counted for purposes of calculating the commercial milestone thresholds set forth in this Section 4.4.2. 

4.4.3. Determination That Milestones Have Occurred. Licensee shall notify MedImmune promptly of the first achievement of each of the
events identified as a milestone in Section 4.4.1 or Section 4.4.2. In the event that, notwithstanding the fact that Licensee has not provided MedImmune such a notice, MedImmune believes that any such milestone has been achieved, it shall
so notify Licensee in writing and the Parties shall promptly meet and discuss in good faith whether such milestone has been achieved. Any dispute under this Section 4.4.3 regarding whether or not such a milestone has been achieved shall be
subject to resolution in accordance with Section 10.6. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 45 

 4.5. Royalties. 

4.5.1. Royalty Rates. As further consideration for the rights granted to Licensee hereunder, subject to Sections 3.3.1(c), 4.5.2
and 4.5.3, Licensee shall pay to MedImmune tiered royalties on increments of aggregate annual Net Sales of all Licensed Products during each Calendar Year at the following rates: 

 

			
	 Portion of aggregate Net Sales of all Licensed Products in the
Territory during
a Calendar Year
	  	 Royalty Rate

		
	Less than or equal to Two Hundred Fifty Million Dollars ($250,000,000)	  	[***]
		
	Greater than Two Hundred Fifty Million Dollars ($250,000,000) but less than or equal to Five Hundred Million Dollars ($500,000,000)	  	[***]
		
	Greater than Five Hundred Million Dollars ($500,000,000)	  	[***]

 For clarity, in the event that, pursuant to Section 3.3.1(c), the Royalty Term does not take effect until
June 30, 2022, Net Sales with respect to the period prior to June 30, 2022 shall nevertheless be counted for purposes of calculating the applicable royalty rate set forth in this Section 4.5.1 for Calendar Year 2022. 

4.5.2. Royalty Term. Licensee shall have no obligation to pay any royalty with respect to Net Sales of Licensed Products in any country
with respect to any period after the Royalty Term in such country has expired, and any Net Sales of Licensed Products in any country with respect to any period after the Royalty Term in such country has expired shall be excluded for purposes of
calculating the applicable royalty rate in Section 4.5.1. 
 4.5.3. Reductions. In the event that: 

(a) in any country in the Territory during any portion of the Royalty Term, a Licensed Product sold in a country in the Territory is not
claimed by a Valid Claim of the Licensed Patents covering such Licensed Product in such country when the Regulatory Exclusivity Period (if any) for such Licensed Product in such country is in effect, the royalty rates set forth in Section 4.5.1
shall be reduced by [***] percent [***] for such Licensed Product in such country. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 46 

 (b) in any country in the Territory during any portion of the Royalty Term, a Licensed
Product sold in a country in the Territory is not claimed by a Valid Claim of the Licensed Patents covering such Licensed Product in such country when no Regulatory Exclusivity Period for such Licensed Product in such country is in effect and,
solely in the case of an Emerging Market Country, the Generic Competition Threshold for such Licensed Product in such Emerging Market Country has been met, the royalty rates set forth in Section 4.5.1 shall be reduced by [***] percent [***] for
such Licensed Product in such country. 
 (c) Licensee enters into an agreement with a Third Party other than [***] or its Affiliates (or
its or their successors) in order to obtain a license to a Patent of a Third Party (other than any Patents Controlled by [***] or any of its Affiliates or its or their successors in interest with respect to any Patents) that is necessary for the
Manufacture, use or sale of a Licensed Product in the Field in a country in the Territory (a “Third Party Patent Right”), Licensee shall be entitled to deduct from royalties payable hereunder in a given Calendar Quarter with respect
to such Licensed Product in such country [***] percent [***] of royalties actually paid to such Third Party with respect to such Calendar Quarter under such agreement, solely to the extent that such royalties are (i) triggered by sales of such
Licensed Product that would, absent such agreement, infringe such a Third Party Patent Right that is licensed in such country in such Calendar Quarter under such agreement and (ii) otherwise exclusively attributable to such Third Party Patent
Right; provided that in no event shall the total deduction under this Section 4.5.3(c) reduce the royalties payable to MedImmune under Section 4.5.1 (as reduced in accordance with Section 4.5.3(a) or Section 4.5.3(b) if
applicable) with respect to a given Licensed Product in a given country in any Calendar Quarter by more than [***] percent [***]. Licensee, upon request by MedImmune, shall provide reasonable evidence, including a copy of any applicable agreement,
of such royalties actually paid to such Third Party with respect to such Third Party Patent Right. For clarity, Licensee shall be solely responsible for, and the foregoing reduction shall not apply to, any royalty or other amount owed to [***]
pursuant to any agreement between Licensee and [***] with respect to the Development or Commercialization of any Licensed Product. 

4.5.4. Maximum Amount of Royalty Reduction. Notwithstanding any term or condition of this Agreement to the contrary, in no event shall
the amounts payable to MedImmune under Section 4.5.1 on a global basis with respect to any Calendar Quarter be less than the amount equal to [***] percent [***] of the amounts that would be payable pursuant to Section 4.5.1 if such amounts
due were calculated (a) without regard to any reductions that may be permitted pursuant to Section 4.5.3 and (b) without limitation to clause (a), in the case of any Combination Product, without regard to any adjustment for
Combination Product that may otherwise be permitted pursuant to the definition of Net Sales. 
 4.6. Royalty Payments and Reports.
Royalties under Section 4.5 shall be calculated and reported for each Calendar Quarter and shall be paid within [***] after the end of the Calendar Quarter. Each such payment shall be accompanied or preceded by a report of Net Sales and
royalties in sufficient detail to permit confirmation of the accuracy of the payment made, including gross sales and Net Sales of Licensed Products on a Licensed Product-by- 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 47 

 Licensed Product and
country-by-country basis, details of any royalty credits taken pursuant to Section 4.5.3(c) on a Third Party Patent Right-by-Third Party Patent Right basis, any applicable adjustments made pursuant to the definition of Net Sales (including in relation to Combination Products), Section 4.5.3(a) or
Section 4.5.3(b), the amounts payable, and the exchange rates used. Without limiting the generality of the foregoing, Licensee shall require its Affiliates and Sublicensees to account for their Net Sales and to provide such reports with respect
thereto as necessary for Licensee to comply with the foregoing provisions of this Section 4.6. In addition to the foregoing reports of Net Sales, commencing with the Calendar Year in which the First Commercial Sale of the first Licensed Product
occurs, and continuing for each Calendar Year during the Royalty Term, no later than September 1 of each Calendar Year Licensee shall submit to MedImmune a rolling three (3)-year forecast of Licensed Product global Net Sales, broken out by
calendar month for the first two (2) Calendar Years of each such forecast. 
 4.7. Mode of Payment; Offsets. All payments to
MedImmune under this Agreement shall be made by deposit of Dollars in the requisite amount to such bank account as MedImmune may from time to time designate by notice to Licensee. For the purpose of calculating any sums due under, or otherwise
reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), Licensee shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate’s
or Sublicensee’s, as applicable, standard conversion methodology consistent with GAAP. Except as provided in Section 4.5.3(c) or Section 4.8, Licensee shall have no right to offset, set off, or deduct any amounts from or against the
amounts due to MedImmune hereunder. 
 4.8. Taxes. 

4.8.1. General. All amounts payable by Licensee to MedImmune under this Agreement, including the upfront fee set forth in
Section 4.1, the [***] fee set forth in Section 4.2, the Technical Services Costs set forth in Section 4.3, and any milestones and royalties payable by Licensee to MedImmune pursuant to this Agreement (each, a
“Payment”) shall be paid free and clear of any and all taxes (which, for clarity, shall be the responsibility of Licensee), except for any withholding of taxes duties, levies, imposts, assessments, deductions, fees, and other
similar charges required by Applicable Law (“Withholding Taxes”). Except as provided in this Section 4.8, MedImmune shall be solely responsible for paying any and all taxes (other than Withholding Taxes required by Applicable
Law to be deducted from Payments and remitted by Licensee) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Licensee shall deduct or withhold from the Payments any taxes that it is required by
Applicable Law to deduct or withhold. 
 4.8.2. Withholding Tax. If Licensee takes any actions that would increase any required
Withholding Taxes that otherwise would not be required absent such action, including a Sale Transaction, change in tax residence, Sublicense or assignment of this Agreement or any rights or obligations hereunder by law or otherwise, except for any
transaction currently contemplated under this Agreement (other than a Sale Transaction involving Licensee, 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 48 

 
a Sublicense, or an assignment by Licensee of this Agreement, with respect to which this exception shall not apply), Licensee shall increase the amount so payable as necessary so that after such
deduction or withholding of Withholding Taxes has been made, MedImmune receives the amount it would have received had no such deduction or withholding been made. Notwithstanding the foregoing, if MedImmune is entitled under any applicable tax treaty
to a reduction of rate of, or the elimination of, applicable Withholding Tax, it may deliver to Licensee or the appropriate governmental authority (with the assistance of Licensee to the extent that this is reasonably required and is requested in
writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Licensee of its obligation to withhold such tax and Licensee shall apply the reduced rate of withholding or dispense with withholding, as the case may
be. If, in accordance with the foregoing, Licensee withholds any amount, it shall pay to MedImmune the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to MedImmune proof of such payment within
[***] following such payment with reasonable supporting documentation and calculations of such Withholding Taxes sufficient to enable MedImmune to claim such payment of Withholding Taxes or otherwise obtain any tax benefit for such Withholding Taxes
within a reasonable time following such payment, and such Withholding Taxes shall be treated for all purposes of this Agreement as having been paid to MedImmune hereunder. The Parties shall reasonably cooperate to minimize, report and withhold any
such Withholding Taxes, including with respect to all documentation required by any taxing authority. Prior to making any deduction or withholding from any payment under this Agreement, Licensee shall provide at least [***] prior written notice to
MedImmune of the amounts subject to deduction or withholding and the legal basis therefore, and provide to MedImmune a reasonable opportunity to furnish forms, certificates or other items that would reduce or eliminate such deduction or withholding.
If Licensee receives a refund of any such withheld taxes, in whole or in part, and whether in the form of cash, credit or other similar offset, Licensee shall promptly refund such amount to MedImmune. MedImmune shall not be liable for any penalties
or interest due to the failure of Licensee to properly withhold or remit such any withholding or deductions to the governmental authorities, unless such failure is due to incorrect or invalid forms, facts, or other similar information given to
Licensee by MedImmune. 
 4.8.3. Value Added Tax. Notwithstanding anything contained in Section 4.8.1 or Section 4.8.2,
this Section 4.8.3 shall apply with respect to value added tax (“VAT”). All Payments are exclusive of VAT. If any VAT is chargeable in respect of any Payments, Licensee shall pay VAT at the applicable rate in respect of any
such Payments following the receipt of a VAT invoice in the appropriate form issued by MedImmune in respect of those Payments, such VAT to be payable on the later of the due date of the payment of the Payments to which such VAT relates and [***]
after the receipt by Licensee of the applicable invoice relating to that VAT payment. 
 4.9. Interest on Late Payments. If any
payment due to either Party under this Agreement is not paid when due, then such paying Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of three

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 49 

 
hundred (300) basis points above the London Interbank Offered Rate for deposits in United States Dollars having a maturity of one (1) month published by the British Bankers’
Association, as adjusted from time to time on the first London business day of each month, such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest. 

4.10. Financial Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, keep complete and accurate
financial books and records pertaining to the Commercialization of Licensed Products hereunder, including books and records of Net Sales, in sufficient detail to calculate and verify all amounts payable hereunder. Licensee shall, and shall cause its
Affiliates and its and their Sublicensees to, retain such books and records for three (3) Calendar Years after the end of the Calendar Year to which such books and records pertain. 

4.11. Audit. At the request of MedImmune, no more than once each Calendar Year, Licensee shall, and shall cause its Affiliates
and its and their Sublicensees to, permit an independent certified public accounting firm of international standing designated by MedImmune and reasonably acceptable to Licensee (the “Auditor”), at reasonable times and upon at least
[***] prior written notice, to audit the books and records maintained pursuant to Section 4.10 in the location where such books and records are maintained, solely to confirm payments due from Licensee hereunder, including in respect of Net
Sales, Net Sales-based milestone payments and royalties for a period covering not more than the preceding three (3) Calendar Years. No Calendar Year shall be subject to audit under this Section 4.11 more than once. The Auditor will execute
a reasonable written confidentiality agreement with Licensee and will disclose to MedImmune only such information as is reasonably necessary to provide MedImmune with information regarding any actual or potential discrepancies between amounts
reported and actually paid and amounts payable under this Agreement. The Auditor will send a copy of the report to Licensee at the same time it is sent to MedImmune. The report sent to both Parties will include the methodology and calculations used
to determine the results. MedImmune shall bear the full cost of such audit, unless the audit reveals an underreporting or underpayment by Licensee by more than five percent (5%) of the amount due for any Calendar Year, in which case Licensee shall
bear the cost of the audit. Unless disputed pursuant to Section 4.12 below, if such audit concludes that (a) additional amounts were owed by Licensee, Licensee shall pay the additional amounts, with interest from the date originally due as
provided in Section 4.9, or (b) excess payments were made by Licensee, MedImmune shall reimburse such excess payments, in either case ((a) or (b)), within [***] after the date on which the Auditor’s report is delivered to Licensee.

 4.12. Audit Dispute. In the event of a dispute with respect to any audit under Section 4.11, MedImmune and Licensee shall work
in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***], the dispute shall be submitted for resolution to an independent certified public accounting firm of
international standing, other than the Auditor that conducted the audit under Section 4.11, jointly 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 50 

 
selected by each Party’s certified public accountants (the “Dispute Auditor”). The decision of the Dispute Auditor shall be final and the costs of such proceeding as well as
the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] after such decision and in accordance with such decision, Licensee shall pay the additional amounts, with interest from
the date originally due as provided in Section 4.9, or MedImmune shall reimburse the excess payments, as applicable. 
 ARTICLE 5

 INTELLECTUAL PROPERTY 

5.1. Ownership of Intellectual Property. 

5.1.1. Background Intellectual Property. As between the Parties, each Party shall own and retain all right, title and interest in and
to any and all Information, inventions, Patents and other intellectual property rights that, in each case, are owned or controlled (other than pursuant to the license grants set forth in Section 2.1 and Section 2.2) by such Party or its
Affiliates or its or their (sub)licensees (or Sublicensees) (as applicable) outside of this Agreement, including, in the case of MedImmune, the Licensed Know-How and the Licensed Patents (including, once
filed, any Patents filed with MedImmune’s consent pursuant to the last two sentences of Section 5.1.2). 
 5.1.2. MedImmune
Intellectual Property. As between the Parties, MedImmune shall own and retain all right, title and interest in and to any and all AstraZeneca Product Improvements, AstraZeneca Product Know-How, AstraZeneca
Product Patents, Licensed Know-How and Licensed Patents (including Patents that become Licensed Patents pursuant to the last two sentences of this Section 5.1.2). Licensee shall, and does hereby, assign
to MedImmune and will cause each of its officers, directors, employees and Affiliates, and its and their Sublicensees, to assign to MedImmune all right, title and interest in and to all AstraZeneca Product Improvements, AstraZeneca Product Know-How, AstraZeneca Product Patents and Patents that become Licensed Patents pursuant to the last two sentences of this Section 5.1.2, without additional compensation, as is necessary to fully effect the sole
ownership provided for in the first sentence of this Section 5.1.2. In the event that Licensee desires to prepare and file a Patent claiming any Licensed Know-How (including any Licensed Know-How regarding the formulation of any Licensed Compound), Licensee shall notify MedImmune and shall obtain MedImmune’s written consent, not to be unreasonably withheld, conditioned or delayed, prior to
filing any such Patent with the applicable patent authority. Any Patent filed by Licensee pursuant to the foregoing sentence shall thereafter be deemed to be a Licensed Patent for all purposes hereunder. 

5.1.3. PhaseBio Intellectual Property. As between the Parties, Licensee shall own and retain all right, title and interest in and to
any and all Know-How and Patents covered by clause (b) of the definitions of each of PhaseBio Know-How and PhaseBio Patents. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 51 

 5.1.4. Joint Intellectual Property. Subject to Section 5.1.2, the Parties shall
jointly own all Joint Inventions and all Joint Patents. Subject to the terms and conditions of this Agreement, and except to the extent that a Party has granted the other Party an exclusive license under such Party’s joint ownership interest in
Joint Inventions and Joint Patents, each Party shall have the right to practice, and to grant licenses under, such Party’s own joint ownership interest in Joint Inventions and Joint Patents without the other Party’s consent, and shall have
no duty to account to the other Party for such practice or license, and each Party hereby waives any right it may have under the laws of any country to require such consent or accounting. 

5.1.5. United States Law. The determination of whether Information, Improvements and other inventions are conceived, discovered,
developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in
the United States in effect at the time of such conception, discovery, development or making, irrespective of where the same occurs. 

5.1.6. Assignment Obligation. 

(a) Employees, Consultants and Third Party Contractors of Licensee and its Affiliates. 

(i) AstraZeneca Product Improvements. Licensee shall cause each employee, individual consultant and Third Party contractor that
Licensee or its Affiliate proposes to engage to conduct activities involving the AstraZeneca Product, including any use of the Ticagrelor Compound, any AstraZeneca Product or any AstraZeneca Product Know-How
under or in connection with this Agreement on behalf of Licensee or its Affiliates (excluding MedImmune and its Affiliates) who conceives, discovers, develops or otherwise makes any AstraZeneca Product Improvement under or in connection with
activities conducted pursuant to this Agreement to be under an obligation to assign to Licensee their rights in any such AstraZeneca Product Improvement. If (A) Licensee is unable to cause such Third Party contractor or consultant
(including any contractor who is, or a consultant who is employed by, a governmental, not-for-profit, or public institution that has standard policies against such an
assignment) to agree to such assignment obligation with respect to AstraZeneca Product Improvements despite Licensee’s using commercially reasonable efforts to negotiate such assignment obligation, or (B) Applicable Law would prohibit
Licensee from requiring such an assignment from such Third Party contractor or consultant, in each case ((A) and (B)) Licensee shall refrain from using such Third Party contractor or consultant to conduct activities pursuant to this Agreement unless
MedImmune consents in writing, such consent not to be unreasonably withheld, conditioned or delayed. MedImmune shall respond to any such request for consent within [***]. Licensee shall require its and its Affiliates’ Sublicensees to be subject
to the obligations set forth in this Section 5.1.6(a)(i) to the same extent as Licensee. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 52 

 (ii) Information and Inventions Other than AstraZeneca Product Improvements. Except
with respect to any AstraZeneca Product Improvement, which shall be governed by Section 5.1.6(a)(i), Licensee shall cause each employee and individual consultant (excluding MedImmune and its Affiliates) of Licensee or its Affiliates (but
excluding Third Party contractors of Licensee and its Affiliates, which are separately addressed in Section 5.1.6(b)) who conceives, discovers, develops or otherwise makes (i) any Information that is directed to a Licensed Compound or
Licensed Product and was not previously in the public domain or (ii) any other Invention directed to a Licensed Compound or Licensed Product (but, in each case ((i) and (ii)), excluding any AstraZeneca Product Improvement), in connection with
activities conducted relating to this Agreement to be under an obligation to assign to Licensee their rights in any such Information or other Invention. In the case of any consultant of Licensee or its Affiliates (excluding MedImmune and its
Affiliates and Licensee’s and its Affiliates’ Third Party contractors), if Licensee is unable to cause such consultant to agree to such assignment obligation despite Licensee’s using commercially reasonable efforts to negotiate such
assignment obligation, then Licensee shall either: (A) cause such consultant to grant an exclusive license, with the right to sublicense through multiple tiers, under their rights in such Information or other Invention to Exploit the Licensed
Compounds and Licensed Products in the Field in the Territory, except where Applicable Law requires otherwise and except in the case of consultants who are employed by governmental, not-for-profit, or public institutions that have standard policies against such an assignment (in which case, Licensee shall use commercially reasonable efforts to obtain a suitable license, or right to
obtain such a license); or (B) refrain from using such consultant to conduct activities pursuant to this Agreement unless MedImmune consents in writing, such consent not to be unreasonably withheld, conditioned or delayed. MedImmune shall
respond to any such request for consent within [***]. Licensee shall require its and its Affiliates’ Sublicensees to be subject to the obligations set forth in this Section 5.1.6(a)(ii) to the same extent as Licensee. 

(b) Third Party Contractors. Except with respect to any AstraZeneca Product Improvement, which shall be governed by
Section 5.1.6(a)(i), Licensee shall use commercially reasonable efforts to obtain from each Third Party contractor that Licensee or its Affiliate proposes to engage to conduct activities under or in connection with this Agreement on behalf of
Licensee or its Affiliates an assignment, an exclusive license, or a non-exclusive license (in order of preference), with the right to sublicense through multiple tiers, to Licensee of (i) any Information
that is directed to a Licensed Compound or Licensed Product and was not previously in the public domain or (ii) any other Invention directed to a Licensed Compound or Licensed Product, that, in each case ((i) and (ii)), such Third Party
contractor conceives, discovers, develops or otherwise makes in connection with activities conducted relating to this Agreement. The Parties acknowledge that it may not be possible to obtain such assignment or license from any such Third Party
contractor on terms acceptable to Licensee or at all (e.g., technology of broad applicability to the operation of such Third Party contractor’s business, or improvements to such Third Party contractor’s own proprietary technology
used in the performance of services on behalf of Licensee or its Affiliate), and accordingly, the Parties agree that the inability of Licensee or its Affiliate, despite the use of commercially reasonable

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 53 

 
efforts, to obtain such assignment or license from a Third Party contractor on terms acceptable to Licensee or at all shall not constitute a breach of Licensee’s obligations under this
Agreement. Licensee shall require its and its Affiliates’ Sublicensees to be subject to the obligations set forth in this Section 5.1.6(b) to the same extent as Licensee. 

5.1.7. Ownership of Licensee Corporate Names and Product Trademarks. As between the Parties, Licensee shall own all right, title and
interest to the Licensee Corporate Names and the Product Trademarks in the Territory. 
 5.1.8. Ownership of MedImmune Corporate
Names. As between the Parties, MedImmune shall retain all right, title and interest in and to the MedImmune Corporate Names and any Trademarks with respect to any AstraZeneca Product (other than Generic Ticagrelor Products). 

5.2. Maintenance and Prosecution of Patents. 

5.2.1. Intent Regarding PhaseBio Patents. Without limiting Section 5.2.2 and Section 5.2.3, Licensee shall use
reasonable efforts to file separately Patents claiming any Licensee-owned invention that is necessary or useful for the development, manufacture, use or sale of any compound (including any Other Active) that is not a Licensed Compound or any product
that is not a Licensed Product. To that end, with respect to any such Patent that claims the composition of matter or formulation of, or any method of treatment or use or Manufacture of, or any means of delivery or dosage of, any Licensed Compound
or Licensed Product, Licensee shall use, and shall instruct its patent counsel to use, reasonable, good faith efforts not to include in any such Patent any claim that would cause such Patent not to be a PhaseBio Selected Patent. In the event
Licensee determines, in good faith and upon advice of outside patent counsel, that it is not practicable or not consistent with applicable patent law and patent office requirements to omit any such claim, or that omitting any such claim is against
Licensee’s interest in establishing strong patent protection for the applicable Invention or against the Parties’ mutual interest in establishing strong patent protection for Licensed Compounds and Licensed Products, Licensee shall so
notify MedImmune at least [***] prior to filing any such Patent, and, subject to execution by the Parties of a reasonable and customary confidentiality and common interest agreement if so requested by Licensee, Licensee shall provide MedImmune with
a draft of such Patent, and the Parties and their respective patent counsel shall promptly confer and attempt in good faith to agree on a course of action. 

5.2.2. Licensed Patents; PhaseBio Selected Patents. As between the Parties, Licensee shall have the first right, but not the
obligation, to prepare, file, prosecute and maintain the Licensed Patents and the PhaseBio Selected Patents, including directing any related interference, re-issuance,
re-examination and opposition proceedings with respect thereto, worldwide, in each case, at its sole cost and expense and through reputable, outside counsel mutually agreed to by the Parties, such agreement
not to be unreasonably withheld, conditioned or delayed, and, with respect to any AstraZeneca Product References in connection with the 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 54 

 
filing, prosecution or maintenance of any such Patents, using only factual statements supported by the approved label for the AstraZeneca Product or presenting a balanced view of the AstraZeneca
Product considering the approved label thereof as a whole. Licensee shall keep MedImmune reasonably informed MedImmune of progress with regard to the preparation, filing, prosecution and maintenance of the Licensed Patents and the PhaseBio Selected
Patents, as applicable, in the Territory, including by providing MedImmune with a copy of material communications to and from any patent authority regarding such Patents and by providing MedImmune drafts of any material filings or responses to be
made to such patent authorities sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for MedImmune to review and comment thereon. Licensee shall consider in good faith the requests and
suggestions of MedImmune with respect to such drafts and with respect to strategies for filing and prosecuting such Licensed Patents or PhaseBio Selected Patents. If, as between the Parties, Licensee decides not to prepare, file, prosecute or
maintain a Licensed Patent or a PhaseBio Selected Patent in a country in the Territory, Licensee shall provide reasonable prior written notice to MedImmune of such intention and MedImmune shall thereupon have the right, in its sole discretion, to
assume the control and direction of the preparation, filing, prosecution and maintenance of such Licensed Patent at its sole cost and expense in such country. MedImmune shall use commercially reasonable efforts, consistent with Applicable Law, to
make employee inventors available to Licensee for consultation from time to time to facilitate Licensee’s prosecution of the Licensed Patents. 

5.2.3. Other PhaseBio Patents. As between the Parties, Licensee shall have the sole right, but not the obligation, to prepare, file,
prosecute and maintain any PhaseBio Patents that are not PhaseBio Selected Patents, including directing any related interference, re-issuance, re-examination and
opposition proceedings with respect thereto, worldwide, at its sole cost and expense and through counsel of its choice, and, with respect to any AstraZeneca Product References in connection with the filing, prosecution or maintenance of such
Patents, using only factual statements supported by the approved label for the AstraZeneca Product or presenting a balanced view of the AstraZeneca Product considering the approved label thereof as a whole. 

5.2.4. AstraZeneca Product Patents. As between the Parties, MedImmune (or its Affiliate or sublicensee) shall have the sole right, but
not the obligation, to prepare, file, prosecute and maintain the AstraZeneca Product Patents, including directing any related interference, re-issuance, re-examination
and opposition proceedings with respect thereto, worldwide, in each case, at its sole cost and expense and through counsel of its choice. 

5.2.5. Joint Patents. The Parties shall decide on a Joint
Invention-by-Joint Invention basis which Party will have the first right to prosecute and maintain Joint Patents (such Party, the “Responsible Party”),
at its sole cost and expense and by reputable, outside counsel mutually agreed to by the Parties, such agreement not to be unreasonably withheld, conditioned or delayed. The Responsible Party shall keep the other Party reasonably informed of
progress with regard to the prosecution and maintenance of Joint Patents for which the 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 55 

 
Responsible Party is responsible under this Section 5.2.5, and shall consult with, and consider in good faith the requests and suggestions of, the other Party. In the event that the
Responsible Party desires not to file, or desires to abandon or cease prosecution or maintenance of, any Joint Patent in any country, the Responsible Party shall provide written notice to the other Party of such intention promptly after the
Responsible Party makes such determination (which notice shall be given no later than [***] prior to the next deadline for any action that must be taken with respect to such Joint Patent in the relevant patent office). In such case, at the other
Party’s sole discretion, upon written notice to the Responsible Party from the other Party, the other Party may elect to continue prosecution or maintenance of any such Joint Patent, at its sole cost and expense and by counsel of its own
choice. 
 5.2.6. Cooperation. The non-prosecuting Party shall, and as necessary shall cause
its Affiliates to, assist and cooperate with the prosecuting Party, as the prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the Licensed Patents, PhaseBio Selected Patents,
AstraZeneca Product Patents and Joint Patents, as applicable. Without limiting the foregoing, the non-prosecuting Party shall, and as necessary shall ensure that its Affiliates, (a) offer its comments, if
any, promptly and (b) provide access to relevant documents and other evidence and make its employees available at reasonable business hours; provided, however, that neither Party shall be required to provide legally privileged
information with respect to such intellectual property unless and until procedures reasonably acceptable to such Party are in place to protect such privilege; and provided, further, that the prosecuting Party shall reimburse the non-prosecuting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. 

5.2.7. Patent Term Extension and Supplementary Protection Certificate. As between the Parties, regardless of which Party is filing,
prosecuting and maintaining any Licensed Patent, PhaseBio Selected Patent or Joint Patent pursuant to this Section 5.2, the Parties shall attempt to make decisions by mutual agreement regarding patent term extensions, in the
Territory, including the United States with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant to supplementary protection certificates, and in all jurisdictions with respect to any other extensions
that are now or become available in the future, wherever applicable, for the Licensed Patents, the PhaseBio Selected Patents and Joint Patents and with respect to Licensed Compounds and Licensed Products, in each case including whether or not to so
apply. If, with respect to any Licensed Compound or Licensed Product and a country, the Parties cannot agree on which Licensed Patent, PhaseBio Selected Patent or Joint Patent as to which the term is to be extended in such country, then with respect
to Licensed Patents, PhaseBio Selected Patents and Joint Patents in such country, the Parties shall mutually agree on a Third Party patent lawyer (whose costs shall be borne equally (50/50) between the Parties) and shall give such lawyer
instructions to resolve such disagreement in a manner designed to maximize the period of exclusivity for such Licensed Compound or Licensed Product, and the decision of such lawyer shall be binding on the Parties. For clarity, Licensee shall have
the sole right to make decisions regarding, and shall have the sole right to 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 56 

 
apply for, patent term extensions in the Territory with respect to PhaseBio Patents that are not PhaseBio Selected Patents. 

5.2.8. Common Ownership Under Joint Research Agreements. Notwithstanding anything to the contrary in this Article 5, neither
Party shall have the right to make an election under 35 U.S.C. 102(c) when exercising its rights under this Article 5 without the prior written consent of the other Party. With respect to any such permitted election, the Parties shall
coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in 35 U.S.C. 100(h).
 
 5.3. Enforcement of Patents. 

5.3.1. Notice. In the event that either Party receives notice of (a) any alleged or threatened infringement of the Licensed
Patents, PhaseBio Selected Patents or Joint Patents in any jurisdiction in the Territory or (b) any certification filed under the BPCI Act claiming that any Licensed Patents, PhaseBio Selected Patents or Joint Patents are invalid or
unenforceable or claiming that any Licensed Patents, PhaseBio Selected Patents, or Joint Patents would not be infringed by the making, having made, use, offer for sale, sale or import of a product for which an application under the BPCI Act is filed
or any equivalent or similar certification or notice in any other jurisdiction in the Territory (an “Infringement”), such Party shall promptly notify the other Party in writing of such Infringement. 

5.3.2. Licensed Patents; PhaseBio Selected Patents. As between the Parties, Licensee shall have the first right, but not the
obligation, to prosecute Infringement with respect to the Licensed Patents and the PhaseBio Selected Patents, including as a defense or counterclaim in connection with any Third Party Infringement Claim, at Licensee’s sole cost and expense,
using reputable, outside counsel mutually agreed to by the Parties, such agreement not to be unreasonably withheld, conditioned or delayed, and, with respect to any AstraZeneca Product References in connection with the prosecution of Infringement
with respect to any such Patents, using only factual statements contained in the approved label for the AstraZeneca Product or otherwise approved by MedImmune in writing. In the event Licensee prosecutes any such Infringement, MedImmune shall have
the right to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost and expense; provided that Licensee shall retain control of the prosecution of such claim, suit or proceeding, including the
response to any defense or defense of any counterclaim raised in connection therewith. If Licensee or its designee does not take and continue to pursue commercially reasonable steps to prosecute an Infringement with respect to the Licensed Patents
or the PhaseBio Selected Patents in the Field within [***] following the date upon which Licensee first receives notice or otherwise learns of such Infringement or such shorter period as may be necessary to preserve MedImmune’s rights to
prosecute such Infringement effectively, unless the Parties otherwise agree in writing, or, provided such date occurs after Licensee receives notice or otherwise learns of such Infringement, [***] before the time limit, if any, set forth in
Applicable Law for filing of 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 57 

 
such actions, whichever comes first, then (i) Licensee shall so notify MedImmune and, (ii) MedImmune may prosecute such alleged or threatened Infringement at its sole cost and expense.

 5.3.3. Other PhaseBio Patents. As between the Parties, Licensee shall have the sole right, but not the obligation, to prosecute
Infringement with respect to any PhaseBio Patents that are not PhaseBio Selected Patents, including as a defense or counterclaim in connection with any Third Party Infringement Claim, at Licensee’s sole cost and expense, using counsel of its
choice and, with respect to any AstraZeneca Product References in connection with the prosecution of Infringement with respect to such Patents, using only factual statements contained in the approved label for the AstraZeneca Product or otherwise
approved by MedImmune in writing. 
 5.3.4. AstraZeneca Product Patents. As between the Parties, MedImmune or its Affiliate shall
have the sole right, but not the obligation, to prosecute Infringement with respect to the AstraZeneca Product Patents, including as a defense or counterclaim in connection with any Third Party Infringement Claim, at MedImmune’s sole cost and
expense, using counsel of its choice. 
 5.3.5. Joint Patents. The Responsible Party shall have the first right, but not the
obligation, to prosecute Infringement with respect to the Joint Patents, including as a defense or counterclaim in connection with any Third Party Infringement Claim, at the Responsible Party’s sole cost and expense, using reputable, outside
counsel mutually agreed to by the Parties, such agreement not to be unreasonably withheld, conditioned or delayed, and, with respect to any AstraZeneca Product References in connection with the prosecution of Infringement with respect to the Joint
Patents, using only factual statements contained in the approved label for the AstraZeneca Product or otherwise approved by MedImmune in writing. In the event the Responsible Party prosecutes any such Infringement, the other Party shall have the
right to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost and expense; provided that the Responsible Party shall retain control of the prosecution of such claim, suit or proceeding,
including the response to any defense or defense of any counterclaim raised in connection therewith. If the Responsible Party or its designee does not take and continue to pursue commercially reasonable steps to prosecute an Infringement with
respect to the Joint Patents in the Field within [***] following the date upon which the Responsible Party first receives notice or otherwise learns of such Infringement or such shorter period as may be necessary to preserve the other Party’s
rights to prosecute such Infringement effectively, unless the Parties otherwise agree in writing, or, provided such date occurs after the Responsible Party receives notice or otherwise learns of such Infringement, [***] before the time limit,
if any, set forth in Applicable Law for filing of such actions, whichever comes first, then (a) the Responsible Party shall so notify the other Party and, (b) the other Party may prosecute such alleged or threatened Infringement at its
sole cost and expense. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 58 

 5.3.6. Cooperation. The Parties agree to cooperate fully in any Infringement action
pursuant to this Section 5.3 with respect to any Licensed Patents, PhaseBio Selected Patents or Joint Patents, including by making the inventors, applicable records, and documents (including laboratory notebooks) with respect to the relevant
Patents available to the enforcing Party on the enforcing Party’s request. With respect to any such action controlled by the applicable enforcing Party, the other Party shall, and as necessary shall cause its Affiliates to, assist and cooperate
with the enforcing Party, as the enforcing Party may reasonably request from time to time, in connection with its activities set forth in this Section 5.3, including, where necessary, furnishing a power of attorney solely for such purpose or
joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours; provided that the enforcing Party shall
reimburse such other Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. Unless otherwise set forth herein, the
enforcing Party shall have the right to settle such claim; provided that neither Party shall have the right to settle any Infringement litigation under this Section 5.3 in a manner that reasonably may have a material adverse effect on
the rights or interest of the other Party or its Affiliates (including, in the case of MedImmune as the other Party, a material adverse effect on the AstraZeneca Product) or in a manner that imposes any costs or liability on, or involves any
admission by, the other Party, without the express written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing or anything to the contrary in this Agreement, MedImmune
shall have the sole and absolute discretion to settle any claims with respect to the AstraZeneca Product or any AstraZeneca Product Patent, without consultation with Licensee and without regard to the effect of such settlements on any Licensed
Product (provided that, if any such settlement of claims with respect to any AstraZeneca Product also involves a settlement of claims with respect to any Licensed Product, MedImmune shall not settle any claims specifically with respect to the
Licensed Product in a manner that would impose any costs or liability on, or involves any admission by, Licensee, without the express written consent of Licensee). In connection with any activities with respect to an Infringement action prosecuted
by the applicable enforcing Party pursuant to this Section 5.3 involving Licensed Patents, the PhaseBio Selected Patents or Joint Patents, the enforcing Party shall (a) consult with the other Party as to the strategy for the prosecution of
such claim, suit, or proceeding, (b) consider in good faith any comments from the other Party with respect thereto, and (c) keep the other Party reasonably informed of any material steps taken, and provide copies of all material documents
filed, in connection with such action. Notwithstanding the foregoing, MedImmune shall have no obligations under this Section 5.3.6, and no right to settle any Infringement action, with respect to any PhaseBio Patents that are not PhaseBio
Selected Patents. 
 5.3.7. Recovery. Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any
recovery realized as a result of such litigation described above in this Section 5.3 (whether by way of settlement or otherwise) shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which
amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder after such reimbursement is made shall be retained by the enforcing Party; provided, 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 59 

 
however, that any recovery realized by Licensee as a result of any action brought and controlled by Licensee with respect to a Licensed Patent pursuant to Section 5.3.2 shall be
allocated as follows: (a) compensatory damages shall: (i) if awarded as lost sales, be treated as Net Sales of Licensed Products in the quarter in which such recovery is received for purposes of Section 4.5; and (ii) if not
awarded as lost sales, be treated as profits or royalties, as appropriate, and shall be used to determine lost sales, which lost sales shall be treated as Net Sales of Licensed Products for purposes of Section 4.5 in the quarter in which such
recovery is received, provided that in no event shall Licensee be obligated to pay to MedImmune more than [***]% of the compensatory damages described in this clause (ii); and
(b) non-compensatory damages shall be allocated [***]% to Licensee and [***]% to MedImmune. 

5.3.8. Biosimilar Applicants. If either Party receives a copy of an application for a Biosimilar Product in the Territory referencing a
Licensed Product, or otherwise becomes aware that such an application has been submitted to a Regulatory Authority for Regulatory Approval in the Territory (such as in an instance described in Section 351(l)(9)(C) of the PHSA), then this
Section 5.3.8 shall apply, and, within [***], such Party shall notify the other Party. The Party that is not the “reference product sponsor,” as defined in Section 351(l)(1)(A) of the PHSA, shall have the right, but not the
obligation, to seek permission or take other steps necessary to view the application and related confidential information from the filer of the application for a Biosimilar Product (“Biosimilar Filer”) to the extent permitted under
Sections 351(l)(1)(B)(iii) and (C) of the PHSA (or the equivalent Applicable Laws in a country other than the U.S. Regardless of the Party that is the “reference product sponsor” for purposes of such Biosimilar Product
application: 
 (a) Licensee shall have the sole right to manage and prosecute biosimilar litigation in the Territory, subject to the
provisions of this Section 5.3.8. 
 (b) Licensee will have the sole right to designate pursuant to Section 351(l)(1)(B)(i) and
(ii) of the PHSA the outside counsel and in-house counsel who will receive confidential access to the Biosimilar Product application and manufacturing process information of the Biosimilar Filer. 

(c) Licensee shall have the sole right to (i) list any Patents, including those licensed hereunder, insofar as they claim or cover the
applicable Licensed Product as required pursuant to Section 351(l)(3)(A), Section 351(l)(5)(b)(i)(II), or Section 351(l)(7) of the PHSA, (ii) respond to any communications with respect to such lists from the Biosimilar Filer
(including as described in 351(l)(3)(C)), and (iii) negotiate with the Biosimilar Filer as to whether to utilize a mechanism for information exchange other than that specified in Section 351(l)(1) of the PHSA and as to the Patents that
will be subject to the initial litigation procedure as described in Section 351(l)(4) of the PHSA, to decide which Patent or Patents shall be selected for initial litigation under Section 351(l)(5)(B)(i)(II) of the PHSA. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 60 

 (d) Licensee shall have the sole right to identify Patents, including those licensed to
Licensee hereunder, or respond to relevant communications under any equivalent or similar listing to those described in the preceding clause (b) in any other jurisdiction outside of the United States. Upon Licensee’s reasonable request,
MedImmune shall assist in the preparation of such list and make such response after consulting with Licensee. 
 (e) Licensee shall consult
with MedImmune prior to identifying any Licensed Patents or PhaseBio Selected Patents to a Biosimilar Filer as contemplated by this Section 5.3.8. Licensee shall consider in good faith advice and suggestions with respect thereto received from
MedImmune, and notify MedImmune of any such lists or communications promptly after they are made, in each case to the extent permitted by Applicable Law. 

(f) Without limitation to the foregoing clauses ((a)-(e)), if a Party receives a notice of commercial marketing from any Biosimilar
Filer pursuant to Section 351(a) of the PHSA, or any equivalent or similar certification or notice in any other country, such Party shall, within [***] of receiving any such notice, notify the other Party and provide the other Party with copies
thereof. Thereafter, the Party controlling any action pursuant to this Section 5.3.8 shall have the first right to seek a preliminary injunction action under Section 351(l)(8)(B) of the PHSA or a declaratory judgment action pursuant to
Section 351(l)(9) of the PHSA, in which event the Parties shall be subject to Section 5.3.6 and Section 5.3.7, to the extent applicable, as if such action had been commenced pursuant to Section 5.3.2. If no such litigation is
ongoing at the time of such notice, then Licensee will have the first right to seek such an injunction. 
 (g) If Licensee elects not to
exercise its rights specified in this Section 5.3.8, it shall notify MedImmune reasonably in advance of the time limits specified for any application for a Biosimilar Product (and in any event within such period as may be necessary to preserve
MedImmune’s rights to exercise such rights), then, to the extent permissible under the PHSA, MedImmune may thereafter elect to exercise those rights with respect to that application for a Biosimilar Product, at MedImmune’s sole expense.
Licensee shall use its commercially reasonable efforts to enable MedImmune to exercise such rights to the maximum extent permitted by Applicable Law, including to provide MedImmune with drafts of any lists or communications described in the
foregoing clauses (b) or (c) prior to providing such lists or communications to the Biosimilar Filer, consider in good faith advice and suggestions with respect thereto received from MedImmune, notify MedImmune of the provision to the
Biosimilar Filer of any such lists or communications promptly after they are made and take such other actions with respect to the Biosimilar Filer on behalf of MedImmune as may be necessary to give effect to the foregoing rights of MedImmune;
provided that MedImmune shall reimburse Licensee for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 61 

 (h) The Parties recognize that procedures other than those set forth above may apply with
respect to applications for Biosimilar Products. In the event that the Parties determine that certain provisions of Applicable Law in the United States or in any other country in the Territory apply to actions taken by the Parties with respect to
applications for Biosimilar Products in such country, the Parties shall comply with any such Applicable Law in such country (and any relevant and reasonable procedures established by Parties) in exercising their rights and obligations with respect
to applications for Biosimilar Products under this Section 5.3.8. The Party that does not control the actions contemplated by this Section 5.3.8 shall cooperate with the controlling Party in implementing any decisions that the controlling
Party elects to take pursuant to this Section 5.3.8. 
 5.4. Infringement Claims by Third Parties. If the Exploitation or
Manufacture of a Licensed Product in the Territory pursuant to this Agreement results in any claim, suit or proceeding by a Third Party against Licensee or any of its Affiliates or its or their Sublicensees alleging infringement (a “Third
Party Infringement Claim”), including any defense or counterclaim in connection with an Infringement action initiated by Licensee or any of its Affiliates pursuant to Section 5.3.2, Licensee shall promptly notify MedImmune thereof in
writing. Except as provided in Section 8.3.2, as between the Parties, Licensee shall have the first right to defend against any such claim, suit or proceeding at its sole cost and expense, using reputable, outside counsel mutually agreed to by
the Parties, such agreement not to be unreasonably withheld, conditioned or delayed, and, with respect to any AstraZeneca Product References in connection with the defense of any such claim, suit or proceeding with respect to a Licensed Patent or
PhaseBio Patent, using only factual statements contained in the approved label for the AstraZeneca Product or otherwise approved by MedImmune in writing; provided that MedImmune shall respond to any request to use an AstraZeneca Product
Reference in connection with any such defense within [***] of receipt of such request. MedImmune may participate in any such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that Licensee shall
retain the right to control such claim, suit or proceeding. MedImmune shall, and as necessary shall cause its Affiliates to, assist and cooperate with Licensee, as Licensee may reasonably request from time to time, in connection with its activities
set forth in this Section 5.4, including, where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence, and
making its employees available at reasonable business hours; provided that Licensee shall reimburse MedImmune for its reasonable and verifiable out-of-pocket
costs and expenses incurred in connection therewith. Licensee shall keep MedImmune reasonably informed of all material developments in connection with any such claim, suit or proceeding. Licensee agrees to provide MedImmune with copies of all
material pleadings filed in such action and to allow MedImmune reasonable opportunity to participate in the defense of the claims. Any damages, or awards, including royalties incurred or awarded in connection with any Third Party Infringement Claim
defended by Licensee under this Section 5.4 shall be borne by Licensee. If Licensee or its designee does not take commercially reasonable steps to defend against such claim, suit or proceeding within [***] following the date upon which Licensee
first receives notice or otherwise learns of such Third Party Infringement 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 62 

 
Claim or, provided such date occurs after Licensee receives notice or otherwise learns of such Third Party Infringement Claim, [***] before the time limit, if any, set forth in Applicable
Law for filing of such actions, whichever comes first, then (a) Licensee shall so notify MedImmune and (b) MedImmune may defend against such Third Party Infringement Claim at its sole cost and expense. For clarity, except as provided in
Section 8.3.2, as between the Parties, MedImmune and its Affiliates shall have and retain the right to defend against any claim, suit or proceeding brought against MedImmune or any of its Affiliates. 

5.5. Invalidity or Unenforceability Defenses or Actions. 

5.5.1. Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or
unenforceability of any of the Licensed Patents, PhaseBio Selected Patents or Joint Patents by a Third Party of which such Party becomes aware. 

5.5.2. Licensed Patents; PhaseBio Patents. Except as provided in Section 8.3.2, as between the Parties, Licensee shall have
(a) the first right, but not the obligation, to defend and control the defense of the validity and enforceability of the Licensed Patents and the PhaseBio Selected Patents at its sole cost and expense, using reputable, outside counsel mutually
agreed to by the Parties, such agreement not to be unreasonably withheld, conditioned or delayed, and (b) the sole right, but not the obligation, to defend and control the defense of the validity and enforceability of any PhaseBio Patents that
are not PhaseBio Selected Patents at its sole cost and expense, using counsel of Licensee’s choice; including, in each case ((a) and (b)), when such invalidity or unenforceability is raised as a defense or counterclaim in connection with an
Infringement action initiated pursuant to Section 5.3; provided that if any such claim is raised as a defense or counterclaim in connection with an Infringement action initiated pursuant to Section 5.3, then the Party controlling
such Infringement action shall have the first right to defend and control the defense of the validity and enforceability of the applicable Patents. With respect to any such claim, suit or proceeding with respect to any of the Licensed Patents or
PhaseBio Selected Patents, MedImmune may participate in such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that Licensee shall retain control of the defense in such claim, suit or proceeding. If
Licensee or its designee elects not to defend or control the defense of the Licensed Patents or PhaseBio Selected Patents or otherwise fails to initiate and maintain the defense of any such claim, suit or proceeding with respect to the Licensed
Patents or PhaseBio Selected Patents, then MedImmune may conduct and control the defense of any such claim, suit or proceeding at its sole cost and expense. 

5.5.3. Joint Patents. Except as provided in Section 8.3.2, as between the Parties, the Responsible Party shall have the first
right, but not the obligation, to defend and control the defense of the validity and enforceability of the Joint Patents at its sole cost and expense, using reputable, outside counsel mutually agreed to by the Parties, such agreement not to be
unreasonably withheld, conditioned or delayed; including when such invalidity or unenforceability is raised as a defense or counterclaim in connection with an Infringement action 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 63 

 
Initiated pursuant to Section 5.3; provided that if any such claim is raised as a defense or counterclaim in connection with an Infringement action initiated pursuant to
Section 5.3, then the Party controlling such Infringement action shall have the first right to defend and control the defense of the validity and enforceability of the applicable Patents. With respect to any such claim, suit or proceeding with
respect to any of the Joint Patents, the other Party may participate in such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that the Responsible Party shall retain control of the defense in such
claim, suit or proceeding. If the Responsible Party or its designee elects not to defend or control the defense of the Joint Patents or otherwise fails to initiate and maintain the defense of any such claim, suit or proceeding with respect to the
Joint Patents, then the other Party may conduct and control the defense of any such claim, suit or proceeding at its sole cost and expense. 

5.5.4. AstraZeneca Product Patents. As between the Parties, MedImmune or its Affiliate shall have the sole right, but not the
obligation, to defend and control the defense of the validity and enforceability of the AstraZeneca Product Patents its sole cost and expense, using counsel of MedImmune’s choice, including when such invalidity or unenforceability is raised as
a defense or counterclaim in connection with an Infringement action initiated pursuant to Section 5.3. 
 5.5.5. Cooperation.
The non-controlling Party in any action pursuant to this Section 5.5 shall, and as necessary shall cause its Affiliates to, assist and cooperate with the controlling Party, as such controlling Party may
reasonably request from time to time, in connection with its activities set forth in this Section 5.5, including, where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to,
such action, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours; provided that the controlling Party shall reimburse the
non-controlling Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith;
provided further that MedImmune shall have no obligation under this Section 5.5.5 with respect to any PhaseBio Patents that are not PhaseBio Selected Patents. In connection with any activities with respect to a defense, claim or
counterclaim relating to the Licensed Patents pursuant to this Section 5.5, Licensee shall (a) consult with MedImmune as to the strategy for such activities, (b) consider in good faith any comments from MedImmune, and (c) keep
MedImmune reasonably informed of any material steps taken and provide copies of all material documents filed, in connection with such defense, claim or counterclaim. 

5.6. Product Trademarks. 

5.6.1. Prosecution of Product Trademarks. Licensee shall be responsible for the registration, prosecution, and maintenance of
the Product Trademarks using counsel of its own choice. All costs and expenses of registering, prosecuting and maintaining the Product Trademarks shall be borne solely by Licensee. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 64 

 5.6.2. Enforcement of Product Trademarks. Subject to Sections 9.4.2(b) and
9.4.3(b), Licensee shall have the sole right during the Term to take such action as Licensee deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution, misappropriation, or other violation of, or unfair
trade practices or any other like offense relating to, the Product Trademarks by a Third Party in the Territory at its sole cost and expense and using counsel of its own choice. Licensee shall retain any damages or other amounts collected in
connection therewith. 
 5.6.3. Third Party Claims. Subject to Sections 9.4.2(b) and 9.4.3(b), Licensee shall have the sole
right during the Term to defend against and settle any alleged, threatened, or actual claim by a Third Party that the use or registration of the Product Trademarks by Licensee or any of its Affiliates or Sublicensees in the Territory
infringes, dilutes, misappropriates, or otherwise violates any Trademark or other right of that Third Party or constitutes unfair trade practices or any other like offense or any other claims as may be brought by a Third Party against a Party in
connection with the use of the Product Trademarks with respect to a Licensed Product in the Territory, at its sole cost and expense and using counsel of its choice. Any damages or awards, including royalties incurred or awarded in connection with
any such claim defended under this Section 5.6.3, shall be for the account of Licensee, except to the extent that any such claim resulted from MedImmune’s, its Affiliate’s or its (sub)licensee’s failure to comply with
Section 5.7.2. 
 5.7. Corporate Names, Licensed Trademarks and Product Trademarks. 

5.7.1. Licensee shall not, and shall not permit its Affiliates or its or their Sublicensees to, (a) use in their respective
businesses, any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that dilutes, any (or any part) of the MedImmune Corporate Names or any Trademarks with respect to any AstraZeneca Product, (b) do any act
that endangers, destroys or similarly affects, in any material respect, the value of the goodwill pertaining to the MedImmune Corporate Names or any Trademarks with respect to any AstraZeneca Product, or (c) attack, dispute or contest the
validity of or ownership of the MedImmune Corporate Names or any Trademarks with respect to any AstraZeneca Product anywhere in the Territory or any registrations issued or issuing with respect thereto or any pending registration thereof. Without
limitation to any term or condition of the Trademark License Agreement, Licensee agrees, and shall cause its Affiliates and Sublicensees, to conform (i) to the customary industry standards for the protection of any Licensed Trademarks and to
such trademark usage guidelines as MedImmune may furnish from time to time with respect to the use of any Licensed Trademarks and (ii) to adhere to and maintain high quality standards with respect to goods sold and services provided under any
Licensed Trademarks. For purposes of Sections 5.7.1 and 5.7.2, references to AstraZeneca Product exclude Generic Ticagrelor Products. 

5.7.2. Without limitation to the foregoing, the use of any Licensed Trademarks by Licensee, its Affiliates and its and their
Sublicensees shall be subject to the terms 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 65 

 
and conditions of this Agreement, including Sections 3.5.6 and 5.7.1, and the applicable Trademark License Agreement. Unless otherwise provided in the Trademark License Agreement, each use
of any Trademark with respect to the AstraZeneca Product by Licensee, its Affiliates and its and their Sublicensees shall be subject to the prior review and approval of MedImmune, such approval not to be unreasonably withheld, conditioned or
delayed. Licensee covenants to MedImmune that, except as expressly permitted in this Agreement and the Trademark License Agreement, Licensee and its Affiliates and its or their Sublicensees shall not (a) in connection with the Development,
Commercialization or other Exploitation of any Licensed Product, use any Licensed Trademark or any other Trademark with respect to the AstraZeneca Product or (b) assist, authorize or enable any Excluded Distributor or other Third Party
contractor of Licensee, its Affiliates or its or their Sublicensees to use any Licensed Trademark or any other Trademark with respect to the AstraZeneca Product. 

5.7.3. MedImmune shall not, and shall not permit its Affiliates or its or their (sub)licensees of the AstraZeneca Product to,
(a) use in their respective businesses, any Trademark that is confusingly similar to, misleading or deceptive with respect to or that dilutes any (or any part) of the Licensee Corporate Names or the Product Trademarks, (b) do any act that
endangers, destroys or similarly affects, in any material respect, the value of the goodwill pertaining to the Licensee Corporate Names or the Product Trademarks, or (c) attack, dispute or contest the validity of or ownership of the Licensee
Corporate Names or the Product Trademarks anywhere in the Territory or any registrations issued or issuing with respect thereto or any pending registration thereof. MedImmune agrees, and shall cause its Affiliates and (sub)licensees, to conform to
the customary industry standards for the protection of the Licensee Corporate Names and the Product Trademarks and to such trademark usage guidelines as Licensee may furnish from time to time with respect to the use of the Licensee Corporate Names
and the Product Trademarks. 
 ARTICLE 6 

CONFIDENTIALITY AND NON-DISCLOSURE 

6.1. Confidentiality Obligations. At all times during the Term and for a period of ten (10) years following termination or
expiration hereof in its entirety, each Party shall and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any
Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential
Information” means any technical, business or other information provided by or on behalf of one Party to the other Party in connection with this Agreement, whether prior to, on or after the Effective Date, including information relating
to the terms of this Agreement (subject to Section 6.4), information relating to any Licensed Compound or Licensed Product (including the Regulatory Documentation), any Development, Manufacture or Commercialization of any Licensed Compound or
Licensed Product, any know-how with respect thereto developed by or on behalf of the disclosing Party or its Affiliates (including Licensed 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 66 

 
Know-How and PhaseBio Know-How, as applicable) or the scientific, regulatory or business affairs or other
activities of such Party. Notwithstanding the foregoing, (a) the terms of this Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the receiving Party and the disclosing Party with
respect thereto and (b) any AstraZeneca Product Know-How and any AstraZeneca Product Improvement shall be deemed to be the Confidential Information of MedImmune, and Licensee shall be deemed to be the
receiving Party and MedImmune shall be deemed to be the disclosing Party with respect thereto. Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 6.1 with
respect to any Confidential Information shall not include any information that the receiving Party can demonstrate by competent evidence: 

6.1.1. is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of
this Agreement by the receiving Party; 
 6.1.2. can be demonstrated by documentation or other competent proof to have been in the
receiving Party’s possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information; 

6.1.3. is subsequently received by the receiving Party on a non-confidential basis from a Third
Party who is not bound by any obligation of confidentiality with respect to such information; 
 6.1.4. has been published by a Third
Party or otherwise enters the public domain through no fault of the receiving Party in breach of this Agreement; or 
 6.1.5. can be
demonstrated by documentation or other competent evidence to have been independently developed by or for the receiving Party without reference to the disclosing Party’s Confidential Information. 

Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the receiving Party merely
because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in
the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the receiving Party unless the combination and its principles are in the public domain or in
the possession of the receiving Party. 
 6.2. Permitted Disclosures. Each Party may disclose Confidential Information to the extent
that such disclosure is: 
 6.2.1. made in response to a valid order of a court of competent jurisdiction or other supra-national,
federal, national, regional, state, provincial and local 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 67 

 
governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the receiving Party’s legal counsel, such disclosure is otherwise required by law, including by
reason of filing with securities regulators; provided, however, that, to the extent practicable under the circumstances, the receiving Party shall first have given notice to the disclosing Party and given the disclosing Party a
reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or agency or, if
disclosed, be used only for the purposes for which the order was issued; and provided, further, that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is
legally required to be disclosed in response to such court or governmental order; 
 6.2.2. made by or on behalf of the receiving
Party in connection with prosecuting or defending litigation; provided, however, that, to the extent practicable under the circumstances, the receiving Party shall first have given notice to the disclosing Party and given the
disclosing Party a reasonable opportunity to obtain a protective order requiring that the Confidential Information and documents that are the subject of such litigation be held in confidence by the Persons prosecuting or defending such litigation
or, if disclosed, be used only for the purposes in connection with such litigation; 
 6.2.3. made by or on behalf of the receiving
Party to the Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval made consistent with the terms and conditions of this Agreement; provided, however, that reasonable measures
shall be taken to assure confidential treatment of such information to the extent practicable and consistent with Applicable Law; 

6.2.4. made by or on behalf of the receiving Party to a patent authority as required for purposes of obtaining or enforcing a Patent as
permitted by this Agreement; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

6.2.5. made by the receiving Party to its Affiliates or potential future or actual sublicensees (including Sublicensees) or
distributors, or by the receiving Party or its Affiliates, sublicensees (including Sublicensees) or distributors to Third Parties, in each case, as may be necessary or useful in connection with the Exploitation of any Licensed Compound or Licensed
Product as contemplated by this Agreement, in the case of Licensee, or the Exploitation of the AstraZeneca Product, in the case of MedImmune or its Affiliate, including subcontracting or sublicensing transactions in connection therewith;
provided, however, that such disclosures are made under obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of
confidentiality and non-use of the receiving Party pursuant to this Article 6 (with a duration of confidentiality and non-use obligations as appropriate that is no
less than five (5) years from the date of disclosure); 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 68 

 6.2.6. made by or on behalf of the receiving Party to [***], consultants of such
receiving Party, or other Third Party service providers performing activities on behalf of such receiving Party hereunder or in connection herewith; provided, however, that (a) such disclosure shall be limited to only that Confidential
Information required to enable such Third Party to perform the applicable activities and (b) such Third Party shall be subject to obligations of confidentiality and non-use with respect to such
Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this Article 6 (with a duration of confidentiality and non-use obligations as appropriate that is no less than five (5) years from the date of disclosure); provided, further, that if either Party seeks to disclose the terms of this Agreement to [***] or
other consultants or Third Party service providers, the Party seeking to disclose this Agreement must obtain the other Party’s prior written consent before disclosing this Agreement (such consent not to be unreasonably withheld, delayed or
conditioned); or 
 6.2.7. made by or on behalf of the receiving Party to potential or actual investors, investment bankers, lenders
or acquirers as may be necessary in connection with their evaluation of such potential or actual investment, loan, financing or acquisition; provided, however, that such persons shall be subject to reasonable obligations of confidentiality
and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this
Article 6, with a duration of confidentiality and non-use obligations that is no less than five (5) years from the date of disclosure; provided, further, that: (a) upon the written
request of either Party, the Parties shall, within [***] of such request, mutually agree in good faith on a redacted version of this Agreement that may be provided by a Party to a bona fide potential investor, acquirer or divestment partner, such
agreement not to be unreasonably withheld, delayed or conditioned, and such redactions not to be so extensive that they do not permit a potential investor, acquirer or divestment partner to gain a reasonable understanding of the relationship
established by this Agreement or to conduct reasonable due diligence regarding this Agreement (such redacted version, the “Redacted Agreement”), and such Party shall have the right to provide any such bona fide potential investor,
acquirer or divestment partner with the Redacted Agreement or a summary thereof; and (b) if a Party seeks to disclose any terms of this Agreement that were redacted from the Redacted Agreement to potential investors, acquirers or divestment
partners, the Party seeking to disclose such terms must obtain the other Party’s prior written consent before disclosing such terms (such consent not to be unreasonably withheld, delayed or conditioned). In no event shall the Party seeking to
disclose Confidential Information of the other Party or the terms of this Agreement to a potential investor, acquirer or divestment partner be required to disclose the identity of such potential investor, acquirer or divestment partner to the other
Party. 
 Notwithstanding the foregoing, Licensee shall not, without MedImmune’s prior written consent, which may be withheld in MedImmune’s sole
discretion, disclose any AstraZeneca Product Know-How (other than AstraZeneca Product Know-How that is or becomes part of the public domain by public use, public general
knowledge or the like through no breach of this Agreement 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 69 

 
by Licensee or any of its Affiliates or its or their Sublicensees) or any other Confidential Information specifically relating to the AstraZeneca Product, any AstraZeneca Product Improvement or
AstraZeneca Product Patents, except in each case to the extent provided in Section 6.2.1 or, with respect to actual Sublicensees but not with respect to potential future sublicensees, Section 6.2.5. 

6.3. Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo or Trademark of the
other Party or any of its Affiliates or any of its or their (sub)licensees (or Sublicensees) (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material or other form of publicity in connection
with this Agreement or activities hereunder without the prior written approval of such other Party. The restrictions imposed by this Section 6.3 shall not prohibit (a) either Party from making any disclosure identifying the other Party to
the extent required in connection with its exercise of its rights or obligations under this Agreement and (b) either Party from making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock
exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). 
 6.4.
Public Announcements. 
 6.4.1. Subject to this Section 6.4.1, neither Party or any of its Affiliates shall issue any public
announcement, press release or other similar formal public disclosure (e.g., a disclosure required to be made in a registration statement, periodic report or similar filing) regarding this Agreement without the other Party’s prior written
consent, such consent not to be unreasonably withheld, delayed or conditioned. The Party proposing to make such public announcement, press release or other similar formal public disclosure shall provide a copy of any such public announcement, press
release or other similar formal public disclosure to the other Party reasonably (to the extent practicable under the circumstances) but in all cases no less than [***] (or, in the case of a disclosure covered by the third sentence of this
Section 6.4.1, one (1) Business Day) in advance of issuing or otherwise publicly disclosing such public announcement, press release or other similar formal public disclosure. In the event and to the extent a Party is, in the opinion of its
counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public announcement, press release or other similar formal public
disclosure, such Party shall submit the proposed public announcement, press release or other similar formal public disclosure in writing to the other Party reasonably (to the extent practicable under the circumstances) but in all cases no less than
one (1) Business Day in advance. Under the circumstances covered in the immediately preceding sentence and subject to Section 5.7, the releasing Party shall not be obligated (a) to delay making any such public announcement, press
release or other similar formal public disclosure beyond the time when the same is required to be made in order to facilitate review and comment by the other Party or (b) to refrain from issuing such public announcement, press release or other
similar formal public disclosure for which approval has not been provided by the other Party. In the event and to the extent a Party is, in 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 70 

 
the opinion of its counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make any
disclosure regarding this Agreement in any required filing, neither Party shall be required to seek the consent of the other Party to repeat such disclosure in a subsequent required filing (but not, for clarity, in any other public announcement or a
press release) by a Party in accordance with this Section 6.4.1; provided that (i) such disclosure remains accurate as of such time in light of the then-applicable circumstances and (ii) the frequency and form of such
disclosure are reasonable, including in light of the context of such disclosure taking into account the passage of time and other circumstances. Subject to Section 3.4.2, Licensee may, without MedImmune’s consent, issue public
announcements, press releases or other similar formal public disclosures solely regarding (x) clinical trials of Licensed Products, including the initiation, enrollment status and results thereof, (y) the filing, or acceptance for filing,
of INDs and Drug Approval Applications for Licensed Products, or (z) the receipt of Regulatory Approvals with respect to Licensed Products; provided, however, that Licensee shall provide a copy of any such public announcements, press
releases or other similar formal public disclosures to MedImmune reasonably (to the extent practicable under the circumstances) but in all cases no less than [***] (or, in the case of a public disclosure covered by the third sentence of this
Section 6.4.1, one (1) Business Day) in advance of issuing such public announcement, press release or other similar formal public disclosure; provided, further, that any such public announcement, press release or other similar
formal public disclosure that includes an AstraZeneca Product Reference shall be subject to MedImmune’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. In addition, either Party may disclose amounts
paid to or received by either Party in respect of the achievement of any milestone events. 
 6.4.2. Without limitation to
Section 6.4.1, which applies to public announcements, press releases and other similar formal public disclosures, and to Section 6.5, which applies to publications in scientific or medical journals, reference publications or scientific or
medical presentations, the Parties acknowledge that, in the course of Developing and Commercializing the Licensed Product, Licensee and its Affiliates will need to communicate orally or otherwise informally with various Third Parties (including
industry analysts and key opinion leaders) concerning the Licensed Product and that, given the relationship of the Licensed Product to the AstraZeneca Product, such communications may implicate the positioning of the Licensed Product in relation to
the AstraZeneca Product. Section 6.4.1 is not intended to cover such oral or other informal communications with Third Parties (other than Regulatory Authorities). Subject to Sections 3.5.6 and 6.1, Licensee shall have the right to engage
in such oral or other informal communications with Third Parties, provided that in engaging in such oral or other informal communications with Third Parties, Licensee and its Affiliates shall ensure that such communications regarding the Licensed
Product are consistent with the then-applicable Approved Product Positioning Principles (approved by MedImmune pursuant to Section 3.10). 

6.4.3. For clarity, in no event shall MedImmune be required to notify Licensee of, or to obtain Licensee’s consent with respect
to, any public announcement, press 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 71 

 
release or other public disclosure regarding the AstraZeneca Product that does not refer to a Licensed Product. 

6.4.4. The terms of this Section 6.4 shall be applicable to any Sublicensee of Licensee or any of its Affiliates. 

6.5. Publications. The Parties recognize the desirability of publishing the results of Development activities under this Agreement.
Accordingly, Licensee shall be permitted to publicly disclose in scientific or medical journals, reference publications or scientific or medical presentations the results of Development activities under this Agreement in accordance with this
Section 6.5. Prior to making any such publication or disclosure, Licensee shall provide MedImmune with drafts of such proposed publication or disclosure, including as applicable proposed abstracts, manuscripts or summaries of
presentations. MedImmune shall respond promptly through its designated representative and in any event no later than [***] after receipt of such proposed publication or presentation or such shorter period as may be required by the publication or
presentation. Licensee agrees to allow a reasonable additional period to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of MedImmune in a
manner consistent with Applicable Law and industry practices. In addition, Licensee shall give due regard to comments furnished by MedImmune and such comments shall not be unreasonably rejected; provided, however, that if
any such abstract, manuscript or summary of presentations contains any AstraZeneca Product Reference that (a) is not supported by the approved labeling for the AstraZeneca Product or presents an unbalanced view of the AstraZeneca Product
considering the approved labeling for the AstraZeneca Product as a whole or (b) contains projections of the market potential of the AstraZeneca Product, Licensee shall correct or remove such AstraZeneca Product Reference or such projections, as
applicable. Notwithstanding the foregoing, subject to any copyrights or intellectual property rights of Third Parties, Licensee’s publications may include reprints of scientific or medical journal articles or reference publications regarding
the AstraZeneca Product that, in each case, follow FDA’s “Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or
Cleared Medical Devices” guidance. The terms of this Section 6.5 shall be applicable to any Sublicensee of Licensee or any of its Affiliates. 

6.6. Securities Laws. MedImmune acknowledges that Confidential Information disclosed or provided to MedImmune by Licensee, including the
results of any clinical trial or other study of a Licensed Product, may constitute or contain material non-public information regarding Licensee and that the United States securities laws prohibit any Person
who has such material non-public information from purchasing or selling securities of a publicly traded company on the basis of such information and from communicating such information to any Person under
circumstances in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities on the basis of such information. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 72 

 6.7. Return of Confidential Information. Upon the effective date of the expiration or
termination of this Agreement for any reason, either Party may request in writing and the non-requesting Party shall either, with respect to Confidential Information to which such non-requesting Party does not retain license rights under the surviving provisions of this Agreement, at the requesting Party’s election, (a) promptly destroy all copies of such Confidential Information in
the possession or control of the non-requesting Party and confirm such destruction in writing to the requesting Party or (b) promptly deliver to the requesting Party, at the
non-requesting Party’s sole cost and expense, all copies of such Confidential Information in the possession or control of the non-requesting Party. Notwithstanding
the foregoing, the non-requesting Party shall be permitted to retain such Confidential Information (i) to the extent necessary or useful for purposes of performing any continuing obligations or exercising
any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (ii) any computer records or files containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such
non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject
to the terms of this Agreement for the period set forth in Section 6.1. 
 ARTICLE 7 

REPRESENTATIONS AND WARRANTIES 

7.1. Mutual Representations and Warranties. MedImmune and Licensee each represents and warrants to the other, as of the Effective Date,
and covenants, that: 
 7.1.1. It is a corporation or limited liability company (as applicable) duly organized, validly existing and
in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

7.1.2. The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action and do not violate: (a) such Party’s charter documents, bylaws or other organizational documents; (b) any requirement of any Applicable Law; or (c) any order, writ, judgment,
injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party; 
 7.1.3.
This Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the
enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity); 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 73 

 7.1.4. It is not under any obligation, contractual or otherwise, to any Person that
conflicts with or is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder; and 

7.1.5. Neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of its Affiliates will
use in any capacity, in connection with the services or activities to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described in such section. It
will inform the other Party in writing promptly if it or any such Person who is performing services or activities hereunder is debarred or is the subject of a conviction described in Section 306 or if any action, suit, claim, investigation or
legal or administrative proceeding is pending or, to the best of its or its Affiliates’ knowledge, is threatened, relating to the debarment or conviction of it or any such Person performing services hereunder. 

7.2. Additional Representations and Warranties of MedImmune. MedImmune further represents and warrants to Licensee, as of the Effective
Date, that: 
 7.2.1. MedImmune Controls the Licensed Patents set forth on Schedule 1.80 as of the Effective Date and has the
right to grant the licenses and other rights specified herein and has not granted to any Affiliate or Third Party any license or other right with respect to any Licensed Compound, Licensed Product, Licensed Patents or Licensed Know-How that conflicts with the licenses and other rights granted to Licensee herein; 
 7.2.2. to
MedImmune’s Knowledge, Schedule 1.80 sets forth all Patents Controlled by MedImmune or its Affiliates that claim the composition of matter or any method of use of MEDI2452; 

7.2.3. there are no agreements in effect as of the Effective Date between MedImmune and a Third Party under which rights with respect
to the Licensed Patents or Licensed Know-How are being licensed to MedImmune; 
 7.2.4. to
MedImmune’s Knowledge, no reexamination, interference, invalidity, opposition, nullity or similar claim or proceeding is pending or threatened with respect to any Licensed Patent; 

7.2.5. MedImmune has not received any written claim or demand alleging that the Development or Commercialization of the Licensed
Products as contemplated herein infringes any Patent owned by any Third Party; and 
 7.2.6. there are no judgments or settlements
against or owed by MedImmune (or any of its Affiliates) with respect to the Licensed Patents or Licensed Know-How, and MedImmune is not a party to any legal action, suit or proceeding relating to the

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 74 

 
Licensed Patents or Licensed Know-How, nor has MedImmune received any written communication from any Third Party, including any Regulatory Authority or
other government agency, threatening such action, suit or proceeding. 
 7.3. DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS
WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE; AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER
WRITTEN OR ORAL, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF
ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 7.4. Anti-Bribery and Anti-Corruption Compliance. Each Party agrees, on behalf
of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of this Agreement (“Representatives”) that for the
performance of its obligations hereunder:  
 7.4.1. such Party and its Representatives shall comply with the Anti-Corruption
Laws and shall not take any action that will, or would reasonably be expected to, cause the other Party or its Affiliates to be in violation of any Anti-Corruption Laws. 

7.4.2. such Party shall promptly provide the other Party with written notice of the following events: (a) upon becoming aware of
any breach or violation by such Party or its Representative of any representation, warranty or undertaking set forth in Section 7.4.1, or (b) upon receiving a formal notification that it is the target of a formal investigation by a
Governmental Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of its Representatives connected with this Agreement that any of them is the target of a formal investigation by a governmental authority for
a Material Anti-Corruption Law Violation. 
 ARTICLE 8 

INDEMNITY 
 8.1.
Indemnification of MedImmune. Licensee shall save, indemnify, defend and hold harmless MedImmune, its Affiliates, its or their (sub)licensees of AstraZeneca Product rights, and its and their respective directors, officers, employees and agents
(collectively, “MedImmune Indemnitees”), from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) to which any
MedImmune Indemnitee becomes subject as a result of any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: [***]; except, in each case
((a), (b) and (c)), to the extent such Losses arise or result from the gross negligence or willful misconduct of any MedImmune 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 75 

 
Indemnitee or the breach by MedImmune of any warranty, representation, covenant or agreement made by MedImmune in this Agreement, as to which Losses each Party shall indemnify the other to the
extent of their respective liability. 
 8.2. Indemnification of Licensee. MedImmune shall save, indemnify, defend and hold harmless
Licensee, its Affiliates, its or their (sub)licensees or its or their distributors or contractors, and its or their respective directors, officers, employees and agents (collectively, “Licensee Indemnitees”), from and against any
and all Losses to which any Licensee Indemnitee becomes subject as a result of any and all Third Party Claims arising from or occurring as a result of: [***]; except, in each case ((a), (b) and (c)), to the extent such Losses arise or result from
the gross negligence or willful misconduct of any Licensee Indemnitee or the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement, as to which Losses each Party shall indemnify the other to the
extent of their respective liability for the Losses. 
 8.3. Indemnification Procedures. 

8.3.1. Notice of Claim. All indemnification claims in respect of a MedImmune Indemnitee or Licensee Indemnitee shall be made solely by
MedImmune or Licensee, respectively (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or
discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this Article 8, but in no event shall the indemnifying Party be liable for any Losses to the extent resulting from any delay in providing
such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly
to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 
 8.3.2.
Control of Defense. The indemnifying Party shall have the right to assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within [***] after the indemnifying Party’s receipt of an Indemnification Claim
Notice. The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor
shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel
in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the indemnifying Party
all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in
Section 8.3.3, the indemnifying Party shall not be liable 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 76 

 
to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically
agreed in writing by the indemnifying Party. 
 8.3.3. Right to Participate in Defense. Any Indemnified Party shall be entitled to
participate in the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s sole cost and expense unless (a) the
employment of such counsel has been specifically authorized in writing by the indemnifying Party in writing (in which case, the defense shall be controlled as provided in Section 8.3.2), (b) the indemnifying Party has failed to assume the
defense and employ counsel in accordance with Section 8.3.2 (in which case the Indemnified Party shall control the defense), or (c) the interests of the indemnitee and the indemnifying Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles (in which case, the Indemnified Party shall control its defense). 

8.3.4. Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim
and that shall not result in the applicable indemnitee(s) becoming subject to injunctive or other relief or otherwise adversely affecting the business of the Indemnified Party in any manner, the indemnifying Party shall have the sole right to
consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third
Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 8.3.2, the indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or
otherwise dispose of such Loss; provided it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the
defense of a Third Party Claim as provided above, the Indemnified Party may defend against such Third Party Claim; provided that the Indemnified Party shall not settle any Third Party Claim without the prior written consent of the
indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed). 
 8.3.5. Cooperation. Regardless of
whether the indemnifying Party chooses to defend any Third Party Claim, the Indemnified Party shall and shall cause each indemnitee to, cooperate in the defense thereof and shall furnish such records, information and testimony, provide such
witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party
to and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide
additional information and explanation of any material provided hereunder and the indemnifying Party shall reimburse the 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 77 

 
Indemnified Party for all its, its Affiliates’ and its and their (sub)licensees’ or their respective directors’, officers’, employees’ and agents’, as applicable,
reasonable and verifiable out-of-pocket expenses in connection therewith. 

8.3.6. Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the
Indemnified Party and its Affiliates and its and their (sub)licensees and their respective directors, officers, employees and agents, as applicable, in connection with any claim shall be reimbursed on a Calendar Quarter basis by the indemnifying
Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the
Indemnified Party. 
 8.4. Special, Indirect and Other Losses. EXCEPT IN THE EVENT OF (a) THE WILLFUL MISCONDUCT OR FRAUD
OF A PARTY OR (b) OF A PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 6 OR SECTION 2.5, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS IN
CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided, however, that this Section 8.4 shall not be construed to limit either Party’s indemnification obligations under Section 8.1 or 8.2 (as applicable) and
Section 8.3. 
 8.5. Insurance. Licensee shall have and maintain such types and amounts of insurance covering its
Exploitation of the Licensed Compounds and Licensed Products as is (a) normal and customary in the biopharmaceutical industry generally for parties similarly situated and (b) otherwise required by Applicable Law. Upon request by MedImmune,
Licensee shall provide to MedImmune evidence of its insurance coverage, including copies of applicable insurance policies. The insurance policies shall be under an occurrence form, but if only a claims-made form is available to Licensee, then
Licensee shall continue to maintain such insurance after the expiration or termination of this Agreement in its entirety for a period of five (5) years. 

ARTICLE 9 
 TERM AND
TERMINATION 
 9.1. Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in
accordance herewith, shall continue in force and effect until the date of expiration of the last to expire Royalty Term in the Territory (such period, the “Term”). On a Licensed Product-by-Licensed Product and country-by-country basis, following the expiration of the Royalty Term for a Licensed Product in
a country in the Territory, the grants in Section 2.1 for such Licensed Product in such country shall become non-exclusive, fully-paid, royalty-free, irrevocable and perpetual. Following the expiration of
the last-to-expire Royalty Term for any and all Licensed Products in the Territory, the grants in Section 2.1 shall become
non-exclusive, fully-paid, royalty-free, irrevocable and perpetual in their entirety. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 78 

 9.2. Termination. 

9.2.1. Material Breach. 

(a) Material Breach Not Related to Diligence. In the event that either Party (the “Breaching Party”) shall be in
material breach in the performance of any of its obligations under this Agreement (other than, in the case of Licensee, Licensee’s diligence obligations under Section 3.2, Section 3.3.1 or Section 3.5.1, which are covered in
Section 9.2.1(b) below), in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party
may terminate this Agreement in its entirety (or, if MedImmune is the Non-Breaching Party, on a country-by-country basis) by
providing ninety (90) days’ (or thirty (30) days’, in the case of a payment default) (the “Section 9.2.1(a) Notice Period”) prior written notice (the
“Section 9.2.1(a) Termination Notice”) to the Breaching Party specifying the breach and its claim of right to terminate, subject to Section 9.2.1(c) below; provided that the termination shall not
become effective at the end of the Section 9.2.1(a) Notice Period if the Breaching Party cures the breach specified in the Section 9.2.1(a) Termination Notice during the Section 9.2.1(a) Notice Period. 

(b) Material Breach of Diligence Obligations. If at any time MedImmune in good faith believes that Licensee is in material breach of
its diligence obligations under Section 3.2, Section 3.3.1 or Section 3.5.1, then MedImmune shall so notify Licensee, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such notice to
discuss in good faith MedImmune’s concerns. If, after such thirty (30) day period, the Parties agree that Licensee is in breach of such obligations or if the Parties do not reach agreement as to whether or not Licensee is in material
breach of such obligations and resolve the issue, then in addition to any other right and remedy MedImmune may have, but subject to Section 9.2.1(c) below, MedImmune may terminate this Agreement by providing ninety (90) days’ (the
“Section 9.2.1(b) Notice Period”) prior written notice (the “Section 9.2.1(b) Termination Notice”) to Licensee specifying the breach and its claim of right to terminate;
provided that (i) the termination shall not become effective at the end of the Section 9.2.1(b) Notice Period if, in the case of a curable breach, Licensee cures the breach specified in the Section 9.2.1(b) Termination Notice
during the Section 9.2.1(b) Notice Period, and (ii) with respect to any uncurable breach or an uncured material breach of such diligence obligations (A) with respect to the EU Market or the United States, MedImmune shall have the
right to terminate the Agreement in its entirety or solely with respect to the EU Market or the United States, as applicable, (B) with respect to China, MedImmune shall have the right to terminate this Agreement solely with respect to China,
and (C) solely with respect to any other country in the Territory, MedImmune shall have the right to terminate this Agreement solely with respect to such country. 

(c) Dispute Regarding Breach. Notwithstanding the foregoing provisions of this Section 9.2.1, in the event that, during the
applicable Notice Period, the allegedly Breaching Party (in the case of Section 9.2.1(a)) or Licensee (in the case of 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 79 

 
Section 9.2.1(b)) shall have initiated dispute resolution in accordance with Section 10.6 with respect to the alleged breach, then the other Party shall not have the right to terminate
this Agreement under this Section 9.2.1 unless and until (i) the Arbitrators, in accordance with Section 10.6, have determined that the Breaching Party (in the case of Section 9.2.1(a)) or Licensee (in the case of
Section 9.2.1(b)) has materially breached this Agreement and (ii) the Breaching Party (in the case of Section 9.2.1(a)) or Licensee (in the case of Section 9.2.1(b)) fails to cure such breach within ninety (90) days (or
thirty (30) days, in the case of a payment default) following the Arbitrators’ decision. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect, and
the Parties shall continue to perform all of their respective obligations hereunder. 
 9.2.2. Termination for Insolvency. In the
event that either Party (a) files for protection under bankruptcy or insolvency laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its
property that is not discharged within ninety (90) days after such filing, (d) proposes a written agreement of composition or extension of its debts generally, (e) is a party to any dissolution or liquidation, (f) files a
petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within ninety (90) days of the filing thereof or (g) admits in writing its inability generally to meet its obligations as they
fall due in the general course, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party. 

9.2.3. Termination by MedImmune. In the event that Licensee or any of its Affiliates or Sublicensees, anywhere in the Territory,
institutes, prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark
Office or its foreign counterparts, any claim, demand, action, or cause of action for declaratory relief, damages, or any other remedy or for an enjoinment, injunction, or any other equitable remedy, including any interference, re-examination, opposition or any similar proceeding, alleging that any claim in a Licensed Patent is invalid, unenforceable, or otherwise not patentable or alleging that any such claim would not be infringed by
Licensee’s activities in the absence of the rights and licenses granted hereunder, then MedImmune shall have the right to immediately terminate this Agreement in its entirety, including the rights of any Sublicensees, upon written notice to
Licensee; provided, however, that if any such proceeding is brought by a Sublicensee, Licensee shall have a period of sixty (60) days to cause such Sublicensee to cease such proceeding or terminate the applicable sublicense agreement, in
which case MedImmune shall not have the right to terminate this Agreement pursuant to this Section 9.2.3 by reason of the proceeding brought by such Sublicensee. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 80 

 9.2.4. Termination by Licensee for Safety/Efficacy Issue or Commercial Viability Issue.

 (a) Notice of Claimed Safety/Efficacy Issue or Commercial Viability Issue. In the event that Licensee believes in good faith
that (i) a Safety/Efficacy Issue with respect to MEDI2452 or any Licensed Product containing MEDI2452 (or, if the Exploitation of MEDI2452 and Licensed Products containing MEDI2452 has previously been abandoned in favor of Exploitation of an
Additional Compound and Licensed Products containing such Additional Compound in accordance with Section 2.4.4(b), a Safety/Efficacy Issue with respect to such Additional Compound or any Licensed Product containing such Additional Compound)
exists or (ii) a Commercial Viability Issue exists, Licensee shall provide written notice thereof to MedImmune, which notice shall include reasonable details (in the case of Commercial Viability Issue, as further set forth in
Section 9.2.4(b)) regarding, as applicable, the claimed Safety/Efficacy Issue and shall indicate whether the same is claimed to be a Global Safety/Efficacy Issue or a Market-Specific Safety/Efficacy Issue, or the claimed Commercial Viability
Issue and shall indicate which of the U.S., EU Market or China Market(s) is affected thereby and whether, based on Licensee’s assessment of such claimed Commercial Viability Issue with respect to such Market(s), such claimed Commercial
Viability Issue is a Global Commercial Viability Issue. Within [***] of delivery of any such notice, the Parties shall discuss the applicable claimed Safety/Efficacy Issue or Commercial Viability Issue and attempt in good faith to reach mutual
agreement (such agreement not to be unreasonably withheld, conditioned or delayed) as to, as applicable: 
 (i) whether or not it in fact
constitutes a Safety/Efficacy Issue or Commercial Viability Issue; 
 (ii) in the case of a Safety/Efficacy Issue, whether the same is a
Global Safety/Efficacy Issue or a Market-Specific Safety/Efficacy Issue; 
 (iii) solely in the case of a Market-Specific Safety/Efficacy
Issue, whether or not such Safety/Efficacy Issue is reasonably curable within six (6) months of Licensee’s notice with the use of Commercially Reasonable Efforts to cure (and, if it is agreed to be so curable, the Parties shall attempt in
good faith to mutually agree upon a curative plan); and 
 (iv) in the case of a claimed Commercial Viability Issue, whether such Commercial
Viability Issue applies to the United States, the EU Market or China Market(s), as applicable, or is a Global Commercial Viability Issue (in each case ((i) through (iv)), a “Section 9.2.4 Matter”). 

If the Parties are unable to reach mutual agreement within a further [***], then, upon the written request of either Party, the matter shall be subject to
resolution in accordance with Section 9.2.4(c). 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 81 

 (b) In the case of any claimed Commercial Viability Issue, Licensee shall provide at a
minimum the following data and other information in support of such Commercial Viability Issue with respect to each applicable Market (including, with respect to the EU Market, for each Major European Market): Development costs that will be incurred
to complete clinical trials required to obtain Regulatory Approval in the applicable Market or country, as applicable, and ten (10) years’ forecasted sales volumes, net selling price per unit, cost of goods per unit, commercialization
costs and other data indicating anticipated revenues in such Market or country, as applicable. 
 (c) Expedited Resolution by Independent
Expert. If the Parties are unable to reach mutual agreement within the period specified in the last sentence of Section 9.2.4(a), then, upon the written request of either Party, the applicable Section 9.2.4 Matter(s) may be referred by
either Party to MedImmune’s senior representative for the AstraZeneca Product and Licensee’s Chief Financial Officer or VP of Marketing/Chief Commercial Officer (or their respective designees) for attempted resolution by good faith
negotiations during a period of [***]. Any final decision mutually agreed to by such senior representatives (or such designees) shall be conclusive and binding on the Parties. If such senior representatives (or such designees) are unable to resolve
any such Section 9.2.4 Matter within such [***] period, then either Party shall have the right to refer such Section 9.2.4 Matter to the Senior Officers for attempted resolution by good faith negotiations during a period of [***]. Any
final decision mutually agreed to by the Senior Officers shall be set forth in writing and signed by both Parties, whereupon it will be conclusive and binding on the Parties. If such Senior Officers (or such designees) are unable to resolve any such
disagreement within such [***] period, then, upon the written request of either Party, the determination of the Section 9.2.4 Matter shall be referred to an Independent Expert. “Independent Expert” means (i) an independent
Third Party expert in the field of drug development and commercialization who is acceptable to both Parties or (ii) if the Parties fail to agree on an independent Third Party expert in accordance with the preceding clause (i) within [***]
after such request for referral, an independent Third Party expert in the field of drug development and commercialization who is selected by mutual agreement of (A) an independent Third Party expert in the field of drug development and
commercialization selected by MedImmune within [***] after such request for referral and (B) an independent Third Party expert in the field of drug development and commercialization selected by Licensee within [***] after such request for
referral (such selection to be made within [***] after the Parties have selected their respective independent Third Party experts). The sole authority of the Independent Expert will be to (x) set a schedule for expedited dispute resolution,
(y) request supporting documentation from each Party with respect to the applicable Section 9.2.4 Matters and (z) make a determination as to each of the applicable Section 9.2.4 Matters based on such supporting documentation.
Unless otherwise agreed by the Parties, the Independent Expert’s determination shall be final and binding upon the Parties. Unless otherwise agreed by the Parties, the Independent Expert shall be required to make his or her determination within
[***] after his or her selection as the Independent Expert. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 82 

 (d) Termination Rights. 

(i) Market-Specific Safety/Efficacy Issue. 

(A) Reasonably Curable. If the Parties mutually agree (including by agreement of their senior representatives or Senior Officers as
provided in Section 9.2.4(c)), or the Independent Expert determines, that (1) a claimed Market-Specific Safety/Efficacy Issue is in fact a Market-Specific Safety/Efficacy Issue and (2) such Market-Specific Safety/Efficacy Issue is
reasonably curable within six (6) months of Licensee’s notice with the use of Commercially Reasonable Efforts to cure, then within thirty (30) days of such mutual agreement or Independent Expert determination (as applicable), the
Parties shall mutually agree in good faith upon a commercially reasonable written curative plan and Licensee shall use Commercially Reasonable Efforts to carry out such curative plan within six (6) months thereafter, or, failing such mutual
agreement on a curative plan within thirty (30) days of such mutual agreement or Independent Expert determination (as applicable), Licensee shall use Commercially Reasonable Efforts to cure such Safety/Efficacy Issue within six (6) months
thereafter. If, despite Licensee’s use of Commercially Reasonable Efforts, such Market-Specific Safety/Efficacy Issue is not cured within such six (6)-month period, then Licensee shall have the right to terminate this Agreement in the country
of the Territory where such Market-Specific Safety/Efficacy Issue exists upon thirty (30) days’ written notice to MedImmune. 

(B) Not Reasonably Curable. If the Parties mutually agree (including by agreement of their senior representatives or Senior Officers as
provided in Section 9.2.4(c)), or the Independent Expert determines, that (1) a claimed Market-Specific Safety/Efficacy Issue is in fact a Market-Specific Safety/Efficacy Issue and (2) such Market-Specific Safety/Efficacy Issue is not
reasonably curable within six (6) months of Licensee’s notice with the use of Commercially Reasonable Efforts to cure, then Licensee shall have the right to terminate this Agreement in the country of the Territory where such
Market-Specific Safety/Efficacy Issue exists upon thirty (30) days’ written notice to MedImmune. 
 (ii) Global Safety/Efficacy
Issue. If the Parties mutually agree (including by agreement of their senior representatives or Senior Officers as provided in Section 9.2.4(c)), or the Independent Expert determines, that a claimed Global Safety/Efficacy Issue is in fact a
Global Safety/Efficacy Issue, then Licensee shall have the right to terminate this Agreement in its entirety upon thirty (30) days’ written notice to MedImmune. 

(iii) Market-Specific Commercial Viability Issue. If the Parties mutually agree (including by agreement of their senior representatives
or Senior Officers as provided in Section 9.2.4(c)), or the Independent Expert determines, that a claimed Commercial Viability Issue with respect to the U.S., EU Market or China Market(s) is in fact a Commercial Viability Issue with respect to
such Market(s), then Licensee shall have the right to terminate this Agreement with respect to such Market(s) (but not in its entirety) upon thirty (30) days’ written notice to MedImmune. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 83 

 (iv) Global Commercial Viability Issue. If the Parties mutually agree (including by
agreement of their senior representatives or Senior Officers as provided in Section 9.2.4(c)), or the Independent Expert determines, that any Commercial Viability Issue(s) constitutes a Global Commercial Viability Issue, then Licensee shall
have the right to terminate this Agreement in its entirety upon thirty (30) days’ written notice to MedImmune. 
 9.2.5.
Termination by Licensee for Withdrawal of AstraZeneca Product. In the event that the AstraZeneca Product is withdrawn by a Regulatory Authority in the United States, the EU Market or China, then Licensee shall have the right to terminate this
Agreement with respect to the United States, the EU Market, or China, as applicable. In the event that the AstraZeneca Product is withdrawn by a Regulatory Authority in both the United States and the EU Market, then Licensee shall have the right to
terminate this Agreement in its entirety. Except as provided in the immediately foregoing sentence with respect to withdrawal in the United States and the EU Market, unless the Parties otherwise agree in writing, in the event that the AstraZeneca
Product is withdrawn by a Regulatory Authority in a Market other than the United States, the EU Market or China, such withdrawal shall not permit Licensee to terminate this Agreement in whole or in part; provided, however, that in such
event Licensee shall be relieved of further diligence obligations under Section 3.2, Section 3.3.1 and Section 3.5.1, as applicable, with respect to such Market. For purposes of this Section, references to AstraZeneca Product exclude
Generic Ticagrelor Products. 
 9.2.6. Termination by Mutual Agreement. The Parties may terminate this Agreement by mutual, written
consent. 
 9.3. Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Licensee or MedImmune
are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous
provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country
or jurisdiction, the Party that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not
already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon the non-subject
Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or, (b) if not delivered under clause (a) above, following the rejection of this
Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 84 

 9.4. Consequences of Termination. 

9.4.1. Effect of Termination on Fully-Paid Licenses. If the Royalty Term with respect to a Licensed Product in any country has expired
on or before any termination of this Agreement prior to its expiration, the grants in Section 2.1 for such Licensed Product in such country shall survive such termination of this Agreement on a
non-exclusive, fully-paid, royalty-free, irrevocable and perpetual basis; provided that such grants shall not survive in the event this Agreement is terminated pursuant to Section 9.2.4. 

9.4.2. Effect of Termination in its Entirety. In the event of a termination of this Agreement in its entirety for any reason, and
subject to Section 9.4.2(k): 
 (a) subject to Section 9.4.1 and Section 9.4.5, all rights and licenses granted by MedImmune
hereunder and any sublicense granted by Licensee pursuant to Section 2.3 shall immediately terminate; 
 (b) Licensee shall and hereby
does, and shall cause its Affiliates and its and their Sublicensees to, effective as of the effective date of termination, assign to MedImmune all of its right, title and interest in and to (i) each Product Trademark and (ii) all
Regulatory Documentation (including any Regulatory Approvals and Licensee Regulatory Documentation) applicable to any Licensed Compound or Licensed Product then owned or Controlled by Licensee or any of its Affiliates or any of its or their
Sublicensees, subject, in each case, to MedImmune’s royalty payment obligations under Section 9.4.2(d); provided that if any such Regulatory Documentation is not immediately transferable in a country, Licensee shall provide
MedImmune with all benefit of such Regulatory Documentation and such assistance and cooperation as necessary or reasonably requested by MedImmune to timely transfer such Regulatory Documentation to MedImmune or its designee or, at MedImmune’s
option, to enable MedImmune to obtain a substitute for such Regulatory Documentation without disruption to MedImmune’s Exploitation or Manufacture of the applicable Licensed Compound(s) or Licensed Product(s); 

(c) all Confidential Information of Licensee to the extent relating specifically to any Licensed Compound or Licensed Product or the
Exploitation thereof shall thereafter be deemed Confidential Information of MedImmune (provided that, for clarity (i) in the case of Confidential Information consisting of PhaseBio Know-How that
has uses or application to retained products or technology of Licensee, this Section 9.4.2(c) is not intended to have such PhaseBio Know-How constitute Confidential Information of MedImmune for purposes
of use or application of such Confidential Information relating to such retained products or technologies, and (ii) this Section 9.4.2(c) is not intended to cause Confidential Information of Licensee that becomes Confidential Information
of MedImmune in accordance with the foregoing to cease to constitute PhaseBio Know-How or Licensee Termination Know-How to the extent the same constituted PhaseBio Know-How or Licensee Termination Know-How immediately prior to termination of this Agreement); 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 85 

 (d) Licensee shall and hereby does, and shall cause its Affiliates and its and their
Sublicensees to, effective as of the effective date of termination, grant MedImmune an exclusive, royalty-free (except to the extent set forth in Section 9.4.2(d)(i)) license, with the right to grant multiple tiers of sublicenses, under the
Licensee Termination Know-How, Licensee Termination Patents, and Licensee’s interest in Joint Inventions and Joint Patents to Exploit and Manufacture in the Territory any Licensed Compound or Licensed
Product; provided that MedImmune is not granted any license in this Section 9.4.2(d) with respect to any Other Active contained in a Combination Product for which (x) no Phase II Clinical Trial has been Initiated for the
applicable Combination Product as of the effective time of termination or (y) the Licensee Termination Know-How with respect to such Other Active or the Licensee Termination Patents that claim such Other
Active are licensed to Licensee or any of its Affiliates by a Third Party and Licensee does not have the right, consistent with the terms and conditions of the applicable Third Party agreement as of the termination of this Agreement, to grant a
sublicense to MedImmune under such Licensee Termination Know-How or Licensee Termination Patents with respect to such Other Active contained in a Combination Product. The Parties further agree as follows: 

(i) in the event that such termination occurs after Initiation of the first Phase II Clinical Trial with respect to a Licensed Product, in
consideration for such license MedImmune shall pay to Licensee a royalty on Net Sales (mutatis mutandis, with references to “Licensee” in the definition of Net Sales deemed to be references to MedImmune for purposes of this
Section 9.4.2(d)) of Licensed Products by MedImmune, its Affiliates and its and their sublicensees in the Territory, at a commercially reasonable rate that takes into account the relative contributions of the Parties (including for purposes of
valuing such relative contributions any contribution of Licensee, taking into account (x) any Other Active in any Combination Product for which a Phase II Clinical Trial has been Initiated as of the effective date of termination and for
which MedImmune receives a license pursuant to Section 9.4.2(d) and (y) any Licensee Termination Know-How that may be included in the Regulatory Documentation transferred to MedImmune pursuant to
Section 9.4.2(b)), which rate (the “Termination Royalty Rate”) shall be mutually agreed upon by the Parties in writing; provided, however, that if the Parties fail to reach mutual written agreement on the Termination
Royalty Rate within the Termination Discussion Period, then either Party may require the Termination Royalty Rate to be determined in accordance with Section 10.7. For purposes of this Agreement, the “Termination Discussion
Period” shall mean the ninety (90)-day period commencing upon Licensee’s receipt of written notice from MedImmune that MedImmune intends to pursue the Development or Commercialization of a
Licensed Product; provided that (A) MedImmune shall notify Licensee in writing of its initial decision to pursue or not to pursue the Development or Commercialization of a Licensed Product within one (1) year after the effective
date of termination, and (B) if MedImmune initially elects not to pursue the Development or Commercialization of a Licensed Product pursuant to clause (A), MedImmune shall promptly notify Licensee in writing of any future decision to pursue
such Development or Commercialization. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 86 

 (ii) MedImmune’s royalty payment obligations under this Section 9.4.2(d) (if any)
shall be subject to reduction in accordance with Section 4.5.3, mutatis mutandis, provided that such royalty reductions shall be subject to the limitation set forth in Section 4.5.4, mutatis mutandis. Royalties under
this Section 9.4.2(d) (if any) shall be payable with respect to each Licensed Product and each country in the Territory on Net Sales during the period beginning on the date of the First Commercial Sale of such Licensed Product in such country
by MedImmune or any of its Affiliates or licensees (other than Licensee or any of its Affiliates or Sublicensees) and ending on the later to occur of (A) the expiration of the
last-to-expire Valid Claim of the Licensed Patents and Licensee Termination Patents covering the manufacture, use or sale of such Licensed Product in such country and
(B) the expiration of the Regulatory Exclusivity Period, if any, for such Licensed Product in such country (the “Termination Royalty Period”); provided, however, that the Termination Royalty Period for a Licensed Product
in a country shall terminate if, and at such time as, the Generic Competition Threshold (mutatis mutandis, as specified below) for such Licensed Product in such country is first met or exceeded. For purposes of the foregoing, references to
AstraZeneca Product in Section 1.61 shall be deemed to refer to Licensed Product, and references to Generic Ticagrelor Products in Section 1.61 shall be deemed to refer to Biosimilar Products (mutatis mutandis, as specified below),
and references to Licensee and its Affiliates in Section 1.20 shall be deemed to refer to MedImmune and its Affiliates. 
 (iii)
notwithstanding anything to the contrary herein, MedImmune shall have the right at any time in MedImmune’s sole discretion to terminate the license granted pursuant to this Section 9.4.2(d) on written notice, in which case, in the case of
a termination of such license in its entirety, MedImmune shall be relieved of any applicable royalty or other payment obligation in connection therewith. Notwithstanding any such termination of the license granted pursuant to this
Section 9.4.2(d), in the event that subsequent to such termination MedImmune or any of its Affiliates use any Regulatory Documentation assigned to MedImmune in Section 9.4.2(b) to obtain or maintain any Regulatory Approval for a Licensed
Product, then MedImmune shall remain obligated with respect to any royalty payment owed pursuant to Section 9.4.2(d)(i) and (ii) in connection applicable Net Sales, calculated pursuant to Section 9.4.2(d)(i) and (ii) as if such
assigned Regulatory Documentation were Licensee Terminated Know-How for which MedImmune retained a license under Section 9.4.2(d). 

(e) notwithstanding any other provision of this Section 9.4.2 to the contrary, to the extent the Licensee Termination Patents include any
Patent licensed to Licensee, its Affiliate or Licensee’s or its Affiliate’s Sublicensee by a Third Party that is subject to royalty or milestone payment obligations to such Third Party with respect to Licensed Compounds or Licensed
Products, then Licensee shall so notify MedImmune within [***] after the effective date of termination, which notice shall include a true, complete and correct description of such royalty and milestone payment obligations and a correct and complete
copy of such Third Party agreement, and the continued inclusion of such Patent in the Licensee Termination Patents licensed to MedImmune under Section 9.4.2(d) shall be subject to 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 87 

 
MedImmune’s agreeing, in writing in accordance with this Section 9.4.2(e), to pay all royalty and milestone payments that become due to such Third Party by reason of the Exploitation of
Licensed Compounds and Licensed Products by or on behalf of MedImmune or any of its Affiliates or (sub)licensees. MedImmune shall pay such amounts in accordance with the terms and conditions of the applicable Third Party agreement, unless MedImmune
declines or terminates such sublicense rights in accordance with this Section 9.4.2(e). Within [***] of MedImmune’s receipt of such notice, MedImmune shall have the right, upon written notice to Licensee, to decline any sublicense under
such Third Party agreement, in which case MedImmune will be deemed not to have received license rights under any such Third Party agreement as of the effective date of termination of this Agreement. If MedImmune does not decline any such Third Party
agreement within such ninety (90)-day period, MedImmune shall have the right in its sole discretion to terminate the sublicense under such Third Party agreement at any time following such [***] period. For
clarity, any such Third Party royalty obligations described in this Section 9.4.2(e) are in addition to the royalties payable by MedImmune to Licensee for the licenses granted by Licensee pursuant to Section 9.4.2(b), the first sentence of
Section 9.4.2(d) and Section 9.4.2(f); 
 (f) Licensee shall and hereby does, and shall cause its Affiliates and its and their
Sublicensees to, effective as of the effective date of termination, grant MedImmune an exclusive, royalty-free (except as set forth in Section 9.4.2(d)) right of reference, with the right to grant multiple tiers of further rights of reference,
in and to all Regulatory Documentation (including any Regulatory Approvals) then owned or Controlled by Licensee or any of its Affiliates or its or their Sublicensees that are not assigned to MedImmune pursuant to clause (b) above to Exploit
and Manufacture in the Territory any Licensed Compound or Licensed Product; 
 (g) Licensee shall provide to MedImmune a list of all
clinical studies ongoing with respect to any Licensed Compound or Licensed Product and, unless expressly prohibited by any Regulatory Authority, at MedImmune’s written request and election in MedImmune’s sole discretion, Licensee shall and
hereby does, and shall cause its Affiliates and its and their Sublicensees to either: (i) wind down in accordance with Applicable Law and observing applicable ethical and regulatory guidelines any or all clinical studies involving Licensed
Products being conducted by or on behalf of Licensee, an Affiliate or a Sublicensee as of the effective date of termination, at Licensee’s cost and expense; or (ii) (x) transfer control to MedImmune of any or all clinical studies
involving Licensed Products being conducted by or on behalf of Licensee, an Affiliate or a Sublicensee as of the effective date of termination and (y) continue to conduct such clinical studies involving Licensed Products being conducted by or
on behalf of Licensee, an Affiliate or a Sublicensee as of the effective date of termination for up to six (6) months to enable such transfer to be completed without interruption of any such clinical study, in each case ((x) and (y)), at
MedImmune’s cost and expense; provided that MedImmune shall not have any obligation to continue any clinical study for which it has elected to have control transferred to MedImmune unless required by Applicable Law; 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 88 

 (h) following good faith discussions by the Parties as to which Licensed Product Agreements
should be assigned to MedImmune, at MedImmune’s written request, Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, assign to MedImmune or its designee any and all Licensed Product Agreements, unless, with respect
to any such Licensed Product Agreement, such Licensed Product Agreement (i) expressly prohibits such assignment (in which case, Licensee, or its Affiliate or Sublicensee, as applicable, shall cooperate with MedImmune in all reasonable respects
to secure the consent of the applicable Third Party to such assignment), or (ii) relates both to Licensed Products and products other than Licensed Products (in which case, at MedImmune’s request, Licensee, or its Affiliate or Sublicensee,
as applicable, shall cooperate with MedImmune in all reasonable respects to secure the written agreement of the applicable Third Party to a partial assignment of the applicable Licensed Product Agreement relating to the Licensed Products) and, in
either case ((i) or (ii)) if any such consent or agreement, as applicable, cannot be obtained with respect to a Licensed Product Agreement, in the case of termination of this Agreement for any reason other than by Licensee pursuant to
Section 9.2.1, at MedImmune’s request in order to continue to Exploit Licensed Products following termination, Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, obtain for MedImmune substantially all of the
practical benefit and burden under such License Product Agreement to the extent applicable to the Licensed Products, including by entering into appropriate and reasonable alternative arrangements on terms agreeable to MedImmune and subject to the
consent and control of MedImmune; provided that Licensee’s obligations shall continue only for so long as is reasonably necessary for MedImmune to secure alternative arrangements directly with one or more Third Parties through the
exercise of commercially reasonable efforts; 
 (i) at MedImmune’s written request, Licensee shall supply to MedImmune the Licensed
Compounds and Licensed Products then being manufactured by or on behalf of Licensee of its Affiliates or Sublicensees, in such quantities as MedImmune indicates in written forecasts and orders therefor from time to time; provided that
Licensee shall not be required to supply quantities that exceed Licensee’s reasonable forecasts, if any, prepared prior to termination and not in anticipation of termination, with respect to necessary clinical or commercial quantities, as
applicable, for the relevant period. Licensee shall supply such Licensed Compounds and Licensed Products at a supply price equal to Licensee’s actual, fully-burdened cost (as determined in accordance with GAAP, consistently applied) to
Manufacture such Licensed Compounds and Licensed Products, as applicable; provided that, in the case of a termination by Licensee pursuant to Section 9.2.1, the supply price for Licensed Compounds and Licensed Products shall be
(A) [***] of Licensee’s actual, fully-burdened cost (as determined in accordance with GAAP, consistently applied) to Manufacture clinical supplies of such Licensed Compounds and Licensed Products, as applicable, and (B) [***] of
Licensee’s actual, fully-burdened cost (as determined in accordance with GAAP, consistently applied) to Manufacture commercial supplies of such Licensed Compounds and Licensed Products, as applicable. Unless MedImmune no longer desires to
obtain such Licensed Compounds and Licensed Products, Licensee shall supply such Licensed Compounds and Licensed Products until the earlier of (i) such time as MedImmune has established an alternate, validated source of supply for the

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 89 

 
Licensed Compounds and Licensed Products and MedImmune is receiving supply from such alternative source and (ii) (x) if such termination occurs prior to the First Commercial Sale of
Licensed Product, the first (1st) anniversary of the effective date of termination of this Agreement or (y) if such termination occurs after the First Commercial Sale of Licensed Product, the second (2nd) anniversary of the effective date of
termination of this Agreement; and 
 (j) the exclusivity commitment of MedImmune under Section 2.5.1 shall immediately terminate and
the exclusivity commitment of Licensee under Section 2.5.2 shall immediately terminate except that, in the case of termination by Licensee pursuant to Section 9.2.4(d)(iv) for a Commercial Viability Issue only, such exclusivity commitment
of Licensee shall survive for a period which is the earlier of the expiration of the Exclusive Period or two (2) years following the effective date of such termination, unless MedImmune informs Licensee in writing that MedImmune elects not to
pursue further Development or Commercialization of any Licensed Compound or Licensed Product; and 
 (k) notwithstanding the foregoing
provisions of clauses (a) through (j) of this Section 9.4.2, solely in the event of termination of this Agreement by MedImmune pursuant to Section 9.2.1 or Section 9.2.2 in its entirety, as applicable, the obligations of
Sublicensees under such Sections, and the obligations of Licensee to cause Sublicensees to perform under such Sections, shall not be applicable with respect to any Sublicensee under any Surviving Sublicense as of the effective date of termination of
this Agreement, but shall be deemed applicable with respect to any such Sublicensee upon any subsequent termination of the Surviving Sublicense that may be have been granted by MedImmune to such Third Party pursuant to Section 2.3.2, and in
such event (i) obligations applicable to Sublicensees under such Sections that apply from or after the date of the termination of this Agreement shall be deemed to apply to such Sublicensees from and after the date of termination of the
Surviving Sublicense, mutatis mutandis and (ii) for purposes of such Sections and the defined terms “PhaseBio Know-How”, “PhaseBio Patents”, “Licensee Termination Know-How” and “Licensee Termination Patents”, references to “during the Term” shall mean in relation to any such Sublicensee the Term of this Agreement or the term of the applicable
Sublicense, whichever is later, and references to “prior to termination of this Agreement” shall mean in relation to any such Sublicensee prior to the termination of this Agreement or the Sublicense, whichever is later. 

9.4.3. Effect of Termination in a Terminated Territory. In the event of a termination of this Agreement with respect to a Terminated
Territory for any reason (but not in the case of any termination of this Agreement in its entirety), and subject to Section 9.4.3(k): 

(a) subject to Section 9.4.1 and Section 9.4.5, all rights and licenses granted by MedImmune hereunder, and any sublicense granted
by Licensee pursuant to Section 2.3, (i) shall automatically be deemed to be amended to exclude, if applicable, the right to (A) market, promote, detail, distribute, import, sell for commercial use, offer for commercial

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 90 

 
sale or otherwise Commercialize, file any Drug Approval Application for, or seek or maintain any Regulatory Approval for Licensed Products in such Terminated Territory, (B) Develop any
Licensed Compound or Licensed Product anywhere in the world for the purposes of obtaining or maintaining Regulatory Approval in such Terminated Territory, and (C) Manufacture any Licensed Compound or Licensed Product anywhere in the world for
purposes of Developing or Commercializing any Licensed Compound or Licensed Product in such Terminated Territory and (ii) shall otherwise survive and continue in effect in such Terminated Territory solely for the purpose of furthering any
Commercialization of the Licensed Products in the Territory or any Development or Manufacturing in support thereof; 
 (b) Licensee shall
and hereby does, and shall cause its Affiliates and its and their Sublicensees to, effective as of the effective date of termination, assign to MedImmune all of its right, title and interest in and to (i) each Product Trademark in such
Terminated Territory and (ii) all Regulatory Documentation (including any Regulatory Approvals and Licensee Regulatory Documentation) applicable to any Licensed Compound or Licensed Product solely in the Terminated Territory then owned or
Controlled by Licensee or any of its Affiliates or any of its or their Sublicensees, subject, in each case, to MedImmune’s royalty payment obligations under Section 9.4.3(d); provided that if any such Regulatory Documentation is not
immediately transferable in a country, Licensee shall provide MedImmune with all benefit of such Regulatory Documentation and such assistance and cooperation as necessary or reasonably requested by MedImmune to timely transfer such Regulatory
Documentation to MedImmune or its designee or, at MedImmune’s option, to enable MedImmune to obtain a substitute for such Regulatory Documentation without disruption to MedImmune’s Exploitation or Manufacture of the applicable Licensed
Compound(s) or Licensed Product(s); 
 (c) all Confidential Information of Licensee to the extent relating specifically to any Licensed
Compound or Licensed Product or the Exploitation thereof solely with respect to the Terminated Territory shall thereafter be deemed Confidential Information of MedImmune (provided that, for clarity (i) in the case of Confidential
Information consisting of PhaseBio Know-How that has uses or application to retained products or technology of Licensee, this Section 9.4.3(c) is not intended to have such PhaseBio Know-How constitute Confidential Information of MedImmune for purposes of use or application of such Confidential Information relating to such retained products or technologies, and (ii) this
Section 9.4.3(c) is not intended to cause Confidential Information of Licensee that becomes Confidential Information of MedImmune in accordance with the foregoing to cease to constitute PhaseBio Know-How
or Licensee Termination Know-How to the extent the same constituted PhaseBio Know-How or Licensee Termination Know-How
immediately prior to termination of this Agreement with respect to the Terminated Territory); 
 (d) Licensee shall and hereby does, and
shall cause its Affiliates and its and their Sublicensees to, effective as of the effective date of termination, grant MedImmune an exclusive, royalty-free (except to the extent set forth in Section 9.4.3(d)(i))

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 91 

 
license, with the right to grant multiple tiers of sublicenses, under the Licensee Termination Know-How, Licensee Termination Patents and Licensee’s
interest in Joint Inventions and Joint Patents to (x) Commercialize the Licensed Compounds or Licensed Products in the Terminated Territory, (y) Develop the Licensed Compounds or Licensed Products anywhere in the world for purposes of
obtaining or maintaining Regulatory Approval for Licensed Products in the Terminated Territory, and (z) Manufacture the Licensed Compounds or Licensed Products anywhere in the world for purposes of Developing and Commercializing the Licensed
Compounds and Licensed Products in the Terminated Territory; provided that MedImmune is not granted any license in this Section 9.4.3(d) with respect to any Other Active contained in a Combination Product for which (I) no
Phase II Clinical Trial has been Initiated for the applicable Combination Product as of the effective time of termination or (II) the Licensee Termination Know-How with respect to such Other Active
or the Licensee Termination Patents that claim such Other Active are licensed to Licensee or any of its Affiliates by a Third Party and Licensee does not have the right, consistent with the terms and conditions of the applicable Third Party
agreement as of the termination of this Agreement, to grant a sublicense to MedImmune under such Licensee Termination Know-How or Licensee Termination Patents with respect to such Other Active contained in a
Combination Product. The Parties further agree as follows: 
 (i) in the event that such termination occurs after Initiation of the first
Phase II Clinical Trial with respect to a Licensed Product in the Terminated Territory, in consideration for such license MedImmune shall pay to Licensee a royalty on Net Sales (mutatis mutandis, with references to “Licensee” in the
definition of Net Sales deemed to be references to MedImmune for purposes of this Section 9.4.3(d)) of Licensed Products by MedImmune, its Affiliates and its and their sublicensees in the Terminated Territory, at a commercially reasonable rate
that takes into account the relative contributions of the Parties (including for purposes of valuing such relative contributions any contribution of Licensee, taking into account (x) any Other Active in any Combination Product for which a
Phase II Clinical Trial has been Initiated as of the effective date of termination and for which MedImmune receives a license pursuant to Section 9.4.3(d) and (y) any Licensee Termination
Know-How that may be included in the Regulatory Documentation transferred to MedImmune pursuant to Section 9.4.3(b)), which rate (the “Terminated Territory Royalty Rate”) shall be
mutually agreed upon by the Parties in writing; provided, however, that if the Parties fail to reach mutual written agreement on the Terminated Territory Royalty Rate within the Terminated Territory Discussion Period, then either Party may
require the Terminated Territory Royalty Rate to be determined in accordance with Section 10.7. For purposes of this Agreement, the “Terminated Territory Discussion Period” shall mean the ninety
(90)-day period commencing upon Licensee’s receipt of written notice from MedImmune that MedImmune intends to pursue the Development or Commercialization of a Licensed Product in the Terminated Territory;
provided that (A) MedImmune shall notify Licensee in writing of its initial decision to pursue or not to pursue the Development or Commercialization of a Licensed Product in the Terminated Territory within one (1) year after the
effective date of termination, and (B) if MedImmune initially elects not to pursue the Development or Commercialization of a Licensed Product in the Terminated Territory pursuant to clause (A), MedImmune shall promptly notify Licensee in

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 92 

 
writing of any future decision to pursue such Development or Commercialization in the Terminated Territory. 

(ii) MedImmune’s royalty payment obligations under this Section 9.4.3(d) (if any) shall be subject to reduction in accordance with
Section 4.5.3, mutatis mutandis, provided that such royalty reductions shall be subject to the limitation set forth in Section 4.5.4, mutatis mutandis. Royalties under this Section 9.4.3(d) (if any) shall be
payable with respect to each Licensed Product in the Terminated Territory on Net Sales during the period beginning on the date of the First Commercial Sale of such Licensed Product in the Terminated Territory by MedImmune or any of its Affiliates or
licensees (other than Licensee or any of its Affiliates or Sublicensees) and ending on the later to occur of (A) the expiration of the last-to-expire Valid Claim of
the Licensed Patents and Licensee Termination Patents covering the manufacture, use or sale of such Licensed Product in the Terminated Territory and (B) the expiration of the Regulatory Exclusivity Period, if any, for such Licensed Product in
the Terminated Territory (the “Terminated Territory Royalty Period”); provided, however, that the Terminated Territory Royalty Period for a Licensed Product in the Terminated Territory shall terminate if, and at such time as,
the Generic Competition Threshold (mutatis mutandis, as specified below) for such Licensed Product in the Terminated Territory is first met or exceeded. For purposes of the foregoing, references to AstraZeneca Product in Section 1.61
shall be deemed to refer to Licensed Product, and references to Generic Ticagrelor Products in Section 1.61 shall be deemed to refer to Biosimilar Products (mutatis mutandis, as specified below), and references to Licensee and its
Affiliates in Section 1.20 shall be deemed to refer to MedImmune and its Affiliates. 
 (iii) notwithstanding anything to the contrary
herein, MedImmune shall have the right at any time in MedImmune’s sole discretion to terminate the license granted pursuant to this Section 9.4.3(d) on written notice, in which case, in the case of a termination of such license in its
entirety, MedImmune shall be relieved of any applicable royalty or other payment obligation in connection therewith. Notwithstanding any such termination of the license granted pursuant to this Section 9.4.3(d), in the event that subsequent to
such termination MedImmune or any of its Affiliates use any Regulatory Documentation assigned to MedImmune in Section 9.4.3(b) to obtain or maintain any Regulatory Approval for a Licensed Product in the Terminated Territory, then MedImmune
shall remain obligated with respect to any royalty payment owed pursuant to Section 9.4.3(d)(i) and (ii) in connection applicable Net Sales in the Terminated Territory, calculated pursuant to Section 9.4.3(d)(i) and (ii) as if
such assigned Regulatory Documentation were Licensee Terminated Know-How for which MedImmune retained a license under Section 9.4.3(d). 

(e) notwithstanding any other provision of this Section 9.4.3 to the contrary, to the extent the Licensee Termination Patents in the
Terminated Territory include any Patent licensed to Licensee, its Affiliate or Licensee’s or its Affiliate’s Sublicensee by a Third Party that is subject to royalty or milestone payment obligations to such Third Party with respect to
Licensed Compounds or Licensed Products, then Licensee shall so notify 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 93 

 
MedImmune within [***] after the effective date of termination, which notice shall include a true, complete and correct description of such royalty and milestone payment obligations and a correct
and complete copy of such Third Party agreement, and the continued inclusion of such Patent in the Licensee Termination Patents licensed to MedImmune under Section 9.4.3(d) shall be subject to MedImmune’s agreeing, in writing in accordance
with this Section 9.4.3(d), to pay all royalty and milestone payments that become due to such Third Party by reason of the Exploitation of Licensed Compounds and Licensed Products by or on behalf of MedImmune or any of its Affiliates or
(sub)licensees in the Terminated Territory. MedImmune shall pay such amounts in accordance with the terms and conditions of the applicable Third Party agreement, unless MedImmune declines or terminates such sublicense rights in accordance with this
Section 9.4.3(e). Within [***] of MedImmune’s receipt of such notice, MedImmune shall have the right, upon written notice to Licensee, to decline any sublicense under such Third Party agreement, in which case MedImmune will be deemed not
to have received license rights under any such Third Party agreement as of the effective date of termination of this Agreement with respect to the Terminated Territory. If MedImmune does not decline any such Third Party agreement within such [***]
period, MedImmune shall have the right in its sole discretion to terminate the sublicense under such Third Party agreement at any time following such [***] period. For clarity, any such Third Party royalty obligations described in this
Section 9.4.3(e) are in addition to the royalties payable by MedImmune to Licensee for the licenses granted by Licensee pursuant to Section 9.4.3(b), the first sentence of Section 9.4.3(d) and Section 9.4.3(f); 

(f) Licensee shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, effective as of the effective date of
termination, grant MedImmune (i) an exclusive, royalty-free (except to the extent set forth in Section 9.4.3(d)) right of reference, with the right to grant multiple tiers of further rights of reference, in and to all Regulatory
Documentation (including any Regulatory Approvals) in the Terminated Territory then owned or Controlled by Licensee or any of its Affiliates or its or their Sublicensees that are not assigned to MedImmune pursuant to clause (b) above to Exploit
and Manufacture in the Terminated Territory any Licensed Compound or Licensed Product and (ii) a non-exclusive, royalty-free (except as set forth in Section 9.4.3(d)) right of reference, with the
right to grant multiple tiers of further rights of reference, in and to all Regulatory Documentation (including any Regulatory Approvals) outside of the Terminated Territory then owned or Controlled by Licensee or any of its Affiliates or its or
their Sublicensees, solely as necessary to Exploit and Manufacture in the Terminated Territory any Licensed Compound or Licensed Product; 

(g) unless expressly prohibited by any Regulatory Authority, at MedImmune’s written request and election in MedImmune’s sole
discretion, Licensee shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to either: (i) wind down in accordance with Applicable Law and observing applicable ethical and regulatory guidelines any or all clinical
studies involving Licensed Products being conducted by or on behalf of Licensee, an Affiliate or a Sublicensee as of the effective date of termination exclusively in and for the Terminated Territory (excluding any clinical study intended to generate
data that will be submitted to Regulatory Authorities in the Territory), at Licensee’s 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 94 

 
cost and expense, or (ii) (x) transfer control to MedImmune of any or all clinical studies involving Licensed Products being conducted by or on behalf of Licensee, an Affiliate or a
Sublicensee as of the effective date of termination exclusively in or for the Terminated Territory (excluding any clinical study intended to generate data that will be submitted to Regulatory Authorities in the Territory) and (y) continue to
conduct such clinical studies involving Licensed Products being conducted by or on behalf of Licensee, an Affiliate or a Sublicensee as of the effective date of termination exclusively in or for the Terminated Territory for up to six
(6) months to enable such transfer to be completed without interruption of any such clinical study, in each case ((x) and (y)), at MedImmune’s cost and expense; provided that MedImmune shall not have any obligation to continue any
clinical study for which it has elected to have control transferred to MedImmune unless required by Applicable Law; and 
 (h) following
good faith discussions by the Parties as to which Licensed Product Agreements should be assigned to MedImmune, at MedImmune’s written request, Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, assign to MedImmune
or its designee any and all Licensed Product Agreements relating solely to the Terminated Territory with respect to which the Parties agree should be assigned to MedImmune, unless, with respect to any such Licensed Product Agreement, such Licensed
Product Agreement (i) expressly prohibits such assignment (in which case, Licensee, or its Affiliate or Sublicensee, as applicable, shall cooperate with MedImmune in all reasonable respects to secure the consent of the applicable Third Party to
such assignment), or (ii) relates both to (A) the Terminated Territory and the Territory or (B) Licensed Products and products other than Licensed Products (which, in either case ((A) or (B)), at MedImmune’s request, Licensee, or
its Affiliate or Sublicensee, as applicable, shall cooperate with MedImmune in all reasonable respects to secure the written agreement of the applicable Third Party to a partial assignment of the applicable Licensed Product Agreement relating to the
Terminated Territory or Licensed Products, as applicable) and, in either case ((i) or (ii)) if any such consent or agreement, as applicable, cannot be obtained with respect to a Licensed Product Agreement, in the case of termination of this
Agreement for any reason other than by Licensee pursuant to Section 9.2.1, at MedImmune’s request in order to continue to Exploit Licensed Products in the Terminated Territory following termination, Licensee shall, and shall cause its
Affiliates and its and their Sublicensees to, obtain for MedImmune substantially all of the practical benefit and burden under such License Product Agreement to the extent applicable to the Licensed Products in the Terminated Territory, including by
entering into appropriate and reasonable alternative arrangements on terms agreeable to MedImmune and subject to the consent and control of MedImmune; provided that Licensee’s obligations shall continue only for so long as is reasonably
necessary for MedImmune to secure alternative arrangements directly with one or more Third Parties through the exercise of commercially reasonable efforts; 

(i) at MedImmune’s written request, Licensee shall supply to MedImmune the Licensed Compounds and Licensed Products then being
manufactured by or on behalf of Licensee of its Affiliates or Sublicensees for Development or Commercialization in or for the Terminated Territory, in such quantities as MedImmune indicates in written forecasts

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 95 

 
and orders therefor from time to time; provided that Licensee shall not be required to supply quantities that exceed Licensee’s reasonable forecasts, if any, prepared prior to
termination and not in anticipation of termination, with respect to necessary clinical or commercial quantities, as applicable, for the Terminated Territory for the relevant period. Licensee shall supply such Licensed Compounds and Licensed Products
at a supply price equal to Licensee’s actual, fully-burdened cost (as determined in accordance with GAAP, consistently applied) to Manufacture such Licensed Compounds and Licensed Products, as applicable; provided that, in the case of a
termination by Licensee pursuant to Section 9.2.1, the supply price for Licensed Compounds and Licensed Products shall be (A) [***] of Licensee’s actual, fully-burdened cost (as determined in accordance with GAAP, consistently
applied) to Manufacture clinical supplies of such Licensed Compounds and Licensed Products, as applicable, and (B) [***] of Licensee’s actual, fully-burdened cost (as determined in accordance with GAAP, consistently applied) to Manufacture
commercial supplies of such Licensed Compounds and Licensed Products, as applicable. Unless MedImmune no longer desires to obtain such Licensed Compounds and Licensed Products, Licensee shall supply such Licensed Compounds and Licensed Products for
Development or Commercialization in or for the Terminated Territory until the earlier of (i) such time as MedImmune has established an alternate, validated source of supply for such Licensed Compounds and Licensed Products and MedImmune is
receiving supply from such alternative source and (ii) (x) if such termination occurs prior to the First Commercial Sale of Licensed Product, the first (1st) anniversary of the effective date of termination of this Agreement or (y) if
such termination occurs after the First Commercial Sale of Licensed Product, the second (2nd) anniversary of the effective date of termination of this Agreement; and 

(j) the exclusivity commitment of MedImmune under Section 2.5.1 shall immediately terminate with respect to the Terminated Territory, and
the exclusivity commitment of Licensee under Section 2.5.2 shall survive with respect to the Territory and shall continue with respect to the Terminated Territory for the Exclusive Period; and 

(k) notwithstanding the foregoing provisions of clauses (a) through (j) of this Section 9.4.3, solely in the event of termination of
this Agreement by MedImmune pursuant to Section 9.2.1 with respect to any Terminated Territory, as applicable, the obligations of Sublicensees under such Sections, and the obligations of Licensee to cause Sublicensees to perform under such
Sections, shall not be applicable with respect to any Sublicensee under any Surviving Sublicense with respect to the Terminated Territory as of the effective date of termination of this Agreement, but shall be deemed applicable with respect to any
such Sublicensee upon any subsequent termination of the Surviving Sublicense that may be have been granted by MedImmune to such Third Party with respect to the Terminated Territory pursuant to Section 2.3.2, and in such event
(i) obligations applicable to Sublicensees under such Sections that apply from or after the date of the termination of this Agreement shall be deemed to apply to such Sublicensees from and after the date of termination of the Surviving
Sublicense, mutatis mutandis and (ii) for purposes of such Sections and the defined terms “PhaseBio Know-How”, “PhaseBio Patents”, “Licensee Termination Know-How” and “Licensee Termination 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 96 

 
Patents”, references to “during the Term” shall mean in relation to any such Sublicensee the Term of this Agreement or the term of the applicable Sublicense, whichever is later,
and references to “prior to termination of this Agreement” shall mean in relation to any such Sublicensee prior to the termination of this Agreement or the Sublicense, whichever is later. 

9.4.4. Intellectual Property Management. Without limitation to any other term or condition of this Agreement, and unless MedImmune
otherwise consents in writing, Licensee shall not, and shall cause each of its Affiliates and its and their Sublicensees not to, assign, sell or divest any of Licensee’s rights in or to any PhaseBio
Know-How covered by clause (b) of the definition of PhaseBio Know-How and PhaseBio Patents covered by clause (b) of the definition of PhaseBio Patents in a
manner that results in Licensee, its Affiliate or Sublicensee, as applicable, no longer Controlling such PhaseBio Know-How or PhaseBio Patents for the purposes of the licenses granted to MedImmune in
Section 9.4.2 and Section 9.4.3, other than to an Affiliate that is controlled by Licensee or in connection with a permitted assignment of this Agreement under Section 10.3. 

9.4.5. Effect of Termination on Sublicensees. In the event of (a) termination of this Agreement in its entirety, any and all
sublicenses granted by Licensee pursuant to Section 2.3, and (b) termination of this Agreement with respect to any Terminated Territory (but not in its entirety), any and all sublicenses granted by Licensee with respect to the applicable
Terminated Territory, in each case ((a) and (b)) shall terminate, except that solely in the event of termination of this Agreement by MedImmune pursuant to Section 9.2.1 or Section 9.2.2 in its entirety, or by MedImmune pursuant to
Section 9.2.1 with respect to any Terminated Territory, as applicable, any Surviving Sublicense granted to any Sublicensee pursuant to Section 2.3.2 shall survive termination of this Agreement in its entirety or with respect to the
applicable Terminated Territory, as applicable, on the terms and conditions set forth in Section 2.3.2 and such Surviving Sublicense. 

9.5. Remedies. Except as otherwise expressly provided herein, termination of this Agreement (either in its entirety or with respect to
one (1) or more country(ies)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. 

9.6. Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement (either in its entirety or with respect
to one (1) or more country(ies)) for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from
obligations that are expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, Sections 2.1 (to the extent provided in Section 9.4.1); 2.2; 2.3.1 (second and third sentences, except in
relation to any Surviving Sublicense with respect to obligations arising after the effective date of termination of this Agreement that become direct obligations of the applicable Sublicensee to MedImmune under any Surviving Sublicense, enforceable
directly by MedImmune against such Sublicensee, as 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 97 

 
provided in Section 2.3.2); 2.4.1; 2.4.4(d); 2.5.2 (to the extent provided in Section 9.4.2(j) or Section 9.4.3(j), as applicable); 3.3.2 (for the period specified therein); 3.5.3;
3.6 (second sentence); 3.8 (with respect to subcontracts entered into prior to termination, but limited in the case of Licensed Product Agreements assigned to MedImmune to obligations and liabilities in relation to such assigned Licensed Product
Agreements arising prior to assignment to MedImmune or out of circumstances or events occurring prior such assignment); 4.5.3-4.5.4 (to the extent provided in Section 9.4.2 or Section 9.4.3, as
applicable); 4.6 (for final accounting but excluding the last sentence); 4.7 (for final accounting); 4.8-4.9; 4.10-4.12 (for the period specified in Section 4.10);
5.1; 5.2.1-5.2.2 (solely with respect to PhaseBio Selected Patents and provided that, for any PhaseBio Selected Patent that solely claims a Licensed Compound or Licensed Product or the Exploitation thereof,
the role of the Parties shall be reversed for purposes of Section 5.2.2); 5.2.5; 5.2.6 (solely in relation to PhaseBio Selected Patents and Joint Patents); 5.2.8; 5.3.1; 5.3.2 (solely with respect to PhaseBio Selected Patents and provided that,
for any PhaseBio Selected Patent that solely claims a Licensed Compound or Licensed Product or the Exploitation thereof, the role of the Parties shall be reversed for purposes of Section 5.3.2); 5.3.4; 5.3.5; 5.3.6 (with respect to PhaseBio
Selected Patents and Joint Patents and with respect to MedImmune’s rights to settle in relation to any AstraZeneca Product Patents); 5.4 (with respect to claims arising from Exploitation prior to termination); 5.5.2 (solely with respect to
PhaseBio Selected Patents); 5.5.3; 5.5.4; 5.5.5 (solely with respect to PhaseBio Selected Patents and Joint Patents); 5.7.1 (first sentence); 6.1-6.2 (for the period specified therein); 6.3-6.7; 9.3; 9.4.1; 9.4.2 or 9.4.3 (as applicable); 9.4.4; 9.4.5; 9.5 and this Section 9.6 and Articles 1 (to the extent necessary to give effect to the other articles and sections set forth in this
Section 9.6), 8 and 10 (other than Section 10.3.1(b) and Section 10.4) of this Agreement shall survive the termination or expiration of this Agreement for any reason. If this Agreement is terminated with respect to the
Terminated Territory but not in its entirety, then following such termination (i) the foregoing provisions of this Agreement shall remain in effect with respect to the Terminated Territory (to the extent they would survive and apply in the
event the Agreement expires or is terminated in its entirety or as otherwise necessary for any of MedImmune and its Affiliates and its and their (sub)licensees to exercise their rights in the Terminated Territory); provided, however,
that in the case of Section 5.2.2 and 5.3.2, notwithstanding the parentheticals above that correspond to each such Section reference and provide for a reversal of the role of the Parties under such provisions, no such reversal of the role of
the Parties shall be applicable if this Agreement is terminated with respect to the Terminated Territory but not in its entirety; and (ii) all provisions not surviving in accordance with the foregoing shall terminate upon termination of this
Agreement with respect to the Terminated Territory and be of no further force and effect (but, for the avoidance of doubt, all provisions of this Agreement shall remain in effect with respect to all countries in the Territory other than the
Terminated Territory). For purposes of this Section 9.6, “Surviving Sublicense” shall mean only any Surviving Sublicense that pursuant to Section 9.4.5 has survived a termination of this Agreement by MedImmune pursuant to
Section 9.2.1 or Section 9.2.2 in its entirety, or by MedImmune pursuant to Section 9.2.1 with respect to any Terminated Territory, as applicable. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 98 

 ARTICLE 10 

MISCELLANEOUS 
 10.1.
Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an
obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes,
embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within
[***] after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope
and no longer duration than is necessary and the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform. Without limitation to the foregoing, in the event that the
suspension of performance continues for [***] after the date of the occurrence and such suspension of performance would constitute a material breach of this Agreement in the absence of this Section 10.1, MedImmune shall have the right to
terminate this Agreement pursuant to Section 9.2.1 without regard to this Section 10.1, except that in such event no cure period shall apply and MedImmune shall have the right in its sole discretion to effect such termination upon written
notice to Licensee, either solely with respect to the country affected by such non-performance or in its entirety. 

10.2. Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from
the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any
products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other
governmental entity in accordance with Applicable Law. 
 10.3. Assignment. Neither Party may assign its rights or, except as
permitted in Section 3.8, delegate its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, which consent shall not be unreasonably withheld,
conditioned or delayed; provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party’s consent: 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 99 

 10.3.1. in connection with the transfer or sale of all or substantially all of the
business of such Party to which this Agreement relates to a Third Party (“Third Party Acquirer”), whether by merger, sale of stock, sale of assets or otherwise, and whether or not such Party is the surviving entity (each, a
“Sale Transaction”); provided that in the event of a Sale Transaction (whether this Agreement is actually assigned or is assumed by the Third Party Acquirer or the surviving corporation resulting from such Sale Transaction by
operation of law (e.g., in the context of a reverse triangular merger)): 
 (a) Information, materials and intellectual property
rights controlled by the Third Party Acquirer (other than as a result of a license or other grant of rights, covenant or assignment by the assigning Party or its Affiliates to, or for the benefit of, such Third Party Acquirer) that existed prior to
the Sale Transaction shall not be included in the technology licensed hereunder or otherwise subject to this Agreement; and 
 (b) in the
case of a Sale Transaction involving MedImmune, the provisions of Section 2.5.1 shall not apply to any Competing Product being developed or commercialized by the Third Party Acquirer or any of its Affiliates (other than MedImmune or any Person
that was an Affiliate of MedImmune prior to the consummation of the Sale Transaction) prior to such Sale Transaction; provided that MedImmune or the surviving corporation, as the case may be, shall establish reasonable internal safeguards
designed to prevent any Licensed Know-How or PhaseBio Know-How from being utilized in furtherance of the development or commercialization of, or otherwise for the
benefit of, such Competing Product; 
 10.3.2. to an Affiliate, provided that the assigning Party shall remain liable and responsible
to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate; 

provided that, in each case (Section 10.3.1 and Section 10.3.2), the assigning Party shall provide written notice to the other Party within
[***] after such assignment. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be
deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any attempted assignment in violation of this Section 10.3 shall be void and of no effect. 

10.4. Other Strategic Transactions Involving MedImmune and its Affiliates. 

10.4.1. In the event that MedImmune or its Affiliate acquires, whether by merger, purchase of stock or purchase of assets, a Third
Party in a transaction that is not a Sale Transaction, or a business unit or a portfolio of products of a Third Party (which portfolio includes one (1) or more Competing Products and one (1) or more other products that are not Competing
Products) (each a “Strategic Transaction”), and the Third Party with which such 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 100 

 
MedImmune Strategic Transaction is consummated or any of its Affiliates (other than MedImmune or any Person which was an Affiliate of MedImmune prior to consummation of the Strategic Transaction)
was engaged in development or commercialization of a Competing Product prior to such consummation (each a “Permitted Competing Product”), then following consummation of such Strategic Transaction the provisions of Section 2.5.1
shall not apply to such Permitted Competing Product, provided that MedImmune shall establish reasonable internal safeguards designed to prevent any Licensed Know-How or PhaseBio Know-How from being utilized in furtherance of the development or commercialization of, or otherwise for the benefit of, the applicable Permitted Competing Product. 

10.4.2. Except in circumstances in which Section 10.3.1(b) applies (in which case Section 10.3.1(b) shall control), in the
event that MedImmune or its Affiliate sells or transfers to any Third Party, in one or more related transactions, properties or assets representing all or substantially all of MedImmune’s or such Affiliate’s consolidated total assets with
respect to the Licensed Compound and Licensed Products, and the Third Party with which such transaction is consummated or any of its Affiliates (other than MedImmune or any Person which was an Affiliate of MedImmune prior to consummation of such
transaction) owns or controls, or is engaged in development or commercialization of, a Competing Product prior to such consummation, then following such consummation of such transaction the Exclusive Period during which the provisions of
Section 2.5.1 apply shall automatically be deemed to be limited to (a) with respect to the conduct of human clinical trials of such Competing Product, the shorter of (i) the period of three (3) years beginning on the effective
date of such transaction or (ii) the period of five (5) years beginning on the Effective Date, and (b) with respect to the sale or offer for sale of such Competing Product, the shorter of (i) the period of five (5) years
beginning on the effective date of such transaction and (ii) the period of seven (7) years beginning on the Effective Date. 

10.5. Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law
and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or
by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid
or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or
unenforceable in any respect. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 101 

 10.6. Dispute Resolution. 

10.6.1. Except as provided in Section 3.5.7, Section 4.12, Section 5.2.7, Section 9.2.4 or Section 10.12, if a
dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a “Dispute”), then either Party shall have the right to refer such Dispute to the
Senior Officers for attempted resolution by good faith negotiations during a period of [***]. Any final decision mutually agreed to by the Senior Officers shall be set forth in writing and signed by both Parties, whereupon it will be conclusive and
binding on the Parties. 
 10.6.2. If such Senior Officers are unable to resolve any such Dispute within such [***] period, except as
otherwise set forth in Section 3.5.7, Section 4.12, Section 5.2.7, Section 9.2.4, Section 10.6.5, Section 10.7 or Section 10.12, either Party shall be free to institute binding arbitration in accordance with
Section 10.6.3 upon written notice to the other Party (an “Arbitration Notice”) and seek such remedies as may be available. 

10.6.3. Upon receipt of an Arbitration Notice by a Party, the applicable Dispute shall be resolved by final and binding arbitration
before a panel of three (3) experts with relevant industry experience (the “Arbitrators”). Each of Licensee and MedImmune shall promptly select one (1) Arbitrator, which selections shall in no event be made later than
[***] after the notice of initiation of arbitration. The third Arbitrator shall be chosen promptly by mutual agreement of the Arbitrator chosen by Licensee and the Arbitrator chosen by MedImmune, but in no event later than [***] after the date that
the last of such Arbitrators was appointed. The Arbitrators shall determine what discovery will be permitted, consistent with the goal of reasonably controlling the cost and time that the Parties must expend for discovery; provided that the
Arbitrators shall permit such discovery as they deem necessary to permit an equitable resolution of the dispute. The arbitration shall be administered by the American Arbitration Association (or its successor entity) (“AAA”) in
accordance with the then current Commercial Rules of the American Arbitration Association including the Procedures for Large, Complex Commercial Disputes (including the Optional Rules for Emergency Measures of Protection), except as modified in this
Agreement. The arbitration shall be held in the State of New York. The Arbitrators shall, within [***] after the conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions
on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the Arbitrators shall be final and non-appealable, and judgment may be entered upon it in
accordance with Applicable Law in any court of competent jurisdiction. The Arbitrators’ authority to award special, incidental, consequential or punitive damages shall be subject to the limitation set forth in Section 8.4. The Arbitrators
shall not be authorized to reform, modify or materially change this Agreement or any other agreements contemplated hereunder. 
 10.6.4.
Each Party shall bear its own counsel fees, costs, and disbursements arising out of the dispute resolution procedures described in this Section 10.6, and 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 102 

 
shall pay an equal share of the fees and costs of the Arbitrators and all other general fees related to any arbitration described in Section 10.6.3; provided, however, the Arbitrators
shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for any or all of its reasonable counsel fees, costs and disbursements (including expert witness fees and expenses,
photocopy charges, or travel expenses), or the fees and costs of the Arbitrators. Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding described in Section 10.6.3 is pending under this
Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of such pending arbitration proceeding. Nothing contained in this Agreement shall deny any Party the right to seek
injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing discussions between the
Senior Officers or any ongoing arbitration proceeding. All arbitration proceedings and decisions of the Arbitrator under this Section 10.6 shall be deemed Confidential Information of both Parties under Article 6. 

10.6.5. Notwithstanding the foregoing, in the event that a Dispute arises with respect to the validity, scope, enforceability,
inventorship or ownership of any Patent, Trademark or other intellectual property rights, either Party may bring an action in a court of competent jurisdiction in accordance with Sections 10.8.2 and 10.8.3 (or, as applicable, with any patent or
trademark authority of competent jurisdiction) to resolve such Dispute, and no such Dispute shall be subject to arbitration pursuant to Section 10.6.2 or Section 10.6.3. 

10.7. Expedited Determination of Royalty Rate. If the Parties are unable to reach mutual agreement as to the Termination Royalty Rate
under Section 9.4.2(d) or the Terminated Territory Royalty Rate under Section 9.4.3(d) within the period specified such Section, then either Party shall have the right to refer such disagreement to MedImmune’s senior representative
for the AstraZeneca Product and Licensee’s Chief Financial Officer or VP of Marketing/Chief Commercial Officer (or their respective designees) for attempted resolution by good faith negotiations during a period of [***]. Any final decision
mutually agreed to by such senior representatives (or such designees) shall be conclusive and binding on the Parties. If such senior representatives (or such designees) are unable to resolve any such disagreement within such ten (10)-Business Day
period, then, upon the written request of either Party, the determination of the Termination Royalty Rate, the Terminated Territory Royalty Rate or the reasonably allocable amount (as applicable) shall be referred to an Independent Financial Expert.
“Independent Financial Expert” means (a) an independent, appropriately qualified Third Party expert at KPMG, Ernst & Young, Deloitte or PwC who is acceptable to both Parties or other Third Party expert mutually agreed
by the Parties or (b) if the Parties fail to agree on an independent Third Party expert in accordance with the preceding clause (a) within [***] after such request for referral, an independent, appropriately qualified Third Party expert at
KPMG, Ernst & Young, Deloitte or PwC who is selected by mutual agreement of (i) an independent, appropriately qualified Third Party expert at KPMG, Ernst & Young, Deloitte or PwC selected by MedImmune within [***] after such
request for referral and (ii) an independent, appropriately 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 103 

 
qualified Third Party expert at KPMG, Ernst & Young, Deloitte or PwC selected by Licensee within [***] after such request for referral (such selection to be made within [***] after the
Parties have selected their respective independent Third Party experts); provided that, in each case ((a) and (b)), if at the time of the disagreement either Party is currently utilizing the services of KPMG, Ernst & Young, Deloitte
or PwC in any significant respect, the Parties will not select an expert from such firm, unless the Parties otherwise agree; provided, further, that, in each case ((a) and (b)), if at the time of the disagreement one or both Parties is
currently utilizing the services of each of KPMG, Ernst & Young, Deloitte or PwC in any significant respect, the Parties shall cooperate in good faith to select an independent, appropriately qualified Third Party not employed by or a
principal in any such firm. The sole authority of the Independent Financial Expert will be to determine Termination Royalty Rate, the Terminated Territory Royalty Rate or the reasonably allocable amount (as applicable). The Independent Financial
Expert’s determination shall be final and binding upon the Parties. The Independent Financial Expert shall be required to make his or her determination within [***] after his or her selection as the Independent Financial Expert. The costs of
such Independent Financial Expert shall be (x) in the event of a termination pursuant to Section 9.2.1, paid by the Breaching Party, and (y) in the event of any other termination, shared equally by the Parties. 

10.8. Governing Law, Jurisdiction and Service. 

10.8.1. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of
the United Nations Convention on Contracts for the International Sale of Goods. 
 10.8.2. Jurisdiction. Subject to Section 10.6
and Section 10.12, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of federal and state courts sitting in the State of New York for any action, suit or proceeding (other than appeals therefrom) arising
out of or relating to this Agreement and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts; provided, however, that in the case of (a) any action, suit or proceeding
with respect to the validity, scope, enforceability, inventorship or ownership of any Patent, Trademark or other intellectual property rights, or (b) any action seeking only injunctive or other equitable relief, including specific performance,
in each case ((a) and (b)) for which (and to the extent) federal and state courts sitting in the State of New York lack authority to issue the relief sought, each Party shall have a right to pursue such action, suit or proceeding in any court of
competent jurisdiction (or, as applicable, with any patent or trademark authority of competent jurisdiction). The Parties irrevocably and unconditionally waive their right to a jury trial. 

10.8.3. Venue. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action,
suit or proceeding 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 104 

 
(other than appeals therefrom) arising out of or relating to this Agreement in federal and state courts sitting in the State of New York and hereby further irrevocably and unconditionally waive
and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum; provided, however, that in the case of (a) any action, suit or proceeding
with respect to the validity, scope, enforceability, inventorship or ownership of any Patent, Trademark or other intellectual property rights, or (b) any action seeking only injunctive or other equitable relief, including specific performance,
in each case ((a) and (b)) for which venue cannot be established in federal and state courts sitting in the State of New York, each Party shall have a right to pursue such action, suit or proceeding in any court of competent jurisdiction (or, as
applicable, with any patent or trademark authority of competent jurisdiction). 
 10.8.4. Service. Each Party further agrees that
service of any process, summons, notice or document by registered mail to its address set forth in Section 10.9.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such
court. 
 10.9. Notices. 

10.9.1. Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under
this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery
service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 10.9.2 or to such other address as the Party to whom notice is to be given may have provided to the other Party in
accordance with this Section 10.9.1. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business Day (at the place of delivery) after
deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 10.9.1 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

10.9.2. Address for Notice. 

If to Licensee, to: 
 PhaseBio
Pharmaceuticals, Inc. 
 1 Great Valley Parkway, Suite 30 

Malvern, PA 19355 
 United
States 
 Attention: Chief Executive Officer 

Facsimile: +1 610-981-6520 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 105 

 with a copy (which shall not constitute notice) to: 

Cooley LLP 
 Reston Town Center

 11951 Freedom Drive 
 14th
Floor 
 Reston, VA 20190-5640 

United States 
 Attention:
Christian Plaza 
 Facsimile: +1 703-456-8100 

If to MedImmune, to: 
 Milstein
Building, Granta Park 
 Cambridge CB21 6GH 

United Kingdom 
 Attention: Head
of Business Operations, 
 with a copy (which shall not constitute notice) to: 

Corporate Legal 
 Middlewood
Court, Silk Road 
 Macclesfield, Cheshire SK10 2NA 

England 
 United Kingdom 

Attention: Assistant General Counsel 

10.10. Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth and constitutes the entire
agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto. Each Party confirms that it is not
relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release or discharge shall be binding on the Parties unless in writing and duly executed by authorized
representatives of both Parties. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. Specifically and without limiting the foregoing, this Agreement
shall supersede (a) that certain Confidentiality Agreement entered into by and between the Parties as of June 2, 2016, and all confidential information exchanged under such Confidentiality Agreement shall be deemed Confidential Information
of the applicable Party under this Agreement and (b) that certain Material Transfer Agreement by and between MedImmune, LLC and Licensee, effective as of August 14, 2017, and any Material (as defined in such Material Transfer Agreement)
provided to Licensee pursuant to such Material Transfer Agreement shall be deemed to be Transferred Inventory under this Agreement. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 106 

 10.11. English Language. This Agreement has been prepared in the English language,
and the English language shall control its interpretation. All notices and other communications under or in connection with this Agreement shall be in the English language. Any translation into any other language shall not be an official version
thereof and in the event of any conflict in interpretation between the English version and such translation, the English version shall control. 

10.12. Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in Section 2.5, Article 5 and
Article 6 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of
any provision of such Section or Articles may result in irreparable injury to such other Party for which there may be no adequate remedy at law. In the event of a breach or threatened breach of any provision of such Section or Articles, the non-breaching Party shall have the right to seek from any court of competent jurisdiction injunctive or other equitable relief, including specific performance, in addition to any other rights or remedies to which
such non-breaching Party may be entitled in law or equity. Nothing in this Section 10.12 is intended or should be construed, to limit either Party’s right to equitable relief or any other remedy for
a breach of any other provision of this Agreement. 
 10.13. Waiver and Non-Exclusion of
Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the
Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by
such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.

 10.14. No Benefit to Third Parties. Except as provided in Article 8, the covenants and agreements set forth in this Agreement
are for the sole benefit of the Parties and their successors and permitted assigns and they shall not be construed as conferring any rights on any other Persons. 

10.15. Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further instruments
and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry
out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 107 

 10.16. Relationship of the Parties. It is expressly agreed that MedImmune, on the one
hand, and Licensee, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MedImmune, on the one hand, nor Licensee, on the other
hand, shall have the authority to make any statements, representations or commitments of any kind or to take any action that will be binding on the other Party without the prior written consent of the other Party to do so. All persons employed by a
Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party. 

10.17. References. Unless otherwise specified, (a) references in this Agreement to any Article, Section or Schedule shall mean
references to such Article, Section or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section, and (c) references to any agreement, instrument or other document in this
Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference
thereto. 
 10.18. Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural,
the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers
to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term
“including,” “include,” or “includes” as used herein shall mean including, without limiting the generality of any description preceding such term. The language of this Agreement shall be deemed to be the language
mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. 
 10.19. Counterparts. This
Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email, or
other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were original signatures. 

[SIGNATURE PAGE FOLLOWS.] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
 108 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written
above. 
  

									
	MEDIMMUNE LIMITED	 		  	PHASEBIO PHARMACEUTICALS, INC.
					
	By:	 	 /s/ A.C.N. Kemp
	 		  	By:	 	 /s/ Jonathan Mow

	Name: A.C.N. Kemp	 		  	Name: Jonathan Mow
	Title: Director	 		  	Title: CEO

 [SIGNATURE PAGE TO LICENSE AGREEMENT] 

 Schedule 1.46 

Emerging Market Countries 

[***] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 1.79 

Licensed Know-How 

Know-How & Methods: 

[***] 
 *UNLESS OTHERWISE PROVIDED, ALL KNOW-HOW AND METHODS DO NOT INCLUDE ANY [***]. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 1.80 

Licensed Patents 
  

																					
	 Family Number
	  	Ctry	 	  	Type	 	  	Filing Date	 	  	Filing Number	 	  	Live/Closed	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 1.85 

Licensee Corporate Names 

PhaseBio 
 PhaseBio
Pharmaceuticals 
 PhaseBio Pharmaceuticals, Inc. 
  

 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 1.96 

[***] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 1.98 

MedImmune Corporate Names 

ASTRAZENECA 
  

 
 MEDIMMUNE 
  

 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.1.1 

Technical Transfer Documents 
  

									
	 INDEX
	  	TITLE	 	  	FILE EXT	 
	 [***]
	  	 	[***]	 	  	 	[***]	 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.1.2(a) 

Transferred Inventory 

[***] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.1.2(b) GLP Samples 

See attached. 
 [***] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.1.4 

IND Deliverables 
  

									
	 MODULE 1: ADMINISTRATIVE INFO & PRESCRIBING
INFO
	  	DMS Document Name/eCTD File Name	 	  	Comments*	 
	 [***]
	  	 	[***]	 	  	 	[***]	 

 In addition, [***] for completion by Licensee 
  

									
	 Module 2: Summaries CTD Section
	  	CTD Section Title	 	  	Comments*	 
	 [***]
	  	 	[***]	 	  	 	[***]	 

  

			
	 Module 3: Quality
	  	Comments*
	 [***]
	  	[***]
		
	 Module 4: Nonclinical Study Reports
	  	Comments*
	 [***]
	  	[***]

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.3.1(d) 

Supply of Ticagrelor Active Metabolite (AR-C124910XX) 

Licensee shall have the right to request Ticagrelor Active Metabolite [***]. 

Shipping to Licensee [***]. 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.4.1 (b) 

Existing Regulatory Documentation 

[***] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 3.4.4(e) 

Serious Adverse Event Reporting Timelines 

[***] 

  
 *** CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]